ǾƷǧƷȐƷǺ
̜ࣟ൙‫ݏڮ‬ൌ޻೴৾‫޻ڮ‬य़ࢅ୹Ѥॶ੔̝࠱ೊय़ࢅ҇యకюҀ೏௰ѝьћ͑ౡა‫޻ݏ‬य़ࢅᆛ‫͒ڱ‬пѽѨ͑಑ൿ‫ڮ‬ᆒय़ࢅᆛ‫̝͒ڱ‬ਈѣय़ࢅ஄౗ૉࣅѹ࠴࿤य़ࢅ࿫҇ࠟѵ͑ӊӠҫҚҢһय़ࢅҮӦҲ̷͒ဗѨѠൌ޻ѣဲᄜюҀय़ࢅયಈ̡ࡀ࠰҇‫ۦ‬ᅀюҀ͑ࢣຎᅧᅀҮӦҲ̷͒рѾџѿ̝ࣟ൙‫ݏڮ‬ൌ޻ѣय़ࢅѣᅆѝьћ୔ᅆџᄃ߇҇‫ݑ‬єьћйѳю̞̜य़ࢅ୹ѣଘєҀӒҶҪӚӦќзҀީय़ࢅခჿѣय़ࢅѤ̝୹‫ۀ‬ѣ๗ᆜс૳҇ॆѨ̝ъѾџҀ౗‫ݑ‬сౡѳҁљљзѿѳю̞ႏ໪၈Ѥ੧໪2໪ࠗѣߋຍ౗‫҇ݑ‬ѳѝѶєѷѣќю̞
̜3127໪๘Ѥ̝ౡა‫޻ݏ‬य़ࢅᆛ‫ ڱ‬੎ၙ‫޻ڮ‬य़ࢅခჿѠࠥᇱᆁ࿎ࢲ଩сඨໟь̝шҁѳќѣ࠱ೊ੎ၙౡ࿿޻̝૱߶ӑ̷Ҟ̷ѣ෪ࡹѝйјєय़ࢅခჿѠ݈нћ̝ҬһӟҬ‫ܥ‬๹ѣ݉ા݂ӑҙҬ҇ᅀйє૱߶ѣ‫ݷ‬౸ѝйјє̝ᆤடѠෟॆьлҀంьйခჿѣय़ࢅѷื‫ގ‬ъҁѽлѝьћйѳ
ю̞ѳє̝ຎᆛ‫ڱ‬ခથଡ᢮य़ࢅခჿѠൌ෮ฮ৭નсඨໟьћ̝ߵ੎ၙѣത໸ౖ‫ڦ‬ૐѠ࠙юҀय़ࢅѹ̝᪒೧੣࡚ୠ҇ߋрьє૳६ຍ࿿ѣप๼ѣ‫ڦ‬ૐ̝ે‫ࠊ̝ڲ‬ᅬс‫ގ‬ઢъҁ̝‫ڭ‬เથ‫ރ‬ဦຍ࿿ѣ੣౦ѷાჿѠ໛ҁћ޻຿‫ޓ‬य़ࢅଅѝѣᇍणс૳ॶьљљзѿѳю̞̜
̜3127໪3ॉѠ߱౗ь̝ઢຍьћйҀ਻ౡ‫ڮ‬ᆒҮӦҲ̷Ѥ̝೴৾‫޻ڮ‬य़ࢅ୹ѝѣᇍण҇఩ҀѮф೴‫ڮ‬य़౹‫ޣ‬ᄈఘࢲ଩с࿲ҮӦҲ̷ේ҇ॎໟь̝ชߵিҮӦҲ̷ේͅࠏඃ᪴຿‫ࢲ޻ݏ‬଩̝͆ంьф‫ގ‬৭ъҁє‫޻ڮ‬࿫਻ౡ‫ڮ‬ᆒ޻৭਷ѣ݁န૓ᆁࢲ଩ѝᆜ҇৾҄ѐћ̝ႏ޻ѠпцҀంьйय़ࢅ̡ఒᆒѣຘ҇ಃѿ‫ގ‬фѮфઢຍьћйѳю̞̜шҁѾѣంьйᆜс݈҄ҀшѝѠѽјћ̝ႏ޻ѠпцҀय़ࢅ཈ืѣ෍ᅻсѳюѳю݈ഓьћѻфшѝ҇࠽ഹьћйѳю̞̜य़ࢅ୹ѣ3љჭѣӒҶҪӚӦќзҀ̝ႏ޻य़ࢅయకѣબ܎ѣოќѷ̝ජ౺ьєफ६ѣด࢞ѹय़ࢅࡀ࠰ࢣຎᅧᅀҪҬҹӓѣ‫ރ‬ಸͅңӞ̷ӊҙҚҕѣߋᅀ͆๸҇෭эћ‫ڵ‬೟ѣୋ૳҇఩јћйѳю̞ႏय़ࢅ୹ ࢣຎᅧᅀҮӦҲ̷с‫ۦ‬ᅀюҀຍ࿿૳६યಈѷॶ੔ॕћഽнѣल‫ݭ‬сక҈ќпѿ̝೨࠽ѣ߱౗сၱѳҁћйѳю̞̜ѳѕѳѕ࿋ୌခџ฿ѷзҀрѝѤપйѳюс̝޻຿‫ޓ‬ѣ࠽ഹѠ‫ܥ‬нຝҀय़ࢅ୹ѠџҀѽл‫ڵ‬೟๗ᆜ҇ьєйѝપйѳю̞‫ފ‬ᄼѣъѾџҀщબ܎̝щࢥᆜ҇пࠫйюҀѝѝѷѠ̝࠸ᕘџйщ‫ڞ‬।ѹщ஄ॹ҇йєѕцҁѥৃйќю̞̜̜̜̜န౗39໪23ॉࣟ൙‫ݏڮ‬ൌ޻೴৾‫޻ڮ‬य़ࢅ୹୹ේ̜౧ྑ̜ᣨᄖ

ᬶƷƷƷƷᓎý⾽ᮾ᳣ཀ᏶┶̜̜2̠ಈᅶफ‫ڧ‬ѝჭษ̜ ̀̀̀̀̀̀̀̀̀̀̀̀̀̀̀̀̀̀̀̀̀̀̀̀̀̀̀̀ ̜2
̜̜3̠೴৾‫޻ڮ‬य़ࢅ୹܏޺̜ ̀̀̀̀̀̀̀̀̀̀̀̀̀̀̀̀̀̀̀̀̀̀̀̀̀̀ ̜3
̜̜4̠೏௰఩̜ ̀̀̀̀̀̀̀̀̀̀̀̀̀̀̀̀̀̀̀̀̀̀̀̀̀̀̀̀̀̀̀̀ ̜8
̜̜5̠௱‫ۀ‬჏၂̜ ̀̀̀̀̀̀̀̀̀̀̀̀̀̀̀̀̀̀̀̀̀̀̀̀̀̀̀̀̀̀̀ ̜9þ⾽౫ಏƷᮾ᳣ᘍ̜̜ؔय़ࢅ‫ݢ‬൏‫ڵ‬ᅦ̜̜̀̀̀̀̀̀̀̀̀̀̀̀̀̀̀̀̀̀̀̀̀̀̀̀̀̀̀̀̀̀̀24Ʒ᧯ܶᲇકᮾ᳣ⲏࣕ
̜̜ခથଡ᢮य़ࢅခჿ̜̜̀̀̀̀̀̀̀̀̀̀̀̀̀̀̀̀̀̀̀̀̀̀̀̀̀̀̀̀̀2:̜̜੎ၙ‫޻ڮ‬य़ࢅခჿ̜̜̀̀̀̀̀̀̀̀̀̀̀̀̀̀̀̀̀̀̀̀̀̀̀̀̀̀̀̀̀35
̜̜ଡ᢮ౡ࿿य़ࢅခჿ̜̜̀̀̀̀̀̀̀̀̀̀̀̀̀̀̀̀̀̀̀̀̀̀̀̀̀̀̀̀̀38̜̜‫ڭ‬เથࡀ໸य़ࢅခჿ̜̜̀̀̀̀̀̀̀̀̀̀̀̀̀̀̀̀̀̀̀̀̀̀̀̀̀̀̀̀3:̜̜‫ڭ‬เથ‫ރ‬ဦຍ࿿ͅ඄༭૲౒ট͆य़ࢅခჿ̜̜̀̀̀̀̀̀̀̀̀̀̀̀̀̀̀̀̀̀̀42ƷӞᴻٛ᪭ᮾ᳣ⲏࣕ
̜̜݈ᆽ౒টय़ࢅခჿ̜̜̀̀̀̀̀̀̀̀̀̀̀̀̀̀̀̀̀̀̀̀̀̀̀̀̀̀̀̀̀46̜̜๻݂౒টय़ࢅခჿ̜̜̀̀̀̀̀̀̀̀̀̀̀̀̀̀̀̀̀̀̀̀̀̀̀̀̀̀̀̀̀4:̜̜‫ڭ‬เથ૱߶य़ࢅခჿ̜̜̀̀̀̀̀̀̀̀̀̀̀̀̀̀̀̀̀̀̀̀̀̀̀̀̀̀̀̀54
̜̜ଡ᢮౒টय़ࢅခჿ̜̜̀̀̀̀̀̀̀̀̀̀̀̀̀̀̀̀̀̀̀̀̀̀̀̀̀̀̀̀̀57

Ʒɟɵɀȯȷɐᮾ᳣Ƀɻɇʀ
̜̜ӊӠҫҚҢһय़ࢅҮӦҲ̷̜̜̀̀̀̀̀̀̀̀̀̀̀̀̀̀̀̀̀̀̀̀̀̀̀̀̀62̜̜ಘᅹษय़ࢅ࿫̜̜̀̀̀̀̀̀̀̀̀̀̀̀̀̀̀̀̀̀̀̀̀̀̀̀̀̀̀̀̀̀̀64̜̜ࠅࢪ९ౖા޳ྐྵ഻य़ࢅ࿫̜̜̀̀̀̀̀̀̀̀̀̀̀̀̀̀̀̀̀̀̀̀̀̀̀̀̀̀66̜̜಑౒ခથ௴ᆎ‫޻ݏ‬य़ࢅ࿫̜̜̀̀̀̀̀̀̀̀̀̀̀̀̀̀̀̀̀̀̀̀̀̀̀̀̀̀71̜̜ึ಺ဦౖ඄༭૲ೖᄅ‫޻ݏ‬य़ࢅ࿫̜̜̀̀̀̀̀̀̀̀̀̀̀̀̀̀̀̀̀̀̀̀̀̀̀73̜ӽ۴֐᧸Ƀɻɇʀ̜̜̀̀̀̀̀̀̀̀̀̀̀̀̀̀̀̀̀̀̀̀̀̀̀̀̀̀̀̀̀̀78ÿ⾽౫ƷᏡὧ̜̜ౡა‫޻ݏ‬य़ࢅᆛ‫̜̜̀̀̀̀̀̀̀̀̀̀̀̀̀̀̀̀̀̀̀̀̀̀̀̀̀̀̀̀̀ڱ‬86̜̜ͅခથଡ᢮य़ࢅခჿ̝੎ၙ‫޻ڮ‬य़ࢅခჿ̝ଡ᢮ౡ࿿य़ࢅခჿ̝‫ڭ‬เથࡀ໸य़ࢅခჿ̝
̜̜̜‫ڭ‬เથ‫ރ‬ဦຍ࿿ͅ඄༭૲౒ট͆य़ࢅခჿ͆

̜̜಑ൿ‫ڮ‬ᆒय़ࢅᆛ‫̜̜̀̀̀̀̀̀̀̀̀̀̀̀̀̀̀̀̀̀̀̀̀̀̀̀̀̀̀̀̀ڱ‬93̜̜݈ͅᆽ౒টय़ࢅခჿ̝๻݂౒টय़ࢅခჿ̝‫ڭ‬เથ૱߶य़ࢅခჿ̝ଡ᢮౒টय़ࢅခჿ͆

̜̜ӊӠҫҚҢһय़ࢅҮӦҲ̷̜̜̀̀̀̀̀̀̀̀̀̀̀̀̀̀̀̀̀̀̀̀̀̀̀̀̀:1̜̜ͅಘᅹษय़ࢅ࿫̝ࠅࢪ९ౖા޳ྐྵ഻य़ࢅ࿫̝಑౒ခથ௴ᆎ‫޻ݏ‬य़ࢅ࿫̝̜̜̜ึ಺ဦౖ඄༭૲ೖᄅ‫޻ݏ‬य़ࢅ࿫̜̜͆ࢣຎᅧᅀҮӦҲ̷̜̀̀̀̀̀̀̀̀̀̀̀̀̀̀̀̀̀̀̀̀̀̀̀̀̀̀̀̀̀ 219Ā⾽ᮾ᳣౺अᘍؔɿǬǽ͙
̜̜2̠ҮӒҽ̷̜ ̀̀̀̀̀̀̀̀̀̀̀̀̀̀̀̀̀̀̀̀̀̀̀̀̀̀̀̀̀̀̀ 226̜̜̜̜ધჂ঱‫ގ‬ҮӒҽ̷̜ ̀̀̀̀̀̀̀̀̀̀̀̀̀̀̀̀̀̀̀̀̀̀̀̀̀̀̀ 226̜̜̜̜य़ࢅҮӒҽ̷̜ ̀̀̀̀̀̀̀̀̀̀̀̀̀̀̀̀̀̀̀̀̀̀̀̀̀̀̀̀̀ 231
̜̜3̠ৄ၈ߋຍ̜ ̀̀̀̀̀̀̀̀̀̀̀̀̀̀̀̀̀̀̀̀̀̀̀̀̀̀̀̀̀̀̀ 235
̜̜4̠य़ࢅ‫ۀ‬ଦц໛ҁ̡ਈ੒ফᅻ̜ ̀̀̀̀̀̀̀̀̀̀̀̀̀̀̀̀̀̀̀̀̀̀̀ 239
̜̜5̠‫ޓ‬࿫य़ࢅ္஄ࣟ๸̜ ̀̀̀̀̀̀̀̀̀̀̀̀̀̀̀̀̀̀̀̀̀̀̀̀̀̀̀ 23:̜̜̜̜‫޻ݏ‬य़ࢅྊ̝ଦ൜य़ࢅྊ̝ಘᅹӊӠҫҚҢһय़ࢅྊџўᮾ᳣ཀ᏶┶

ギㄿ ▚ᴗểἵ㈳ᬶ᫢
̜னᇭ59໪6ॉѠႏ޻य़ࢅଅѣ঳ᅵษџय़ࢅయకѝ̝ѽѿ‫ڵ‬೟ѣय़ࢅѣষ௒҇ჭษѝьћय़ࢅᅀൌचࡀ࠰҇େඩษѠࠊᅬ̡‫۫ۦ‬юҀєѶѣࢣຎय़ࢅ૭сಈ඙ъҁє̞னᇭ69໪5ॉѠ໩സྐྵᄑ໛߷ಠஶѣय़ࢅѝ໩സඒ‫ڱ‬ѣ཈ื๒௒ਈѝѣ‫ڮ‬ᆒࢥᆜ҇ჭษѝьћࣟ൙‫ݏڮ‬ൌ޻໩സ‫޻ڮ‬य़ࢅ୹̝пѽѨ‫ڭ‬เ޻ѣࢲ‫̡ڲ‬य़ࢅ҇ჭษѝьєఘᆭ‫ڭ‬เ޻य़ࢅ୹ͅౡ݂޻࿫ჸ͆с‫ގ‬ಈъҁє̞ᅑனᇭ6:໪6ॉѠ‫ڭ‬เ޻ѣᆤட‫ܥ‬ᅀѭѣ৮फ़ѝඒ‫ڱ‬ଃ‫ݶ‬ѠпцҀҮӦҲ̷ษᄃ߇҇൷лшѝ҇ჭษѝьћ̝ఘᆭ‫ڭ‬เ޻य़ࢅ୹Ѡᆤட࿫ჸсတಈъҁє̞̜шҁѾ࠼ಈѣࢣຎय़ࢅ૭̝໩സ‫޻ڮ‬य़ࢅ୹ࡹѨఘᆭ‫ڭ‬เ޻य़ࢅ୹҇၁ളѝьћ೴৾‫޻ڮ‬य़ࢅ୹ѣಈᅶ৔ೢс‫ݯ‬ౡн̝န౗८໪5ॉ2໙̝࠱ೊ‫޻ݏڮ‬य़ࢅ࿫ჸ̝໎૔૱߶य़ࢅ࿫ჸ̝ആ࠰඙ߺ
य़ࢅ࿫ჸ̝с҈य़ࢅ࿫ჸ̝ఘᆭ‫ڭ‬เ޻य़ࢅ࿫ჸ̝໩സ‫޻ڮ‬य़ࢅ࿫ჸ̝ࢣຎᅧᅀ࿫ჸͅ RI ҮӦҲ̷̝ຍ࿿ે‫ڲ‬ҮӦҲ̷͆ѣ8࿫ჸќ೴৾‫޻ڮ‬य़ࢅ୹с‫ގ‬ಈъҁє̞̜೴৾‫޻ڮ‬य़ࢅ୹ೖಈѣ࠱ႏၒఖѤ૒ѣ5љрѾ౗Ҁ̞
̜2̠ॾйजѣय़ࢅᆛ‫ڱ‬ѠোҀшѝџф̝ᆤடय़ࢅѠෟॆьє࠱ೊษय़ࢅѠଘࠤ҇඙ф̞̜3̠૳੒ѣय़ࢅѠѤ̝ྵ݆ь‫ڠ‬йӊӠҫҚҢһय़ࢅ҇ຐ໛юҀ̞
̜4̠ઍ޻ࢣຎय़ࢅѣయక҇఩Ҁ̞̜5̠‫ޓއ‬ফᅻ҇యకюҀ̞̜юџ҄і̝ႏय़ࢅ୹Ѥ̝࠱ೊ̡ᆤட҇ࠟѶႏ޻ѣᄼ̴џခჿѣಕჸ‫ݍ‬сେѳјћຠซѣ‫ݢ‬൏Ѡവьћ‫ڵ‬љѣय़ࢅңӞ̷ӊ҇љфѿީ૜ѣय़ࢅ౗‫҇ݑ‬๼৾ьћᆤடѠ‫ܥ‬ᅀьћйфѝйлၒૡѣѷѝќ̝ႏ޻ѣ‫ڮ̡޻ڮ‬ᆒѣষ௒ѝय़ࢅѣߋౖ݂҇఩Ҁшѝ്҇‫ڵ‬ѣჭษѝьћйҀ̞ъѾѠ̝ႏ޻ީ৭਷ѣީଠय़ࢅߋຍѭѣ܎஄ѹધჂ঱‫ގ‬৭਷҇‫਺ގ‬ь̝य़ࢅ౗‫ৄ҇ݑ‬ф཈௹юҀшѝ҇‫ڞ‬఩ьћйҀ̞̜ࣟ൙‫ݏڮ‬ൌ޻сೖᅶ41ଯ໪҇हнєန౗26໪2ॉѠѤ̝೴৾‫޻ڮ‬य़ࢅ୹ѷ‫ގ‬ಈ25໪ѝџѿ̝૑ൊѠവ‫ܥ‬ьє೏௰‫ރ‬ဩс૳યъҁє̞य़ࢅଛၔѣక့ѹӂҗҹҢ̡ӝҨ̷Ҵ̡ҮӦҲ̷ѣဍ࿫‫޻ݏ‬ஷ໢݉Ѡཕлࢣຎᅧᅀࡀ࠰ѣ৐ం̡ޫൌ҇ຄѳнћ̝੎ၙ‫޻ڮ‬य़ࢅ࿫ჸ̝಑క‫ڮ‬ᆒय़ࢅ࿫ჸ̝ఘᆭ‫ڭ‬เ޻य़ࢅ࿫ჸͅౡ݂޻̟ᆤட‫ڭ‬เ޻̝͆ခથଡ᢮޻य़ࢅ࿫ჸ̝ࢣຎᅧᅀ࿫ჸͅRI
ҮӦҲ̷̝ຍ࿿ે‫ڲ‬ҮӦҲ̷̝ज഻ࡀ࠰ҮӦҲ̷̝ӂҗҹҢ̡ӝҨ̷Ҵ̡ҮӦҲ̷͆ѣ6࿫ჸ౒ќ਻ୟ཈ьє̞̜ѳє̝န౗27໪๘рѾ‫ޓ‬࿫ૄࣟѠѽҀ࠽ॻ࿌тय़ࢅ࿫ჸсంєѠ‫ގ‬ಈъҁ̝ॶ੔Ѥຠအय़ࢅ࿫ѝ࿸ిѣ࠴࿤य़ࢅ࿫сߋຍьћйҀ̞̜32్ࡉѠ໛ѿ̝ҥӁӓ‫ڮ‬ᆒ̟਻ౡ‫ڮ‬ᆒ๸ѣ‫޻ڮ‬य़ࢅѣకืѤჭ޳ѳьф̝ђльєय़ࢅ௢ࢴѣဦ݂Ѡവ‫ܥ‬юѮф̝န౗34໪7ॉѠѤంєџ೏௰‫ރ‬ဩспшџ҄ҁє̞ລೖౖсзѿрљᆤடѝљџсҀय़ࢅ҇కѶҀ͑ౡა‫޻ݏ‬य़ࢅᆛ‫͒ڱ‬пѽѨ͑಑ൿ‫ڮ‬ᆒय़ࢅᆛ‫̝͒ڱ‬ਈѣय़ࢅ஄౗ૉࣅѹ࠴࿤य़ࢅ࿫҇ࠟѵ͑ӊӠҫҚҢһय़ࢅҮӦҲ̷͒ဗѨѠय़ࢅયಈ̡ࡀ࠰‫ۦ‬ᅀѣєѶѣ͑ࢣຎᅧᅀҮӦҲ̷͒ѝйл3य़ࢅᆛ‫ڱ‬пѽѨ3ҮӦҲ̷рѾџҀ5ႏදѣ೏௰ള౒ѝџѿ̝य़ࢅ๸сకѶѾҁћйҀ ¢㸫㸫クㄿ ἕ۰ٛકᮾ᳣ཀᗅⰩ
౪༔ゝゝә౫ ㅤギザサザ౫ㅥ
4ॉ34໙

്212‫ݸ‬ᅬૉ‫ݶ‬Ѡпйћ̝೴৾‫޻ڮ‬य़ࢅ୹ಈᅶс஢໢5ॉ 2໙೴৾‫޻ڮ‬य़ࢅ୹‫ގ‬ಈ୹ේѠઆ੟‫ڋ‬ᇚࢲ଩̝࿲୹ේѠ໸ಗৗ໐ࢲ଩଱ໟ
໎૔૱߶य़ࢅ࿫ჸࢲ଩Ѡ౹ಗ̜उ̝൑শඕ࿎̝৹ࢳ௹࿎̝ആ࠰඙ߺय़
ࢅ࿫ჸࢲ଩Ѡ෦ಗᆃઃ̝с҈य़ࢅ࿫ჸࢲ଩Ѡ‫ڔ‬൦াဲ̝ძ໋ࡠඎ̝ఘ
ᆭ‫ڭ‬เ޻य़ࢅ࿫ჸࢲ଩Ѡ஫ႏ̜ᄕ̝໩സ‫޻ڮ‬य़ࢅ࿫ჸࢲ଩Ѡ਩຀࠯‫ڵ‬
҇ໟა

7ॉ27໙

ആ࠰඙ߺय़ࢅ࿫ჸࢲ଩Ѡ‫ࡶ٭‬෦ฮഉ҇ໟა8ॉ 2໙࿲୹ේѠ஛ใ๦ଡ଼࿎ࢲ଩଱ໟͅంໟ͆౪༔ㄻク౫ ㅤギザザキ౫ㅥ
4ॉ 5໙

്2‫ݸ‬೴৾‫޻ڮ‬य़ࢅ୹୤ࡇҮӒҽ̷૳યࣟͅ൙ધဍ݂ӎ̷Ӟ͆5ॉ 2໙с҈य़ࢅ࿫ჸࢲ଩Ѡ৹๦სପ̝ᇌഡ̜ᄈ҇ໟა

22ॉ21໙

്2‫ݸ‬ସࡇҮӒҽ̷૳યࣟͅ൙‫ݏڮ‬ൌ޻ C52৭ࡠ૭͆

22ॉ38໙ ͑ࣟ൙‫ݏڮ‬ൌ޻೴৾‫޻ڮ‬य़ࢅ୹໪၈ Vol.2ͅ2:9:͆͒҇཈৫༖࿌౪༔ㄻグ౫ ㅤギザザギ౫ㅥ
3ॉ38໙

്3‫ݸ‬୤ࡇҮӒҽ̷૳યࣟͅ൙ધဍ݂ӎ̷Ӟ͆:ॉ 2໙࿲୹ේѠძ໋ࡠඎࢲ଩଱ໟͅంໟ͆

21ॉ23໙

്3‫ݸ‬ସࡇҮӒҽ̷૳યࣟͅ൙‫ݏڮ‬ൌ޻ C52৭ࡠ૭͆౪༔ㄻケ౫ ㅤギザザク౫ㅥ
2ॉ 2໙໎૔૱߶य़ࢅ࿫ჸࢲ଩Ѡ຿ใ्ઃ̝஫‫̜گ‬໡҇ໟა

4ॉ 2໙

്4‫ݸ‬୤ࡇҮӒҽ̷૳યࣟͅ൙ધဍ݂ӎ̷Ӟ͆

5ॉ 2໙

്3ൊ୹ේѠઆ੟‫ڋ‬ᇚࢲ଩ͅ਻ໟ̝͆࿲୹ේѠ஛ใ๦ଡ଼࿎ࢲ଩ͅတ
ໟ̝͆ძ໋ࡠඎࢲ଩଱ໟͅ਻ໟ͆

21ॉ 2໙ ఘᆭ‫ڭ‬เ޻य़ࢅ࿫ჸࢲ଩Ѡ৹ࢳেன҇ໟა
21ॉ42໙

്4‫ݸ‬ସࡇҮӒҽ̷૳યࣟͅ൙‫ݏڮ‬ൌ޻ C52৭ࡠ૭͆౪༔ㄻゲ౫ ㅤギザザグ౫ㅥ
3ॉ39໙

്5‫ݸ‬୤ࡇҮӒҽ̷૳યࣟͅ൙ધဍ݂ӎ̷Ӟ͆

22ॉ 7໙ ്5‫ݸ‬ସࡇҮӒҽ̷૳યࣟͅ൙‫ݏڮ‬ൌ޻ C52৭ࡠ૭͆౪༔ㄻコ౫ ㅤギザザケ౫ㅥ
3ॉ38໙

്6‫ݸ‬୤ࡇҮӒҽ̷૳યࣟͅ൙ધဍ݂ӎ̷Ӟ͆

21ॉ3:໙

്6‫ݸ‬ସࡇҮӒҽ̷૳યࣟͅ൙‫ݏڮ‬ൌ޻ C52৭ࡠ૭͆౪༔ㄻゴ౫ ㅤギザザゲ౫ㅥ
3ॉ37໙

്7‫ݸ‬୤ࡇҮӒҽ̷૳યࣟͅ൙ધဍ݂ӎ̷Ӟ͆㸫㸫

5ॉ 2໙

്4ൊ୹ේѠఄႏᣨနࢲ଩ͅంໟ̝͆࿲୹ේѠძ໋ࡠඎࢲ଩ͅ਻ໟ̝͆
౧ಗਅઃࢲ଩ͅంໟ͆଱ໟ
࠱ೊ‫޻ݏڮ‬य़ࢅ࿫ჸࢲ଩Ѡ౹ಗࡠႮ̝ఘᆭ‫ڭ‬เ޻य़ࢅ࿫ჸࢲ଩Ѡࡶ९ѝѴથ̝໎૔૱߶य़ࢅ࿫ჸࢲ଩Ѡె‫̜گ‬క҇ໟა22ॉ29໙

്7‫ݸ‬ସࡇҮӒҽ̷૳યࣟͅ൙‫ݏڮ‬ൌ޻ C52৭ࡠ૭͆౪༔ㄻサ౫ ㅤギザザコ౫ㅥ
4ॉ21໙

്8‫ݸ‬୤ࡇҮӒҽ̷૳યࣟͅ൙ધဍ݂ӎ̷Ӟ͆

5ॉ 2໙

്5ൊ୹ේѠఄႏᣨနࢲ଩଱ໟͅ਻ໟ̝͆࿲୹ේѠძ໋ࡠඎࢲ଩ͅ਻
ໟ̝͆౧ಗਅઃࢲ଩ͅ਻ໟ͆଱ໟ

7ॉ 2໙࠱ೊ‫޻ݏڮ‬य़ࢅ࿫ჸࢲ଩Ѡ຀ಗাઃᇥ҇ໟა

23ॉ25໙

്8‫ݸ‬ସࡇҮӒҽ̷૳યࣟͅ൙‫ݏڮ‬ൌ޻ C52৭ࡠ૭͆౪༔ㄻザ౫ ㅤギザザゴ౫ㅥ
4ॉ 3໙

്9‫ݸ‬୤ࡇҮӒҽ̷૳યࣟͅ൙ધဍ݂ӎ̷Ӟ͆

5ॉ 2໙

്6ൊ୹ේѠఄႏᣨနࢲ଩ͅ਻ໟ̝͆࿲୹ේѠძ໋ࡠඎࢲ଩ͅ਻ໟ̝͆
౧ಗਅઃࢲ଩ͅ਻ໟ͆଱ໟ

22ॉ 2໙ ്9‫ݸ‬ସࡇҮӒҽ̷૳યࣟͅ൙‫ݏڮ‬ൌ޻ C52৭ࡠ૭͆౪༔ギキ౫ ㅤギザザサ౫ㅥ
4ॉ 9໙്:‫ݸ‬୤ࡇҮӒҽ̷૳યࣟͅ൙ધဍ݂ӎ̷Ӟ͆

5ॉ 2໙

്7ൊ୹ේѠძ໋ࡠඎࢲ଩ͅంໟ͆
̝࿲୹ේѠஎใஷজࢲ଩଱ໟͅంໟ͆

22ॉ39໙

്:‫ݸ‬ସࡇҮӒҽ̷૳યࣟͅ൙‫ݏڮ‬ൌ޻ C52৭ࡠ૭͆౪༔ギギ౫ ㅤギザザザ౫ㅥ
4ॉ25໙

്21‫ݸ‬୤ࡇҮӒҽ̷૳યࣟͅ൙ધဍ݂ӎ̷Ӟ͆

6ॉ34໙

ࣟ൙‫ݏڮ‬ൌ޻೴৾‫޻ڮ‬य़ࢅ୹21ଯ໪ࡌ໫৫ૉѣ‫਺ގ‬ࣟͅ൙ધဍ݂ӎ̷Ӟ͆

21ॉ34໙

്21‫ݸ‬ସࡇҮӒҽ̷૳યࣟͅ൙‫ݏڮ‬ൌ޻ C52৭ࡠ૭͆

23ॉ 2໙ ͑ࣟ൙‫ݏڮ‬ൌ޻೴৾‫޻ڮ‬य़ࢅ୹‫ގ‬ಈ21ଯ໪ࡌ໫ૂ͒ѣߪ৫౪༔ギク౫ ㅤクキキキ౫ㅥ
4ॉ 6໙്22‫ݸ‬୤ࡇҮӒҽ̷૳યࣟͅ൙ધဍ݂ӎ̷Ӟ͆

5ॉ 2໙

്8ൊ୹ේѠਘ౧̜ᔾࢲ଩ͅంໟ͆
̝࿲୹ේѠஎใஷজࢲ଩଱ໟͅ਻ໟ͆

6ॉ 2໙໩സ‫޻ڮ‬य़ࢅ࿫ჸࢲ଩Ѡච௒̜ီ̝с҈य़ࢅ࿫ჸࢲ଩Ѡ࠯ത‫ڵ‬ᇥ҇ໟ
ა

8ॉ 2໙

ആ࠰඙ߺय़ࢅ࿫ჸࢲ଩Ѡ‫ڔ‬ಗᒽຘ҇ໟა21ॉ39໙

്22‫ݸ‬ସࡇҮӒҽ̷૳યࣟͅ൙‫ݏڮ‬ൌ޻ C52৭ࡠ૭͆౪༔ギグ౫ ㅤクキキギ౫ㅥ
4ॉ22໙

്23‫ݸ‬୤ࡇҮӒҽ̷૳યࣟͅ൙ધဍ݂ӎ̷Ӟ͆5ॉ 2໙࿲୹ේѠ৹ࢳत૔ࢲ଩ͅంໟ͆с଱ໟ㸫㸫22ॉ21໙്23‫ݸ‬ସࡇҮӒҽ̷૳યࣟͅ൙‫ݏڮ‬ൌ޻ C52৭ࡠ૭͆౪༔ギケ౫ ㅤクキキク౫ㅥ
4ॉ 4໙

്24‫ݸ‬୤ࡇҮӒҽ̷૳યࣟͅ൙ધဍ݂ӎ̷Ӟ͆

5ॉ 2໙

്9ൊ୹ේѠ౧ಗਅઃࢲ଩ͅంໟ̝͆࿲୹ේѠ஫‫̜گ‬໡ࢲ଩ͅంໟ̝͆
ඩಗଷனࢲ଩ͅంໟ͆с଱ໟ5ॉ 2໙ӂҗҹҢ ¦ ӝҨ̷Ҵ ¦ ҮӦҲ̷с೴৾‫޻ڮ‬य़ࢅ୹ѣ݁࿫೏௰ѝџҀ22ॉ 3໙ ്24‫ݸ‬ସࡇҮӒҽ̷૳યࣟͅ൙‫ݏڮ‬ൌ޻ C52৭ࡠ૭͆౪༔ギゲ౫ ㅤクキキグ౫ㅥ
2ॉ 2໙୍ᅗѣ8࿫ჸ౒рѾ6࿫ჸ౒ͅ੎ၙ‫޻ڮ‬य़ࢅ࿫ჸ̡಑క‫ڮ‬ᆒय़ࢅ࿫ჸ̡
ఘᆭ‫ڭ‬เ޻य़ࢅ࿫ჸ̡ခથଡ᢮޻य़ࢅ࿫ჸ̡ࢣຎय़ࢅ࿫ჸ͆ѭ೏௰҇
‫ރ‬ဩ

4ॉ 3໙

്25‫ݸ‬ધჂ঱‫ގ‬ҮӒҽ̷૳યࣟͅ൙ધဍ݂ӎ̷Ӟ͆

21ॉ37໙

്26‫ݸ‬ધჂ঱‫ގ‬ҮӒҽ̷૳યࣟͅ൙ધဍ݂ӎ̷Ӟ͆౪༔ギコ౫ ㅤクキキケ౫ㅥ
3ॉ32໙

്25‫ݸ‬य़ࢅҮӒҽ̷૳યࣟͅ൙‫ݏڮ‬ൌ޻ C52৭ࡠ૭͆

5ॉ 2໙

്:ൊ୹ේѠઆႏ̜൦ࢲ଩ͅంໟ̝͆࿲୹ේѠ஫‫̜گ‬໡ࢲ଩ͅ਻ໟ̝͆
ඩಗଷனࢲ଩ͅ਻ໟ͆с଱ໟ5ॉ 2໙࠴࿤य़ࢅ࿫ჸ͑ྂ࿝ఊࣚ޻य़ࢅ࿫ჸͅӁӃӞҹҖҬӈҔ̷ӑ͆͒҇‫ގ‬ಈ̝࿫ჸ౾ໟଅѠ౹੟̜িࡱ‫ࢲۀ‬଩҇ໟა

7ॉ 2໙࠴࿤य़ࢅ࿫ჸ͑ҲҠҨҬय़ࢅ࿫ჸͅয়຃ౄ͆͒҇‫ގ‬ಈ̝࿫ჸ౾ໟଅѠ௹ಗ৹߳ࢲ଩҇ໟა:ॉ 2໙

്21ൊ୹ේѠ஫‫̜گ‬໡ࢲ଩ͅంໟ̝͆࿲୹ේѠඩಗଷனࢲ଩ͅ਻ໟ͆
с଱ໟ

21ॉ34໙

്27‫ݸ‬ધჂ঱‫ގ‬ҮӒҽ̷૳યࣟͅ൙ધဍ݂ӎ̷Ӟ͆

23ॉ 2໙ ຠအय़ࢅ࿫ჸ͑ࠅࢪ९ౖા޳ྐྵ഻य़ࢅ࿫ჸ͒҇‫ގ‬ಈ̝࿫ჸ౾ໟଅѠ਩̴ძ‫ڵ‬໲ࡱ‫ࢲۀ‬଩҇ໟა౪༔ギゴ౫ ㅤクキキゲ౫ㅥ
3ॉ37໙

്26‫ݸ‬य़ࢅҮӒҽ̷૳યࣟͅ൙‫ݏڮ‬ൌ޻ C52৭ࡠ૭͆5ॉ 2໙

്22ൊ୹ේѠ஫‫̜گ‬໡ࢲ଩ͅ਻ໟ̝͆࿲୹ේѠඩಗଷனࢲ଩ͅ਻ໟ̝͆
ච௒̜ီࢲ଩ͅంໟ͆с଱ໟ

21ॉ33໙

്28‫ݸ‬ધჂ঱‫ގ‬ҮӒҽ̷૳યࣟͅ൙ધဍ݂ӎ̷Ӟ͆౪༔ギサ౫ ㅤクキキコ౫ㅥ
3ॉ29໙

്27‫ݸ‬य़ࢅҮӒҽ̷૳યࣟͅ൙‫ݏڮ‬ൌ޻ྐྵ‫ۈ‬ంࠜ23‫ޏ‬ൌ‫ࡣݶ‬૭͆

5ॉ29໙

೴৾‫޻ڮ‬य़ࢅ୹̝ᆤடय़ࢅ๮рѾ࠱ೊय़ࢅ๮ѭ‫ڥ‬฽

21ॉ32໙

്29‫ݸ‬ધჂ঱‫ގ‬ҮӒҽ̷૳યࣟͅ൙ધဍ݂ӎ̷Ӟ͆㸫㸫౪༔ギザ౫ ㅤクキキゴ౫ㅥ
3ॉ 4໙

്28‫ݸ‬य़ࢅҮӒҽ̷૳યࣟͅ൙‫ݏڮ‬ൌ޻ྐྵ‫ۈ‬ంࠜ23‫ޏ‬ൌ‫ࡣݶ‬૭͆

21ॉ 7໙ ്2:‫ݸ‬ધჂ঱‫ގ‬ҮӒҽ̷ࣟͅ൙ધဍ݂ӎ̷Ӟ͆౪༔クキ౫ ㅤクキキサ౫ㅥ2ॉ 2໙ࠅࢪ९ౖા޳ྐྵ഻य़ࢅ࿫ჸѣൊྴଅ҇ဦ৐̝ൊྴଅѠ਩̴ძ̜ᄽࢲ଩
҇ໟა

3ॉ 3໙

്29‫ݸ‬य़ࢅҮӒҽ̷૳યࣟͅ൙‫ݏڮ‬ൌ޻ྐྵ‫ۈ‬ంࠜ23‫ޏ‬ൌ‫ࡣݶ‬૭͆

5ॉ 2໙

്23ൊ୹ේѠ‫ڔ‬൦াဲࢲ଩ͅంໟ̝͆࿲୹ේѠච௒̜ီࢲ଩ͅ਻ໟ̝͆
ᄖౄෟࡶࢲ଩ͅంໟ͆с଱ໟ

21ॉ29໙

്31‫ݸ‬ધჂ঱‫ގ‬ҮӒҽ̷૳યࣟͅ൙ધဍ݂ӎ̷Ӟ͆౪༔クギ౫ ㅤクキキザ౫ㅥ
3ॉ 8໙

്2:‫ݸ‬य़ࢅҮӒҽ̷૳યࣟͅ൙‫ݏڮ‬ൌ޻ྐྵ‫ۈ‬ంࠜ23‫ޏ‬ൌ‫ࡣݶ‬૭͆

5ॉ 2໙

്24ൊ୹ේѠ‫ڔ‬൦াဲࢲ଩ͅ਻ໟ̝͆࿲୹ේѠච௒̜ီࢲ଩ͅ਻ໟ̝͆
ᄖౄෟࡶࢲ଩ͅ਻ໟ͆с଱ໟ

6ॉ27໙

೴৾‫޻ڮ‬य़ࢅ୹‫ގ‬ಈ31ଯ໪ࡌ໫৫ૉ҇૳ય
31ଯ໪ࡌ໫৭‫ࣟͅݶܐ‬൙‫ݏڮ‬ൌ޻ྐྵ‫ۈ‬ంࠜ23‫ޏ‬ൌ‫ࡣݶ‬૭͆

21ॉ 4໙ ്32‫ݸ‬ધჂ঱‫ގ‬ҮӒҽ̷૳યࣟͅ൙ધဍ݂ӎ̷Ӟ͆
22ॉ41໙ ͑31ଯ໪ࡌ໫ૂ͒ѣ཈৫౪༔クク౫ ㅤクキギキ౫ㅥ
3ॉ 6໙

്31‫ݸ‬य़ࢅҮӒҽ̷૳યࣟͅ൙‫ݏڮ‬ൌ޻ྐྵ‫ۈ‬ంࠜ23‫ޏ‬ൌ‫ࡣݶ‬૭͆

5ॉ 2໙

്25ൊ୹ේѠච௒̜ီࢲ଩ͅంໟ̝͆࿲୹ේѠᄖౄෟࡶࢲ଩ͅ਻ໟ͆
с଱ໟ

21ॉ34໙

്33‫ݸ‬ધჂ঱‫ގ‬ҮӒҽ̷૳યࣟͅ൙ધဍ݂ӎ̷Ӟ͆౪༔クグ౫ ㅤクキギギ౫ㅥ
3ॉ 5໙

്32‫ݸ‬य़ࢅҮӒҽ̷૳યࣟͅ൙‫ݏڮ‬ൌ޻ྐྵ‫ۈ‬ంࠜ23‫ޏ‬ൌ‫ࡣݶ‬૭͆5ॉ 2໙಑క‫ڮ‬ᆒय़ࢅ࿫ჸѠච຿౞ࡠࢲ଩҇ໟა7ॉ 2໙೏௰ѣ‫ރ‬ဩ21ॉ 9໙ ്34‫ݸ‬ધჂ঱‫ގ‬ҮӒҽ̷૳યࣟͅ൙ધဍ݂ӎ̷Ӟ͆౪༔クケ౫ ㅤクキギク౫ㅥ
3ॉ21໙

്33‫ݸ‬य़ࢅҮӒҽ̷૳યࣟͅ൙‫ݏڮ‬ൌ޻ྐྵ‫ۈ‬ంࠜ23‫ޏ‬ൌ‫ࡣݶ‬૭͆

21ॉ24໙

്35‫ݸ‬ધჂ঱‫ގ‬ҮӒҽ̷૳યࣟͅ൙ધဍ݂ӎ̷Ӟ͆౪༔クゲ౫ ㅤクキギグ౫ㅥ
3ॉ 9໙

്34‫ݸ‬य़ࢅҮӒҽ̷૳યࣟͅ൙‫ݏڮ‬ൌ޻࠱ೊय़ࢅ๮3‫ࡣݶޏ‬૭͆

5ॉ 2໙

്26ൊ୹ේѠඩಗଷனࢲ଩ͅంໟ̝͆࿲୹ේѠᄖౄෟࡶࢲ଩ͅ਻ໟ͆
с଱ໟ

21ॉ2:໙

്36‫ݸ‬ધჂ঱‫ގ‬ҮӒҽ̷૳યͅၿᎣంဎ31‫ޏ‬ӎ̷Ӟ͆㸫㸫౪༔クコ౫ ㅤクキギケ౫ㅥ
3ॉ 8໙

്35‫ݸ‬य़ࢅҮӒҽ̷૳યࣟͅ൙‫ݏڮ‬ൌ޻࠱ೊय़ࢅ๮3‫ࡣݶޏ‬૭͆5ॉ 2໙ခથଡ᢮य़ࢅခჿѠ౹‫ޣ‬ᄈఘࢲ଩с଱ໟ5ॉ 2໙࠴࿤ࢅ࿫͑಑౒ခથ௴ᆎ‫޻ݏ‬य़ࢅ࿫͒҇‫ގ‬ಈͅय़ࢅൊྴଅ̜ॾ‫ݍ‬ൌᄣࢲ଩͆21ॉ29໙

്37‫ݸ‬ધჂ঱‫ގ‬ҮӒҽ̷૳યͅၿᎣంဎ31‫ޏ‬ӎ̷Ӟ͆౪༔クゴ౫ ㅤクキギゲ౫ㅥ
3ॉ 7໙

്36‫ݸ‬य़ࢅҮӒҽ̷૳યࣟͅ൙‫ݏڮ‬ൌ޻࠱ೊय़ࢅ๮3‫ࡣݶޏ‬૭͆

5ॉ 2໙

്27ൊ୹ේѠ౧ྑᣨᄖࢲ଩଱ໟͅంໟ̝͆࿲୹ේѠච຿౞ࡠࢲ଩ͅం
ໟ͆с଱ໟ

5ॉ 2໙

࠴࿤य़ࢅ࿫͑ึ಺ဦౖ඄༭૲ೖᄅ‫޻ݏ‬य़ࢅ࿫͒҇‫ގ‬ಈͅय़ࢅൊྴଅ̜
ᄖౄෟࡶ௩൜ࢲ଩͆

21ॉ28໙

്38‫ݸ‬ધჂ঱‫ގ‬ҮӒҽ̷૳યͅၿᎣంဎ31‫ޏ‬ӎ̷Ӟ͆౪༔クサ౫ ㅤクキギコ౫ㅥ
3ॉ23໙

്37‫ݸ‬य़ࢅҮӒҽ̷૳યࣟͅ൙‫ݏڮ‬ൌ޻࠱ೊय़ࢅ๮3‫ࡣݶޏ‬૭͆5ॉ 2໙੎ၙ‫޻ڮ‬य़ࢅခჿѠࠥᇱᆁ࿎ࢲ଩҇ໟა

21ॉ26໙

്39‫ݸ‬ધჂ঱‫ގ‬ҮӒҽ̷૳યͅၿᎣంဎ31‫ޏ‬ӎ̷Ӟ͆㸫㸫グㄿ ẻόࡖ ㅤ౪༔クゴ౫ಏㅥٛક⤴ٛકᲇ
⦘ᖴٛᲇগક

᭓⚘ક⤴᭓⚘કᲇ᧯ܶᲇકᮾ᳣ⲏࣕ
ո੿⃪᪝ᮾ᳣ո⦕
ẫ₰ٛકᮾ᳣ո⦕

গક⭐ٛકᮾ᳣ᲇ
গક⭐᭓⚘કᮾ᳣ᲇ
ࡖሤⴆ⃪᪝᧯ᢼᮾ᳣ո⦕
⣻Ό੿ᑿ⃆ᮾ᳣ո⦕
⣻Ό੿ტংؔᢼ
⏄᫛✤֝൧⾸ᮾ᳣ո⦕Ӟᴻٛ᪭ᮾ᳣ⲏࣕ
গકᩰ⭐‫֝⽶ף‬൧ᮾ᳣ո⦕
કገᗕ͆Ʒ⦘ᖴٛᲇগક

⦘ᖴٛᲇগક
ᕱ╀లᕡᩰ⭐

Ṥ‫֝ك‬൧ᮾ᳣ո⦕
⣻Ό੿ᩩตᮾ᳣ո⦕
⃪᪝֝൧ᮾ᳣ո⦕
‫ٸ‬ʶẫ₰ᮾ᳣ո⦕ἕ۰ٛકᮾ᳣ཀ

ɟɵɀȯȷɐᮾ᳣Ƀɻɇʀ
༦ᨪ᫢ᮾ᳣⤴
ᦹऴ‫ڤ‬ම╋╏ᩰຎᮾ᳣⤴
⾷ᣀ֌ᮾ᳣⤴
Ӟ֝ո੿Ⳓᄦᲇકᮾ᳣⤴
⾷૙⭂ᮾ᳣⤴
ঙᠬংම⏄᫛✤‫ׅ‬⍗ᲇકᮾ᳣⤴
⾷૙⭂ᮾ᳣⤴

Ȳʀɟɻɱɤ

ӽ۴֐᧸Ƀɻɇʀ
ؔᢼᶩᥴૅყଙἠયӴᶩᥴૅ
ᑿࠔᶩᥴૅ
ᩰᥴẻόૅ
̗‫ؘ‬ୋ

ᮾ᳣ဝ⢳⤴

㸫㸫

ᮾ᳣ဝ⢳☁
⾷ἕ۰ٛકᮾ᳣ཀྒഝ⾸ケㄿ ⁬‫ݲ‬۵᷽ ㅤ౪༔クゴ౫ಏㅥ
୹̜ේ

౧ྑ̜ᣨᄖ

࿲୹ේ

ච຿̜౞ࡠ

ƛ᧯ܶᲇકᮾ᳣ⲏࣕDepartment of Life Scienceᆛ‫ڱ‬ේ̡ࢲ଩

౹‫̜ޣ‬ᄈఘ

௩൜ࢲ଩

ච௒̜̜ီ

Ʒո੿⃪᪝ᮾ᳣ո⦕ƷDivision of Molecular Oncology and Virologyࢲ̜଩౹‫̜ޣ‬ᄈఘ

ຠໟࢲ଩

ใඩ̜ᔣથ

य़ࢅ‫ۀ‬

൧ჿ̜ࡍഌ

௩൜ૉჄ‫ۀ‬ၿಗ̜ᅊથƷẫ₰ٛકᮾ᳣ո⦕ƷDivision of Cell Medicine৭̜નࡻ‫̜̜܂‬Ⴞ

৭̜ન

൮শ̜̜ఊ

Ʒ⃪᪝᧯ᢼᮾ᳣ո⦕ƷDivision of Tumor Biology
୩ࢲ଩

ഥใ̜ᆁ۸

Ʒ⣻Ό੿ᑿ⃆ᮾ᳣ո⦕ƷDivision of Molecular and Cell Biology
஄̜ଛ

ඩഡ̜ᄜ৸

Ʒ⣻Ό੿ტংؔᢼ⾷⏄᫛✤֝൧⾸ᮾ᳣ո⦕ƷDivision of Protein Regulation Research
୩ࢲ଩

ใ੟̜ᆁઞ

ƛӞᴻٛ᪭ᮾ᳣ⲏࣕƷDepartment of Advanced Medicineᆛ‫ڱ‬ේ̡ࢲ଩

ච຿̜౞ࡠ

௩൜ࢲ଩

ᄖౄ̜ෟࡶ

Ʒ‫֝⽶ף‬൧ᮾ᳣ո⦕ƷDivision of Aging Researchຠໟࢲ଩ͅတ΁͆

ܱ੟̜ୢᇚ

୩ࢲ଩

๦੟̜ქ࿎

஄̜ଛ

આႏ̜೶થ

̜Ṥ‫֝ك‬൧ᮾ᳣ո⦕Division of AGEs Research (Advanced Glycation End-products Research)
ࢲ̜଩

ච຿̜౞ࡠ

஄̜ࢲ

௒ใ̜ඬઝ

஄̜ࢲ

ℛใ̜ട௹

ຠซ஄ࢲ

ࡴ‫̜گ‬٪ࡉથ

࡚ୠ‫ۀ‬

આ̜ࠠᄤથ
㸫㸫

Ʒ⣻Ό੿ᩩตᮾ᳣ո⦕ƷDivision of Genomic Medicine୩ࢲ଩ం‫گ‬ใ̜ᅆ

஄̜ࢲ

ྑ੟̜̜ଚ

࡚ୠ‫ͅۀ‬တ΁͆৹౎̜‫܀‬થƷ⃪᪝֝൧ᮾ᳣ո⦕ƷDivision of Cancer Therapeutics
ࢲ̜଩ͅတ΁͆८ᄩ̜ᆖ૔Ʒ‫ٸ‬ʶẫ₰ᮾ᳣ո⦕ƷDivision of Single Cell Research
͘
̜͘

͘
͘
̜̜

ƛɟɵɀȯȷɐᮾ᳣ɃɻɇʀƷProject Research CenterҮӦҲ̷ේ̡ࢲ଩ͅတ΁͆ ရ೙̜ଷఘ̜̜̜̜̜
Ʒ༦ᨪ᫢ᮾ᳣⤴ƷDivision of Innovative Research୩ࢲ଩ͅတ΁͆౧௟̜રથӐҬһ̡ҼҢҲ̷஫ใ̜ৃࡶຠซ࡚ୠ‫ۀ‬ච຿̜রञƷᦹऴ‫ڤ‬ම╋╏ᩰຎᮾ᳣⤴ƷDivision of Vision Research for Environmental Healthࢲ̜଩ͅတ΁͆਩̴ძ̜ᄽࢲ̜଩ͅတ΁͆஛๦̜౞ྗ஄̜ࢲͅတ΁͆୸ਖ਼̜ຽ෦થ

ƷӞ֝ո੿Ⳓᄦᲇકᮾ᳣⤴ƷDivision of Anticipatory Molecular Food Science and Technologyࢲ̜଩ͅတ΁͆ॾ‫̜ݍ‬ൌᄣ

୩ࢲ଩ͅတ΁͆ࣟ—̜गഉ୩ࢲ଩ͅတ΁͆

ၿใ̜ରে

ຠซ஄ଛ

Seon Myeong Lee

ຠซ஄ଛ

ય̜̜̜ఄ

Ʒঙᠬংම⏄᫛✤‫ׅ‬⍗ᲇકᮾ᳣⤴ƷDivision of Systems Bioscience for Drug Discovery௩൜ࢲ଩ͅတ͆

ᄖౄ̜ෟࡶࢲ̜଩ͅတ͆

౹‫̜ޣ‬ᄈఘ

୩ࢲ଩ͅတ͆

๦੟̜ქ࿎ƛӽ۴֐᧸ɃɻɇʀƷResearch Support CenterҮӦҲ̷ේ̡ࢲ଩ͅတ͆ ౹‫̜ޣ‬ᄈఘ
௩൜ࢲ଩

ඩಗ̜ଷன

Ʒؔᢼᶩᥴૅ̜2I¿FHIRU$QLPDO5HVRXUFHVࢲ̜଩ͅတ΁͆ඩഡ̜̜৏୩ࢲ଩ͅတ͆ใ੟̜ᆁઞ㸫㸫ଘໟ࡚ୠ‫ۀ‬৪‫৻̜گ‬઩

࡚໸‫ۀ‬

ၿჿ̜୤ପ

࡚໸‫ۀ‬

ࡧႏ̜۰૔

࡚໸‫ۀ‬

෌આ̜ୢ৫

࡚໸‫ۀ‬

ಝ̜̜එᅱ

ƷყଙἠયӴᶩᥴૅƷ5DGLDWLRQ6DIHW\2I¿FHࢲ̜଩ͅတ͆

౹‫̜ޣ‬ᄈఘ

৭̜નͅတ͆

൮শ̜̜ఊƷᑿࠔᶩᥴૅƷ2I¿FHIRU5HVHDUFK(TXLSPHQWDQG5HVRXUFHVࢲ̜଩ͅတ͆

౹‫̜ ޣ‬ᄈఘ৭̜નͅတ΁͆ഡ௒̜̜޻৭̜નͅတ͆

ࡻ‫̜̜܂‬Ⴞ৭̜નͅတ͆

൮শ̜̜ఊ஄̜ࢲͅတ͆

௒ใ̜ඬઝ஄̜ࢲͅတ͆

ℛใ̜ട௹

஄̜ଛͅတ͆

ඩഡ̜ᄜ৸ଘໟ࡚ୠ‫ۀ‬ච९̜வბ௩൜ૉჄ‫ͅۀ‬တ͆ၿಗ̜ᅊથƷᩰᥴẻόૅƷHistology Laboratoryࢲ̜଩ͅတ͆

౹‫̜ޣ‬ᄈఘ

࡚໸‫ۀ‬

໐ࡻ̜۸ბ

࡚ୠ‫ͅۀ‬တ͆આ̜ࠠᄤથ̜̜̜̜̜̜̜̜̜̜̜̜̜̜̜̜̜
ƛᮾ᳣ဝ⢳☁⾷ἕ۰ٛકᮾ᳣ཀྒഝ⾸
‫̜ݢ‬ේ

ਖ਼८̜ఙ઩

ૉჄ‫ۀ‬

આႏ̜ྗ࠯઱

ૉჄ‫ۀ‬

ൌ೙̜೶ྗ

ૉჄ‫ۀ‬

ၿഡ̜ᄔથ

ͅတ΁̜͆‫޻ڮ‬࿫̡ࠈধ޻࿫๸сႏჄќय़ࢅ୹တໟ㸫  㸫

㇐㇎㇏㇓౫ಏㄻᮾ᳣ᘍؔ

ᮾ᳣☁Ⲥʶ╒̜ခჿ჏̜̜઴̜̜჏!

̜̜̜̜̜̜̜̜य़!ࢅ!‫!ݢ‬൏̜

Ǉ᧯ܶᲇકᮾ᳣ⲏࣕǈո੿⃪᪝ᮾ᳣ո⦕
̜̜౹‫̜ޣ‬ᄈఘRNA ॆ৾‫ہ‬થ Y25ѣࡀ໸‫ݷ‬౸̜̜ใඩ̜ᔣથ

૜ঃ৊ളс‫ݵ‬੔юҀკ‫ౖ۽‬ఋफ૱߶ѣఒඊӑ̷Ҟ̷ѣ‫ގ‬཈ѝ཈ஶྐྵ഻Ѡ࠙юҀग़ກ

̜̜ච௒̜̜ီ

਻ࢺ߷ಠஶӈӜӆҙҗӞҬ߷ಠѠпцҀവ‫ܥ‬ѝჵ൏฿̢ఋफ௺ୀౖ
Ѡљйћ̜̜൧ჿ̜ࡍഌ

EJC ҇৔౗юҀ‫ہ‬થѣ੎ၙ຿ࣆ੔‫ݷ‬౸ẫ₰ٛકᮾ᳣ո⦕
̜̜ࡻ‫̜̜܂‬Ⴞ

5༗ള XP ੎ၙѣପᅶпѽѨ઺‫ޓ‬ಧ߷ଦౖ̜̜൮শ̜̜ఊ

ҽҴӘӜӞҠӜ̷T ӝӦӄଡ੎ၙѠпцҀҮӜӒҼ‫ږ‬ഝౖ੎ၙળᄥ
ຐࡀ৔ѣ‫ݷ‬ბ⃪᪝᧯ᢼᮾ᳣ո⦕
̜̜ഥใ̜ᆁ۸

ఊޮౡ࿿ѠпцҀ RhoGDI ѣᄃ߇⣻Ό੿ᑿ⃆ᮾ᳣ո⦕
̜̜ඩഡ̜ᄜ৸

Ӆһଡ᢮ѠпцҀ RNA ॆ৾‫ہ‬થѣ཈ॶ‫ݷ‬౸⣻Ό੿ტংؔᢼ ㅤ⏄᫛✤֝൧ㅥ ᮾ᳣ո⦕̜̜ใ੟̜ᆁઞ

2̠UBR5/p711-HPV27 E8ೱঘ੣ᅀѠѽҀ཈с҈ӔҞҾҭӓ
3̠D-ribose ᄥຐള EdAP ѠѽҀ໙ႏ໹ܑҙҗӞҬ࿸౦೒‫ޕ‬

ǇӞᴻٛ᪭ᮾ᳣ⲏࣕǈ‫֝⽶ף‬൧ᮾ᳣ո⦕
̜̜ܱ੟̜ୢᇚ

ҮӜӒҼ̺ҬӈҖӦҧӒқӝӦͅSM͆ӃӜӦҬ҇Ҳ̷ҥҶһѠь
єଡ᢮ౖқҢҰҰ̷ӓ౒টѠѽҀ໎૔ౖ༭ेྐྵѠവюҀంࡋ૔ᆒၔ
ѣ‫ގ‬཈̜̜๦੟̜ქ࿎

ࠣߵ੎ၙѝ੎ၙ୸࠽݂Ѡࢣ෭юҀခથࡀ৔ѣ‫ݷ‬ბѝ੎ၙ‫ޓ‬஛ၙѣ‫ݑ‬єюᄃ߇ѣ‫ݷ‬ბ㸫  㸫

̜̜આႏ̜೶થ

ࠣ੎ၙѠпцҀқҢҰҰ̷ӓѣଙѿਕѴࡀ৔ѝ੎ၙ຿ຍ഻ѣ‫ݷ‬ბṤ‫֝ك‬൧ᮾ᳣ո⦕
̜̜ච຿̜౞ࡠ

ౡߋ଻߸ྐྵѣ཈ஶ̡కืѠпцҀ Toxic AGEsͅTAGE͆ѣ࠙ᄮѝђѣ೒લ̜̜௒ใ̜ඬઝ

ӜҶһ୸ൊ༘ᅋ௿ࣗ੎ၙѠпцҀ੎ၙ຿ TAGE ජ౺ѝ੎ၙௐ‫ޕ‬

̜̜ℛใ̜ട௹

Ӆһߗ݂᪴ࠊ௒༘ྂࠣᅋ੎ၙѠпцҀ TAGE ౡ౗ࡹѨ TAGE ݂඄༭૲ѣ൸੬⣻Ό੿ᩩตᮾ᳣ո⦕
̜̜ం‫گ‬ใ̜ᅆ2.̜‫ڭ‬เ޻ษग़ਯͅ‫ڭ‬เથग़ਯ̝ಠ௲ളग़ਯ͆ѣ‫ގ‬཈ѝ࿘ࡹ
3.̜Ӆһ‫ڭ‬เౖ૱߶҇ӕҺӞѝьєౡളӟӌӞѠпцҀ‫ڭ‬เથࡀ໸ѣ‫ݷ‬ბѝఒඊ̡૔ᆒѭѣ‫ܥ‬ᅀ̜̜ྑ੟̜̜ଚ

2.̜ᆤட੎ၙ‫ڭ‬เ޻ѣஃ࡚ୠѣ‫ۮ‬ഃ݂пѽѨঞबଅᅋ౗ࢲ‫ڲ‬ӊӠңӜӓѣ‫ޱ‬ᅶ
3.̜ೱঘ฽਷ဲ‫ہ‬ଅѣӝҬҢྵ݆пѽѨ्௜ૌ࢒ૌѣ݉໸ౖྵ݆ѣय़ࢅ⃪᪝֝൧ᮾ᳣ո⦕
̜̜८ᄩ̜ᆖ૔

ҝҠҨӝӊӜҴӦѣఋफ̡े‫ۼ‬຤ౖѠവюҀఘઅᅋ۰๱ѣᆤட঳‫ݑ‬ѝђѣခથࡀ৔

‫ٸ‬ʶẫ₰ᮾ᳣ո⦕
͘
̜̜̜̜͘

͘
̜͘

ƷǇɟɵɀȯȷɐᮾ᳣Ƀɻɇʀǈ̜̜ရ೙̜ଷఘ

ेࠊӀҶһӢ̷Ңज౗ѣ౒টࡀ৔ѣ‫ݷ‬ბ༦ᨪ᫢ᮾ᳣⤴
̜̜౧௟̜રથ

ീૌ࠽ҳҗҝҠҪӦࠅࢪၰᇕѣ஛ૌѣ्৆ۭࢾѠљйћѣय़ࢅ̜̜஫ใ̜ৃࡶ

ѭтඒ৹ᆽ݂ଃ‫ݶ‬ѠпцҀ௿ѣ्৆‫ڮ‬ᆒҪҬҹӓ৔ඞѠ࠙юҀय़ࢅпѽѨ໹ज഻̡ࡀ໸௝၈҇ѷійє๼৾૫෕ஶѣౡ࿿޻ษຠ෈ѣ‫ݷ‬ბ㸫  㸫

ᦹऴ‫ڤ‬ම╋╏ᩰຎᮾ᳣⤴
̜̜਩̴ძ̜ᄽ

๫࢝ไᆜ࿶๦്‫ڵ‬९થᆜ཈ไ୹ѠпцҀࣘࡽ੣ࣅ୍ૉଅѣၑ૾ಧྈѥфᆙѝరபളਣ൞཈ஶѠ࠙юҀ෕ਯ̜̜஛๦̜౞ྗ

Ӓӝ༃ᄥ཈ࠤௐ‫ޕ‬ѝҦӦҲҢһӟӦҭѣ࠙ᇍ̜̜୸ਖ਼̜ຽ෦થ

ӑӀҠӦच UV ल഑೼඙҇ᅀйєࠤ࿫ UV ྈѥфᆙѣ౗ఘѝ஛ૌѣཿ޶Ӟ֝ո੿Ⳓᄦᲇકᮾ᳣⤴
̜̜ॾ‫̜ݍ‬ൌᄣ৹๘คє҈Ѧф૲௴ѠѽҀ๻ໝྐྵఠஶѣ‫ރ‬ಸࡀஇѣ‫ݷ‬ბ̜̜

̜̜ࣟ—̜गഉ

৹๘คє҈Ѧф૲௴ѠѽҀ๻ໝྐྵఠஶѣ‫ރ‬ಸࡀஇѣ‫ݷ‬ბ̜̜ၿใ̜ରে

৹๘คє҈Ѧф૲௴ѠѽҀ๻ໝྐྵఠஶѣ‫ރ‬ಸࡀஇѣ‫ݷ‬ბঙᠬংම⏄᫛✤‫ׅ‬⍗ᲇકᮾ᳣⤴
̜̜ᄖౄ̜ෟࡶ

ೖᄅय़ࢅ‫ގ‬཈

Ǉӽ۴֐᧸Ƀɻɇʀǈ̜̜ඩಗ̜ଷன

୪ࠅ࠰૱߶ѣ‫޻۽‬य़ࢅؔᢼᶩᥴૅ̜̜ඩഡ̜৏

ҕӟӞҡ̷пѽѨ૜ঃკ‫۽‬૱߶ѣྐྵ഻‫ݷ‬ბ㸫  㸫

᧯ܶᲇકᮾ᳣ⲏࣕ

ㅽո੿⃪᪝ᮾ᳣ո⦕ㅾ
2̠य़ࢅ̜౹‫ޣ‬ᄈఘࢲ଩ѝ൧ჿय़ࢅ‫ۀ‬Ѥ̝ຠѠ RNA ॆ৾ӕҴ̷ӈ҇ૐљҲӦӄҢ૲ѣంࡋࡀ໸൸੬҇ჭફь̝ంьй‫ݷ‬౸࡚ୠѹय़ࢅଛၔѠଙѿ೏҈ќйҀ̞Һ̷Ҳӌ̷Ҭ҇ߋᅀьє૱߶ӑ̷Ҟ̷‫ڭ‬เથѣग़੬ѹҥӁӓဩେѠѽҀ‫ڭ‬เથ‫ރ‬ဦџў҇ଙѿ໛ҁ̝ଘѠӑҙҬѝ༘ᅋ੎ၙ҇ᅀйє૳६प҇ᅧᅀьћтє̞န౗38໪๘ѣय़ࢅ౗‫ݑ‬Ѥ̝౹‫ࢲޣ‬଩Ѿс‫޻ڮ‬ౡ࿿޻ไથ५ྒࢽ࡚ୠ޻
‫̝ݶ‬੎ၙౡ࿿޻‫̝ݶ‬ခથౡ࿿޻‫ݶ‬џўќ཈ྴ҇৫јћтє̞౹‫ࢲޣ‬଩сय़ࢅൊྴଅѝьћ‫޻ݏ‬य़ࢅྊ္஄ࣟͅ࠱཰ C͆҇ߋᅀьћ̝ྯษѝюҀ Y25ͅRBM9A͆ҲӦӄҢ૲ѣӝӦઓ݂‫ݷ‬౸Ѡ࠙юҀ౗‫҇ݑ‬཈ྴьћтє̞шѣᇫဍќѤ Y25ҲӦӄҢ૲ѣ PhosTag ҥӞѠѽҀӝӦઓ݂‫ݷ‬౸̝੎ၙ຿ӝӦઓ݂࿫‫ڕ‬ѣຎซѝӝӦઓ݂ѣ‫ࡠڞ‬Ѡљйћ၈ਇюҀшѝсќтєͅExp. Biol.
̞݈нћ̝ࢣຎय़ࢅѠћ8၈ѣ۸থᇫဍѝ2၈ѣᇭဍ೴ಋ҇ࢣරќ཈ྴьћ
Med. 351: 549, 3126͆
тє̞ใඩञથຠໟࢲ଩Ѥ̝ఋफ੎ၙҪҽӊҬଦᄵള҇ྯษѝюҀީଠ૜ঃ৊ളѣग़ୟप҇৔ඞь̝಻ਈஃયಈрѾѣ৊ളఒඊ‫ږ‬ᅙ҇ଦц̝ᆤடय़ࢅѠ࠙҄Ҁ:၈ѣ۸ဍᇫဍ҇ࢣරѝьћ཈ྴьє̞ѳє̝৊ NMDA ଦᄵള৊ളѣ੎ၙࡀ໸ѭѣۭࢾ҇ბѾрѠюҀєѶ̝ඩਈણ႘৒
ᅾ޻ౡѣᅪბय़ࢅ‫ۀ‬ѝఋफ੎ၙѣफ૑ษज഻ဦ݂̝ไࡃౡᅬ޻ษ‫ݷ‬౸҇৫јєͅᇫဍ୯ྐ
ඩ̞͆ѳє̝ᅪ۱ඕय़ࢅ‫ۀ‬ѝ৫јє૜ঃ৊ളѠѽҀຍ࿿ӕҺӞ੣౦ѣᇫဍсढੑѠઽјєͅTohoku J. Exp. Med. 348: 43:, 3126̞͆
3̠ࢲ‫ڲ‬
̜౹‫ࢲޣ‬଩Ѥ̝‫޻ڮ‬࿫ќ͑ౡაѣ‫̝͑͒޻ݏ‬೴৾ఘࠗ‫ڮͅ޻ݏ‬ᆒѝ ATGC̝͆͒͑‫޻ڮ‬۸থ III͒џўѣ৭ࡠ҇৫й̝‫޻ڮ‬य़ࢅ‫ݏ‬Ѡћ޻‫ڕ‬ᇫဍ௾ਯпѽѨ͑ခથౡ࿿޻໛ჸ͒҇൷๵ьє̞ѳє‫ڮ‬޻य़ࢅ‫ݏ‬ခથଡ᢮޻৭਷ѣൌ޻‫ۈ‬ౡѝьћ̝ంєѠඩਈрѾ༊౟။ऊ҇हнє̞ใඩຠໟࢲ଩
Ѥ̝‫޻ڮ‬࿫4̝5̝7໪૒ѣఋफ޻৭ࡠпѽѨൌ޻‫ۈ‬ѣᇫဍ௾ਯ҇൷๵ьє̞ѳє̝೴ಋ‫ږ‬ᅙѠ‫ܥ‬э̝ࢲ‫஀ݏ‬૪ྥѠѷ࠙҄јєͅClin. Exp. Neuroimmunol. 7: 81, 3126; ണ2:၈̞͆
4̠ࠊᅬ̡‫۫ۦ‬̜౹‫ࢲޣ‬଩Ѥ̝ၑ૾ಧଙ‫ڀ‬ଘໟଅ̝೏ߺн DNA ‫಻ڋ‬ଘໟଅѝьћީଠఈ౪ѣ஄ॹ̝௾ਯ҇৫й̝۹ౡ‫ݶۀښ‬пѽѨय़ࢅయక‫҇ࡣݶ‬ѤэѶѝюҀय़ࢅप‫ݶۀښ‬Ѡѷ‫ۀښ‬ѝьћઅ‫ݭ‬ьћтє̞ใඩຠໟࢲ଩Ѥ̝OSCE ‫ۀښݶۀښ‬ѝьћ OSCE ѣ‫۫ۦ‬пѽѨુ६ჵ൏੣౗Ѡ࠙҄јє̞
5̠ᆤட࿫ჸѝѣᇍण̜ყᅔษ‫ڭ‬เથ཈ॶ‫ݷ‬౸Ѡѽѿ IgG5࠙ᇍ૱߶ѣྐྵ഻‫ݷ‬ბѠ৮फ़ьєඩ๦ѾѣᇫဍͅPLoS ONE.
21: e1237693, 3126͆ѹ̝૒్ൊҪ̷ҤӦҨ̷҇ᅧᅀьћ಻ҥӁӓ‫ݷ‬౸҇৫јєࡧใѾѣᇫဍѠ৮फ़юҀшѝсќтєͅGenome Announc. 4: e11332, 3126̞͆ѳє̝౹‫ࢲޣ‬଩Ѥ̝‫ڭ‬เથ‫ڮ‬ᆒҮӦҲ̷ѣီࢬ‫ݶ‬Ѡઅ݈ьћ̝͑‫ڭ‬เ૱߶ѝ਻ౡ‫ڮ‬ᆒ͒ѝ൏ьєҮӒҽ̷҇৫јє̞န౗39໪Ѡ୦ীьєႏ޻ѣ਻ౡ‫ڮ‬ᆒҮӦҲ̷ќѤ̝੎ၙ݈ী૭ѹग़ਯ૭ͅ૳६૭͆ѣ৔ඞ҇৫й̝ᆤட‫ڮ‬ѣ૳६҇બ܎юҀࠅࢪњфѿ҇కѶћтє̞ใඩຠໟࢲ଩Ѥ̝ୄ3໙ѣఋफ຿‫ޓݏ‬ᅗఒᆒ҇൷๵ьє̞
6̠ଃ‫ߋݶ‬ຍ̜౹‫ࢲޣ‬଩Ѥ̝‫޻ڮ‬ౡ࿿޻ไથ५ྒࢽ࡚ୠ޻‫ݶ‬ѣᅬૉ҇ჄѶ̝ၿᅳҕҗҰһ̷ӊय़ࢅ‫ߵ̡ݶ‬ૉџў҇ჄѶћтє̞ใඩຠໟࢲ଩Ѥ̝ӄ̷ҠӦҰӦྐྵय़ࢅ‫ݶ‬ѣ్ᇮఘ҇ჄѶ̝‫ڮ‬ન‫ݶ‬ঞ܎ѣय़ࢅ‫ݶ‬ќӔҺҖҞӞҬҲҶӈ҇വொѝьћ৭‫ߋܐ‬ຍ҇৫јє̞ͅဍ౾̜౹‫̜ޣ‬ᄈఘ͆㸫  㸫

౹‫̜ޣ‬ᄈఘͅࢲ଩͆
य़ࢅ‫ݢ‬൏̢RNA ॆ৾‫ہ‬થ Y25ѣࡀ໸‫ݷ‬౸य़ࢅ‫ޘ‬ᅆ̜RNA ॆ৾ҲӦӄҢ૲࿸৾ള҇ज౗юҀ MAGOH ѝ Y25с̝ӁҶҢҳҙӦюҀшѝѠѽѿ M࠽ѠпцҀ੎ၙଯ࠽ฅલ҇‫ۃ‬тࡎшь̝ҕӐһ̷ҪҬ҇ᄥຐюҀшѝѹ̝EJC ѣஜџфѝѷ‫ڵ‬࿫сඩ௿ളѭࣆ੔юҀшѝ҇၈ਇьћтє̞̜ъѾѠ Y25ҲӦӄҢ૲ѣӝӦઓ݂Ѡධჭьћय़ࢅ҇৫јћтє̞ુ६ࠊ຿ӝӦઓ݂प҇৔ඞь̝ॆ৾‫ہ‬થѣ MAGOH ѣู݈с໶๘‫ږ‬ഝษѠӝӦઓ݂Ѡ೒‫ޕ‬ษѠຌфшѝ҇ბѾрѠьћ
тє̞‫ړ‬௒ѣ૳६ॆ‫ݑ‬Ѥ̝Y25ѤҲӦӄҢ૲ѝьћ৾౗ъҁєෟঞѠӝӦઓ݂ଳ௫҇ଦц̝ђѣঞ MAGOH ѝ࿸৾ള҇ज౗ьћޮ຿ѭ‫ڥ‬৫юҀшѝ҇૙ਫюҀѝ৤нћйҀͅExp. Med.
Biol. 351: 549, 3126̞̜͆ӝӦઓ݂ѣ‫ࡠڞ‬ѠљйћѤୌခბѾрѠъҁћйџйс̝Ⴕ཈ྴҺ̷ҲќѤ੎ၙ຿ќѣࣆ੔Ѡрр҄ҀшѝсბѾрѠъҁљљзҀ̞єѕь̝ӝӦઓ݂҇৫лҠҽ̷үѣႏളѠљйћѤ
ႵѕѠຎซќтћйџй̞ુ६ࠊ຿ӝӦઓ݂पќѤ̝࿸ిѣҠҽ̷үс Y25҇ӝӦઓ݂юҀшѝсќтєѣќ̝੎ၙ຿ќѷ࿸ిѣҠҽ̷үс Y25҇ӝӦઓ݂ьћйҀѣрѷьҁџй̞шҁѤ‫ړ‬ಷѠ৫јє siRNA ӜҗӉӜӝ̷ѣຐ໛Ѡѽѿ̝2‫ڭ‬เથѣѴѣӁҶҢҳҙӦќѤ Y25ѣӝӦઓ݂сॳଖьџрјєॆ‫ݑ‬ѝѷ‫ڵ‬කюҀ̞̜ьрь̝RNA ߴறќѤ߱಻Ѡ‫ڭ‬เથѣ཈ॶ҇ர૫ъѐҀшѝѤ໎ьйєѶѠ̝ҥӁӓဩେ࡚ୠ҇ᅧᅀьєҠҽ̷ү‫ڭ‬เથѣӁҶҢҕҙһ҇৫јћѴє̞шҁѳќѣ၈ਇрѾ Y25ѣᄜᆜџҠҽ̷үম္ќзҀ SRPK2Ѡљйћ̝Crispr/Cas:ѠѽҀဦ‫ڤ‬ຐ໛҇৫јє̞ђѣॆ‫ू̝ݑ‬૫џўѠѽѿӈӟ̷ӓҪӈһ҇ࡎшьє੎ၙߗс࿸ిଠຝѾҁ̝SRPK2‫ڭ‬เથѣ཈ॶѤѰѱர૫ьћйє̞PhosTag ҥӞѠѽѿӁҶҢҕҙһ੎ၙќѣ Y25ѣӝӦઓ݂҇‫ݷ‬౸ьєс̝ӝӦઓ݂ѣॳଖѤ಻ф໢ѶѾҁџрјє̞ьєсјћ̝SRPK2൴ລс੎ၙ຿ќӝӦઓ݂҇৫јћйҀ݉໸ౖѤࣈѶћคйѝ৤нћйҀ̞̜SRPK2ӈҔӒӝ̷ѹᆭ૊Ҡҽ̷үсӝӦઓ݂юҀ݉໸ౖ҇৤н̝SRPK ӈҔӒӝ̷ѹᆭ૊ьєҠҽ̷үќзҀ CLK ӈҔӒӝ̷ѣҗӦӅӆҲ̷҇છᅀьӝӦઓ݂ѣ‫ݷ‬౸҇৫јєс̝਻ॶౖѣзҀბ‫ޱ‬џਮ‫ڤ‬Ѥ໢ѶѾҁџрјє̞ьрь̝шѣѽлџ੎ၙ҇ᅀйєҬҢӝ̷ҾӦңपќѤॻ‫މ‬ѷзҀєѶѠ̝ҲӦӄҢ૲ࠗѣೱঘ੣ᅀ҇ᅧᅀьєყᅔษџҬҢӝ̷ҾӦңѣप҇ᅀйћ‫ݷ‬౸҇৫јћйҀ̞࣮ളษѠѤ̝ӝҦӦӆҽӦһ Y25ҲӦӄҢ૲҇ᅀйє੎ၙӜҗҮ̷һѣӊӞҳҙӦҕҶҮҗप҇৔ඞь̝ॆ৾ьєҲӦӄҢ૲҇૲ᆙခ౸ќຎซьћ৫фपѝ̝੎ၙ຿ѠҲңྯૢьє Y25ҲӦӄҢ૲҇཈ॶъѐ̝ࢣ෡ьћфҀҲӦӄҢ૲҇ຎซюҀप҇৔ඞඩќзҀ̞சᅗษѠѤ̝ണѣӈҔӒӝ̷ѠљйћѷӝӦઓ݂౒ট҇ყᅔษѠ‫ݷ‬ბь̝RNA ࠙ᇍ‫ہ‬થѣଳ௫౒টҪҬҹӓ҇ბѾрѠьєйѝ৤нћйҀ̞㸫  㸫

ใඩ̜ᔣથͅຠໟࢲ଩͆
य़ࢅ‫ݢ‬൏̢૜ঃ৊ളс‫ݵ‬੔юҀკ‫ౖ۽‬ఋफ૱߶ѣఒඊӑ̷Ҟ̷ѣ‫ގ‬཈ѝ཈ஶྐྵ഻Ѡ࠙юҀग़ກय़ࢅ‫ޘ‬ᅆ
̜ఋफ੎ၙѣҪҽӊҬѹଦᄵള҇ྯษѝюҀ૜ঃ৊ളс࠙ᄮюҀკ‫ౖ۽‬ඩీఋफ૱߶Ѥ̝3115
໪Ѡ৊ aquaporin 5৊ള҇ౡэҀાఋफ౽఼ܑͅNMO͆с၈ਇъҁћ‫ړ‬ᅗධჭѣᆛ‫ڱ‬ѝџјћйҀ̞3118໪ѠѤ NMDAR GluN2ѠവюҀ৊ള҇ౡэҀ૜ঃკ‫ౖ۽‬ဪ‫ܖ‬प໹ܑс཈।ъҁ̝ъѾѠ LGI2̝AMPAR̝GABABR̝GlyR џўѠ৊ള҇ౡэ̝ຠ෈ษఋफஶম҇ฉюҀ૱߶ѣ၈ਇсೱ૒йќйҀ਼̞ࣞѤ̝шҁѳќ९‫ہ‬࿋ბќзјєાఋफ̡໹౽఼ܑѣ‫ڵ‬࿫Ѡ৊ MOG ৊ളсग़ୟъҁҀшѝсბѾрѠџѿ̝૔ᆒษࠒ฿рѾධჭъҁћйҀ̞шҁѾѣ৊ളѤ̝ђҁѓҁѣࡀ໸඄༭Ѡᅶള৔ഉ‫ږ‬ഝษѠॆ৾юҀєѶ̝৊ളѣग़ୟѠѤ̝ީ඄༭ѣ cDNA ҇
transfect ьє੎ၙѣ႟ྴოѠ཈ॶюҀଦᄵളџў҇৊९ѝюҀ cell-based assay сྣᅆќ̝шҁѾѣ৊ളఒඊс݉໸џયಈѤђҁѓҁਈ຿ќ2-3Ҟ୹ьрџй̞ใඩѤ̝шҁѾѣ৊ളѣതф҇ҞӃ̷юҀ৊ളग़ୟप҇੣౗ьєшѝрѾ̝಻ਈఒᆒયಈрѾѣ৊ളఒඊѣ‫ږ‬ᅙѠ‫ܥ‬эћпѿ̝തфѣᆤடय़ࢅѠ࠙҄јєͅMult. Scler. 33: 687, 3127; Neuro-Ophthal. 4:: 324, 3126; Mult.
Scler. 32: 77:, 3126; Clin. Neurol. Neurosurg. 243: :, 3126; BMJ Open. 6: e118877, 3126; Epi. Disord.
28: 9:, 3126; Tohoku J. Exp. Med. 346: 334, 3126; J. Neurol. 373: 89, 3126; Brain Dev. 48: 256,3126̞͆ѳє̝೴ಋ‫ږ‬ᅙѠ‫ܥ‬э̝ࢲ‫஀ݏ‬૪ྥѠѷ࠙҄јєͅClin. Exp. Neuroimmunol. 7: 81, 3126
ണ2:ဩ̞͆
̜཈ஶྐྵ഻Ѡ࠙юҀग़ກѝьћѤ̝߶ଅᄢᅗѣ IgG ৊ള҇ఆຆ‫پ‬ӐӦӊѠћӑҙҬѣ໹૭຿Ѡૐഘ๩ᄮь̟৊ NMDAR ໹ܑѣຠ෈ќзҀࡌეௐ‫҇ޕ‬ӑҙҬќ਻ॶьєॆ‫҇ݑ‬໹ѣ೏௰޻ษग़
ກ݈҇нћ၈ਇьєͅTohoku J. Exp. Med. 348: 43:, 3126̞͆ъѾѠ̝ᄼ̴џᆤட٪चѣഝ੔ѹ૔ᆒམ‫ౖܥ‬ѣਮ‫҇ڬ‬ౡэҀ९‫ہ‬ѝьћ̝ީ৊ളс఑ᇭౖ҇ᄜюҀқӇһ̷ӊѣೱ‫̝ڬ‬ђѣॆ‫ݑ‬ѝьћ৊ളႛѣఋफࡀ໸Ѡࡹѱюۭࢾс‫ڤ‬џҀ݉໸ౖс৤нѾҁҀшѝрѾ̝NMDAR ީ subunitѣ೏Ѵ৾҄ѐͅGluN2 + GluN3A/3B/3C џў͆ќѣ̝߶ଅ৊ളѣॆ৾ຠౖѣਮ‫̝ڬ‬৊९཈ॶ੎
ၙќѣ time lapse ѠѽҀफ૑ษџज഻ဦ݂ࠒੴ̝ީ৊ളѣӑҙҬ‫އ‬༊ҬӜҗҬྯႏќѣේ࠽ഄࢬᄥຐѠࡹѱюۭࢾџў҇ग़ກьє̞ъѾѠ̝ӑҙҬ໹ީ࿫‫ڕ‬Ѡ཈ॶьћйҀ NMDAR Ѡљйћ̝ީ subunit ѣ೏Ѵ৾҄ѐѠѽҀ཈ॶ࿫‫ڕ‬ຠౖѠљйћ̝ђҁѓҁѣຠ‫ڤ‬৊ള҇ᅀйћѣკ‫۽‬೏௰޻ษग़ກ҇৫јєͅᇫဍ୯ྐඩ̞͆㸫  㸫

ච௒̜ီͅ௩൜ࢲ଩͆
य़ࢅ‫ݢ‬൏̢਻ࢺ߷ಠஶӈӜӆҙҗӞҬ߷ಠѠпцҀവ‫ܥ‬ѝჵ൏฿̢ఋफ௺ୀౖѠљйћय़ࢅ‫ޘ‬ᅆ
̜ӉӜҫӞѠпцҀ3126໪рѾ3127໪Ѡഘф Zika ҙҗӞҬͅӈӜӆҙҗӞҬѣ‫ڵ‬ଠ͆ѣᅻ৫ѤҝӝӦӇҶҢ‫ͅ਺ގ‬3127໪9ॉ͆ѷзјєૉрѾ్̝‫މ‬ඩѣධჭ҇ᅐѨћйҀ̞‫ރ‬Ѷћ਻ࢺ߷ಠஶѝьћ̝ӈӜӆҙҗӞҬ߷ಠсѷєѾюӝҬҢ̝ྐྵ९ౖѠљйћ৤ੴь̝बഘьћऴ௏҇ვѾьћйфྣᅆౖсࢀѶѾҁћйҀ̞
̜Zika ҙҗӞҬ߷ಠќධჭъҁћйҀѣѤ஛ຉஶѝѣ࠙ᇍќзҀ̞шѣҙҗӞҬ߷ಠќѤଘѕјєஶ௢Ѥ཈໩̝ຉ෬̝ࣗ໖෬̝ॆ႟ܑ๸ќзѿ̝໙ႏ໹ܑҙҗӞҬͅJEV͆ѝཿѮҁѥཿ޶ษवஶќзҀ̞࿋५ౖ߷ಠѷതф̝зѳѿ௿༖юҀѷѣќѤџй̞ьрь̝ၴຉѠୡѮєѽлѠ஛ຉஶ҇ᄜюҀంౡૌсതి̝।ୟъҁћрѾൌтџჵ൏ѝџјћйҀ̞Zika ҙҗӞҬ߷ಠѠѽјћ໹೏௰̝ീ཰೏௰ќѣҙҗӞҬഄ௮с໢ѶѾҁћйҀ̞ьрьџсѾ̝ђѣૉ૳ѤണѣӈӜӆҙҗӞҬ̝ຠѠ JEV ѣѽлѠఋफ೏௰ѭѣ߷ಠ̝௺ୀౖсફลъҁћйҀૉ૳҇৤нҁѥ̝๵಺ѣૉѝѷйнҀ̞JEV ߷ಠѠཕлྐྵ९ౖ̝ຠѠ͑ఋफ఑ᇭౖ͒ѠљйћѤ‫ރ‬ѶћධჭюѮт฿ќз҂л̞̜JEV ѠзјћѤҙҗӞҬߗࠗѠпцҀྐྵ९ౖѣਮ‫ڤ‬ѷൌтй̞‫̴ݫ‬сय़ࢅ੕ᆎѝьћᅀйћйҀ JaGAr12ߗѤඩઆߗͅ‫ړ‬ಷӢҢҴӦߗѝьћછᅀъҁћйє̝ຎэ‫ڭ‬เથच4चѣҙҗӞҬߗ͆ѝѤ‫ڤ‬џѿ̝ඩీఋफ௺ୀౖсࢬй਼̞ࣞ‫̴ݫ‬сခᅲьє‫ڭ‬เથच2चѣ౹ಗߗ
ͅ 3 1 2 1 ͆ Ѥ ̝ ఋ फ ೏ ௰ Ѡ п ц Ҁ ҙ җ Ӟ Ҭ ഄ ௮ ౖ ѷ ค й ш ѝ с ခ р ј є ͅ Ta k e g a m i e tal.͑Japanese Encephalitis͒SMG e-Book, 3126̞͆шльєྐྵ९ౖѣਮ‫ڤ‬сўшрѾᅗҀѣрѤ࿋ბќзҀ̞‫ڵ‬љѤϼҲӦӄҢ૲๸ѣҙҗӞҬഋѠзѿ̝ണѠѤ୘ଘഋѠзҀѝᄬೢъҁҀ̞җӦҲ̷ӈҚӠӦѠവюҀ߷ଦౖѷ࠙ओюҀ̞ѳѕ‫ݷ‬ბс࿋ୌခќзҀйфљрѣ‫ݢ‬൏̝ᆰнѥ̝߷ಠ୸࠽ѣ੎ၙ႟ѭѣҙҗӞҬࡺඨ̝੎ၙ຿ѠпцҀ஛ၙള ER ќѣҙҗӞҬ RNA ѹҲӦӄҢ৾౗‫ݦ‬น̝ᆀથज౗๸ќѳѕѳѕ⋰сзҀ̞ӈӜӆҙҗӞҬ߷ಠ̡࿸౦ѣခથࡀ৔ѣ‫ݷ‬౸Ѥ̝৊ҙҗӞҬ੓ѣ‫ގ‬཈ѠѷљџсҀ୔ᅆџ‫ݢ‬൏ќзҀ̞
̜Zika ҙҗӞҬѠѽҀྐྵ९ౖͅఋफ௺ୀౖ͆сଙѿਰദъҁҀ3127໪ќзҀс̝ӈӜӆҙҗӞ
Ҭ҇჆‫ڎ‬ѠࢯсҀшѝџф̝౞ьфҙҗӞҬᅬ‫҇ݷ‬ఇѶҀૉѷ୔ᅆѝ৤нҀͅඒ‫ڱ‬ѭѣ཈௹ѝьћ͑‫ډ‬੟ාҕҞҪҕѣᅱ͒৭‫̝ܐ‬3127໪7ॉ23໙̞͆໙ႏќ61໪ಷѠ‫ގ‬཈ъҁ̝ᆿઞษѠѷேბъҁћйҀᄜ঳џ JEV ӢҢҴӦѠљйћѤђѣ୔ᅆъ҇਻‫ޱ‬໢ьћйфшѝѷൌૉџ฿ќзҀ̞̜џпӈӜӆҙҗӞҬय़ࢅѣ‫ڵ‬ൿќѷзҀϺचࠏܑҙҗӞҬѣҲӦӄҢ૲ NS4ѣࡀ໸Ѡљйћѷ၈ਇь̝‫ۃ‬тഘт੎ၙ݂ࠣѝѣ࠙ᇍౖѠљйћ৤ੴ҇కѶћйҀͅMol. Med. Rep. 23: 621:,
3126̞͆㸫  㸫

൧ჿ̜ࡍഌͅय़ࢅ‫͆ۀ‬य़ࢅ‫ݢ‬൏̢EJC ҇৔౗юҀ‫ہ‬થѣ੎ၙ຿ࣆ੔‫ݷ‬౸य़ࢅ‫ޘ‬ᅆ
̜Y25Ѥ̝MAGOH ѝӋҹӠ໐ᆙള҇ज౗юҀ RNA ॆ৾ҲӦӄҢ૲ќзҀ̞ѳє̝ҬӊӜҗҪ
Ӧң૑Ѡ mRNA ѣқҢҰӦѣљџуჭ࿌ࣞќ Exon Junction ComplexͅEJC͆ѝॿѥҁҀ࿸৾ള҇ज౗юҀ̞шѣ࿸৾ളѤ̝Y25̝MAGOH̝eIF5A4̝CASC4҇Ҧҕѝьћ৔౗ъҁ̝RNA ѣᄑ೾̝཈ॶ෕ಊѹခ‫ݷ‬๸ѣൊଆफᇔѠ࠙ᄮюҀ̞ѳє̝ࣞ໪̝RNPS2๸ѣ‫ہ‬થ҇‫ݵ‬ьћ‫ڵ‬࿫ѣRNA ѣҬӊӜҗҪӦңѠྣᅆќзҀшѝс૙ਫъҁћпѿ̝੎ၙ຿ѣଠ̴ѣࡀ໸Ѡۭࢾ҇ࡹѱюѝ৤нѾҁҀ̞ണѠѷ̝੎ၙ૲Ѡпйћ̝Y25Ѥ MAGOH̝PYM ѝॆ৾ь̝࿸৾ള҇ज౗юҀшѝсඑѾҁћйҀ̞ъѾѠ̝ӅһѠпйћ Y25‫ڭ‬เથѣဦ‫ू̡ڤ‬૫ѤᛧਓूഠࡹѨे஛ཝѣॳஜ҇ཕл TAR ஶমऍ҇ᄥ཈ь̝ѳє̝eIF5A4ѠљйћѤђѣ‫ڭ‬เથѣྌ႐ᄆᆛ‫ڱ‬ѣဦ‫ڤ‬Ѡѽѿ̝಻ఓѣਓज౗ѣ‫ڤ‬௜҇ཕл Richieri-Costa-Pereira ஶমऍ҇‫ۃ‬тࡎшюшѝсඑѾҁћйҀ̞̜шҁѳќѠ̝ఋफ੎ၙѣࡀ໸̝ਓज౗ѹे஛ཝઍౡ੎ၙќзҀ࢏ޮࢄѣ౗୞сඩ௿ളѣज౗ѝఇфрр҄ҀшѝѠඨჭьћय़ࢅ҇৫й̝Y25̡MAGOH сඩ௿ളѠࣆ੔юҀшѝ҇ბѾрѠьћтє̞ъѾѠ̝Y25̡MAGOH̡eIF5A4ѣӁҶҢҳҙӦѠѽѿඩ௿ളѣ൴ࣈѳєѤതࣈज౗с‫ۃ‬тࡎшъҁҀшѝрѾ̝ඩ௿ളज౗Ѡ EJC ѝьћ࠙ᄮюҀшѝс৤нѾҁє̞੧໪๘ѠпйћѤ̝ඩ௿ളѠпцҀ EJC ‫ہ‬થѣࣆ੔҇ბѾрѠюҀшѝ҇ჭษѝьћ̝ҪӚ๻Ⴚ๘঴༖‫ܚ‬௿ѠѽҀඩ௿ള‫ݭ‬ခѣౣ౦๸҇৫й̝EJC Ҧҕ5‫ہ‬થѣඩ௿ളѭѣࣆ੔҇ბѾрѠьє̞ѳє̝ඩ௿ള‫ݭ‬ခ҇ RNaseA ୷ᅬঞѠ‫ݸ‬ମьє௙৾Ѡпйћѷ̝EJC ‫ہ‬થѣഝ੔с‫ޱ‬໢ќтєшѝрѾ̝RNA Ѡॆ৾юҀണѣҲӦӄҢ૲Ѡ࿌఺ьћඩ௿ളѠࣆ੔юҀѣќѤџйшѝс૙ਫъҁє̞ьрь̝CASC4ѠљйћѤ̝шҁѳќѠӁҶҢҳҙӦѠѽҀඩ௿ളѣ‫ڤ‬௜҇‫ޱ‬໢ќтћпѾя̝ඩ௿ളѣ౞௜џ࿸౦ѠѤ Y25̡MAGOH̡eIF5A4рѾџҀ pre-EJC с୔ᅆќзҀѝ৤нѾҁє̞̜ђшќ̝န౗38໪๘ѠпйћѤ̝CRISPR/Cas:ၔѠѽѿ̝CASC4ѣӁҶҢҕҙһ੎ၙ҇੣౗ь̝CASC4ྌഝ੔݁ќѣඩ௿ളࡀ໸ѣ‫ݷ‬౸҇కѶє̞CASC4ӁҶҢҕҙһ੎ၙѠпйћѷш
ҁѳќѝຎᄼѠ̝Y25̡MAGOH̡eIF5A4ѣඩ௿ളѠпцҀࣆ੔с໢ѶѾҁ̝ѳє̝კ‫۽‬෡৶ѣॆ‫ݑ‬рѾ pre-EJC с੎ၙ຿ќ‫ڋ‬ซษѠഝ੔юҀшѝсბѾрѝџјєшѝрѾ̝pre-EJC ज౗сඩ௿ള࿸౦пѽѨ EJC ‫ہ‬થѣඩ௿ളࣆ੔ѠྣᅆќзҀѝ৤нѾҁє̞ॶ੔̝ъѾѠ௉੎Ѡ
EJC ‫ہ‬થѣ੎ၙ຿ࣆ੔ࡀ৔҇‫ݷ‬౸юҀєѶ̝EJC ‫ہ‬થѠљйћऱরҲӦӄҢ૲ॆ৾ӈӜңӔӦ
һ҇੣౗ь̝य़ࢅ҇కѶћйҀ̞㸫  㸫

ㅽẫ₰ٛકᮾ᳣ո⦕ㅾ
̜੎ၙ‫޻ڮ‬य़ࢅခჿѤࡻ‫܂‬Ⴞ৭ન̝൮শఊ৭નѣ3ఘќ৔౗ъҁћйҀ̞ࡻ‫܂‬৭નѤ୍̝ᅗѣ੎ၙ‫޻ڮ‬य़ࢅခჿѣय़ࢅͅፑ໚ᆭ੎ၙѠпцҀ DNA ৔ഉѝ༗ిౖဦߺѠљйћѣय़ࢅ͆҇ຄୀьћйҀ̞൮শ৭નѤ̝ခથଡ᢮य़ࢅခჿрѾѣबഘय़ࢅќзѿ̝န౗37໪๘ѽѿષᅶൌ޻ಘᅹษय़ࢅ࠱཰ज౗ૉࣅͅ No.S 2312115 :H 3123 - 26͆ѣӔӦӃ̷ѝьћ໙ႏ໹ܑҙҖӞҬͅJapanese Encephalitis Virus, JEV͆߷ಠ୸࠽ѠпцҀ੎ၙ႟઼૲ҬӈҖӦҧӒқӝӦѣᄃ߇Ѡљйћ‫ݷ‬౸҇৫јћйҀ̞̜ॶ੔̝ࡻ‫܂‬৭નѤӅһ௲೎ౖߦྂஶͅXeroderma Pigmentosum, XP̝௜ಠ௲ളᇁౖ‫ڭ‬เྐྵ͆߶ଅᄢᅗѣ੎ၙ҇ᅀйത༗ള݂҇৫јћйҀ̞шҁѳќ̝౞௜Ӆһಧ‫ݯڦ‬੎ၙ̝XP ੎ၙ҇ᅀйћത༗ള݂૳६҇৫јћтєс̝ᄜॻခᇃନა҇ૐљєѶ̝ത༗ള݂ѤપлѽлѠಷѭకѳџрјє਼̞̝ࣞҹӠӔӜ̷үࡴ฽૽ৱ೎‫ڭ‬เથѠѽѿ࿋ળ݂ъҁє౞௜੎ၙѹ XP ੎ၙ҇ᅀ
йћ5༗ള੎ၙ҇ପᅶьћйҀ̞̜൮শ৭નѤ̝໙ႏ໹ܑҙҖӞҬಅඨ̡߷ಠѠпцҀҬӈҖӦҧӒқӝӦͅSM͆ѣᄃ߇ѠљйћౣᆜษѠय़ࢅ҇৫јћпѿ̝шҁѳќѠҬӈҖӦҧӒқӝӦ৾౗ৱ೎ͅSMS͆2Ѡѽѿ৾౗ъҁҀ੎ၙ႟ SM с JEV ߷ಠѠ୔ᅆџᄃ߇҇‫ݑ‬єюшѝ҇૙юॆ‫҇ݑ‬཈ྴьћйҀ̞݈нћ̝೴৾‫޻ڮ‬य़ࢅ୹ѣࣅჄќзҀ RI ҮӦҲ̷ѣ૳Ⴤ౾ໟଅ̝ࡀ࠰ࠊᅬ౾ໟଅ҇ჄѶџсѾ̝ࢣຎय़ࢅ҇৫й̝෗തၮџ໙̴҇೾јћйҀ̞ͅဍ౾̜ࡻ‫̜܂‬Ⴞ͆㸫  㸫

ࡻ‫̜܂‬Ⴞͅ৭ન͆
य़ࢅ‫ݢ‬൏̢5༗ള XP ੎ၙѣପᅶпѽѨ઺‫ޓ‬ಧ߷ଦౖय़ࢅ‫ޘ‬ᅆ
̜௲೎ౖߦྂஶͅXeroderma Pigmentosum, XP͆Ѥ̝໙র‫ݦ‬࿉ѠѽҀ௲೎෡ඨѹߦ̝ྂྂ࿝ࠣ
҇ౡэ̝઺‫ޓ‬ಧͅUV͆Ѡѽјћज౗ъҁҀ DNA ഠ஌҇ଳ࿳юҀҿҢӟҝҴҼ஋ࢍଳ࿳Ѡ‫ڤ‬௜҇ѷљ௜ಠ௲ളᇁౖ‫ڭ‬เྐྵќзҀ̞шѣ UV ѠѽҀ DNA ଳ࿳໸Ѥ‫ڵ‬ซќѤџф̝Ѱѝ҈ўଳ࿳ќтџй੎ၙрѾ౞௜Ѡࣞйѷѣѳќഝ੔юҀ̞ॶ੔̝шҁѾѣ XP ੎ၙѤ੎ၙᄪ৾ѠѽҀ࿋ซ࠽ DNA ৾౗ͅunscheduled DNA synthesis, UDS͆໸҇ફྯѝьєೱ္ౖҹҬһќ̝XP-A̼
G ऍѣ8ऍѝ variant ऍѠခᆭъҁћйҀ̞шҁѳќ̝XP ੎ၙѠљйћ UDS̝UV ౡഝᅵ̝ӇӝӒҫӦҳҗӑ̷஋ࢍ໸̝DNA ৾౗ѣᅍ౒џўѣय़ࢅсതి၈ਇъҁћйҀс̝йяҁѷ2വѣೱຎಠ௲ള҇࠱ႏѝюҀ੎ၙќѣ၈ਇќзѿ̝࿸ిവ҇ૐљത༗ള੎ၙѣ UV ߷ଦౖѤ࿋ბќзҀ̞̜‫̴ݫ‬Ѥ̝шҁѳќതфѣ੎ၙќത༗ള੎ၙ҇੣౦ь̝ത༗ള੎ၙѣౖ૲҇ग़੬ьћтє̞ѝш҂с̝Ӆһಧ‫ݯڦ‬੎ၙѣത༗ള੎ၙ੣౦Ѥਙ໎҇ᅆьє̞шҁѤ̝Ӆһಧ‫ݯڦ‬੎ၙѤᄜॻഄ௮໸҇ૐљ੎ၙќзҀєѶ̝ේ࠽༘ᅋѠѽҀफ‫ࠒݦ‬ੴ̝зҀйѤҢӠ̷ҾӦңѠѽҀ൴ᅲ༘ᅋѤᇢ݂҇ཕйത༗ള੎ၙѣପᅶѤਙ໎ќзҀшѝсᅬᄢѝъҁҀ̞ђшќ̝ҹӠӔӜ̷үࡴ฽૽ৱ೎‫ڭ‬เથѠѽѿ࿋ળ݂ъҁєӅһಧ‫ݯڦ‬੎ၙ҇ᅀйҀшѝѠѽѿ5༗ള੎ၙѣ੣౦҇౗লъѐ၈ਇьє̞̜ਘ‫̝ݸ‬ຎᄼѠҹӠӔӜ̷үࡴ฽૽ৱ೎‫ڭ‬เથѠѽѿ࿋ળ݂ъҁє XP ੎ၙ҇ᅀйത༗ള੎ၙ
੣౦ѝത༗ള੎ၙѠпцҀౖ૲҇ग़ກьє̞̜ҺӔҦӞҪӦќ୷ᅬъҁє XP ੎ၙѤത༗ള݂ь̝ᄅ੓஋ࢍঞѣबൊ༘ᅋѠпйћѷത༗ള੎ၙс‫ڦ‬ૐъҁє̞шҁѾѣത༗ള੎ၙѤӈӠ̷ҨҗһӔ̷Ҳ̷ͅFCM͆҇ᅀйє DNA ӅҬһңӜӓ‫ݷ‬౸Ѡѽѿ̝5༗ള XP ੎ၙќзҀшѝс‫ޱ‬໢ъҁє̞ѳє̝5༗ള XP ੎ၙѣഄ௮໸̝੎ၙခᇃ໸Ѥ3༗ള XP ੎ၙѝຎน๘ќзјє̞‫ړ‬௒ѣॆ‫ݑ‬рѾ5༗ള XP ੎ၙс੣౦ъҁєѝ৤нѾҁҀ̞̜ѳє̝૳६Ѡᅀйє XP ੎ၙѤ C ऍѠခᆭъҁ̝UV Ѡവьћ৹߷ଦౖ҇૙ю੎ၙќзҀ̞ьрь̝5༗ള XP ੎ၙѣ UV ߷ଦౖͅUV ౡഝᅵ͆Ѥ3༗ള XP ੎ၙѝཿ޶ь̝ค߷ଦౖ҇૙юॆ‫ݑ‬сຝѾҁєͅCytologia 92: 9:, 3127̞͆шѣॆ‫ݑ‬ѽѿ5༗ള XP ੎ၙѣ UV வ૾ঞѣ DNA ଳ࿳ࡀ৔̝ຠѠ UV வ૾Ѡѽѿज౗ъҁҀҪҢӠӉҲӦचӇӝӒҫӦҳҗӑ̷ͅCPD͆пѽѨ7-5রઍ࿿ѣ஋ࢍଳ࿳໸с3༗ള XP ੎ၙѝ5༗ള XP ੎ၙќೱ‫ڬ‬сзҀѝ৤нय़ࢅ҇కѶєѝш҂̝
CPD Ѥ3༗ള XP ੎ၙ̝5༗ള XP ੎ၙќѤѰѝ҈ўଳ࿳ъҁџрјє̞ьрь̝7-5রઍ࿿Ѥ5༗
ള XP ੎ၙќѤ7૑ࠗќѰѝ҈ўଳ࿳ъҁ̝3༗ള XP ੎ၙќѤ35૑ࠗѠпйћѷѳѕഠ஌ѝьћગјћйҀ௢഻ќзјє̞7-5রઍ࿿ѣສ಺ဦ‫ڤ‬ᄥ཈໸Ѥ CPD ѠཿѮޭඍѠࢬф̝ౡ౗ᆙѤஜџйѷѣѣ̝઺‫ޓ‬ಧѣౡ࿿ѠᄮнҀۭࢾ҇৤нҀлнќ୔ᅆџഠ஌ќзҀѝ৤нѾҁћй
Ҁ̞шѣшѝѽѿ̝5༗ള XP ੎ၙѣ઺‫ޓ‬ಧѠവюҀౡഝᅵѣষ௒ѠљџсјћйҀѣќѤџ
йрѝయੴюҀ̞㸫  㸫

൮শ̜ఊͅ৭ન͆
य़ࢅ‫ݢ‬൏̢ҽҴӘӜӞҠӜ̷T ӝӦӄଡ੎ၙѠпцҀҮӜӒҼ‫ږ‬ഝౖ੎ၙળᄥຐࡀ৔ѣ‫ݷ‬ბय़ࢅ‫ޘ‬ᅆ
̜ҬӈҖӦҧ઼૲ѤҬӈҖӦҧ‫࠱҇࠱ܝ‬ႏਓޭѠѷљ઼૲ќзѿ̝ҬӈҖӦҧҪӦ̝ҮӜӒҼѹҬӈҖӦҧӒқӝӦͅSM͆џўсзҀ̞ҮӜӒҼѤ੎ၙ຿ҪңҽӞเ൦ခથѝьћඑѾҁћпѿ̝੎ၙળ̝੎ၙᇢ݂̝੎ၙଯ࠽ฅલѹҝ̷һӈҔҫ̷ᄥຐѠ࠙ᄮюҀ̞੎ၙ຿ҮӜӒҼѣഄ݈ѠѽҀ੎ၙળࡀ৔Ѥ̝ࠣ੎ၙѠവюҀ৊с҈੓୷ᅬѹ̝ၑ૾ಧவ૾џўќ‫ޱ‬໢ъҁћйҀ̞ьрьџсѾ̝ђѣခથӔҞҾҭӓѤതᄼќзѿ̝ѳѕѳѕђѣ݁ᅻѣҲ̷ҥҶһခથѤခрјћйџй̞̜န౗38໪๘ѠпйћѤ̝ҽҴӘӜӞҠӜ̷T ӝӦӄଡ੎ၙͅKHYG-2͆ѣ੎ၙળᄥຐѠпцҀҮӜӒҼѣᄃ߇Ѡљйћ‫ݷ‬౸ьє̞KHYG-2੎ၙѤђѣഄ௮ѠҗӦҲ̷ӠҗҠӦ3ͅIL-3͆сྣధќзѿ̝IL-3ѣঈߌѠѽѿഓѹрѠ੎ၙળ҇ᄥຐюҀ̞‫ړ‬ಷѠ̝шѣ੎ၙળѣ੒ѠѤҮӜӒҼсഄ݈юҀшѝсခрјћйєс̝ђѣခથӔҞҾҭӓѤ࿋ბќзјє̞ђшќ̝IL-3ѣ
ঈߌ૑ѣҮӜӒҼѣഄ݈с੎ၙ຿ѣ݄୷ќࡎшјћйҀрѠљйћ෕Ѯєѝш҂̝੎ၙ຿ѣӜҗҰұ̷ӓѠජ౺ьћйҀшѝ̝ӜҗҰұ̷ӓќഄ݈ьєҮӜӒҼсӜҗҰұ̷ӓҲӦӄҢ૲ќзҀ cathepsin B ҇ߋౖ݂юҀшѝќ caspase-4҇ߋౖ݂ь̝caspase ‫ږ‬ഝౖѣҕӐһ̷ҪҬ҇ࡎшюшѝсბѾрѝџјє̞ѳє̝cathepsin B ѣߋౖ݂૑ѠѤ caspase-4ѣߋౖ݂ѕцќѤџ
ф̝ђѣ೒‫ہޕ‬થќзҀ X-linked inhibitor of apoptosisͅXIAP͆сခ‫ݷ‬ьћйҀшѝѷბѾрѝ
џѿ̝IL-3ঈߌঞѠ IL-3҇਻๩ᄮюҀшѝќ XIAP сഄ݈ь̝IL-3ঈߌ૑ѣ caspase-4ߋౖ҇ᅍ౒юҀшѝсბѾрѝџјє̞ႏय़ࢅॆ‫ݑ‬Ѥᇫဍѝьћ၈ਇьєͅCell Death Dis. 7: e2828,
3126̞͆
̜ѳєႏ໪๘Ѥ̝ SM ৾౗ৱ೎ूഠӑҙҬͅ SMS-KO ͆ѠпцҀྐྵ഻ӕҺӞѣ੣౦ѝ‫ݷ‬౸ѷ৫јћпѿ̝ђѣྐྵ഻ӕҺӞ੣౦Ѡ࠙ьћ̝೴ಋѠѳѝѶєͅ૱߶ӕҺӞѣ੣౦ѝᅧᅀ ઼૲ൊଆ‫ڤ‬௜ѝ࠙ᇍ૱߶݁߭͟͞ : p459, 3126̞͆㸫  㸫

ㅽ⃪᪝᧯ᢼᮾ᳣ո⦕ㅾ
̜ଡ᢮ౡ࿿य़ࢅခჿѣ৔౗‫ۀ‬Ѥഥใᆁ۸୩ࢲ଩2ఘќзҀ̞ଡ᢮Ѥ೏௰ѝьћѷ੎ၙѝьћѷ‫ڵ‬љѣౡтѷѣѣѽлѠఁҀѳй̝ᄼ̴џࠅࢪѠᆤࡀ‫ܥ‬ဦѠവ‫ܥ‬юҀ̞ђѣѽлџౡ࿿޻ษຠ
ౖѠ࠱њфଡ᢮੎ၙѣ‫ౖ݂ٶ‬కืѣࡀ৔ѣ‫ݷ‬ბ҇य़ࢅҹ̷ӑѝьћйҀ̞͑с҈͒ѣ࠼౗‫ޘ‬໫ѠံѾ҄ҁяѠ̝൴੎ၙఊޮౡ࿿ѷࠟѶєఊޮౡ࿿಻ള҇ાჿѠ໛ҁћ‫ౖ݂ٶ‬కืѣय़ࢅ҇కѶћйҀ̞य़ࢅ୹ႏᅗѣછაќзҀय़ࢅѠ௝໩҇औцљљ̝ࢲ‫̝ڲ‬य़ࢅҨӐ̷һ̝ࡀ࠰ࠊᅬџўѠ࠙ьћѷߋຍьћйҀ̞ͅဍ౾̜ഥใ̜ᆁ۸͆㸫  㸫

ഥใ̜ᆁ۸ͅ୩ࢲ଩͆
य़ࢅ‫ݢ‬൏̢ఊޮౡ࿿ѠпцҀ RhoGDI ѣᄃ߇य़ࢅ‫ޘ‬ᅆ
2̠с҈‫ౖ݂ٶ‬కืѠпцҀ RhoGDI ѣᄃ߇̜‫̴ݫ‬ѤшҁѳќѠ̝ RhoGDI ԓсࠣѣ‫ౖ݂ٶ‬కืѠ࠙҄јћйҀшѝ̝ RhoGDI ԓсcentrosome Ѡࣆ੔ь̝௒ྂ੎ၙѣࣈౖѹЄ࠽ѣ౒টѠ࠙҄јћйҀшѝ҇ბѾрѠьє̞ъѾѠ̝Rho ҬҗҶҴ౒টࡀ৔ӕҺӞ҇ᅀйє RhoGDI ѣᄃ߇ѣ in silico ‫ݷ‬౸Ѡѽѿ̝RhoGDI ѤшҁѳќඑѾҁћйєѽлџ Rho ߋౖ݂ᅍ౒ࡀ໸ѕцќџф̝Rho ߋౖ‫ڦ‬ૐࡀ໸ѷૐљ݉໸ౖсзҀшѝ҇૙ьє̞̜ਘ໪๘‫̴ݫ‬Ѥ̝Ӆһࠣ੎ၙߗͅHeLa͆Ѡпйћၑ૾ಧவ૾ঞѠ RhoGDI ԓс caspase-4Ѡѽѿಃඊъҁ̝ђѣಃඊઍ࿿ќзҀӵ N-RhoGDI ԓс Cdc53ѣߋౖ҇ᅍ౒ь̝੎ၙࣈౖѣެᅟпѽѨൊ஍ౖѣഄ௮҇‫ۃ‬тࡎшюшѝ҇ბѾрѠьєͅJ. Cell. Physiol. 342: 35:4, 3127̞͆RhoGDIԓѤଠ̴ѣ੎ၙќҕӐһ̷ҪҬѠ੒ьћ caspase-4ѠѽѿಃඊъҁҀшѝсඑѾҁћйҀс̝ђѣ‫ࡠڞ‬Ѥ࿋ბѣ฿сതрјє̞ѳє̝৊с҈੓૔ᆒ૑Ѡс҈੎ၙќ caspase- 4сߋౖ݂ъҁ̝шҁсс҈੎ၙѣ਻ഄ௮Ѡ࠙҄Ҁшѝс၈ਇъҁћйҀс̝ђѣࡀ৔Ѥ࿋ბќзјє̞ਘ‫ݸ‬ѣ‫̴ݫ‬ѣ཈।Ѥ caspase-4Ѡѽѿಃඊъҁє RhoGDI ԓс̝৊с҈੓૔ᆒঞѣс҈੎ၙѣ਻ഄ௮ѹకืѠ࠙҄Ҁшѝ҇૙ьћйҀ̞

3̠ҹһӜӅӔҽѠпцҀ RhoGDI ѣᄃ߇̜RhoGDI Ѥ಻ћѣఊޮౡ࿿Ѡഝ੔ь࿘ာษџࡀ໸сᄬೢъҁҀ̞౽෨ຍ࿿ѝѤप๼཈ౡษѠൌтф޹єјє൴੎ၙఊޮౡ࿿ќзҀҹһӜӅӔҽͅTetrahymena thermophila͆ѠпцҀ
RhoGDI ѣ੎ၙ຿ࣆ੔҇৊Ӆһ RhoGDI ৊ള҇ᅀйєऱরკ‫۽‬ಠ௲Ѡѽѿग़ກь̝шҁс basal
bodyͅፑ໚ᆭ੎ၙѣ centriole/basal body Ѡೱ๵͆ѣଯ‫ܖ‬࿫Ѡࣆ੔юҀшѝ҇।йѕьє̞ऱরკ‫۽‬ಠ௲ѣಠ௲ӄҲ̷ӦѹҙқҬҲӦѣॆ‫ݑ‬рѾ̝шѣ৊ളс໢ૢюҀခથѤ basal body ѣ౗୞Ѡ࠙ओюҀ k-antigens ѝॿѥҁҀႵຎซѣҲӦӄҢ૲ќзҀшѝсయ഑ъҁє̞шҁ҇ग़ேюҀєѶѠ̝ᄼ̴џၒၔќшѣ৊ളс໢ૢюҀҲӦӄҢ૲ѣຎซ҇ુѴєѝш҂̝шҁсҹһ
ӜӅӔҽѣ RhoGDI ќѤџф Granule lattice protein 2ͅGrl2͆ѝॿѥҁҀҲӦӄҢ૲ќзҀшѝ
сࢬф૙ਫъҁє̞Grl2с k-antigens џѣръѾѠग़ே҇కѶћйҀ̞㸫  㸫

ㅽ⣻Ό੿ᑿ⃆ᮾ᳣ո⦕ㅾ
̜ॶ੔ѣ৔౗‫ۀ‬Ѥඩഡᄜ৸஄ଛ2჏ѣѴѝџјћйҀ̞ඩഡ஄ଛѤय़ࢅଅѝьћѤລᅶѐяѠ̝ခથଡ᢮य़ࢅခჿѝࢣຎќय़ࢅ҇৫јћтє̞य़ࢅခჿѣ჏஻ѠѪъ҄ьф‫ڭ‬เથѣѷљࡀ໸҇‫ݷ‬тბрьћйфшѝ҇ҹ̷ӑѝьћйҀ̞ଘᅆџҹ̷ӑќзҀ RNA ॆ৾‫ہ‬થѣ‫ݷ‬౸҇ყᅔษџ‫ڭ‬เથ‫ݷ‬౸ѠॆѨљцћ̝ంࡋѣ૱߶ᄬঞӑ̷Ҟ̷҇‫ގ‬཈ќтҀѽлџय़ࢅҹ̷ӑѠ්ಘьћйҀ̞̜ѳє̝ไથ५ྒࢽ๸ѠѽҀज഻ࠒੴଛၔѣ‫ގ‬཈Ѡљйћѷ̝എѣේйઘૉќѤзҀс̝ခથౡ࿿޻ѭѣ‫ܥ‬ᅀ҇ჭફьћ‫ރ‬ᆖ҇୔ѢћᅗћйҀ̞ѝѿ҄цࣞ໪ࡽഓѠ࿘ࡹьћтєంࡋҦ̷ҹҖӦң੓ѠѽҀ೽ਯचไથ५ྒࢽࠒੴѠљйћ̝җҝӦ‫ۼ‬ളѹຐไౖӐӝӑ̷҇ߋᅀьєҨӦӊӞ෕౦࡚ୠѠධᆜьћйҀ̞җҝӦ‫ۼ‬ള҇ᅀйєࠒੴၔѤಠ௲ളྯႏѣࠒੴѳќсౣ‫ڵ‬༐ѝ৤нћйҀ̞ਘঞѤѽѿ‫݆ڋ‬ќଙ‫ڀ‬сᄵ‫ڠ‬џంࡋຐไӐӝӑ̷ѠѽҀࠒੴѠ්ಘьћ৫фᄬซќзҀ̞ѽѿౣ੎Ѡ࿿ള҇ࠒੴќтҀѽлુ৫੭দ҇୔Ѣ̝‫ڭ‬เથѣࡀ໸‫ݷ‬౸Ѡᄃᅶћћйтєйѝ৤нћйҀ̞̜ඩഡ஄ଛѤࢣຎᅧᅀҮӦҲ̷҇တໟьћйҀѣќ̝ࡀ࠰ѹҰӈһҙқҕѣࠊᅬࣅჄ҇৫лѝѝѷѠ̝࡚ୠ҇ߋрьћ޻຿ѝѣࢣຎय़ࢅѷ৫јћтє̞ਘঞѤ̝ъѾѠ‫ڭ‬เથ‫ݷ‬౸࡚ୠѣ଻ຝѠჄѶ̝य़ࢅબ܎ѣѤѥѷৄчћйтєйѝ৤нћйҀ̞ͅဍ౾̜౹‫̜ޣ‬ᄈఘ͆㸫  㸫

ඩഡ̜ᄜ৸ͅ஄ଛ͆
य़ࢅ‫ݢ‬൏̢Ӆһଡ᢮ѠпцҀ RNA ॆ৾‫ہ‬થѣ཈ॶ‫ݷ‬౸य़ࢅ‫ޘ‬ᅆ
̜‫ڭ‬เથࡀ໸य़ࢅခჿќѤ RNA ॆ৾‫ہ‬થѣࡀ໸‫ݷ‬౸҇ඩ௿ѝьћय़ࢅ҇కѶћтє̞ͅExp.
Biol. Med. 351: 549, 3126͆ຠѠ̝࠼ഝѣ‫ڭ‬เથҺ̷Ҳӌ̷Ҭ҇ߋᅀьћ‫ౖٶ‬ଡ᢮ѣᄬঞӑ̷Ҟ̷ѣग़੬҇৫џјћтє̞шҁѾѣॆ‫ߋ҇ݑ‬ᅀь̝ᆤட‫ڮ‬ѝࢣຎय़ࢅ҇‫ގ‬ઢьє̞Ӆһଡ᢮೏௰Ѡћম္‫ڭ‬เથѣ཈ॶ‫ݷ‬౸҇৫й̝ᄬঞӑ̷Ҟ̷ѝьћѣᄜᅀౖ҇ग़ກඩќзҀ̞̜‫ڵ‬ၒ̝೽ਯचไથ५ྒࢽͅScanning electron microscope, SEM͆ѠѽҀౡ࿿ુᆎѣࠒੴଛၔѣ‫ގ‬཈Ѡѷଙѿ೏҈ќтє̞ไથ५ྒࢽѤไથಧவ૾҇ᅧᅀь̝ҨӦӊӞ҇ఊࣲඩѠ඙йћࠒੴюҀ̞шѣєѶ̝ҨӦӊӞѣ੣౦ѠѤঀซ̝൩ర̝Ҧ̷ҹҖӦңѠѽҀຐไ୷ᅬ๸ѣъѳыѳ
џ೧੣сྣᅆќзјє̞ьрь̝ࣞ໪၈ਇсೱ૒йѕҗҝӦ‫ۼ‬ളѠѽҀ SEM ࠒੴၔѤ̝ࣈѶћࠋိџ೧੣Ѡѽѿࠒੴс݉໸ќзѿ̝ъѳыѳџౡ࿿ુᆎѣࠒੴѠ‫ܥ‬ᅀъҁઢѶћйҀ̞җҝӦ‫ۼ‬ളѤ௜ܾќ‫ۼ‬ളѣ‫ܝ‬ќ̝ᄾ༙ѝьћᅧᅀъҁҀѕцќџф̝ไࡃ݂޻ѹไඖ౦ഉѠߋᅀъҁћтє೎੕ќзҀ̞җҝӦ‫ۼ‬ളсไથ५ྒࢽࠒੴѠછᅀъҁҀѽлѠџјћтєᅬᄢѤ̝ไથ५ྒࢽ຿ѣ৹ఊࣲ௢഻ќѷ௥཈ѐяҨӦӊӞྴოѠຐไౖ҇ૐєѐҀшѝсќтҀрѾќ
зҀ̞തфѣҗҝӦ‫ۼ‬ളѤതஜѣ໯ౖсзҀєѶѠ̝ђѣѳѳછᅀюҀѝҨӦӊӞ௒Ѡગഝьћьѳй̝ഃѣࠒੴс໎ьфџҀєѶ̝రџўќ࠶଒ьћྴოѣҦ̷ҹҖӦң੓ѝьћછ҄ҁҀшѝѷതф̝࠶଒ьћѷҨӦӊӞྴოѣຐไౖѤဲєҁћйҀѝ৤нѾҁћйҀ̞ьєсјћ̝җҝӦ‫ۼ‬ളѣᅧᅀ૑ѠѤ̝໯ౖ҇݁чҀєѶѠห๵џᄾ༙ѠѽҀ࠶଒ѝ݈ܾсᄜ঳ќзҀс̝࠶଒ьюуҀѝҴӖ̷ҫҕҶӊ҇தфєѶѠ̝ᄬྐ૳६ѠѽҀ௟ॊಈซсྣᅆѝџҀ̞шѣѽлџඩќ̝ઽห௟ॊ҇।љцҀшѝќӅһ༔с҈ᄢᅗ੎ၙͅA65:͆ѣࠒੴ҇пшџјћ
тєѣќ̝шҁѾѣඑ।҇ѳѝѶћ೴ಋѝьћ཈ྴьєͅJ. Kanazawa Med. Univ. 51 : 236 ,
3126̞͆
਼̜ࣞѤ୍̝ᅗѣҗҝӦ‫ۼ‬ളѠൊ҄ҀຐไౖӐӝӑ̷сిതф‫ގ‬཈ъҁћпѿ̝Ҧ̷ҹҖӦң੓ѝьћᄜᅀџѷѣѷ।љрјћтє̞န౗38໪๘рѾѤ̝ђҁѾ҇ᅧᅀьћ༘ᅋ੎ၙѽѿѷྒ੎џқҠҰҰ̷ӓѣఢഓџ SEM ྯႏ੣౦ၔѣ‫ގ‬཈҇ુѴћйҀ̞㸫  㸫

ㅽ⣻Ό੿ტংؔᢼ ㅤ⏄᫛✤֝൧ㅥ ᮾ᳣ո⦕ㅾ
̜ႏय़ࢅခჿѤ̝န౗34໪๘ѣ೏௰‫ރ‬ဩќౡა‫޻ݏ‬य़ࢅᆛ‫ڱ‬Ѡೖಈъҁ̝ใ੟ᆁઞ୩ࢲ଩ѣඨໟѠѽјћ̝န౗35໪3ॉ2໙ѠҬҲ̷һьє̞य़ࢅള౒Ѥใ੟୩ࢲ଩пѽѨ๚ࡶਿ೶‫ࢥڵ‬ᆜय़ࢅ‫ۀ‬ќзҀ̞੎ၙ຿̝ౡള຿ѣᄼ̴џॶொࡹѨྐྵ഻̝҇ҙҗӞҬ̝ҲӦӄҢ૲ခથѣા฿рѾय़ࢅюҀшѝ҇ଘѝьћйҀ̞ѳє̝ใ੟୩ࢲ଩Ѥ̝ࢣຎᅧᅀҮӦҲ̷ຍ࿿ࠊᅬ૭౾ໟଅѝьћ̝યಈѣ‫ۦ‬ᅀ̝ࢲ‫ڲ‬ऌᇊ๸ѣࠊᅬࣅჄ҇৫јћйҀ̞͕य़ࢅ͖န౗38໪๘Ѥ̝،͑ UBR 5 /p 711 -HPV 27 E 8ೱঘ੣ᅀѠѽҀ཈с҈ӔҞҾҭӓ̝͒‫؍‬
͑D-ribose ᄥຐള EdAP ѠѽҀ໙ႏ໹ܑҙҗӞҬ࿸౦೒‫͑؎̝͒ޕ‬JC ҙҗӞҬѣ࿸౦ӔҞҾҭӓ
Ѡ࠙юҀय़ࢅ͒Ѡଙѿ೏҈ѕ̞،Ѥ̝‫ݏ‬य़ྊ࠱཰य़ࢅͅန౗36໪๘̼န౗38໪๘͆ѝьћ੃ൗъҁєय़ࢅќзҀ̞‫؍‬ѣ‫ݢ‬൏Ѥ̝ච௒ီ௩൜ࢲ଩ѝၿಗᅊથ௩൜ૉჄ‫ͅۀ‬ခથଡ᢮޻य़ࢅခ
ჿ̝͆ൌᆭᄽࢲ଩ͅ‫ܨ‬࿄ᄅ‫ݏ‬ൌ޻̝͆ె९໐ઃඎࢲ଩ͅ๫࢝ᅬ‫ݏ‬ൌ޻͆ѝѣࢣຎय़ࢅќзҀ̞؎Ѥ̝๚ࡶਿ೶‫ࢥڵ‬ᆜय़ࢅ‫ͅۀ‬ఋআࠅࢪဲ्य़ࢅ୹ྒౡ࿿࿫࿲࿫ේ͆ѝѣࢣຎय़ࢅќзҀ̞͕ࣅ౼͖န౗38໪๘Ѥ̝९රᇫဍ3၈ͅMicrobiol. Immunol. 6:: 349, 3126; 71: 364, 3127͆҇཈ྴьє̞޻‫ݶ‬཈ྴѤ്̝74‫ݸ‬໙ႏҙҗӞҬ޻‫޻ݶ‬ୠେ‫ͅݶ‬3ॊ്̝͆49‫ݸ‬໙ႏခથౡ࿿޻‫ݶ‬໪‫̝ݶ‬
്61‫ݸ‬໙ႏ໹ܑҙҗӞҬౡ഻޻य़ࢅ‫ݶ‬Ѡпйћ̝ल5‫ݸ‬৫јє̞͕޻‫ߋݶ‬ຍђѣണ͖୹ക޻‫ݶ‬Ѥ̝໙ႏခથౡ࿿޻‫̝ݶ‬໙ႏ୒‫̝ݶ޻ڮ‬໙ႏ૳६ຍ࿿޻‫̝ݶ‬໙ႏ૳६ຍ࿿‫̝ݶ޻ڮ‬໙ႏҙҗӞҬ޻‫̝ݶ‬ၿᅳ૳६ຍ࿿य़ࢅ‫ݶ‬ќзҀ̞ၿᅳ4ॢѣຍ࿿૳६યಈ࠙
ओଅќ৔౗ъҁҀၿᅳ૳६ຍ࿿य़ࢅ‫ݶ‬ѣय़ࢅ‫ݶ‬ᄃ‫ۀ‬ѝьћ്̝63‫ݸ‬ၿᅳ૳६ຍ࿿य़ࢅ‫ͅݶ‬န౗39໪3ॉ38໙̝ࣟ൙‫ݏڮ‬ൌ޻ྐྵ‫ۈ‬ంࠜ23‫ޏ‬ൌ‫ࡣݶ‬૭͆҇ଘੀьє̞ͅဍ౾̜ใ੟̜ᆁઞ͆㸫  㸫

ใ੟̜ᆁઞͅ୩ࢲ଩͆
य़ࢅ‫ݢ‬൏̢2̠UBR5/p711-HPV27 E8ೱঘ੣ᅀѠѽҀ཈с҈ӔҞҾҭӓ
̜̜̜̜̜3̠D-ribose ᄥຐള EdAP ѠѽҀ໙ႏ໹ܑҙҗӞҬ࿸౦೒‫ޕ‬य़ࢅ‫ޘ‬ᅆ
2̠UBR5/p711-HPV27 E8ೱঘ੣ᅀѠѽҀ཈с҈ӔҞҾҭӓ̜UBR5‫ڭ‬เથѤ̝UBR-box ᆛ‫ࠟ҇ڱ‬ѵခથᆙᄄ711 kDa ѣ࢏ൌҲӦӄҢ૲҇Ҧ̷Ҽь̝әӆҠҴӦपѣ‫ڵ‬љ N-end rule फᇔѣ࠱૲໢ૢৱ೎ќзҀѝ৤нѾҁћйҀ̞९ઢษџನფනрѾӅһѳќక݂ษѠဲഝъҁћйҀс̝ђѣౡᅬࡀ໸Ѥѽфခрјћйџй̞ࣞ໪̝થࡻḽс҈ѣ९‫ہ‬ќзҀ HPV27ѣ E8с҈ҲӦӄҢ૲ѝ࿸৾ള҇৔౗ь̝с҈݂ѝѣ࠙ᇍс૙ਫъҁє̞ႏय़ࢅѤ̝UBR5-E8ೱঘ੣ᅀѣခથࡀ৔ѝђѣౡ݂޻ษ‫ݷ҇ࡠڞ‬౸ь̝с҈݂ӔҞҾҭӓ‫ݷ‬ბѠ࠴ᄮюҀшѝ҇ჭษѝюҀ̞ಷ໪๘ѳќѣय़ࢅќ̝E8ѝ UBR5ѝѣॆ৾ѠѤ̝N-end rule ࠱૲ѣ໢ૢѠ୔ᅆџ UBR boxͅᄄ91ҕӒӁઓગ࠱͆ᆛ‫ڱ‬с࠙҄јћйҀૉс૙ਫъҁє̞UBR
box с E8ॆ৾ᆛ‫ڱ‬ќзҀѣрўлр̝3෭ѿѣॆ৾೒‫૳ޕ‬६҇৫јє̞ђѣॆ‫̝ݑ‬N-end rule ࠱૲ॆ৾ѝ E8ॆ৾сঘйѠࢢ৾ьзлૉсခрјє̞૒Ѡ̝E8ҲӦӄҢ૲ѣ༘ᅋ੎ၙќѣൊଆษ‫ڋ‬ซౖ҇෕Ѯє̞E8ѤӊӠҹҕҰ̷ӓ೒‫ޕ‬੓ഝ੔݁ќ‫ڋ‬ซ݂ь̝ҲӦӄҢ૲฽૽೒‫ޕ‬੓ҨҗҢӠӋҠҪӒҼഝ੔݁ќѤ̝ൾନაќзҀшѝсခрјє̞UBR5ूഠ MEFs ќѤ̝ჿౡचMEFs ѝཿ޶ьћ̝ E 8ҲӦӄҢ૲Ѥѽѿ࿋‫ڋ‬ซ݂юҀૉѷ૙ъҁє̞шҁѾѣॆ‫ݑ‬рѾ̝
UBR5Ѥ UBR box ᆛ‫ݵ҇ڱ‬ьћ E8ѝॆ৾ь̝‫ڋ‬ซ݂юҀᄃ߇҇ૐјћйҀ݉໸ౖс૙ਫъҁє̞
3̠D-ribose ᄥຐള EdAP ѠѽҀ໙ႏ໹ܑҙҗӞҬ࿸౦೒‫ޕ‬̜໙ႏ໹ܑҙҗӞҬѣകюҀӈӜӆҙҗӞҬѤ̝ҙҗӞҬ૜ఓѣ RNA ‫ږ‬ഝౖ RNA ৾౗ৱ೎Ѡѽјћ࿸౦с৫҄ҁћйҀ̞шѣৱ೎Ѥ̝୘ଘ੎ၙѠѤഝ੔ѐя̝৊ҙҗӞҬᄅѣҲ̷ҥҶһѝьћධჭъҁћйҀ̞ຠ‫ౖڤ‬ѣ৹й୘ଘӐӝӔӜ̷үѠཿѮћ̝ҙҗӞҬᄢᅗӐӝӔӜ̷үѤ࠱૲ຠ‫ౖڤ‬сคйшѝсඑѾҁћйҀ̞ႏय़ࢅќѤ̝DNA ӐӝӔӜ̷үѣ࠱૲ќзҀҺҝ
ҠҪӝӏ̷Ҭѣᆭ૊৔ഉ҇ૐљ EdAP ѣ৊ҙҗӞҬ঳‫෕҇ݑ‬Ѯє̞໙ႏ໹ܑҙҗӞҬ߷ಠ੎ၙѠ EdAP ୷ᅬ҇৫јєѝш҂̝ᄜ‫ڞ‬џ৊ҙҗӞҬ੣ᅀс।Ѿҁє̞шѣॆ‫ݑ‬Ѥ̝୘ଘӐӝӔӜ̷үѭѣ off-target ঳‫ݑ‬ѣคй̝৊ҙҗӞҬޮઓ‫ڮ‬ᄅѣ‫ގ‬཈Ѡ৮फ़ќтҀѝ৤нћйҀ̞㸫  㸫

Ӟᴻٛ᪭ᮾ᳣ⲏࣕ

ㅽ‫֝⽶ף‬൧ᮾ᳣ո⦕ㅾㄻㄻㄻㄻ
̜ႏခჿќѤ̝݈ᆽѠཕлॶொќѷзҀ͑с҈͒ѝ͑ᇢ݂̝͒ђьћ݈ᆽ҇౒টюҀєѶѣ
͑਻ౡ‫ڮ‬ᆒ͒҇य़ࢅവொѝь̝2͆૱߶ѣ९‫ہ‬ѣ‫ݷ‬ბ̝3͆ྵ݆ఒඊၒၔѣ‫ގ‬཈̝4͆‫ڮ‬ᄅ࿁ѣ‫ގ‬཈ѣࠒ฿рѾ̝͑૔ᆒၒၔѣ‫ގ‬཈рѾᄬၼ‫޻ڮ‬ѭѣื‫͒ގ‬Ѡѵцћय़ࢅ҇৫јћйҀ̞ॶ੔̝ܱ੟ୢᇚຠໟࢲ଩ͅတໟ̝͆๦੟ქ࿎୩ࢲ଩ͅခჿ౾ໟଅ̝͆આႏ೶થ஄ଛѣल4჏Ѡѽѿ৔౗ъҁћйҀ̞̜
̡ܱ੟ຠໟࢲ଩Ѥ̝န౗35໪๘ષᅶൌ޻ಘᅹษय़ࢅ࠱཰ज౗બ܎ૉࣅ઼͑૲Ӣ̷ӞҼѣᆤட‫ܥ‬ᅀ҇ჭફюय़ࢅ࢑฿ज౗̝͒࿧ใ‫޻ݏ‬ఁࢺ੗ඇຠซय़ࢅ஄౗͑໎૔૱߶ѠവюҀҬӈҖӦҧ઼૲౒ট҇ྯษѝюҀ႟ӒҢӠҼӔҗӦᆒၔѣ‫ގ‬཈͒Ѡ੃ൗъҁћпѿ̝ҬӈҖӦҧ઼૲ѣࠒ฿рѾ໎૔ౖଡ᢮૱߶ѠവюҀంࡋ૔ᆒၔѣ‫ގ‬཈य़ࢅ҇৫јћйҀ̡̞๦੟୩ࢲ଩Ѥ̝шҁѳќѣ glycogen synthase kinase 4ԓс᪴ࠣ҇ࠟѵതфѣர݂࠰ࠣѠࢣ෭юҀ૔ᆒྯษќзҀшѝ҇ბѾрѠьћтєय़ࢅ҇ъѾѠకѶћ̝GSK4ԓ҇Ҳ̷ҥҶһѝь
єޮઓ‫ڮ‬ᄅѣೖᄅ̝ђьћࠣ੎ၙрѾ༎ୟъҁҀқҢҰҰ̷ӓѠ࠙юҀय़ࢅ҇৫јћйҀ̞ѳє̝ࠣߵ੎ၙѠ࠙юҀ཈।рѾ̝ђҁѾ҇౞௜੎ၙѠ‫ܥ‬ᅀьє੎ၙ୸࠽݂Ѡ࠙юҀय़ࢅҹ̷ӑѷဗ৫ьћ৫јћйҀ̡̞આႏ஄ଛѤ̝๦੟୩ࢲ଩ѝѝѷѠ̝ᇍणьћޮઓ‫ڮ‬ᄅѠ࠙юҀय़ࢅ̝қҢҰҰ̷ӓѠ࠙юҀय़ࢅ̝੎ၙ୸࠽݂Ѡ࠙юҀީଠ‫ݷ‬౸҇৫јћйҀ̞ͅဍ౾̜๦੟̜ქ࿎͆㸫  㸫

ܱ੟̜ୢᇚͅຠໟࢲ଩͆
य़ࢅ‫ݢ‬൏̢ҮӜӒҼ̺ҬӈҖӦҧӒқӝӦͅSM͆ӃӜӦҬ҇Ҳ̷ҥҶһѠьєଡ᢮ౖқҢҰҰ̷ӓ౒টѠѽҀ໎૔ౖ༭ेྐྵѠവюҀంࡋ૔ᆒၔѣ‫ގ‬཈य़ࢅ‫ޘ‬ᅆ
̜ӑӞҴӧҚҫҢӞളͅMVB͆຿ќ̝қӦҼҨҗһ̷ҪҬъҁєज૲႟ѣ‫ڵ‬࿫сқҢҰҰ̷ӓѝьћઍୟъҁ̝қӦҼҰ̷ӓѣӝҨҗҢӝӦңᄼफᇔѠѽѿ੎ၙ‫ޓ‬ѭၑୟъҁҀ̞ෟझ211-511 nm ѣ႟஛ၙളќзҀқҢҰҰ̷ӓѤ̝౺Ѵ‫ݞ‬ѝьћҪңҽӞ̡ҲӦӄҢ̝miRNA̝DNA̝฽૽‫ہ‬થџў҇ࠟѴ̝ђѣ઼૲ϩ୔႟Ѥ႟ӒҢӠҼӔҗӦ҇৔౗юҀҬӈҖӦҧ઼૲сၠ࿐ќзҀ̞༭ेྐྵ੎ၙѤଡ᢮ౖқҢҰҰ̷ӓ҇੎ၙࠗҦӒӘҾҤ̷Ҳ̷ѝьћઍౡ̝ၑୟ
ь̝ҝ̷һҢӜҗӦษѠ༭ेྐྵ૜ঃ੎ၙѣഄ௮҇ᄥຐь ¥ ѳє̝ӄӜҢӜҗӦษѠਓ఼ྒ஛ࠅ
ࢪ੎ၙͅ੎ၙௐ‫ ౖޕ‬T ੎ၙ̝৊ଡ᢮ౖਓ఼ࢄѹӑҢӠӈҔ̷ҫ͆҇ଡ᢮ഄ௮ၒষѭࡀ໸ဦߺюҀ̞‫̴ݫ‬ѤҬӈҖӦҧ઼૲ҬӈҖӦҧӒқӝӦͅSM͆౒টсқӦҼҰ̷ӓќѣଡ᢮ౖқҢҰҰ̷ӓѣᄑ೾ಱအѠ࠙ᄮюҀૉ҇཈।ь̝ҬӈҖӦҧӒқӝӦ৾౗ৱ೎ͅSMS͆҇‫ݵ‬ьєҮӜӒҼ /SM ӃӜӦҬ౒টѠѽҀ႟৔ഉဦ݂сଡ᢮ౖқҢҰҰ̷ӓѣઍౡ̝ၑୟ̝ଙѿਕѴࡀ৔෕ಊѠ୔ᅆќзҀѝ৤нҀ̞ႏय़ࢅќѤ̝༭ेྐྵ੎ၙߗѝ‫ڭ‬เથ‫ރ‬ဦӑҙҬ༭ेྐྵӕҺӞ҇ᅀйћଡ᢮ౖқҢҰҰ̷ӓѣຍ഻ͅ႟ӒҢӠҼӔҗӦ΃қӦҼҰ̷ӓ΃қҢҰҰ̷ӓѣઍౡ̝ၑୟ͆҇ҬӈҖӦҧ઼૲Ѡѽѿ౒টюҀшѝќ̝༭ेྐྵ੎ၙѠ੎ၙળ҇ᄥຐюҀࡀ৔҇җӦ̡ӆһӠ੎ၙपѝҗӦ̡ӆӏຍ࿿ӕҺӞќ‫ݷ‬ბюҀ̞ђѣ౗‫࠱҇ݑ‬Ѡ̝ SMS ҇‫ݵ‬ьєҬӈҖӦҧ
઼૲౒ট҇Ҳ̷ҥҶһѝьєଡ᢮ౖқҢҰҰ̷ӓᅍ౒঳‫ݑ‬ѠѽҀӅһ༭ेྐྵѣంࡋ৊с҈૔ᆒၔѣ‫ގ‬཈ѣൿ୾ѝьєй̞̜௒ࡌѣय़ࢅჭษ҇൦౗юҀєѶѠ̝3126໪๘Ѥ̝ҬӈҖӦҧ઼૲ѣᄼ̴џ૱߶ѠпцҀྐྵ഻ࡀ໸ѠпцҀ‫ࡠڞ‬Ѡљйћ‫ݷ‬౸ьͅInt. J. Clin. Oncol. 31: 549, 3126; Cell Death Dis. 7: e2828,
3126; Sci. Rep. 6: 23:71, 3126; Mol. Cells 49: 593, 3126; Sphingolipids: Biology, Synthesis andFunctions, Chapter 6, edited by Catala Angel. NOVA science, 3126; Leuk. Res. 4:: :75, 3126; Bioactive
Sphingolipids in Cancer Biology and Therapy, Chapter2, 34-62, 3126; Oncogene 3126: 441, 3126; Am. J.
Physiol. Cell Physiol. 422: C26, 3127; Autophagy 23: 333, 3127; Mol. Biol. Cell 38: 3148, 3127̝͆੎ၙѠпцҀज૲႟҇ඩ௿ѝьєᄼ̴џ஛࠰߲ѣౣ౦ѝခᅲ̝џѾѨѠђѣ઼૲ခ౸ၔѣ‫ގ‬཈҇৫јєͅJ. Lipid Res. 67: 26:5, 3126; J. Biochem. 26:: 684, 3127̞͆㸫  㸫

๦੟̜ქ࿎ͅ୩ࢲ଩͆
य़ࢅ‫ݢ‬൏̢ࠣߵ੎ၙѝ੎ၙ୸࠽݂Ѡࢣ෭юҀခથࡀ৔ѣ‫ݷ‬ბѝ੎ၙ‫ޓ‬஛ၙѣ‫ݑ‬єюᄃ߇ѣ‫ݷ‬ბय़ࢅ‫ޘ‬ᅆ
̜੎ၙခྀ஛ၙќзҀқҢҰҰ̷ӓѤ੎ၙрѾခྀъҁҀൌтъ 61-311nm น๘ѣ઼૲໐୔႟
৔ഉ҇ѷљ஛ၙќзҀ̞ࣞ໪ѣय़ࢅѠѽѿ̝қҢҰҰ̷ӓѤ੎ၙࠗೱঘ੣ᅀѣ༙ളѝьћ୔ᅆџᄃ߇҇ૐі̝қҢҰҰ̷ӓ҇ଦцଙјє੎ၙѣज૲҇ဦ݂ъѐҀџў̝ౡაѣ཈ౡ̝კ‫̝۽‬ߵ੎ၙ̝੎ၙ୸࠽݂๸̝࿴ৄйౡაॶொѣ౒টѠ࠴ᄮьћйҀшѝс၈ਇъҁћйҀ̞шѣय़ࢅခჿѤѳѕ୸࠽ඍ‫ޏ‬Ѡзѿ̝ microRNA ̝ mRNA џўѣқҢҰҰ̷ӓѭѣҰ̷ҹҖӦңࡀ৔̝ђьћଦцଛഋѣ੎ၙѠѽҀқҢҰҰ̷ӓѣଙѿਕѴࡀ৔ѝйјє࠱ೊษџခથࡀ৔ѠљйћѤୌခѠ‫ݷ‬ბъҁћйџй̞ࠣ฽‫ڥ‬ѠпйћѷқҢҰҰ̷ӓсࠣѣ฽‫ڥ‬ьѹюйྒ஛ࠅࢪ৔ඞѠຌйћйҀ݉໸ౖс૙ਫъҁћйҀ̞̜‫̴ݫ‬с‫ގ‬཈ьє੎ၙࠗೱঘ੣ᅀ҇‫ݷ‬౸юҀєѶѣంєџ༘ᅋᄵ࠰ͅNICO-2̢New
Intercellular Communication Observation plate ver2̢WO3126/12::49Ѱр͆҇ᅀйћ̝‫ݷ‬౸҇੧໪๘ѽѿ‫ۃ‬тഘйћ৫џјћйҀ̞ႏय़ࢅ‫ݦ‬นѠпйћ̝қҢҰҰ̷ӓѣҬҢӝ̷ҾӦңपѝьћѣߋᅀс݉໸ќзҀшѝ҇।ୟьє̞ѳє̝ᄅ੓ѠѽѿқҢҰҰ̷ӓѣຍ഻с‫ڤ‬џҀшѝ҇
।ୟь̝‫ݷ‬౸ҷ̷Ӟѣ‫ގ‬཈ࡹѨྵ݆҇৫џјћйҀ̞шҁѾѠ࠙ьћѤ̝ਈᅶс҈य़ࢅҮӦҲ̷ѝѣࢣຎय़ࢅсక৫ඩќзҀ̞̜ъѾѠ̝‫̴ݫ‬Ѥ̝шҁѳќѠ glycogen synthase kinaseͅGSK͆4ԓс᪴ࠣ҇ࠟѵതфѣர݂࠰ࠣѠࢣ෭юҀ૔ᆒྯษќзҀшѝ҇ბѾрѠьћтє̞ຠѠ᪴ࠣѠљйћѤ̝ђѣ੣ᅀӔҞҾҭӓѠљйћბѾрѠьћтћйҀс̝қҢҰҰ̷ӓѣౡ౗̝༎ᝄѠѷ GSK4ԓс࠙ᄮьћйҀшѝ҇।ୟь̝GSK4ԓ҇Ҳ̷ҥҶһѠьє૔ᆒᄅ‫ގ‬཈ѣєѶѠ̝๫࢝ীࣅൌ޻ѣ౟ྑ୩ࢲ଩Ѿѣय़ࢅңӞ̷ӊѝ̝GSK4ԓ҇Ҳ̷ҥҶһѠьєంࡋޮઓѣ‫ގ‬཈҇৫јћйҀ̞ђѣ৊ଡ᢮঳‫ݑ‬ѝ੎ၙѭѣଙѿਕѴ໸Ѡљйћѣྵ݆҇৫јєॆ‫̝ࠣݑ‬੎ၙѠവюҀಱൗษџ৊ଡ᢮঳‫҇ݑ‬໢Ѷ̝ຠ࢕ୟࠫ҇৫јє̞ႏय़ࢅѤ̝ඩ࿫‫ࠅ܆‬ҦӦҰ̷ҪҕӓрѾѣ္஄ࣟѠѽҀय़ࢅќзҀ̞̜੧໪๘ѽѿ̝ࠣߵ੎ၙࡹѨ੎ၙ୸࠽݂Ѡࢣ෭юҀంєџӔҞҾҭӓѠ࠙юҀय़ࢅ҇बഘьћпѿ̝ంєџӔҞҾҭӓ҇཈।ьєєѶ̝ॶ੔ຠ࢕ୟࠫѠষцћ̝ީଠҺ̷Ҳ҇ଙຝඩќзҀ̞㸫  㸫

આႏ̜೶થͅ஄ଛ͆
य़ࢅ‫ݢ‬൏̢ࠣ੎ၙѠпцҀқҢҰҰ̷ӓѣଙѿਕѴࡀ৔ѝ੎ၙ຿ຍ഻ѣ‫ݷ‬ბय़ࢅ‫ޘ‬ᅆ
̜੎ၙࠗೱঘ੣ᅀ҇൷лқҢҰҰ̷ӓѝॿѥҁҀ੎ၙခྀ஛ၙѣय़ࢅѠ̝ࣞ໪ൌтџධჭсେѳјћйҀ̞қҢҰҰ̷ӓѤ઼૲໐୔႟ќज౗ъҁҀෟझ61-311nm ѣ஛ၙќ̝ౡളќѤന‫ۼ‬ѹे‫̝ۼ‬ໝ๸ѣള‫ۼ‬ඩќࠒੴъҁ̝༘ᅋ੎ၙѣ௒౟ќѷࠒੴъҁҀ̞mRNA ѹ micro-RNA̝඄༭૲с຿၆ъҁ̝ђҁѾѣ଩ଦѠѽјћ࿴ৄйౡაॶொѭ࠙ᄮь̝ຠѠࠣ੎ၙѣခྀюҀқҢҰҰ̷ӓѤࠣ฽‫ڥ‬Ѡпйћ୔ᅆџᄃ߇҇൷јћйҀ݉໸ౖс૙ਫъҁћйҀ̞ౡള຿ќѤᄼ̴џ௢഻ѣ੎ၙсࢣഝь̝ђҁѓҁсೱঘ੣ᅀьћйҀѝ৤нѾҁҀєѶ̝ೱঘ੣ᅀѣᄜ჆Ѡѽѿ੎ၙрѾѣခྀ࿿с‫ڤ‬џјћйҀ݉໸ౖсзҀ̞шѣєѶ̝ೱঘ੣ᅀय़ࢅќѤ̝ೱঘ੣ᅀюҀࠅࢪ݁ќ೗ၒ҇बഘษѠ૑ࠗफ‫ݦ‬ѝࢣѠࠒੴюҀшѝс୔ᅆќзҀ̞‫̴ݫ‬ѣࢲ૭ќѤ̝੎ၙࠗೱঘ੣ᅀ҇ࠒੴюҀ༘ᅋӊӟ̷һͅNICO-2͆҇‫ގ‬཈̡૳ᅀ݂ьћпѿ̝шҁѾ҇ᅀйє૳६पќѤ̝ౡള຿ѠࣞйࠅࢪќခྀъҁҀқҢҰҰ̷ӓ҇‫ݵ‬ьє੎ၙࠗೱঘ੣ᅀѣग़ୟс݉໸ќзҀ̞௒ࡌѣᅧ฿҇ౡрь̝ౡള຿ќࡎшјћйҀқҢҰҰ̷ӓଙѿਕѴѝђѣ੎ၙ຿ຍ഻
Ѡљйћ̝ђѣᄢᅗ҇ࣥအьєခથࡀ৔ѣ‫ݷ‬ბ҇৫лєѶѠ̝ѳяѤ̝૳६प҇৔ඞьє̞န
౗38໪๘Ѥ̝шҁѾѣྵ݆पѣєѶѣ࠱ႏษ‫ݷ‬౸҇৫јє̞қҢҰҰ̷ӓ҇݉ા݂ьє໐ଠᆭѣ੎ၙߗѣପᅶѠ౗লь̝шҁѾѣ੎ၙѝ NICO-2҇ᅀйҀшѝѠѽѿ̝੎ၙ຿ᄢᅗѣқҢҰҰ̷ӓѝ੎ၙ‫ޓ‬ᄢᅗѣқҢҰҰ̷ӓ҇ૢအюҀшѝс݉໸ѝџјє̞࣮ളษѠѤ̝GFP ඄༭҇қҢҰҰ̷ӓྴო඄༭૲ќзҀ CD74ѠӜӌӞьє੎ၙ҇‫ڵ‬ၒѣ༘ᅋઁѠ໛ҁ̝ࠗѠ੎ၙс෭ѿཌྷцџйӈҖӞҲ̷҇໛ҁҀшѝѠѽѿ̝མവഋ༘ᅋઁѣ੎ၙ຿Ѡпйћ̝GFP сग़ୟъҁє੎ၙ຿ࣂେളѤ̝੎ၙ‫ޓ‬ᄢᅗѣқҢҰҰ̷ӓᄢᅗќзҀшѝс૙ਫъҁҀ̞шҁѾѠљй
ћ̝ခથౡ࿿޻ษྵ݆ѝ̝র޻ษџྵ݆҇৫јє̞ॆ‫૳̝ݑ‬६‫ގ‬ઢঞ̝৹߷๘५ྒࢽ҇ᅀйє௙̝৾59૑ࠗঞѠѤ̝མവഋ༘ᅋઁѠଙѿਕ҈ѕқҢҰҰ̷ӓѝપ҄ҁҀࣂେ‫҇ݹ‬໢ѶєшѝѠѽѿ̝੎ၙ຿ѣқҢҰҰ̷ӓଙѿਕѴѠ࠙юҀྵ݆с݉໸ѝપ҄ҁє̞‫ڵ‬ၒ̝৹߷๘ќѤџй५ྒࢽќѤ̝231૑ࠗঞѳќқҢҰҰ̷ӓѣଙѿਕѴ҇ࠒੴюҀшѝсୟᅗџрјє̞шҁѾѣग़ୟपѠѤ̝५ྒࢽѣ߷๘сൌтфۭࢾюҀшѝсბѾрѝџјє̞ѳє̝ީଠ඄༭૲ѣ‫ڥ‬ຍѠљйћѣྵ݆ѷ৫јє̞59૑ࠗঞѠѤམവഋѠᄄ2 / 5ᆙѣ඄༭૲сग़ୟъҁєшѝр
Ѿ̝шҁѾӈҖӞҲ̷҇ᅀйє૳६पќ੎ၙࠗೱঘ੣ᅀѠљйћѣग़ກс݉໸ќзҀшѝсბѾрѝџјє̞ਘঞѤ̝ᄅ੓ѠѽҀқҢҰҰ̷ӓѣခྀѹଙѿਕѴᆙѣ‫ڬ‬йѠљйћग़ກьћйфᄬซќзҀ̞㸫  㸫

ㅽṤ‫֝ك‬൧ᮾ᳣ո⦕ㅾㄻㄻㄻㄻㄻ
̜ႏခჿќѤ̝ౡള຿ќౡ౗ъҁҀީଠହႩ๻݂ઍ࿿ͅ advanced glycation end-products,
AGEs͆ѣඩќѷ̝ӉҼҙ๻ѹ‫ݑ‬๻ൊଆඩࠗളѣңӝҮӞҕӞҺӅҼѠᄢᅗюҀ AGEsͅtoxic
AGEs, TAGE ѝა჏͆Ѡຠ݂ьєय़ࢅ҇శ৫ьћпѿ̝͑ౡߋ଻߸ྐྵѣ཈ஶ̡కืѠпцҀ
TAGE ྐྵ‫ہ‬ಋ్͒҇‫މ‬Ѡ಑࣫цћดஔьћйҀ̞̜န౗38໪๘ѷ޻຿‫ޓ‬ѣय़ࢅ૭ѝࢣຎय़ࢅ҇૳યь̝ᇫဍ9ဩ̝೴ಋ4ဩ̝ຠ࢕ୟࠫ2ॊ̝޻‫ݶ‬
཈ྴ2:‫ͅݸ‬лі‫ޓއ‬2‫͆ݸ‬ѣय़ࢅࣅ౼҇࢒чєണ̝ච຿౞ࡠࢲ଩Ѥຽᆖంဎଃଘ਺ҪӦӐҫҙ
ӓѣ࠱෕৭‫ܐ‬Ѡпйћ͑๻݂҇ၼйќҕӦҴқҗҫӦң̼ॶൊѣ௴଻߸Ѡಡѵ҄џ̼͒ѝ൏ьє৭‫҇ܐ‬৫й̝๻݂౒টѣ୔ᅆౖ҇‫ڵ‬ཥষцѠခрѿ‫ڠ‬фி‫ݵ‬ьє̞ъѾѠ̝ච຿ࢲ଩Ѥန౗38໪๘ඩ࿫ඒࣥ‫ڮ‬ᆒ̡ӃҗҝपҪ̷ҭ཈ྴ‫ݶ‬Ѡпйћ͑๻݂҇ၼйќౡߋ଻߸ྐྵᄬၼ̼Toxic
AGEsͅTAGE͆ྐྵ‫ہ‬ಋрѾѴєంєџᄬၼ̺૔ᆒಘᅹ̼͒ѝ൏ьєশຉ཈ྴпѽѨӐҬҲ̷཈ྴ҇৫й̝TAGE य़ࢅѣૉࣅ݂ѭѣ݉໸ౖ҇ৄфி‫ݵ‬ьє̞̜य़ࢅྊ࠙ᇍќѤ̝ࡴ‫گ‬٪ࡉથຠໟ஄ࢲсൊྴय़ࢅଅќ̝ంєѠ‫ݏ‬य़ྊଔଛय़ࢅͅ B͆͑ౡߋ଻߸ྐྵ҇ᄬ।юҀంьй๻݂඄༭૲ѣຎซ̝пѽѨ૱߶ᄬၼ௴࿁౗ခѣ൸੬͒Ѡ੃ൗъҁє̞
ѳє̝ℛใട௹஄ࢲсൊྴќ̝‫ݏ‬य़ྊଔଛय़ࢅͅB͆͑ହႩ๻݂ઍ࿿Ѡඨჭьє๻ໝྐྵတ཈᪴
ࠣഊక඄༭૲ѣຎซࡹѨ߼࡫ᆭࠟᄜ݂৾࿿ѣ੣ᅀ̝͒ච຿ࢲ଩сൊྴ̝௒ใඬઝ஄ࢲ̝ℛใ஄
ࢲсခ൷य़ࢅଅќ̝‫ݏ‬य़ྊ࠱཰य़ࢅͅB͆͑ॶൊѣ௴଻߸ѣຠ෈ѝྌҕӞҦ̷Ӟ઼ౖၶౖࠏௐ
‫ޕ‬ѣ཈ஶ̡కืѝѣ࠙ᇍౖѠ࠙юҀय़ࢅ̝͒ච຿ࢲ଩сൊྴ̝ࡴ‫گ‬ຠซ஄ࢲсத᩸य़ࢅଅќ̝ၿᅳӜҗӈҨҗқӦҬҢӜҬҲ̷͑ౡߋ଻߸ྐྵѣ཈ஶ̡కืѠпцҀంࡋҲ̷ҥҶһѝьћѣTAGE ѣ࠙ᄮѝђѣ೒લ͒Ѡѷबഘ੃ൗъҁє̞ъѾѠ̝ච຿ࢲ଩Ѥ്̝3:‫ݸ‬ၿᎣс҈࠱ࣟ஄౗ࣟૉࣅ͑‫ౖٶ‬ଡ᢮ѣ཈ஶ̡కืѠпцҀ຤ౖହႩ๻݂ઍ࿿ͅToxic AGEs, TAGE͆ѣ࠙ᄮ͒Ѡѷ੃ൗъҁ̝ৄф TAGE य़ࢅ҇ื‫ގ‬ьє̞̜ࢲ‫ڲ‬ოќѤ̝ච຿ࢲ଩Ѥൌ޻‫޻ڮۈ‬य़ࢅ‫ݏ‬ౡა‫޻ݏڮ‬ಕ্ͅౡളခથ‫ݷ‬౸޻͆य़ࢅફຐࢲ‫ۀ‬џѾѨѠय़ࢅ‫ۀښ۫ۦݏ‬ѝьћ̝޻‫ڕ‬௾ਯѹ໛ુࣅჄѠण҄јєണ̝ၿᅳൌ޻пѽѨৄ๦ਈ੒ൌ޻ީᄅ޻࿫Ѡпйћຠအ৭ࡠ̝҇ѳє̝჏ॾܵધᅶൌ޻ൌ޻‫ۈ‬Ѡпйћೖᄅౡა‫޻ݏ‬ຠအ৭ࡠ҇൷๵ьє̞௒ใ஄ࢲѤ̝૨ྑࠈধಕჸ޻৒ѣྌ௜࣍৭નѝьћ‫ݷ‬ၩౡᅬ޻ I ѣ৭ࡠͅ2:૑ࠗ͆҇൷๵ьє̞ѳє̝௒ใ஄ࢲ̝ℛใ஄ࢲѤ‫޻ڮ‬࿫്3޻໪ѣ PBLͅౡᅬ޻ II͆ѹ໛ુࣅჄ҇൷јє̞̜‫ߋݶۀښ‬ຍќѤ̝ච຿ࢲ଩Ѥ޻຿‫ޓ‬ѣ‫ݶۀښ‬ѣ‫ۀښ‬ѹ޻‫ݶ‬ѣྵࡣ‫ۀ‬ѝьћީଠ‫ݶۀښ‬ѹ޻‫ݶ‬‫۫ۦ‬Ѡ୍ૉьєണ̝௒ใ஄ࢲ̝ℛใ஄ࢲѤࢣຎᅧᅀҮӦҲ̷ѣࡀ࠰ࠊᅬ૭ѣ‫ۀڵ‬ѝьћ̝ࡀ࠰ѣࠊᅬࣅჄ๸҇൷јє̞ͅဍ౾̜ච຿̜౞ࡠ͆㸫  㸫

ච຿̜౞ࡠͅࢲ଩͆
य़ࢅ‫ݢ‬൏̢ౡߋ଻߸ྐྵѣ཈ஶ̡కืѠпцҀ Toxic AGEsͅTAGE͆ѣ࠙ᄮѝђѣ೒લय़ࢅ‫ޘ‬ᅆ
̜шҁѳќ̝ౡള຿ќౡ౗ъҁҀީଠହႩ๻݂ઍ࿿ͅadvanced glycation end-products, AGEs͆
ѣඩќѷ̝ӉҼҙ๻ѹ‫ݑ‬๻ൊଆඩࠗളѣңӝҮӞҕӞҺӅҼѠᄢᅗюҀ AGEsͅtoxic AGEs,
TAGE ѝა჏͆с̝AGEs ଦᄵളͅreceptor for AGEs, RAGE͆҇‫ݵ‬ьћౡߋ଻߸ྐྵѣ཈ஶ̡కื
Ѡࢬф࠙҄јћйҀшѝ҇‫ݷ‬ბьћтє਼̞ࣞќѤ̝੎ၙ຿ TAGE ѣౡ౗̺ජ౺пѽѨ੎ၙௐ‫ޕ‬Ѡཕлेඩѭѣ TAGE ѣ‫ڸ‬൩сౡߋ଻߸ྐྵѣ཈ஶ̡కืѠ୔ᅆќзҀшѝс૙ъҁћтћп
ѿ̝ంєџय़ࢅ҇ื‫ގ‬ьћйҀ̞̜ਘ໪๘ѣࡌ໫юѮтࣅ౼Ѥ̝ခჿय़ࢅଅ5჏сࢣරѠџѿ̝ࣟ൙‫ݏڮ‬ൌ޻‫ݶ޻ڮ‬51ଯ໪ࡌ໫ຠେ৽Ѡ͑ౡߋ଻߸ྐྵѣ཈ஶ̡కืѠпцҀ Toxic AGEsͅTAGE͆ѣ࠙ᄮ͘ంєџᄬၼಘᅹ͘
̼௴ૉౖ AGEs пѽѨ๻຤ౖѣఊ૳̼͒ѝ൏ьє೴ಋ҇঱ྴьєшѝќзҀ̞ѳє̝͑ྌҕӞҦ̷Ӟ઼ౖၶࠏௐ‫ ͅޕ‬NAFLD ͆пѽѨҕӞҦ̷Ӟౖࠏௐ‫ ͅޕ‬ALD ͆ѠпцҀ Toxic AGEs
ͅTAGE͆ྐྵ‫ہ‬ಋ͒ѝ൏ьє೴ಋ҇ Int. J. Diabetes Clin. Res. 3: 5, 3126Ѡ̝ъѾѠ̝͑ྌҕӞҦ̷Ӟ઼ౖၶࠏܑͅNASH͆Ѡ࠙ᇍьєࠏ੎ၙࠣѣ཈ஶ̡కืѠпцҀ TAGE-RAGE पѣ࠙ᄮ͒Ѡ࠙юҀ೴ಋ҇ World J. Hepatol. 8: 356:, 3126Ѡ঱ྴьє̞̜ेඩ TAGE ᆙ഑ซѣᆤடษ‫҇ࡠڞ‬૙юᇫဍѝьћ̝2. ྌ B ྌ C चࠏࠣ߶ଅќѤ NASH ൴ລ߶ଅѠཿѮћेඩ TAGE ᆙсᄜ‫ڞ‬Ѡ৹йшѝͅJ. Clin. Lab. Anal. 3:: 591, 3126̝͆3. ‫ܩ‬ଲѣಷষтҦӎ̷һय़ࢅͅEuropean Prospective Investigation into Cancer and NutritionͅEPIC͆cohort͆ѣ‫ڵ‬ࠅѝьћ3,211ग़ളѣेඩ TAGE ᆙ҇഑ซьєॆ‫े̝ݑ‬ඩ TAGE ᆙс৹йऍќѤෟීࠣѣӝҬҢсᄜ‫ڞ‬Ѡഄ݈юҀшѝͅCancer Epidemiol. Biomarkers Prev. 35: 2966, 3126̝͆4. ्௜ଅѠཿѮћ๼৾૫෕ஶ߶ଅќѤेඩ TAGE ᆙсᄜ‫ڞ‬Ѡ৹ф̝ఒඊӑ̷Ҟ̷ѝьћѣ݉໸ౖсзҀшѝ
ͅNeurosci. Lett. 6:4: 62, 3126͆҇঱ྴьє̞̜ђѣണ̝޻‫ޓ‬ѝѣࢣຎय़ࢅѠѽѿ̝2. ᆸૠ‫ڮ‬ᆒ‫޻ݏ‬ൌ̡ᄅѝѤ̝Sci. Rep. 6: 24424, 3126̝
3. ࡶᅾရൌ̡‫ڮ‬ѝѤ̝J. Clin. Endocrinol. Metab. 211: E84:, 3126̝4. ৄ๦ਈ੒ൌ̡ᄅണѝѤ Nutr.
Food Technol. 2: 3, 3126; Med. Hypotheses 95: 5:1, 3126̝5. ਩‫ݱ‬ൌ̡‫ڮ‬ѝѤ̝Heart Vessels, 3126
Dec 34. [Epub ahead of print] ѣᇫဍ҇঱ྴьє̞㸫  㸫

௒ใ̜ඬઝͅ஄ࢲ͆
य़ࢅ‫ݢ‬൏̢ӜҶһ୸ൊ༘ᅋ௿ࣗ੎ၙѠпцҀ੎ၙ຿ TAGE ජ౺ѝ੎ၙௐ‫ޕ‬य़ࢅ‫ޘ‬ᅆ
਼̜ࣞҕӦҴқҗҫӦңѝйлॹᅄ҇૛Ѡьџй໙сџйѝйлน̝шѣॹᅄѤӑҬҦӒѣඩќ࿈ཤѠଙѿ௒чѾҁћйҀ̞ᇢ݂ѣ९‫ہ‬ѣѧѝљѠହႩ๻݂ઍ࿿ͅadvanced glycation endproducts, AGEs͆ѝйлᇢ݂࿿૲сࡲর҇ᅐѨћйҀ̞໙௜ౡߋѣඩќ௴ౡߋѠ࠙҄Ҁౡള຿ќѣᇢ༌࿿ѣජ౺ѝйлࠒ฿рѾྣ಺ษѠඨჭъҁҀ̞шѣ AGEs ѤଘѠ๻ໝྐྵ̝ђҁѠ༄ౡьє৾တஶ̝ҕӞҷӂҗӑ̷ྐྵ̝ྌҕӞҦ̷Ӟ઼ౖၶࠏܑͅNASH͆๸̝തфѣౡߋ଻߸ྐྵѠ࠙ᄮюҀѝъҁћйҀ̞ђѣѽлџ૱ྐྵѣඩќ௿ेࠊྐྵဦѤຍႿড়݂ஶџўѠඨჭъҁћйҀ
ѷѣѣ̝௿ആѠ࠙ьћѣෟಅษџۭࢾѠљйћѣ၈ਇѠѤॻѿсзҀѣсॶ௢ќзҀ̞ષєіѤ๻ൊଆѣඩࠗളќзҀ glyceraldehyde ͅ GA ͆Ѡඨჭь̝ GA ᄢᅗ AGEs ͅ GA-AGEs, toxicAGE; TAGE͆ѣౡളѠпцҀ຤ౖ཈ॶࡀ৔Ѡ࠙ьћ༘ᅋ௿ࣗ੎ၙ҇ᅀйћ‫ݷ‬౸ьћйҀ̞̜шҁѳќѣॆ‫ݑ‬ѽѿ̝༘ᅋ௿ࣗ੎ၙѣ༘ඒѠู݈ьє GA ѣ໶๘‫ږ‬ഝษѠ௿ࣗ੎ၙѣ௿༪ిсค݁юҀшѝсབბь̝5 mM ѣ໶๘ќ7૑ࠗ‫ړ‬຿Ѡ௿༪ѤฅલюҀшѝсბѾрѠџј
є̞ජ౺ьє TAGE ᆙ҇ Slot blot ၔќ‫ݷ‬౸ь̝ъѾѠ WST-9ુᄅ҇ᅀйћ੎ၙౡഝᅵ҇ग़ກьєॆ‫ ̝ݑ‬TAGE ජ౺сഄ݈юҀน̝ౡഝᅵѤॳஜьћйфшѝѷბѾрѠџјє̞ѳє̝
Western blotͅWB͆ၔќ TAGE ज౗ѣຠ‫ڤ‬ษӃӦҼс61~71 kDa ѠୟॶюҀѣѠവь̝TAGE ज౗೒‫ޕ‬੓ѣ‫ڵ‬ଠќзҀ AminoguanidineͅAG͆ќಷ୷ᅬюҀѝ WB ќ௒ࡌѣຠ‫ڤ‬ษӃӦҼсர૫юҀшѝѷ҄рјє̞ъѾѠ GA ໶๘‫ږ‬ഝษѠ༘ᅋ௿ࣗ੎ၙѣ TAGE ৊ളѠѽҀკ‫۽‬ಠ௲ѣࢬ๘сഄюшѝѷࠒੴъҁє̞‫ړ‬௒ѣшѝрѾ TAGE ѣಷ࣫ളќзҀ GA ༘҇ᅋ௿ࣗ੎ၙѠู݈ьє௙̝৾௿ࣗ੎ၙѤௐ‫҇ޕ‬ଦцҀшѝсბѾрѠџјє̞ќѤ GA с௿ࣗ੎ၙ຿Ѡ໛јє૑ўѣѽлџजќ຤ౖ཈ॶ҇ฉьћйҀѣќз҂лр̤̜ਘ‫ݸ‬шѣ཈ॶࡀ৔ѣ‫ݷ‬ბѣєѶ੎ၙ຿‫ڤ‬࿿ҲӦӄҢ૲ѣர݂̝஋ࢍࡀ৔Ѡ࠙ᄮюҀҝ̷һӈҔҫ̷Ѡඨჭьћग़ກ݈҇нє̞༘ᅋ௿ࣗ੎ၙѠ GA ู݈ঞ̝फ૑ษѠ੎ၙ҇‫ݸ‬ମь̝WBၔќ‫ݷ‬౸ьєॆ‫̝ݑ‬ҝ̷һӈҔҫ̷ज౗҇૙ю LC 4 -I рѾ LC 4 -II ѭ‫ڥ‬৫юҀ߇৾ͅ LC 4 -II/
LC4-I͆с GA 5 mM ู݈ঞ23૑ࠗќॳஜьћйҀшѝс҄рјє̞ъѾѠ GFP-LC4҇ᅀйє૳६ќ GA ໶๘‫ږ‬ഝษѠҝ̷һӈҔҫ̷҇૙ю dot ѣిсॳஜьћйфшѝѷ҄рјє̞ਘѳќѣ GA ู݈ѠѽҀ༘ᅋ௿ࣗ੎ၙѣྐྵᅬ޻ษ୹।рѾҕӐһ̷ҪҬഃѤஜџф̝ӀҢӠ̷ҪҬഃсതйшѝсࠒੴъҁћпѿ̝੎ၙળѭઽҀ‫ݦ‬นѠҝ̷һӈҔҫ̷ѠѽҀ੎ၙળѷ৤нѾҁҀ̞шѣҝ̷һӈҔҫ̷Ѥ੎ၙ҇ၼটюҀოѝௐ‫҇ޕ‬ଗࡎюҀოѣ3ოౖ҇ૐі৾҄ѐћйҀ
шѝсඑѾҁћпѿ̝੎ၙѠ AGEs ู݈҇ьє௙̝৾ҝ̷һӈҔҫ̷сॳஜюҀѝйл၈ਇѝ̝ഄ݈юҀѝйл၈ਇсзѿਣຶѝьє௢ࢴќзҀ̞ਘ‫ݸ‬ѣग़ກќ̝GA ู݈ѠѽҀ੎ၙ຿
TAGE ѣౡ౗̺ජ౺Ѥ̝௿ࣗ੎ၙѣҝ̷һӈҔҫ̷҇ॳஜъѐҀшѝсბѾрѠџјє̞㸫  㸫

ℛใ̜ട௹ͅ஄ࢲ͆
य़ࢅ‫ݢ‬൏̢Ӆһߗ݂᪴ࠊ௒༘ྂࠣᅋ੎ၙѠпцҀ TAGE ౡ౗ࡹѨ TAGE ݂඄༭૲ѣ൸੬य़ࢅ‫ޘ‬ᅆ
̜᪴ࠣѤ:1% с᪴ࠊ௒ྂѠ཈ౡь̝ఒඊ૑ѠѤ๻ໝྐྵ҇တ཈ьћйҀຠ෈сзҀс̝ᆋଅѣ࠙ᇍѤბѾрѠъҁћйџй̞৹े๻௢഻ќѣ᪴ࠊ௒ྂࠣ੎ၙ຿Ѡ̝ӉҼҙ๻ѹ‫ݑ‬๻ൊଆඩࠗള
ѣңӝҮӞҕӞҺӅҼͅGA͆ѠᄢᅗюҀ Glycer-AGEsͅToxic AGEs̟TAGE ѝა჏͆сౡ౗̺ජ౺ь̝᪴ࠣ҇ഊకъѐҀѝйл݃ಋ҇ᅶћє̞ђшќ̝৹ңӞҦ̷Ҭ༘ඒќ༘ᅋьєӅһߗ݂᪴ࠊ௒༘ྂࠣᅋ੎ၙ PANC-2ѣ੎ၙ຿Ѡ TAGE ҇ౡ౗̺ජ౺ъѐ̝੎ၙѠౡэҀॶொ҇‫ݷ‬౸ьє̞̜шҁѳќѠ WST-9ુᄅ҇ᅀйє੎ၙౡഝᅵુ६ќ GA ໶๘‫ږ‬ഝษѠ੎ၙౡഝᅵсค݁юҀшѝ҇ბѾрѠь̝৊ TAGE ৊ള҇ᅀйє Western blotͅWB͆ခ౸ࡹѨ੎ၙკ‫۽‬ಠ௲Ѡѽѿ̝
GA ໶๘‫ږ‬ഝษѠ੎ၙ຿ TAGE сౡ౗̺ජ౺ъҁҀшѝ҇ბѾрѠьє̞ьрь੎ၙ຿ TAGEѣซᆙсൌтџ‫ݢ‬൏ќзјє̞̜ђшќ̝ႏ໪๘Ѥ Slot blotͅSB͆ခ౸ѠѽҀ৹߷๘ TAGE ซᆙၔ҇ంࡋѠ‫ގ‬཈ьє̞ѳє̝
WB ခ౸Ѡѽѿ̺ࠣҕӐһ̷ҪҬ࠙ᇍ඄༭૲ Aminopeptidase NͅAPN̝͆HSP:1Ԓ̝HSP:1ԓ̝
HSP 81̝ HSP 38̝ caspase- 4ѣခથᆙѣဦ݂҇‫ݷ‬౸ьєॆ‫ ̝ݑ‬APN ̝ HSP :1ԓ̝ HSP 81̝
HSP38̝pro-caspase-4ѠѤ৹ခથ݂ӃӦҼѣୟॶс‫ޱ‬໢ъҁєс̝HSP:1ԒѠљйћѤ৹ခથ݂ӃӦҼсग़ୟъҁџрјє̞pro-caspase-4ѣߋౖचќзҀ cleaved caspsae-4Ѥ̝ӕӁӑ̷ࡹѨ৹ခથ݂ӃӦҼѣйяҁѷग़ୟъҁџрјє̞‫ړ‬௒ѣॆ‫ݑ‬рѾ̝GA ໶๘‫ږ‬ഝษџ PANC-2ѣ੎ၙળѤ̝੎ၙ຿ TAGE ѣౡ౗ѝ࠙ᇍюҀшѝс૙ъҁє̞ॶ੔̝APN̝HSP:1ԓ̝HSP81̝
HSP38̝pro-caspase-4ѣ৹ခથ݂с̝TAGE ݂ѠѽҀѷѣќзҀ݉໸ౖ҇௉੎Ѡग़ກඩќзҀ̞̜ђѣണ̝ంౡઙӜҶһ୸ൊ༘ᅋ௿ࣗ੎ၙ຿ќѣ TAGE ౡ౗̝҇‫ގ‬཈ьє SB ခ౸ќซᆙь̝
PANC-2‫ޓړ‬ѣ༘ᅋ੎ၙѠѷ‫ܥ‬ᅀќтҀшѝ҇‫ޱ‬໢ьє̞ъѾѠ̝TAGE ౡ౗ PANC-2рѾ੎ၙ‫ޓ‬ѭ‫ڸ‬൩ьє TAGE ݂඄༭૲҇ซᆙюҀєѶѣ SB ѣ௟ॊ҇ग़ກඩќзҀ̞݈нћ̝ӜҶһ೏௰຿Ѡౡ౗̺ජ౺ьє TAGE ඄༭૲҇ซᆙюҀєѶѣ SB ѣ௟ॊѷग़ກඩќзҀ̞㸫  㸫

ㅽ⣻Ό੿ᩩตᮾ᳣ո⦕ㅾ
̜‫ڭ‬เથ૱߶य़ࢅခჿќѤ̝಑ึౖ̡‫ڭ‬เౖ૱߶ѠവюҀ‫ڭ‬เ‫ڮ‬ᆒͅ‫ڭ‬เ޻ษग़ਯ̝‫ڭ‬เҞҙӦҮӝӦң͆ѣ࿘ࡹѝ̝‫ڭ‬เౖ૱߶рѾѴєౡളӟӌӞѠпцҀӅһ‫ڭ‬เથࡀ໸ѣ‫ݷ‬౸҇ҹ̷ӑѠय़ࢅ҇శ৫ьћйҀ̞̜ಷଅѠ࠙ьћѤ̝2͆ࣟ൙‫ݏڮ‬ൌ޻ྐྵ‫ۈ‬େ޻ษ‫ڮ‬ᆒ࿫‫ڭ‬เથ‫ڮ‬ᆒҮӦҲ̷ѠпцҀ‫ڭ‬เ‫ڮ‬ᆒѣ૳ರ̝3͆࠶ஜ‫ڭ‬เౖ૱߶ѠവюҀఒඊબ܎̝4͆ంࡋ‫ڭ‬เ޻ษఒඊၔѣ‫ގ‬཈҇4ႏදѝьћ૳ರьћйҀ̞ࣟ൙‫ݏڮ‬ൌ޻ྐྵ‫ڭۈ‬เથ‫ڮ‬ᆒҮӦҲ̷ќѤ̝ॶ੔261‫ړ‬௒ѣ૱߶Ѡവь311‫ړ‬௒ѣ‫ڭ‬เથग़ਯс݉໸ѝџјћпѿ̝ਈ຿ќѷһҶӊҢӜҬѣ‫ڭ‬เఒᆒ࿫ჸ҇૳ॶьћйҀ̞шҁ҇݉໸ѠьєѣѤ‫̴ݫ‬сລ૜Ѡ‫ގ‬཈ьє৹ౣ๘рљค݆ޭѣ࿘ࡹच‫ڭ‬เથဦ‫ڤ‬ҬҢӝ̷ҾӦ
ңၔͅCHIPS ၔ͆ќзҀ̞࢏ൌ‫ڭ‬เથѣဦ‫ݷڤ‬౸ѠѤ૒్ൊҪ̷ҢқӦҨ̷сᅀйѾҁҀѣс
਼ࣞѣଘᅻќзҀс̝ҦҬһოќ߇৹ќзѿ̝йѳѕѠ࿘ࡹьћйҀѝѤॹй໎й̞ᆤடॶ௙
ќෟოюҀჵ൏Ѥ̝ᆤடఒඊѤཿ޶ษᄵ‫ڠ‬ќзѿ̝ఒᆒҟҗҼӜҗӦ௒ѹҞҙӦҮӝӦңѣ௒ќ‫ڭ‬เથఒඊсྣధќзҀѠѷрр҄Ѿя̝ൌതిѣ૱߶ќ౾ໟ‫ڭ‬เથс࢏ൌќзѿᄵ‫ڠ‬Ѡ‫ݷ‬౸сୟᅗџйѝйл฿ѠзҀ̞CHIPS ၔ҇ᅀйҁѥ211қҢҰӦน๘ѣҬҢӝ̷ҾӦңс̝९
݆4,111‫܆‬นќ̝єјє2໙ќହᆈюҀ̞ьрѷ̝зѾѻҀ‫ڭ‬เથ̝‫ڭ‬เजૡѠห‫ܥ‬ќт̝૳६௟ॊ҇಻ћຎ‫ڵ‬ѝьћзҀєѶ̝‫ڵ‬๘Ѡ࿸ిѣ‫ڭ‬เથѣग़ਯѷ݉໸ќзҀ̞шѣѽлѠ CHIPS
ၔѤт҄Ѷћ૳ರษџҬҢӝ̷ҾӦңଛၔќзѿ̝န౗38໪๘Ѥђѣ௉੎҇࿸ిѣ۸ဍૂѠி‫ݵ‬ьєͅGene Technolgy 5: 4, 3126; Adv. Tech. Biol. Med. 4: 4, 3126; Pharma. Anal. Acta 7: 22, 3126;
Enz. Eng. 5: 242, 3126̞͆ѳє̝๵ခჿќ‫ڭ‬เથ‫ݷ‬౸҇৫јєஶᆰѣлі̝‫޻ڮ‬ษѠ୔ᅆќзјєѷѣѣйфљр҇ Case report ѝьћѳѝѶєͅHered. Genet. S8: 115, 3126; Clin. Med. Imag.
Lib. 2: 3, 3126; J. Dermatol. 53: 2198, 3126; Brain Dev. 49: 7, 3127̞̜͆‫ڭ‬เથѣౡളӟӌӞѠпцҀࡀ໸Ѥຍ࿿ଠѠѽѿਮсзҀєѶѠ̝ఘࠗѠпйћຠซѣ‫ڭ‬เથѠ‫ڤ‬௜҇тєьє੒Ѡ݄сౡэҀѣр҇එҀєѶѠѤ਼̝ହษѠѤӕҺӞຍ࿿ќѤџф̝ఘࠗѠᅶіါѿ̝࠶ஜ‫ڭ‬เౖ૱߶҇‫ݷ‬౸юҀྣᅆсзҀ̞‫̴ݫ‬Ѥ‫ڭ‬เౖ૱߶̝҇،ࣗҫҬһӠӈҖ̷ѣᄼѠ‫ڭ‬เથઍ࿿с਼ହษџࡀ໸҇൷јћпѿ̝ђѣࡀ໸ௐ‫ޕ‬Ѡ࠱њфྐྵ഻҇ฉюҀ࿫࿁ྐྵͅParts disease̝͆‫ॆ؍‬ಊౖড়݂ஶѣѽлѠ‫ڭ‬เથઍ࿿сခથӄҬҙҚҗ௒ѣҲӦӄҢ૲ќзѿ̝ђѣӄҬҙҚҗѣࡀ໸ௐ‫ޕ‬Ѡ࠱њфྐྵ഻҇ฉюҀӄҬҙҚҗྐྵͅPathway disease̝͆؎ಠ௲ള‫ڤ‬௜пѽѨ฽૽‫ہ‬થѹӅҬһӦଳ௫‫ڭ‬เથџўѣ‫ڤ‬௜Ѡѽѿ̝࿸ిѣ‫ڭ‬เથс‫ڵ‬๘Ѡ཈ॶᆙѣۭࢾ҇ଦцҀшѝѠѽҀҥӁӓྐྵͅGenome disease͆ѠခᆭьћйҀ̞шҁѾѣ಻ћѠവь̝૱߶ѣ९‫ہ‬ѝџҀҥӁӓဦ‫҇ڤ‬঳ᅵษѠ‫ݷ‬౸юҀଛၔѣ‫ގ‬཈Ѡଙѿ೏҈ќйҀ̞ͅဍ౾̜ం‫گ‬ใ̜ᅆ͆㸫  㸫

ం‫گ‬ใ̜ᅆͅ୩ࢲ଩͆
य़ࢅ‫ݢ‬൏̢2̠‫ڭ‬เ޻ษग़ਯͅ‫ڭ‬เથग़ਯ̝ಠ௲ളग़ਯ͆ѣ‫ގ‬཈ѝ࿘ࡹ̜̜̜̜̜3̠Ӆһ‫ڭ‬เౖ૱߶҇ӕҺӞѝьєౡളӟӌӞѠпцҀ‫ڭ‬เથࡀ໸ѣ‫ݷ‬ბѝఒඊ̡૔ᆒѭѣ‫ܥ‬ᅀय़ࢅ‫ޘ‬ᅆ
̜ਘ໪๘ѤຠѠ̝‫ڭ‬เ޻ษग़ਯѣ࿘ࡹ҇୔ાьєय़ࢅߋຍ҇৫јє̞ӔӦҺӞ‫ڭ‬เྐྵѠവюҀ‫ڭ‬เથग़ਯѤ࡚ୠѝьћѤ‫ޱ‬ᅶь̝࠼Ѡᄼ̴џ૱߶ѣఒඊ૔ᆒҟҗҼӜҗӦѹફซ໎ྐྵѣఒඊ࠱୯ѠౢѿਕѳҁћйҀ̞ьрьᆤடॶ௙ѠпцҀҾ̷ҭѝѤᅯ࿷Ѡ̝‫ڮ‬ᆒဲ४౒๘ѣ‫ڬ‬йрѾ̝‫ܩ‬ရѝཿ޶ьਈ຿ќѤ‫ڭ‬เથग़ਯѤႋў࿘ࡹьћйџйॶ௢сзҀ̞‫ڭ‬เથग़ਯѣ९݆Ѥ
21̼31Ⴏ‫ ܆‬/ ग़ളѝ৹݆ќзҀс̝‫ܩ‬ရќѤᆖй‫ڮ‬ᆒဲ४Ѡ݈໛ќтҀඩઍ‫ړ࢈ޏ‬௒ѣଅѠѝјћѤ̝4,111ଠᆭ‫ړ‬௒ѣ‫ڭ‬เથग़ਯсဲ४ќҞӃ̷ъҁ̝૳૲2̼3Ⴏ‫܆‬ќᆤடग़ਯѝьћด࢞ъҁћйҀ̞‫ڵ‬ၒ໙ႏќѤ̝3127໪ѣ‫ރ‬ซќဲ४ମੑъҁє‫ڭ‬เ޻ษग़ਯѤ83৷ჭѠഄнєс̝ఒᆒ၈୆с‫ڵ‬ᅴ4,991฿ѝซѶѾҁћпѿ̝੃઎ౖѣჵ൏рѾग़ਯ‫ݶ‬ଃќ૳યъҁћй
ҀѣѤ9৷ჭѣ‫ڭ‬เથग़ਯѝಠ௲ളग़ਯѣѴќзҀ̞ਈ຿ѠпцҀ‫ڭ‬เ޻ษग़ਯѣ࿘ࡹѤࡽჄќзҀс̝ग़ਯྊᅀѣൌ࿴џҦҬһҳҙӦсџъҁџйॻѿѤ࿋݉໸ќзҀ̞‫̴ݫ‬Ѥшѣჵ൏̝҇৹߷๘рљคҦҬһѣ‫ڭ‬เથဦ‫ڤ‬ҬҢӝ̷ҾӦңၔќзҀ CHIPSͅCEL nuclease mediatedheteroduplex incision with polyacrylamide gel electrophoresis and silver staining͆ၔ҇‫ގ‬཈юҀшѝќ‫ृݷ‬ьє̞ႏၔ҇ᅀйє‫ڭ‬เથग़ਯѤࣟ൙‫ݏڮ‬ൌ޻ྐྵ‫ڭۈ‬เથ‫ڮ‬ᆒҮӦҲ̷ќ૳ರъҁћпѿ̝ఊᗌџ‫ڭ‬เҞҙӦҮӝӦңѝຎ૑Ѡ̝ҝӦҺӑӦҼќ߶ଅъ҈Ѡྣᅆџ‫ڭ‬เથग़ਯ҇ด࢞ьћйҀ̞ॶ੔юќѠ261҇෗нҀ‫ڭ‬เౖ૱߶ѠവюҀग़ਯс݉໸ќзѿ̝ඒ‫ڱ‬ѣ‫ڮ‬ᆒర୯ѣষ௒Ѡ৮फ़ьћйҀ̞ग़ਯྊᅀѷ23,111‫܆‬Ѡಈซьћзѿ̝ࣟ൙‫ݏڮ‬ൌ޻ྐྵ‫ڭۈ‬เથ‫ڮ‬ᆒҮӦҲ̷ќग़ਯ҇ଦцҁѥ̝ဲ४หᅀѣзҀџьѠ࠙҄Ѿя߶ଅѣ૜ঃ࿠൷Ѥຎ޾ќзҀ̞̜шѣѽлџଙѿ೏ѴѤ్‫މ‬Ѡпйћѷᆭ҇Ѵџйѷѣќзѿ̝ਈ຿‫ޓ‬ѠпцҀ‫ڭ‬เ‫ڮ‬ᆒޭਮ౐౞ѣєѶѣด‫ڏ‬ѝьћ୔ᅆќзҀ̞ਘ໪๘Ѥ CHIPS ၔѣ௉੎ѝᄜᅀౖѠљт̝ਈ຿‫ޓ‬ѠଯඑюҀૉ҇ჭྯѠߋຍ҇৫јє̞಻ਈ޻‫ݶ‬ќѣ཈ྴ3‫ݸ‬ѣണ̝࿸ిѣ۸ဍૂќӁҙӂҙ҇ி‫ݵ‬ьєͅGene Technolgy 5: 4, 3126; Adv. Tech. Biol. Med. 4: 4, 3126; Pharma. Anal. Acta 7: 22, 3126;
Enz. Eng. 5: 242, 3126̞͆ѳє̝‫ڭ‬เથ‫ݷ‬౸҇৫јєஶᆰѣлі̝‫޻ڮ‬ษѠ୔ᅆџ୹।сຝѾҁє5ஶᆰ҇ Case report ѝьћѳѝѶєͅHered. Genet. S8: 115, 3126; Clin. Med. Imag. Lib. 2: 3,
3126; J. Dermatol. 53: 2198, 3126; Brain Dev. 49: 785, 3127̞͆㸫  㸫

ྑ੟̜ଚͅ஄ࢲ͆
य़ࢅ‫ݢ‬൏̢2̠ᆤட੎ၙ‫ڭ‬เ޻ѣஃ࡚ୠѣ‫ۮ‬ഃ݂пѽѨঞबଅᅋ౗ࢲ‫ڲ‬ӊӠңӜӓѣ‫ޱ‬ᅶ̜̜̜̜̜3̠ೱঘ฽਷ဲ‫ہ‬ଅѣӝҬҢྵ݆пѽѨ्௜ૌ࢒ૌѣ݉໸ౖྵ݆ѣय़ࢅ

2̠ज഻ခᆭ޻ษഋო҇ૐљᆤட੎ၙ‫ڭ‬เ޻ѠпцҀ࡚ୠဲᄜଅсॳஜьћйҀ੧ਘ̝ђѣ࡚ୠѣᅆ฿͜Ҧҷ҇‫ۮ‬ഃ݂ьћпт̝ঞबଅѣᅋ౗ѠᄃᅶћѽлѝьћйҀ̞࠼Ѡ̝ಠ௲ളྯႏ
੣౦ѠљйћѤϩႏѣຍ‫҇ݭ‬җӦҲ̷ӀҶһ௒ѣӎ̷ӓӍ̷ҫѠҕҶӊьє࣎ͅ৬चಠ௲ള‫ڤ‬௜ http://www.g-band.com ѽѿ‫܃‬ᅦ݉໸̞͆ಠ௲ളྯႏ੣౦ќѤયಈຠᄜѣၒၔсзѿ̝ྯ୯݂ѣુѴѤзҀѷѣѣࠅࢪᅆ‫ہ‬Ѡൌтфۭࢾ҇лцҀєѶ̝ྯ୯݂Ѥрџѿਙ໎рѝ৤нҀ̞ୟᅗ௒сјєྯႏѣ૲ษྵ݆ၔ҇‫ޱ‬ᅶьћ̝шҁ҇ѷјћ G ӃӦҼѣ࿁૲ྵ݆҇૳યь̝ྯ୯݂ѣࡣᇫ҇౺Ѵ୔ѢћйҀ๒ඩќзҀ̞ѳєಠ௲ളྯႏ੣౦‫ޓړ‬ѣ FISH ၔџўѷຎᄼѠຍ‫̡ݭ‬‫ۮ‬ഃ݂ь̝YouTube џўѣҗӦҲ̷ӀҶһ༙ളќ཈௹ьћйфᄬซќзҀ̞

3̠Stengel-Rutkowski ѾѣӝҬҢྵ݆ၔ҇ᅧᅀьћೱঘ฽਷ဲ‫ہ‬ଅѣӝҬҢྵ݆҇21໪‫ړ‬௒૳યьћйҀ̞шѣྵ݆ၔѤ̝ཅ୔߂௹ౡ಑ౡͅ๫ၿൌ޻ઍ࿏ఘ‫ࢲݏ‬଩͆с໙ႏᆤட‫ڭ‬เ޻‫ݶ‬ͅॶ̡໙ႏ‫ڭ‬เҞҙӦҮӝӦң޻‫͆ݶ‬ќ཈ྴъҁєѷѣќзҀ̞ೱঘ฽਷ဲ‫ہ‬ଅќѤ̝ॳి്‫ڵ‬ခᇃ̡ઠ݆ಠ௲ളज౗рѾࡎшҀခᅲᄼૡѠѽјћ̝ᄼ̴џ࿋࣎৬च฽਷༖ࣳથсౡэҀ̞шҁѝ౞௜༖ࣳથсଦౣьє௙̝৾࿋࣎৬च฽਷ѣ‫ڵ‬࿫ѤୟౡюҀ݉໸ౖсзѿ̝ണѤ໠௼୸࠽ѠᅻઍюҀ̞шѣ݉໸ౖѣྵ݆Ѥ̝฽਷ဲ‫ہ‬ଅҞҶӊӞѣ‫ڭ‬เҞҙӦҮӝӦңќѤᅗඏଅрѾྣяఝѢѾҁҀшѝќз҂л‫ڏ‬ॊќ̝шѣଠѣ‫ڭ‬เҞҙӦҮӝӦңќѤ୯ྐьћпрџцҁ
ѥџѾџйҺ̷Ҳѣ‫ڵ‬љќзҀ̞шѣѽлџ୔ᅆџҺ̷Ҳѣྵ݆ၔѠ࠙ьћѤ్̝‫މ‬ษ჏රѝьћ৹фྵ݆ъҁћйҀ Chromosome Abnormalities And Genetic Counseling 5th ed.ͅGardner R.J.
Oxford University Press 3123͆ѹ̝໙ႏѠпцҀᆤட੎ၙ‫ڭ‬เ޻ѣઽ၊ѝѷྵъҁҀই̡߄‫گ‬౞಑ౡͅઆশൌ޻჏ᄯࢲ଩͆сဩએъҁє͑ಠ௲ള‫ڤ‬௜҇।љцєѾ͒ͅ http://www.cytogen.jp/
index/index.html̝໙ႏఘᆭ‫ڭ‬เ޻‫ݶ‬ᆤட‫ڭ‬เ޻໢ซડ౒๘‫ݶۀښ‬Ӣ̷ҠӦңңӞ̷ӊࠊᅬ̡‫ۦ‬۫͆ќଙѿ௒чѾҁ̝‫ݷ‬ಋсџъҁћйҀ̞ྑ੟஄ࢲѤඖใ࿉ᇥຠໟ୩ࢲ଩ͅૠૌ๦ൌ޻͆ѝѝѷѠ̝3116໪5ॉ37໙ѽѿӎ̷ӓ̷Ӎ̷ҫ͑࣎৬चಠ௲ള‫ڤ‬௜͒҇‫ގ‬ಈь̝௒ࡌӝҬҢ઎ୟѣҨ̷ӆҬ҇ӏӜӦҹҖҕќ৫й̝ॶ੔ѠઽјћйҀ̞㸫  㸫

ㅽ⃪᪝֝൧ᮾ᳣ո⦕ㅾ
̜݁ࡌѣय़ࢅҹ̷ӑќߋຍඩќзҀ̞̜ҬҠӞҬ‫ࠣڨ‬ѣ࿷႟ༀଠѣခથࡀ৔ѣ‫ݷ‬ბѠљйћѤ̝‫ࠣڨ‬੎ၙഄ௮ѝࠣࠗ૲ѣࡽाџഄౡࡀஇѣ‫ݷ‬ბ҇෭ьћ̝ࠣྒ஛ࠅࢪѣంєџા฿Ѡ࠱њфࠗ૲҇ඩ௿ѝьє૔ᆒѣ‫ގ‬཈҇ѶыьћйҀ̞ႏྐྵ഻ຠ‫ڤ‬ษџంࡋӃҗҝӑ̷Ҟ̷ѣ཈।̝ѧйћѤంєџॽအ݂૔ᆒѠষцєᆤட‫ܥ‬ᅀѭѣื‫҇ގ‬ાჿѠ໛ҁћйҀ̞шҁѳќѠ CXCR5/CXCL23 axis ѣ࿷႟ѭѣആ࠰ಱൗౖ฽
‫ڥ‬ഄ௮̝ъѾѠ࿷రઍౡ҇ཕлࡽౖഄ‫ٶ‬Ѡ EGFR/EGFR ligands axis с̝ъѾѠѤҬҠӞҬ‫ࠣڨ‬ຠ‫ڤ‬ษџ MET/HGF axis ѣ࠙ᄮ҇ბѾрѠьћйҀ̞̜с҈݂޻ᆒၔѣ঳‫਼҇ݑ‬ൌॻѠ཈࠹ъѐҀєѶѠѤ̝࿲੣ᅀവ੫ͅબૐᆒၔ͆с୔ᅆќзҀ̞‫ڮ‬ᆒᅀࠂၒ౦੓ఘઅᅋ۰๱ѣఋफ੎ၙဲধ੣ᅀ̡ഉेഊక੣ᅀѠඨჭь̝৊с҈੓ҝҠҨӝӊӜҴӦѣఋफ຤ౖѝे‫ۼ‬຤ౖѣᆋଅѠവюҀఘઅᅋ۰๱ѣᄜ঳ౖѠ࠙ьћ̝ਈᅶс҈य़ࢅҮӦҲ̷य़ࢅ୹̡჏ॾܵધᅶൌ޻ᄅ޻࿫̡࣢ଲൌ޻े‫ۼ‬य़ࢅયಈѝѣࢣຎय़ࢅ҇యకඩќзҀ̞шҁѳќѠҝҠҨӝӊӜҴӦѠѽҀӑҙҬႩ஬ఋफௐ‫ޕ‬ӕҺӞѠпцҀఘઅᅋ۰๱ѣᄜ঳ౖ҇ბѾрѠьє̞ൌීࠣୠঞ္஄݂޻ᆒၔѝьћ FOLFOX ᆒၔѳєѤ XELOX ᆒၔ҇ଦцҀ߶ଅ҇വொѠӜӦҳӓ݂ཿ޶ુ६ͅHOPE-3͆҇૳યඩќ̝ࣞ໙ඩѠ๏ᇪсହᆈюҀᄬซќзҀ̞ఋफ̡े‫ޓړۼ‬Ѡྂ࿝຤ౖͅXeloda ѠѽҀଛഒஶমऍ͆Ѡѷఘઅᅋ۰๱ѣ঳‫ݑ‬сџйр‫ݷ‬౸ඩќзҀ̞ъѾѠҝҠҨӝӊӜҴӦ‫ޓړ‬Ѡ̝FECͅ6-FU + Epirubicin + Cyclophosphamide͆ᆒၔпѽѨ DOCͅDocetaxel͆ᆒၔ҇ଦцҀ໚ࠣ߶ଅѠпцҀे‫ۼ‬຤ౖѠവюҀఘઅᅋ۰๱ѣ঳‫ ҇ݑ‬RCT ќग़ேюҀᆤடુ६ͅNYTBC͆ѷ૳યඩќзҀ̞̜᪴ࠣѣ཈ౡѠ K-ras ѣ࠙ᄮсბѾрѠъҁћйҀс̝шҁѾѠ TGF-beta ଦᄵള‫ڭء‬เથ
ͅTGFBR2͆ѣ‫ڤ‬௜݈҇ႴьєӑҙҬ᪴ࠣӕҺӞ҇ᅀйћ̝ҬӈҖӦҧӒқӝӦ৾౗ৱ೎
ͅSMS͆ѣ౒টѠѽҀంࡋ᪴ࠣ૔ᆒၔѣ‫ގ‬཈҇ჭફьћйҀ̞᪴ആຠ‫ڤ‬ษџ KRAS ߋౖ݂Ѡѽѿ̝Ӆһѣ PanINͅPancreatic intraepithelial neoplasia̝᪴௒ྂ຿ଡ᢮ౖྐྵဦ͆Ѡѽф૊єྐྵဦсୟॶюҀ̞᪴ആຠ‫ڤ‬ษ KRAS ߋౖ݂ +TGFBR2 ӁҶҢҕҙһѠѽѿ̝ࠗ૲ѣරბџഄౡ̡ಧ‫ڦ‬݂҇ཕлခ݂चࠊ௢ಪࠣсୟॶь̝Ӆһ᪴ࠣഃ҇ѽф਻ॶюҀ̞ђѣ࠱ೊษ૳६҇߱ᆈь̝૳੒Ѡ᪴ࠣѣ཈ౡ‫ݦ‬นѠ SMS сўѣѽлѠ࠙ᄮюҀр҇ბѾрѠьљљзҀ̞ॶ੔ SMS ჿౡचѝ SMS ӁҶҢҕҙһचѣ3ऍࠗќౡഝᅵѣਮсџйр‫ݷ‬౸ඩќзҀ̞ͅဍ౾̜८ᄩ̜ᆖ૔͆㸫  㸫

८ᄩ̜ᆖ૔ͅࢲ଩͆
य़ࢅ‫ݢ‬൏̢ҝҠҨӝӊӜҴӦѣఋफ̡े‫ۼ‬຤ౖѠവюҀఘઅᅋ۰๱ѣᆤட঳‫ݑ‬ѝђѣခથࡀ৔य़ࢅ‫ޘ‬ᅆ
̜ႏय़ࢅѤ̝ൌීࠣѣྯ୯ษ૔ᆒᄅќзҀҝҠҨӝӊӜҴӦͅL-OHP͆ѣଠ̴ѣᄜ‫ޕ‬ૉொѠവюҀࠂၒ౦੓ఘઅᅋ۰๱ͅNYT͆ѣതოษџ঳‫҇ݑ‬ᆤடુ६џѾѨѠခથౡ࿿޻ษ̡૳६ᄅ
ᅬ޻ษѠ‫ݷ‬ბюҀшѝ҇ჭษѝьє̞̜ᆤடษѠѤ̝ྌӜӦҳӓ݂ӄҗӠҶһુ६ќзҀ HOPE-2ͅHerbal Medicine for Oxaliplatininduced Peripheral Neuropathy Evaluation Study-2͆Ѡћ‫ݷ‬౸ьຝє33ᆰඩ̝L-OHP ᆬ౺๩ᄮᆙс
611 mg/m3‫ړ‬௒҇‫܂‬нє:ᆰќѤ grade 4‫ړ‬௒ѣႩ஬ఋफௐ‫҇ޕ‬໢ѶєᆰѤџф̝grade 1с3ᆰ̝
grade 2с6ᆰ̝grade 3с3ᆰќзјє̞ђѣঞ̝ӜӦҳӓ݂ཿ޶ુ६ͅRCT͆ѝьћఘઅᅋ۰๱
๩ᄮऍѝྌ๩ᄮऍѣ3ऍ҇ཿ޶юҀ HOPE-3҇૳યඩќзҀ̞န౗39໪7ॉ32໙ॶ੔ќ49჏с๏ᇪъҁћйҀ̞ఋफ຤ౖ̡े‫ۼ‬຤ౖъѾѠྂ࿝຤ౖѠљйћѷ‫ݷ‬౸݉໸ќзҀ̞̜ຍ࿿ӕҺӞѠпцҀ‫ݷ‬౸ќѤ̝჏ॾܵધᅶൌ޻ൌ޻‫ۈ‬ᄅ޻य़ࢅ‫ݏ‬ѝࢣຎय़ࢅ҇৫јћйҀ̞
L-OHP ѣႩ஬ఋफௐ‫ޕ‬ќзҀᆱ෬޳‫ݦ‬࿉пѽѨࡀ‫ކ‬ษҕӠҺҖҾҕѠവюҀ NYT ѣ੣ᅀ҇ ddyपᄩౖӑҙҬќ‫ݷ‬౸ь̝ѳєђѣᄜ঳ౖ҇ in vitro ќѷྵ݆ьє̞ L-OHP ѣ࿷১຿๩ᄮѠѽѿ̝ӑҙҬѣᆱ෬޳пѽѨࡀ‫ކ‬ษજाѠവюҀ෬޳᷒ඐѤѝѷѠ๩ᄮрѾ4̼6໙ჭќค݁ь̝
L-OHP ѠѽҀఋफௐ‫⌣ౖޕ‬෬сࠒੴъҁє̞ђҁѠവьћ̝NYT қҠҬѤӅһ௜ᅀᆙѣ6༗ᆙѣ๩ᄮќђҁѓҁᄜ‫ڞ‬Ѡ‫ރ‬ಸьє̞PC23੎ၙ҇ nerve growth factor ѝѝѷѠ35૑༘ࠗᅋьє૑Ѡ௸ืюҀఋफສࡎѤ̝1.4 μM ѣ L-OHP ѣู݈Ѡѽѿᄜ‫ڞ‬Ѡ೒‫ޕ‬ъҁ̝ౡഝ੎ၙిѷᄜ‫ڞ‬Ѡॳஜьє̞L-OHP ѝຎ૑Ѡ NYT қҠҬ༘҇ඒѠู݈юҀѝ̝411 μg/mL ѣ໶๘ќᄜ‫ڞ‬Ѡఋफສࡎకืᅍ౒ѣ‫ݸ‬࿳с໢ѶѾҁєс̝ౡഝ੎ၙిѠѤۭࢾѤџрјєͅJ. Nat. Med. 7: : 642 ,
3126̞͆ॶ੔̝ҝҠҨӝӊӜҴӦќ୷ᅬьєӑҙҬ౽఼ঞਡಊͅDRG͆ѠവюҀఋफສࡎకื
ᅍ౒੣ᅀѣკ‫۽‬ಠ௲ѣҺ̷Ҳ҇ଙ҂лѝьћйҀ̞̜े‫ۼ‬຤ౖѠവюҀ NYT ѣ঳‫ݑ‬Ѥ࣢ଲൌ޻ൌ޻‫޻ڮۈ‬य़ࢅ‫ۈ‬૒్ൊ‫ڮ‬ᆒय़ࢅ‫ގ‬཈ခჿѝѣࢣຎय़ࢅѠѽѿ̝L-OHP ѠѽҀਓ఼ᅍ౒Ѡവьћ NYT қҠҬсђҁ҇वॳъѐҀшѝ̝҇ӑҙҬѣႩ஬े੎ၙి‫ݷ‬౸̝ਓ఼੎ၙѣ flow cytometry ‫ݷ‬౸пѽѨ࠙ᇍ‫ڭ‬เથѣ real-time PCR ‫ݷ‬౸Ѡћ‫ޱ‬໢ьє̞ॶ੔̝ᆤடे‫ۼ‬ग़ളѣ‫ݷ‬౸ඩќзҀ̞㸫  㸫

㊕㊫㉶㉥㉭㊆ᮾ᳣㉹㊱㉽ㅖㅽ㊕㊫㉶㉥㉭㊆ᮾ᳣㉹㊱㉽ㅖㅾ̜ӊӠҫҚҢһय़ࢅҮӦҲ̷Ѥ్̝‫މ‬ӟӌӞ҇ჭફю಑ൿय़ࢅѹᆤடѝෟॆьєӊӠҫҚҢһ
य़ࢅпѽѨઍ޻ࢣຎय़ࢅ҇యకюҀჭษќႏ޻೴৾‫޻ڮ‬य़ࢅ୹Ѡಈ඙ъҁћйҀ̞ಘᅹษय़ࢅ࿫
̜ྯࡌѣჭษѣయక҇఩ҀєѶ̝೴৾‫޻ڮ‬य़ࢅ୹҇ඩ௿ѝьћဍ࿫‫޻ݏ‬ஷѣӂҗҹҢ̡ӝҨ̷Ҵ̡ҮӦҲ̷ౙྐૉࣅѭѣ౺ࣈษџ‫ܥ‬ြсకѶѾҁ̝2::8໪рѾ4ॊѣӊӠҫҚҢһс੃ൗъҁє̞ъѾѠ2:::໪ѠѤҳҗҝҠҪӦ๸ѣࠅࢪ‫ܟ‬ಠѠ࠙юҀय़ࢅӊӠҫҚҢһс̝3113໪ѠѤຍ࿿૳६҇ଘളѝюҀय़ࢅӊӠҫҚҢһсђҁѓҁ੃ൗъҁє̞шѣӂҗҹҢ̡ӝҨ̷Ҵ̡ҮӦҲ̷сॶӊӠҫҚҢһय़ࢅҮӦҲ̷ѣ࠱཰ѝџјћйҀ̞3113໪ѽѿӂҗҹҢ̡ӝҨ̷Ҵ̡ҮӦҲ̷Ѥ೴৾‫޻ڮ‬य़ࢅ୹Ѡ೏Ѵ໛ҁѾҁ̝3114໪ѣय़ࢅ୹‫ރ‬೏Ѡѽјћय़ࢅ୹ࢣຎᅧᅀ࿫ჸ
ѣ‫ڵ‬љѝџјє̞3116໪ѠѤ2:::໪੃ൗѣҳҗҝҠҪӦӊӠҫҚҢһсबഘ੃ൗъҁ̝ъѾѠ
3118໪рѾѤంєџ4ॊѣӊӠҫҚҢһс੃ൗъҁ̝ީଠ৹๘಑ൿࡀ࠰сຐ໛ъҁҀѝѝѷѠ
౗‫҇ݑ‬௒чє̞ӂҗҹҢ̡ӝҨ̷Ҵ̡ҮӦҲ̷ౙྐૉࣅ҇ࠟѵષᅶൌ޻޻ୠय़ࢅ৹๘݂యకૉ
ࣅѤ̝3119໪рѾಘᅹษय़ࢅ࠱཰ज౗બ܎ૉࣅѝьћबഘѝџѿ̝ႏ޻рѾѤлљѠ࠙юҀӊӠҫҚҢһс3119໪рѾѣ4໪ल‫ݭ‬ќ੃ൗъҁ౗‫҇ݑ‬௒чє̞3122໪7ॉѣय़ࢅ୹೏௰‫ރ‬ဩѠѽѿ̝ӂҗҹҢ̡ӝҨ̷Ҵ̡ҮӦҲ̷ѤӊӠҫҚҢһय़ࢅҮӦҲ̷Ѡ‫ࠊڥ‬ѝџѿಘᅹय़ࢅ࿫ѝџјћйҀ̞ॶ੔̝3123໪੃ൗѣ3ॊѣಘᅹษय़ࢅ࠱཰ज౗બ܎ૉࣅӊӠҫҚҢһͅ،઼૲Ӣ̷ӞҼѣᆤட‫ܥ‬ᅀ҇ჭફюय़ࢅ࢑฿ज౗̢य़ࢅൊྴଅ ܱ੟ୢᇚຠໟࢲ଩̝‫؍‬৹ᆽ݂ѣకѵ‫ݦ‬೉ඒ‫ڱ‬ѠпцҀӜҗӈ̡җӁӌ̷ҪӚӦೖୟ̢य़ࢅൊྴଅ ಗ—৆েࢲ଩͆с6໪ल‫ݭ‬ќశ৫ъҁћпѿ̝န౗38໪๘ќ5р໪ჭ҇ହн̝39໪๘ќ߱ॆѣᄬซќзҀ̞ӊӠҫҚҢһय़ࢅҮӦҲ̷̜ӊӠҫҚҢһय़ࢅҮӦҲ̷ѠѤန౗38໪๘૑฿ќ̝‫݁ړ‬ѣ4љѣय़ࢅ࿫сಈ඙ъҁћпѿߋ཈џय़ࢅߋຍ҇శ৫ьћйҀ̞ީय़ࢅ࿫ѣ௉ьйय़ࢅ຿ᄵѠљйћѤ̝ީ࿫ѣ၈ਇ҇અவъҁєй̞
)2*!ࠅࢪ९ౖા޳ྐྵ഻य़ࢅ࿫ͅय़ࢅ࿫౾ໟଅ̜਩̴ძ̜ᄽࢲ଩͆
)3*!಑౒ခથ௴ᆎ‫޻ݏ‬य़ࢅ࿫ͅय़ࢅ࿫౾ໟଅ̜ॾ‫̜ݍ‬ൌᄣࢲ଩͆
)4*!ึ಺ဦౖ඄༭૲ೖᄅ‫޻ݏ‬य़ࢅ࿫ͅय़ࢅ࿫౾ໟଅ̜ᄖౄ̜ෟࡶ௩൜ࢲ଩͆

ҝ̷ӊӦӜӏ
̜ӊӠҫҚҢһय़ࢅҮӦҲ̷ќѤҝ̷ӊӦӜӏ҇ಈ඙ь̝૜ᄢ๘҇ૐјєೖഉษџၛ‫ݯ‬य़ࢅ̝ࢣຎय़ࢅ҇యకюҀ௙ѝьћ̝޻຿य़ࢅଅсൾ࠽ࠗͅ3Өॉ̼2໪͆છᅀќтҀ૳६૭҇ด࢞ьћйҀ̞ͅဍ౾̜ရ೙̜ଷఘ͆㸫  㸫

ရ೙̜ଷఘͅࢲ଩͆
य़ࢅ‫ݢ‬൏̢ेࠊӀҶһӢ̷Ңज౗ѣ౒টࡀ৔ѣ‫ݷ‬ბय़ࢅ‫ޘ‬ᅆ
̜ेࠊज౗̡ంౡѤ೏௰ѣ཈ౡ̡‫ڦ‬ૐѠྣధќзҀѕцќџф̝с҈ഄ௮̡฽‫̝ڥ‬๻ໝྐྵेࠊ
৾တஶџўതфѣ૱߶ѣ཈ౡѹకืѠఇф࠙҄јћйҀ̞ьєсјћ̝ेࠊज౗ѣ౒টࡀ৔ѣ‫ݷ‬ბѤ̝౗ఘྐྵѣਅ࿵ѝйл‫ݢ޻ڮ‬൏҇‫ृݷ‬юҀлнќ୔ᅆќзҀ̞‫̴ݫ‬Ѥ‫݁ړ‬ѣ‫ݢ‬൏Ѡљтय़ࢅ҇৫јћйҀ̞2̠݉ᄾच VEGF ଦᄵള݉ͅᄾच Flt-2͆ѣઍౡ౒টࡀ৔
̜ेࠊంౡᅍ౒‫ہ‬થѝьћຌф݉ᄾच Flt-2҇ઍౡюҀ Flt-2 mRNA ಷ࣫ളѣಱൗษ4͂ൿӊӠҮҪӦңѤ̝Flt-2‫ڭ‬เથѣҗӦһӠӦ24Ѡೱ๵юҀ AU-rich elementͅARE͆Ѡѽјћ౒টъҁћйҀшѝ҇ბѾрѠь̝ARE Ѡॆ৾юҀ hnRNP D ҇౒টҲӦӄҢ૲ѝьћຎซьє̞hnRNP
D ѤҕӞҡҾӦગ࠱сӔҴӞ݂ъҁҀшѝсඑѾҁћйҀшѝрѾ̝ҕӞҡҾӦӔҴӞ݂с݉ᄾच Flt- 2ѣઍౡѠ࠙ᄮьћйҀрўлр҇‫ݷ‬౸ьєॆ‫̝ݑ‬ӔҴӞ݂ъҁє hnRNP D с Flt- 2
pre-mRNA Ѡॆ৾юҀшѝѠѽѿ݉ᄾच Flt-2ѣઍౡсᅍ౒ъҁћйҀшѝс૙ъҁє̞‫ړ‬௒ѣ౗‫ݑ‬Ѥ Mol. Cell Biochem. 524: 266, 3127Ѡढੑъҁє̞3̠ఋफ͘ेࠊೱঘ੣ᅀѠѽҀेࠊज౗ѣ౒টࡀ৔̜ఋफѝѣೱঘ੣ᅀѠѽѿेࠊ຿ྂ੎ၙќߋౖ݂ъҁҀ‫ڭ‬เથѣ൸੬̝҇Ӆһ୸ൊ༘ᅋფ੎े
ࠊ຿ྂ੎ၙѝӑҙҬঞਡఋफಊ୸ൊ༘ᅋ੎ၙѣࢣ༘ᅋप҇ᅀйћ৫й̝฽૽‫ہ‬થќзҀ JunB҇।ୟьє̞ӑҙҬീૌྂ࿝ѠпцҀ JunB ѣ཈ॶ҇‫ݷ‬౸ьєॆ‫̝ݑ‬JunB Ѥఋफѝࣞಅьє‫ڵ‬࿫ѣेࠊ຿ྂ੎ၙѠ཈ॶьћйє̞JunB ҇ेࠊ຿ྂ੎ၙќࢬ౒཈ॶпѽѨ཈ॶᅍ౒प҇ᅀйћ̝ेࠊ຿ྂ੎ၙѣ4૒८ҦӜ̷ҥӦҥӞѭѣेࠊంౡ໸҇‫ݷ‬౸ьєॆ‫̝ݑ‬JunB сेࠊంౡѠവьћഊకษѠࡀ໸юҀшѝсბѾрѝџјє̞ѳє̝ӑҙҬീૌྂ࿝Ѡ shRNA ҇཈ॶюҀӟӦҴҙҗӞҬ҇ධ໛ь̝཈ౡ࠽ѣेࠊ຿ྂ੎ၙѣ JunB ѣ཈ॶ҇ᅍ౒юҀѝ̝ेࠊѣ೽৫ౖ̝ఋफѝѣဗ೽ౖѠဦ݂сࠒੴъҁє̞‫ړ‬௒ѣॆ‫ݑ‬рѾ̝Ⴉ஬ఋफрѾѣҪңҽӞเ൦Ѡѽѿेࠊ຿ྂ੎ၙѠ JunB ѣ཈ॶсᄥຐъҁ̝ेࠊంౡѹेࠊѣӝӕҺӝӦңсഊకъҁҀшѝ
с૙ъҁє̞㸫  㸫

ㅽ༦ᨪ᫢ᮾ᳣⤴ㅾ౧௟̜રથͅ୩ࢲ଩͆
य़ࢅ‫ݢ‬൏̢ീૌ࠽ҳҗҝҠҪӦࠅࢪၰᇕѣ஛ૌѣ्৆ۭࢾѠљйћѣय़ࢅय़ࢅ‫ޘ‬ᅆ
̜ӌһҽӓ̡ҳҽӦધѣҳҗҝҠҪӦ‫ܟ‬ಠඒ‫ڱ‬Ѡпйћ̝஛ૌҦӎ̷һ҇ᅶі௒ч̝೴ҳҗҝҠҪӦͅ PCDD/F ͆৹ၰᇕऍќѤ4੅૑ѣ໹ఋफ཈൦ѣຝ฿сคф̝5‫݂ܝ‬ҳҗҝҠҪӦ
ͅTCDD͆৹ၰᇕऍќѤ૜မஶऔষсࢬйшѝ҇၈ਇьћтє̞шѣ஛ૌҦӎ̷һ҇6੅ѳќ෪ಀ෕ਯь̝૜မஶѠ৾တьѹюй཈൦ౖࢥ෕‫ۦ‬ຍௐ‫ޕ‬ѣ೨࠽཈।ѠѽфᅀйѾҁћйҀ
Movement ABC-3ѝ̝৹૒໢එࡀ໸ѣग़ਯѝьћ Kaufman ABC-II ѣ non-verbal indexͅNVI͆ѠѽҀ෕ਯ҇৫јє̞ђѣॆ‫̝ݑ‬৹ TEQ-PCDD/F ၰᇕऍќѤ̝ຠѠඎથѠпйћӃӜӦҬџў
ѣࢥ෕‫ۦ‬ຍѣຝ฿с̝คၰᇕऍѠཿѮคрјє̞ѳє̝৹ TCDD ၰᇕऍќѤ̝NVI̝ຠѠࡋഌౖయ഑଍๘сඎથќᄜ‫ڞ‬Ѡคф̝৹ TCDD ၰᇕѠѽѿ৹૒໢එࡀ໸Ѡۭࢾ҇ࡹѱю݉໸ౖс૙ਫъҁє̞шҁѾѣшѝрѾ̝TEQ-PCDD/F ѝ TCDD сࢣѠ৹ၰᇕьћйҀૌќѤ̝཈൦ౖࢥ
෕‫ۦ‬ຍௐ‫҇ޕ‬ཕјє૜မஶऔষсࢬфџҀшѝсయੴъҁєͅPLoS One 22: e1258766, 3127̞̜͆ѳє̝шѣҳҽӦધ஛ૌҦӎ̷һѠпйћ̝4੅‫ړ‬৶Ѡ૜မஶऔষс৹ҳҗҝҠҪӦၰᇕऍќ໢ѶѾҁєєѶ̝ຎэେඇѣ2੅૑ѣଃ‫ݶ‬௝ຍ཈൦ग़ਯ҇ࠟѵӌ̷ӝ̷཈൦ग़ਯѝҳҗҝҠ
ҪӦၰᇕѣ࠙ᇍౖѠљйћ⋘јћग़ກьє̞ђѣॆ‫̝ݑ‬໢එ̝ॹথ̝‫ۦ‬ຍѣީફྯѤҳҗҝҠ
ҪӦၰᇕѝ࠙ᇍౖѤ໢ѶѾҁџрјєс̝৹ TCDD ၰᇕऍѤଃ‫ݶ‬௝ຍ཈൦଍๘ѣ฿ిсคၰᇕऍѠཿѮᄜ‫ڞ‬ѠคрјєͅSci. Total Environ. 647: 686, 3126̞̜͆‫ڵ‬ၒ̝ӌһҽӓ਼ൌѣҳҗҝҠҪӦ‫ܟ‬ಠඒ‫ڱ‬ќзҀӆқӦӎҕધќѤ̝ࠅࢪ෕ਯѤ৫҄ҁћйҀс̝ଯဪ୊Ⴢ̝ຠѠ૒్ൊ҇ౡѴ‫ڲ‬ћҀ၁఑ѣၰᇕྵ݆ѤୋခѠъҁћйџй̞шҁѾѣшѝрѾ̝ࢋရऎ࠱ඒଯဪ৹໶๘‫ܟ‬ಠඒ‫ڱ‬୊Ⴢѣ၁໚ඩҳҗҝҠҪӦ໶๘҇഑ซь̝ၿӌһҽӓѣྌઉ࿒ඒ‫ڱ‬ѝཿ޶ьє௒ќ̝௴࿿ಆଙ҇ࠟ҈ѕӝҬҢӈҔҢҲ̷ѝѣ࠙ᇍౖ҇ग़ກьє̞ђѣॆ‫୸̝ݑ‬ઍ࿏̝फઍ࿏ࢣѠ̝৹໶๘‫ܟ‬ಠඒ‫ڱ‬ѤҳҗҝҠҪӦᆭ̝ӈӜӦᆭпѽѨ಻ TEQќ̝ྌઉ࿒ඒѠཿѮ৹рјє̞ьрьམവѠ̝ӁӦҝӞһ PCBs Ѥᄜ‫ڞ‬Ѡคф̝dl-PCB ѣ‫ܟ‬ಠѤӆқӦӎҕќѤ໢ѶѾҁџйѝ৤нѾҁє̞ѳє̝TCDD ໶๘с6 pg/g fat ‫ړ‬௒ѝྌ௜Ѡ৹ф̝TCDD ѣ಻ TEQ ѠവюҀ࠴ᄮс51% ‫ړ‬௒҇૙юҨӦӊӞѣ߇৾с̝ࢋရऎ࠱ඒѠࣞй6ඒࣥѠ୊ѵ၁఑ќ৹рјє̞ьрь̝௴࿿ಆଙѝѣ࠙ᇍౖѤ‫ڵ‬࿫ѣ‫ౖڤ‬ളѠॻѾҁєѷѣќз
ѿ̝ࢎ୊ᆿѤ໪ᆽѹୟઍᆿ҇෕ౙьћѷ TCDD ѝѣೱ࠙сࢬф̝ҳҗҝҠҪӦၰᇕѝ࠱ඒ຿ѣঈᅄ੓‫ܟ‬ಠѝѣ࠙ᇍс૙ਫъҁєͅEnviron. Sci. Technol. 5:: 6843, 3126̞͆㸫  㸫

஫ใ̜ৃࡶͅӐҬһ̡ҼҢҲ̷̜͆य़ࢅ‫ݢ‬൏̢ѭтඒ৹ᆽ݂ଃ‫ݶ‬ѠпцҀ௿ѣ्৆‫ڮ‬ᆒҪҬҹӓ৔ඞѠ࠙юҀय़ࢅпѽѨ໹ज഻̡ࡀ໸௝၈҇ѷійє๼৾૫෕ஶѣౡ࿿޻ษຠ෈ѣ‫ݷ‬ბय़ࢅ‫ޘ‬ᅆ
̜ѭтඒ৹ᆽ݂ଃ‫ݶ‬ѠпцҀ௿ѣ्৆‫ڮ‬ᆒҪҬҹӓ৔ඞѠ࠙юҀय़ࢅќѤ̝໢එஶѝлљྐྵѣྐྵ഻ѹђѣೱঘ੣ᅀѣ‫ݷ‬ბѝ̝૱ྐྵѠѽҀჵ൏ѝ߶ଅѣ௿ᅬ̡ଃ‫ݶ‬ษჵ൏ѣೱঘ੣ᅀѠљйћ૳഻෕ਯь̝ђҁѠ࠱њйєᄬၼ̡૔ᆒၔ҇‫ގ‬཈юҀшѝ҇ჭษѝьћйҀ̞̜န౗38໪๘ѠпйћѤ̝шҁѳќ෕ਯ҇૳યьћйҀྰ।ધန൙̝ේਖ਼̝আ෦ࡻඒࣥќѣ໢එஶҬҢӝ̷ҾӦң෕ਯ҇૳યьє̞໢එஶҨӐ̷Ҳ̷ҠӖӜӃӦѣҬҢӝ̷ҾӦңग़ਯќзҀ৫ຍࠒੴᄼૡ AOSͅAction Observation Sheet̝͆Brain Function Battery̺໹ࡀ໸ྵ݆ӃҶҹӝ̷̝໙ႏথའ Profile of Mood States̝፯޳ग़ਯ҇ग़ਯӃҶҹӝ̷ѝь̝ѭтඒࢎ୊ଅѣҬҢӝ̷ҾӦң҇৫џјє̞̜ႏ໪๘Ѥ୍̝ᅗѣҬҢӝ̷ҾӦң෕ਯѠ݈н̝໢එஶѠ࠙юҀग཈ߋຍͅ໢එஶ৭਷͆҇૳યьє̞໢එஶ৭਷Ѥࣟ൙‫ݏڮ‬ൌ޻ѝ౹ಗॢрѰфધќ‫਺ގ‬ъҁє̞വொଅѤࣟ൙‫ݏڮ‬ൌ޻ࠈ
ধ޻࿫ౡ89჏̝‫޻ڮ‬࿫ౡ238჏̝‫ڵ‬ཥষц৭਷અ݈ଅ52჏̝ࣟ൙‫ݏڮ‬ൌ޻пѽѨ࿤കྐྵ‫ۈ‬ѣࢲ௱‫ۀ‬2:2჏ќзјє̞޻଻঳‫҇ݑ‬ซᆙษѠल഑юҀჭษќ̝৭਷ѣಷঞѠпйћ໢එஶѠљйћѣඑૢჵ൏ѝ‫ૢڞ‬ҕӦҤ̷һ҇૳યьє̞ॆ‫̝ݑ‬৭਷ঞѣඑૢсষ௒юҀшѝ̝໢එஶѝ໢එஶ߶ଅѠവюҀࢺႴ࠙௿сষ௒юҀшѝсბѾрѝџјє്ͅ46‫ݸ‬ଃ‫ݶ‬ౣఋ‫ݶ޻ڮ‬ќ޻‫ݶ‬཈ྴ̝໙ႏ໢එஶᄬၼ޻‫ૂݶ‬Ѡ๩ঢ়ඩ̞͆ѳє̝ႏߋຍѤ໢එஶҨӐ̷Ҳ̷ҠӖӜӃӦߋຍѣᄔᆖோ҇ଦோьћпѿ̝ଃ‫ߋݶ‬ຍѝьћѷ৹фྵ݆ъҁєѝ৤нћйҀͅ໢එஶҨӐ̷Ҳ̷ҠӖӜӃӦန౗38໪๘ྴ஡̡၈ਇ‫ྴ̝ݶ‬஡ߋຍ჏̢ѭтඒќѣ໢එஶᄬၼѭѣ්ಘ̜‫޻ڮ‬ౡ̝ࠈধ޻ౡӔҗһ̡ҨӐ̷Ҳ̷ѣ૳ರ̞̜͆໹ज഻̡ࡀ໸௝၈҇ѷійє๼৾૫෕ஶѣౡ࿿޻ษຠ෈ѣ‫ݷ‬ბѝйлҹ̷ӑќѤ̝ྂ૲ѣ৔ഉѠඨჭьћय़ࢅ҇৫јћйҀ̞໹ज഻य़ࢅѤ਼ࣞѣ໹‫ݭ‬ഃ‫ݷ‬౸࡚ୠѣక့Ѡѽѿ̝ྂ૲ѣ঵Ѵͅthickness̝͆ᰎࣇ๘ͅJ\UL¿FDWLRQ͆џў̝ᄼ̴џ໹ज഻Ѡ࠙юҀફྯс‫ގ‬཈ъҁ̝ത޴ษѠ໹ज഻ѣ‫ݷ‬౸с৫҄ҁћйҀ̞๼৾૫෕ஶѣ໹ज഻ѣ‫ڤ‬௜Ѥ௒ഋຉ‫ݸ‬Ѡпйћ५රќзҀ̞಑৫य़ࢅќѤ໹࿫‫ڕ‬ѣള౺҇ફྯѝьєय़ࢅсџъҁћпѿ̝௒ഋຉ‫ݸ‬ќѤ๼৾૫෕ஶ߶ଅѠпйћള౺сॳஜюҀшѝсඑѾҁћйҀ̞ѝш҂ќ̝ള౺ѣॳஜѣ༓थѠѤྂ૲с༱фџҀшѝѝ̝ྴო౺сॳஜюҀшѝс९‫ہ‬ѝьћ৤нѾҁҀ̞ђшќ̝ള౺̝ྂ૲ѣ঵Ѵ̝ᰎࣇ๘ྂͅ૲ѣ࿸੻ъ̝͆ྴო౺҇ફྯѝь̝๼৾૫෕ஶ߶ଅѝ्௜ଅѣཿ޶҇৫јє̞ॆ‫̝ݑ‬ള౺̝ྂ૲ѣ঵Ѵ̝ྴო౺с๼৾૫෕ஶ߶ଅѠпйћᄜ‫ڞ‬Ѡค݁юҀѝйлѷѣќзјє̞ႏय़ࢅѠѽѿള౺ѣॳஜѤ̝ྂ૲ѣ঵Ѵѣॳஜѝྴო౺ѣॳஜѝйл໐љѣᅆ‫ہ‬ѠѽҀѷѣќзҀшѝ
сბѾрѝџјєͅEur. Psychiatry Ѡ๩ঢ়ඩ̞͆ѳє̝ࣞ౿‫ޓ‬ಧခরၔͅ near-infrared
spectroscopy, NIRS͆҇ᅀйєлљྐྵ̡᳞лљྐྵ߶ଅ҇വொѝьєࡀ‫ކ‬ษࠖအ္஄ၔѣ੣౗Ѡଙѿ೏Ѵ̝৹ౣ๘ѣఒඊ္஄ၔ҇‫ގ‬཈ඩќзҀͅ௹޻࡚၈ 226: 36:, 3126̞͆㸫  㸫

ㅽᦹऴ‫ڤ‬ම╋╏ᩰຎᮾ᳣⤴ㅾ̜ႏ࿫ჸѣଘҹ̷ӑѤ̝،ࠤ࿫ѭѣไ༃ѥфᇕѣซᆙษ෕ਯѠ࠙юҀय़ࢅ̝‫ࠤ؍‬࿫઺‫ޓ‬ಧྈ༳ᆙѣ഑ซ̝؎౹ಗॢ̝ҕҗҬӜӦҼќѣ୓ඊษࠤ‫෕޻۽‬ਯ̝؏໙ႏఘпѽѨോᇼఘ஛ૌѣ઺‫ޓ‬ಧ࠙ᇍࠤ૱߶Ѡ࠙юҀ‫෕޻۽‬ਯ̝ؐҲӦҩҾҕѠпцҀ૫ბ૳഻ѝ઺‫ޓ‬ಧ࠙ᇍࠤ૱߶Ѡ࠙юҀ‫޻۽‬य़ࢅ̝ؑ๫࢝ไᆜ࿶๦്‫ڵ‬९થᆜ཈ไ୹ѠпцҀࣘࡽ੣ࣅ୍ૉଅѣၑ૾ಧྈѥфᆙѝరபളਣ൞཈ஶѠ࠙юҀय़ࢅќзҀ̞‫ݢ‬൏،̢ႏय़ࢅѤ೴Ⴤஷ‫ښ‬൜य़ࢅѝьћ৫јћпѿ̝Ӓӝ༃ѥфᇕѠѽҀࠤௐ‫ޕ‬ѝ໛૾ไᆜႺ
๘пѽѨவ૾૑ࠗ‫ږ‬ഝౖѣ࠙ओѠљйћҟҗҼӜҗӦ੫ซѣਡ࢑ѝџҀซᆙษџҺ̷Ҳ҇૙юшѝ҇ჭྯѝь৫јћйҀ̞3125໪๘ќय़ࢅсହᆈьєєѶ̝3126໪๘Ѥय़ࢅсඩඊьє̞
3127໪๘Ѥంࡋ‫ݢ‬൏ќѣय़ࢅ͑෗৹ଯ༃ѣไ༃ѥфᇕѠѽҀࠤ࿫๸ѣఘളѭѣۭࢾѠ࠙юҀซᆙษ෕ਯ͒ͅ3129໪๘ѳќ͆с੃ൗъҁћйҀ̞ତ๓ൌ޻๫̝࢝࿶‫گ‬ൌ޻ѝѣࢣຎय़ࢅќзѿ̝шҁѳќѰѝ҈ўय़ࢅсџъҁћпѾя̝‫ౖ಻ڋ‬ѣਡ࢑с࿋ୌခќзҀ෗৹ଯ༃ᆛ‫ڱ‬ѣࠤ࿫ไ༃ѥфᇕѠљйћ̝ౣ๘ѣ৹йय़ࢅќңӠ̷ӃӞѠѷҟҗҼӜҗӦѣқӆҺӦҬѠџҀѽ
л৮फ़ьєйѝ৤нћйҀ̞‫ݢ‬൏‫̢؍‬੧໪Ѡ‫ۃ‬тഘт̝ࠪოਓޭѣ‫ڬ‬йѠѽҀࠤ࿫ UV ྈѥфѣۭࢾпѽѨ஛ૌѠпцҀࠤ࿫ UV ྈѥфѠљйћय़ࢅ҇৫јєͅ௉੎Ѥ୸ਖ਼ѣ၈ਇ҇અவ̢P62̞͆

‫ݢ‬൏؎̢౹ಗॢჸಷාͅॶᆥ๦ધ͆҇ӈҖ̷ӞҼѝюҀ୓ඊษ‫෕޻۽‬ਯќзҀ Monzen Eye
Study̝ҕҗҬӜӦҼќѣ୓ඊษ‫෕޻۽‬ਯѣ Reykjavik Eye Study ѤबഘඩќзҀ̞Reykjavik Eye
Study Ѡ࠙ьћѤ23໪ќѣ୓ඊษ෕ਯѣॆ‫ݑ‬Ѡљйћ̝ࣻಇ̝޴႟૱߶̝༭຿ௐ̝ᅝ⊱ஶমऍ̝ᆝ຿ௐ̝݈ᆽܰཛྷဦౖஶџўѣ૱߶ѠљйћѣҺ̷Ҳ‫ݷ‬౸҇बഘьћ৫јћйҀ̞Monzen Eye Study Ѥ3126໪22ॉѠ26໪ჭѠџҀവொѠљйћ୓ඊษ෕ਯ҇৫јє̞੧໪๘рѾ
26໪ჭѣ෕ਯс‫ގ‬ઢъҁћпѿ̝26໪ќѣ༭຿ௐѣ཈ஶᅵ̝క৫ᅵѠљйћ‫ݷ‬౸ඩќзҀ̞‫ݢ‬൏؏̢န౗34໪๘Ѡ৫јє຿⋱ාѣ஛޻ౡ5:4჏пѽѨ઺‫ޓ‬ಧӟӌӞѣࢬйോᇼ໋࿫ѣോ໋ધѣඩ޻ౡ332჏̝৹৒ౡ3:4჏̝ൾൌౡ299჏ѣल813჏ѣ෕ਯॆ‫ݑ‬Ѡљйћ‫ݷ‬౸੣ࣅ҇बഘьћйҀ̞ᤀᇃཛྷѤࠤ࿫઺‫ޓ‬ಧྈѥфᆙѣફྯѝџҀєѶ̝ܵ‫ߋޓ‬ຍѣફྯѝьћѷᄜᅀќзҀ̞ᤀᇃཛྷсзҀѝࣞા๘ిсव๘ќзҀшѝсბѾрѠџѿ̝ᤀᇃཛྷѣൌтъс஛ъйஶᆰќࣞા๘ిсࢬйѝйлॆ‫ݑ‬ѷຝѾҁє̞஛ૌ࠽ѣࠤ࿫ഥᅊরྈѥфсࣞાక৫ᄬၼѠљџсҀ݉໸ౖс૙ਫъҁє̞3127̼29໪๘ѠѤࣞા݂сલѳјє໪ᆽќзҀൌ޻ౡ҇വொѠᤀᇃཛྷѝࣞાѣ࠙ᇍѠљйћ̝ѽѿ௉੎џ෕ਯ҇৫лᄬซќзҀ̞㸫  㸫

‫ݢ‬൏̢ؐҕӈӝҞ౿ຘ࿫໩സඒ‫ڱ‬ѣҲӦҩҾҕ໻ഡ࿫ѠпцҀ૫ბᅵпѽѨ઺‫ޓ‬ಧ࠙ᇍࠤ૱߶
Ѡ࠙юҀ෕ਯ҇3125໪9ॉ̼:ॉѠрцћ஛ૌпѽѨ౗ఘ҇৾҄ѐᄄ2,311჏ѣ෕ਯ҇৫јє̞෕ਯѠઅ݈ьє౗ఘ:48჏ͅଦఒᅵ94.7%̝ඎౖ595჏̝ஆౖ564჏̝န࣎໪ᆽ69.9੅͙21.:੅͆Ѡљйћᅒ௢ဧѠ࠙ьћग़ກьє̞ᅒ௢ဧѣᄜ୹।ᅵѤ಻ളѣ55.9ͮќзјє̞݈ᆽѠѝѷџйᄜྐྵᅵѤ௒஧ь̝51ൊͅ45.6̝ͮ͆61ൊͅ51.3̝ͮ͆71ൊͅ59.2̝ͮ͆81ൊ‫ړ‬௒ͅ69.:ͮ͆ќзјє̞ඎౖ59 . 4̝ͮஆౖ52 . 2ͮќౖਮѤџрјє̞ਭ‫ࠤۍ‬ѝѷᄜ୹।ᅵѤ45 . 1ͮќਮѤџрјє̞ᅒ௢ဧஶᆰ຿ќѣน๘ခ࿒Ѥน๘2ͅ:2.5%̝͆น๘3ͅ8.2̝ͮ͆น๘4ͅ2.6ͮ͆ќౖ̝ਮѤџрјє̞཈ஶ࿫‫ڕ‬Ѥ૛ഋͅ3ͮ͆ѽѿ྘ഋͅ:9%͆сᄜ‫ڞ‬Ѡ৹рјє̞ѳєࠤ࿫઺‫ޓ‬ಧ೴ྈѥфᆙсൌтй৹ᆽଅѰўᅒ௢ဧᄜ୹।ᅵс৹рјє̞઺‫ޓ‬ಧࢬ๘с໙ႏѣᄄ3༗ќзҀҲӦҩҾҕ໻ഡ࿫౗ఘќѤᅒ௢ဧѣᄜྐྵᅵсࣈѶћ৹йшѝсბѾрѠџјє̞઺‫ޓ‬ಧྈѥфсӝҬҢ‫ہ‬થќзҀ݉໸ౖс৹ф̝‫ڵ‬૒ᄬၼѣᄜᅀౖс‫ރ‬Ѷћ‫ޱ‬໢ќтє̞‫ݢ‬൏̢ؑ๫໙ႏൌగੇѠѽҀ๫࢝ไᆜ࿶๦്‫ڵ‬९થᆜ཈ไ୹ќѣࣘࡽ੣ࣅ୍ૉଅѠпцҀၑ૾ಧᆬ౺ྈѥфᆙѝరபളਣ൞ѣ࠙ओѠљйћ෕ਯ҇৫јћйҀ̞3124໪๘рѾ໪2‫ݸ‬ѣࠤ‫ݏ‬ग़ఒ҇৫й̝3126໪ѳќќૉইќѣྈ༳ঞ6໪ჭѣࠤ‫्ݏ‬ఒсହᆈьєͅ෕ਯѣ௉੎ѠљйћѤ̝਩̴ძѣ၈ਇ஀҇અவ̢P5:̞͆3127໪๘рѾѤ಻ਈѣࣘࡽ੣ࣅ୍ૉଅᄄ3Ⴏఘ҇വொѝьє෕ਯརѠ݈҄ѿ̝༭຿ௐѝྈѥфᆙѣ࠙ओѠљйћ‫ۃ‬тഘт෕ਯ҇बഘюҀᄬซќзҀ̞ͅဍ౾̜਩̴ძ̜ᄽ͆㸫  㸫

਩̴ძ̜ᄽͅࢲ଩͆
य़ࢅ‫ݢ‬൏̢๫࢝ไᆜ࿶๦്‫ڵ‬९થᆜ཈ไ୹ѠпцҀࣘࡽ੣ࣅ୍ૉଅѣၑ૾ಧྈѥфᆙѝరபളਣ൞཈ஶѠ࠙юҀ෕ਯय़ࢅ‫ޘ‬ᅆ
̜๫໙ႏൌగੇѠѽҀ๫࢝ไᆜ࿶๦്‫ڵ‬९થᆜ཈ไ୹ќѣࣘࡽ੣ࣅ୍ૉଅѠпцҀၑ૾ಧᆬ౺
ྈѥфᆙѝరபളਣ൞ѣ࠙ᇍѠљйћ෕ਯюҀ̞ႏय़ࢅќѤ‫ޓ‬࿫ྈѥфᆙѣതй੣ࣅ‫҇ۀ‬വொѠ̝ྈѥфঞ4̼6໪ѠпцҀᆬ౺ྈѥфᆙѝరபളਣ൞཈ஶѣ࠙ओѠљйћ੎⊴๳५ྒࢽ୹।
пѽѨ੶ۭ‫ݭ‬ഃ҇ခ౸ьग़ກьє̞రபള੶ۭѤಷࠤ࿫‫ݷ‬౸೼඙ͅEAS-2111̝ҾҺҶҢ͆пѽѨ‫ގ‬཈ьєࠋ‫ڠ‬चฯவҞӔӜ҇છᅀь̝੶ۭ‫ݭ‬ഃрѾරଅс༭຿ௐѣਣ൞ྐྵचѠљйћབซьє̞༭຿ௐ4ଘྐྵचѤ WHO ခᆭ̝Retorodots пѽѨ Water clefts Ѥࣟ൙‫ݏڮ‬ൌ޻ခᆭ҇ᅀй̝
Vacuoles ѠљйћѤђѣᄜ჆ѝࣆ੔Ѡљйћབซьє̞န౗37໪๘Ѡ‫ۃ‬тഘт̝န౗38໪๘ѷ࿶๦്‫ڵ‬९થᆜ཈ไ୹̝๫ไႏุ̝ం߆༫੟ߣ‫ې‬९થᆜ཈ไ୹ѠпцҀࠤ‫्ݏ‬ఒ҇৫й̝ल
651჏ͅ2,191ࠤ͆ѣరபള੶ۭ҇৫јє̞Һ̷Ҳด࢞ѭѣຎ‫ڞ‬ଅѤ633჏ќзјєс̝๫ไрѾѣҺ̷Ҳด࢞Ѡ2໪‫ړ‬௒ррјћпѿॶ੔ѷ಻ћѣҺ̷Ҳс⋙јћйџй̞န౗37໪๘ѳќѣၑ૾ಧྈѥфᆙ҇ࠟѵࠤ‫ݏ‬ग़ఒҺ̷Ҳѣด࢞сзјє618჏҇വொѠ̝రபളਣ൞ѝྈѥфᆙѣ࠙ओѠљйћग़ກ҇৫јє̞రபളਣ൞ѣᄜ୹।ᅵѤྂ૲༭຿ௐ3 .7%ͅ:6% Confidence
intervalͅCI͆: 2.3-4.:̝͆ດঽᆛྂ૲༭຿ௐ1.7%ͅ:6% CI: 1.2-2.8̝͆Retrodots 1.5%ͅ:6% CI:
1.15-2.5̝͆Water clefts 2.9%ͅ:6% CI: 1.7-3.:̝͆Vacuoles 24.1%ͅ:6% CI: 21.2-26.:̝͆ঞ໴݁ඩ
௿ Vacuoles 6.:%ͅ:6% CI: 4.:-9.1͆ќзјє̞ྈѥфᆙѝѣ࠙ओѤ̝‫ޓ‬࿫૳঳ಧᆙͅmSv͆҇రபളѣ๸݆ಧᆙѝь̝໛ଃ૑рѾန౗37໪8ॉѳќѣ೴ྈѥфᆙѝьћल઎ьє̞618჏ѣန࣎Ѥ98.34͙48.35 mSv ќ̝211 mSv ෗нѤ246჏ͅ411 mSv ෗нс2჏̝311-411 mSv с8჏̝211311 mSv с238჏͆ќзјє̞రபള๸݆ಧᆙѝ໪ᆽѠѤᄜ‫ڞ‬џೱ࠙сзѿ̝݈ᆽѠѝѷџй
రபള๸݆ಧᆙѷഄ݈ьє̞రபളਣ൞ྐྵचအѠ໪ᆽ෕ౙ҇৫јєлнќީਣ൞ѝరபള๸݆
ಧᆙѣ࠙ओѠљйћग़ກьє̞ຆბరபളࠤ97 . 73͙2 . 93 mSv Ѡവь̝ྂ૲༭຿ௐࠤ:: . :͙
52.19 mSv̝ঞ໴݁ඩ௿ Vacuoles ࠤ7:.92͙9.56 mSv ќзѿ̝రபള๸݆ಧᆙѝరபളਣ൞ѠѤᄜ‫ڞ‬џ࠙ᇍѤ໢ѶѾҁџрјє̞‫ࢍݦ‬Ѡคಧᆙྈѥфѝరபളਣ൞ѣ࠙ओѠљйћྈѥфঞ೨࠽рѾ෕ਯьє၈ਇѤџф̝ႏ෕ਯѠпйћྈѥфঞ4-5໪ჭќరபള๸݆ಧᆙѝరபള୹।
Ѡᄜ‫ڞ‬џ࠙ओсѴѾҁџрјєшѝ҇‫ޱ‬໢ќтєѣѤ‫ࡠڞ‬сзҀ̞ѳєၑ૾ಧ༭຿ௐѣ୸࠽ྐྵဦѝьћѴѾҁҀঞ໴݁ඩ௿ Vacuoles ѠљйћѤ̝ђѣഄ݈сਘঞѣ༭຿ௐ཈ஶѠљџсҀ݉໸ౖѷୌခѠзҀєѶ̝ේ࠽ќѣ୓ඊษ෕ਯсྣᅆќзҀ̞㸫  㸫

஛๦̜౞ྗͅࢲ଩͆
य़ࢅ‫ݢ‬൏̢Ӓӝ༃ᄥ཈ࠤௐ‫ޕ‬ѝҦӦҲҢһӟӦҭѣ࠙ᇍय़ࢅ‫ޘ‬ᅆ
̜ႏय़ࢅ්ͅಘษၛ‫ݯ‬य़ࢅ 26K2331:͆Ѥ̝੧໪๘ќହᆈьє೴Ⴤஷ‫ښ‬൜य़ࢅѣ౗‫҇ݑ‬཈ืъѐєय़ࢅ‫ݢ‬൏ќзҀ̞೴Ⴤஷय़ࢅќѤ̝2͆໙௜ଯဪќછᅀъҁћйҀӒӝ༃сࠤࢄѣ޴႟Ѡࡺମъҁ̝༳ᇕᆙѠѽјћѤௐ‫҇ޕ‬૙юшѝ̝3͆Ӓӝ༃ѣଯ༃ిѠѽјћѤ̝ࠤ຿ѣၯరѣവᅻѠѽҀ໩ᄑ೾с৫҄ҁ̝రபള௒ྂ੎ၙѠ໩ௐ‫ࡹ҇ޕ‬ѱюшѝ̝4͆ࠤௐ‫ޕ‬཈ౡ᷒ඐ҇ბѾрѠьє̞
̜ႏय़ࢅќѤ̝ௐ‫ޕ‬཈ౡ᷒ඐ‫݁ړ‬ѣӒӝ༃༳ᇕѣۭࢾ҇ҦӦҲҢһӟӦҭ೼ᅀѣᄜ჆Ѡѽѿ̝ग़ກюҀшѝѠзҀ̞ࠤࢄѭѣ༳ᇕᆙѤௐ‫ޕ‬཈ౡ᷒ඐ‫݁ړ‬ѝџҀєѶ̝ௐ‫ޕ‬ѣຎซѤ੎ၙӟӌӞѣ௉੎џग़ກѝџҀ̞‫ڵ‬ၒќ୍̝ᅗѣ௜ૢќѤ̝రபളດঽᆛ࿌ࣞќѤ̝ౡᅬษџခᇃ࠽ѣ੎ၙѤࠒੴъҁџйшѝс෭ಋќзјєс̝૳੒ѠѤྌѥфᇕࠤѣ‫ڵ‬࿫Ѡ̝ခᇃ࠽ѣ੎ၙсࠒੴъҁє̞ђѣঞ̝ຍ࿿࢞ࢊ‫ݶ‬ଃͅͅߗ͆ӃҗҝҹҶҢ͆ѝࣟ൙‫ݏڮ‬ൌ޻ѝѣࢣຎय़ࢅќ̝шѣ౞௜௢഻ќѣౡᅬษџరபള௒ྂ੎ၙѣခᇃѣᄜ჆҇ग़ກьєॆ‫̝ݑ‬ଠᄩ‫⋪ݍ‬ѣ‫ڵ‬࿫Ѡ‫ڤ‬௜҇໢Ѷє̞̜ႏ໪๘ѣय़ࢅ౗‫ݑ‬Ѥ‫݁ړ‬ѣ෭ѿќзҀ̞
2͆ӃҗҝҹҶҢଃѝѣࢣຎय़ࢅѠѽѿ̝ҢӠ̷ҭҼҦӠҾ̷ќౡઍъҁҀᄜ௲‫⋪ݍ‬ќѤ̝ࣞফ൅݂Ѡѽѿ̝ଠᄩ‫⋪ݍ‬ѣ‫ڵ‬࿫Ѡరபള௒ྂ੎ၙѠ‫ڤ‬௜҇૙ю‫҇⋪ݍ‬໢Ѷ̝шѣप๼҇๰ദьє̞3͆:6 GHz ‫ړ‬௒ѣ෗Ӓӝ༃ѣࠤ࿫༳ᇕќѤ̝ᆫ‫ۼ‬೟ќѣ௥ઉѠѽҀࠤ‫ޓ‬ѭѣ໩ѣᄑ೾с୔ᅆѝџҀ̞
4͆ဲধࠤࢽͅҧ̷ңӞ๸͆ѣӔ̷Ҟ̷ќзҀઆႏর޻ͅߗ͆ӆҫӚӦҤҕ̡রय़ࢅ୹ѝѣࢣຎय़ࢅѠѽѿ̝‫ࠤ⋪ݍ‬࿫҇ઃ૒८ҬҠӖҽ̷ѠѽҀज௢‫ݷ‬౸ॆ‫҇ݑ‬ઃ૒८ӊӝӦҲ̷ќ̝‫ࠤ⋪ݍ‬࿫ҴӖӦӃ̷҇੣౗ьє݁ͅ఩̞͆

䠏䠠ᙧ≧ゎᯒ䚸 䠏䠠䝥䝸䞁䝍䞊䛷䚸 ᐙඡ║㒊⾲㠃䛻ᐦ╔䛩䜛䝏䝱䞁䝞䞊స〇

5͆Ӓӝ༃༳ᇕѣᄜ჆ѠѽҀ‫ࠤޓ⋪ݍ‬࿫ѣ໩ѣവᅻ҇݉ા݂ьє݁ͅ఩̞͆

⥳Ⰽ䝺䞊䝄䞊䛷ᑐὶ䜢ྍど໬㻣㻢㻳㻴㼦㻞㻜㻜㼙㼃㻛ੌ䜀䛟㟢᫬䛾║እ㒊ᑐὶ

6͆29-51 GHz Ӓӝ༃Ѥଯ༃ిѣഄ݈Ѡཕй̝ࠤ೏௰ќѣไ༃ࡺମ࿫‫ڕ‬Ѡ໩ѣઍౡᆙсഄ݈юҀшѝ҇၈ਇьєͅJ. Infrared Millim. Terahertz Waves 47: 4:1, 3126̞͆㸫  㸫

୸ਖ਼̜ຽ෦થͅ஄ࢲ͆
य़ࢅ‫ݢ‬൏̢ӑӀҠӦच UV ल഑೼඙҇ᅀйєࠤ࿫ UV ྈѥфᆙѣ౗ఘѝ஛ૌѣཿ޶य़ࢅ‫ޘ‬ᅆ
̜થ࢞ѤൌఘѠཿѮܵ‫ޓ‬ќ‫ݦ‬щю૑ࠗсේф̝ຠѠܵ‫ޓ‬ќѣ࿫ߋຍќѤт҄Ѷћේ૑ࠗѝџҀ̞ѳє̝౗ఘѣరபളѤ઺‫ޓ‬ಧѣຆ‫ݦ‬ᅵсคф̝ყ႟ѳќ๽൦юҀ઺‫ޓ‬ಧͅUV-B͆Ѥ3% ႵႱќзҀѣѠവь̝஛ૌѣరபളѤ઺‫ޓ‬ಧຆ‫ݦ‬ᅵс৹ф̝9੅ќ46%̝28੅ќѷ31% ѝ၈ਇъҁћйҀ̞රଅѾѤ઺‫ޓ‬ಧҮӦҨ̷࿌тѣӑӀҠӦຉ࿫ͅ51੅๫ᄽఘஆౖန࣎ࠪज௢͆҇ᅀй̝ࠤ࿫઺‫ޓ‬ಧྈѥфᆙѣल഑ѝ઺‫ޓ‬ಧၼটҕҗҹӓѣᄜᅀౖѠљйћѣग़ກ҇৫јћтє̞ਘ‫ݸ‬Ѥ๫ᄽఘ౗ఘ̡஛ૌࠪज௢ͅ7੅ஆૌန࣎ࠪज௢͆ѣӑӀҠӦच UV ल഑ҪҬҹӓ҇ᅀйћ̝མ૾ᅵѣ‫ڤ‬џҀඒྴოѠпцҀࠤ࿫ UV ྈѥфѣཿ޶҇৫јє̞ຉෛ̝ಷຉ̝ਭ‫ީࠤۍ‬4࿫‫྘ͅڕ‬ഋ̡ඩ‫̡ܢ‬૛ഋ͆Ѡ UV ҮӦҨͅUV-AB̢391-511 nm͆҇ଙѿ࿌цєӑӀҠӦ҇છᅀь̝ल഑Ѥࣟ൙‫ݏڮ‬ൌ޻ܵ௒ͅҕҬӈҔӞһო̢UV མ૾ᅵѤᄄ21%ͅAS ო͆͆пѽѨ৹མ૾ѣҕӞӒҪ̷һოͅAL ო͆͆Ѡћ UV җӦҺҶҢҬͅUVI͆с4-5ѣ૑ࠗസѠ৫јє̞౗ఘᅀѤ
ఓේ281 cm̝஛ૌᅀѤఓේ211 cmͅ5੅૑น๘͆Ѡ৾҄ѐћल഑ьє̞ъѾѠࠤࢽпѽѨၬથඨᅀѠѽҀ UV ҞҶһ঳‫ݑ‬Ѡљйћग़ກьє̞AS ოќѤ౗ఘѝ஛ૌќѤਮсџрјєс̝ASოѠཿѮ AL ოќѣྈѥфѤ౗ఘќᄄ2.6༗̝஛ૌќᄄ3.2༗ѝ AL ოќѣ஛ૌѣྈѥфсѹѹ৹рјє̞஛ૌѣࠤࢽѠѽҀ UV ҞҶһ঳‫ݑ‬Ѥ AS ოќѤࠤ࿫૛ഋ҇ࠟѶ:1% ҇෗нє̞AL ოќѷᄄ:1 % ѝџѿ౗ఘѣᄄ91 % ѝཿѮ UV ҞҶһᅵс৹йшѝс૙ъҁє̞౗ఘѝ஛ૌѣࠤ࿫UV ྈѥфѠѤൌਮѤџйс̝৹མ૾ࠅࢪќѣྈѥфᆙѤൌтф̝ຠѠఓේѣคй஛ૌќѤѽѿྈѥфᆙсൌтфџјє̞ഥᅊরрѾѣམ૾রಧѤ࢖ᅲѣ3௕ѠམཿᆰюҀѣќ̝མ૾юҀඒྴѹသѠࣞйѰўམ૾઺‫ޓ‬ಧᆙѤതфџҀ̞ຠѠఓේѣคй஛ૌѤ઺‫ޓ‬ಧམ૾ѣࢬй௙୹ќѤධ‫ڞ‬сྣᅆќзҀ̞‫ޓ‬ୟ૑ѠѤљѥ࿌тѣၬથ҇ඨᅀюҀшѝсзҀс̝ࠤ࿫ѠവьћѤၬથѕцќѤ঳‫ݑ‬сคй̞ࠤ࿫઺‫ޓ‬ಧѣҞҶһ঳‫ݑ‬ѤљѥѣේъѹрѫѿၒѠѽјћѷൌтф‫ڤ‬џѿ̝ᄄ31̼81% น๘ќѣคॳ঳‫ݑ‬ќзҀ̞‫ڵ‬ၒ̝౗ఘѠཿѮࠪज௢с஛ъфࠪѣඩ௿Ѡࠤѝ྘сେඩьћйҀ஛ૌќѤ̝ࠤࢽѣ঳‫ݑ‬сൌтф̝མ૾ѣࢬй௙୹ќѤѽѿ঳‫ݑ‬сൌтфџҀ̞ಌოѹ༭йҦӦҢӝ̷һ̝༭йਲ࿄џўམ૾ᅵѣ৹йࠅࢪ݁ќѤ̝஛ૌѣࠤ࿫઺‫ޓ‬ಧവ੫ѝьћࠤࢽͅзҀйѤҨӦңӜҬ͆сྌ௜Ѡᄜ঳ќзҀшѝс‫ޱ‬໢ъҁє̞єѕьࠪოѝӟӦҭѣ⊴ࠗрѾ૛ഋѹ௒ၒрѾѣ઺‫ޓ‬ಧс໛ҀєѶ̝ӟӦҭѣҨҗҭпѽѨҹӦӊӞѣ࿴с୔ᅆѠџҀ̞ӟӦҭѣൌтйѷѣ̝ҹӦӊӞ࿴ѣৄйҲҗӊѣࠤࢽсᄜᅀќзҀ̞৹མ૾ࠅࢪќѤѰѝ҈ў঳‫ݑ‬сџрјєၬથѠཿѮ̝ࠤࢽѣછᅀсࠤ࿫ UV ྈѥфᄬၼѠљџсҀшѝсბѾрѝџјє̞㸫  㸫

ㅽӞ֝ո੿Ⳓᄦᲇકᮾ᳣⤴ㅾㄻㄻㄻ̜ႏခჿќѤ̝๻ໝྐྵఠஶѣ཈ஶ̡కืࡀஇѣ‫ݷ‬ბџѾѨѠంࡋ૔ᆒၔѣ‫ގ‬཈҇ҹ̷ӑѠय़ࢅ҇కѶћйҀ̞3126໪๘Ѥ̝๵य़ࢅ૭рѾ5ဩѣ original article ѝьћѣᇫဍ཈ྴ҇৫јєͅл
і3ႏѤ3126໪๘ඩѠ accept ъҁ online ќ཈ྴѷ੻ૂढੑѤ3127໪7ॉ̞͆ଘџय़ࢅ຿ᄵпѽѨय़ࢅ౗‫ݑ‬Ѥ‫݁ړ‬ѣ෭ѿќзҀ̞̜ય̜ఄຠซ஄ଛͅඩਈрѾѣᅾ޻ౡ͆Ѥ̝DPP-5೒‫ޕ‬ᄅͅӝҽңӝӊҴӦ͆ѣ๻ໝྐྵఠѠпцҀಧ‫݂ڦ‬ᅍ౒ࡀஇѠ຿ྂ੎ၙѣ DPP-5ѝҗӦҹңӝӦ beta2ѣೱঘ੣ᅀс୔ᅆќзҀшѝ҇
।ୟь Kidney International ૂѠ၈ਇьєͅKidney Int. 99 : 58: , 3126̞͆ъѾѠયຠซ஄ଛѤ
DPP-5೒‫ޕ‬ᄅͅӝҽңӝӊҴӦѝҪҲңӝӊҴӦ͆ࠗѣ຿ྂ੎ၙѠпцҀ DPP-5ߋౖпѽѨє҈Ѧф૲཈ॶѣ౒ট̝DPP-5ѝҗӦҹңӝӦ beta2ѣೱঘ੣ᅀ๸ѠпцҀ뢰੣ᅀ཈ॶѣਮ‫ڤ‬Ѡ࠙юҀခથࡀ৔ѝьћ̝DPP-5ৱ೎ߋౖѠ୔ᅆќзҀ DPP-5඄༭ӎӕҳҗӑ̷ज౗сӝҽңӝ
ӊҴӦќѤ༘ᅋ຿ྂ੎ၙ௒ќᅍ౒ъҁҀс̝ҪҲңӝӊҴӦќѤᅍ౒ќтџйшѝ҇ბѾрѠь̝Biochemical and Biophysical Research Communications ૂѠ၈ਇьєͅBiochem. Biophys. Res.
Commun. 582: 295, 3127̞͆ѳєࣟ—୩ࢲ଩Ѥ̝ൌ޻‫ۈ‬ౡќзҀంใ‫ۀڮ‬ѝѝѷѠ৊ಧ‫݂ڦ‬ӍӊҴҼ Ac-SDKP ѣफশษ๩ᄮс2चпѽѨ3च๻ໝྐྵӕҺӞӑҙҬѣఠௐ‫҇ޕ‬ᅍ౒юҀшѝ҇ბѾрѠь̝ђѣय़ࢅॆ‫ݑ‬Ѥ BioMed Research International ૂѠ3126໪๘຿Ѡ accept ъҁ̝ႏᇫဍѤంใ‫ۀڮ‬ѣ޻‫ڕ‬ᇫဍѝџјєͅBiomed Res. Int. 3127: :283268, 3127̞͆ъѾѠၿใ୩ࢲ଩Ѥ̝৹๘คє҈Ѧф૲௴с̝3च๻ໝྐྵ͗྇ႱӜҶһӕҺӞѠпцҀ࠼Ѡకืьєఠௐ‫҇ޕ‬mTORC2ͅmammalian target of rapamycin complex2͆ѣᅍ౒ѠѽҀҝ̷һӈҔҫ̷ࡀ৔ѣᄥຐ҇‫ݵ‬ьћරბѠ‫ރ‬ಸюҀшѝ҇।ୟь̝ Diabetologia ૂѠ၈ਇьєͅDiabetologia 6: : 2418 ,
3127̞͆๵य़ࢅ૭ќѤђѣണ̝۸ဍ೴ಋ4ဩ̝޻‫ޓ‬ѣय़ࢅ૭ѝѣࢣරѝьћ7ဩѣᇫဍ҇཈ྴьћйҀ̞ͅဍ౾̜ၿใ̜ରে͆㸫  㸫

ॾ‫̜ݍ‬ൌᄣͅࢲ଩̝͆ࣟ—̜गഉͅ୩ࢲ଩̝͆ၿใ̜ରেͅ୩ࢲ଩̝͆
Seon Myeong Leeͅຠซ஄ଛ̝͆ય̜ఄͅຠซ஄ଛ͆
य़ࢅ‫ݢ‬൏̢৹๘คє҈Ѧф૲௴ѠѽҀ๻ໝྐྵఠஶѣ‫ރ‬ಸࡀஇѣ‫ݷ‬ბय़ࢅ‫ޘ‬ᅆ
̜ਘ໪๘Ѥ๵य़ࢅခჿрѾ̝௒ࡌय़ࢅ‫ݢ‬൏ѠпцҀय़ࢅ౗‫ ҇ݑ‬Diabetologia 6:: 2418, 3127Ѡ཈ྴюҀшѝсќтє̞‫݁ړ‬Ѡђѣय़ࢅ‫ޘ‬ᅆ҇૙ю̞͕ჭษ͖๻ໝྐྵఠஶѣ௴ૉᆒၔќѤ̝५ౖఠஶ࠽рѾє҈Ѧф૲౒ॻсయ஖ъҁћйҀс̝ђѣఠဲধ঳‫ͅݑ‬ຠѠໝ੎ࠊࠗ૲ѠവюҀ঳‫͆ݑ‬ѠവюҀ௉੎џခથษࡀஇѤბѾрќѤџй̞ႏय़ࢅќѤ̝3च๻ໝྐྵӜҶһѣకืьєఠஶѠവюҀ৹๘คє҈Ѧф૲௴ѣఠဲধ঳‫ݑ‬ѝђѣࡀஇ҇ბѾрѠюҀшѝ҇ჭษѝьє̞
͕ၒၔ͖3च๻ໝྐྵ Wistar fattyͅfa/fa͆ӜҶһͅDM͆ͅ35ୄᆽᄩ͆пѽѨവவӜҶһͅCont͆҇ђҁѓҁ෭௜௴ͅSTD: є҈Ѧф૲34.9%઼̝૲27.9%̝ൽర݂࿿6:.5%͆ऍѝ৹๘คє҈Ѧф
૲௴ͅVLPD: є҈Ѧф૲6.9%઼̝૲27.6%̝ൽర݂࿿88.9%͆ऍѠခအь̝31ୄࠗѣે‫ڲ‬ঞ̝‫̞݆ྵ҇݁ړ‬ള୔̝ఠ୔ᆙ̝န࣎े‫̝پ‬ໝҕӞӉӒӦͅUALB̝͆L-FABPͅLFAB͆/Cr̝ेඩҪҬҲҴӦ CͅCysC̝͆HbA2c̝೴ҦӟҬҹӠ̷ӞͅT-CHO̝͆ඩ઼ౖၶͅTG̝͆ఠಧ‫̢݂ڦ‬ӑҶҰӦһӝҢӠ̷ӓಠ௲̡4चҦӜ̷ҥӦ mRNA ཈ॶ̝ໝ੎ࠊ੎ၙௐ‫̢ޕ‬Kim-2კ‫۽‬೏௰݂޻ (IHC)/mRNA ཈ॶܑ̝ஶ̢CD79 IHC/mRNA ཈ॶ̝MCP2̡IL7̡TNF- Ԓ̡TLR3 mRNA ཈ॶ̝ӒһҦӦҼӝҕͅMt͆ज഻ษࠒੴͅไ५̝͆ҕӐһ̷ҪҬ̢cleaved caspase4཈ॶ̝ҝ̷һӈҔҫ̷ͅAP͆ѝ mTORC2ҪңҽӞဦ‫̢ڤ‬p73ѝ p-S7RP IHC̞͕ॆ‫͖ݑ‬ള୔̝ఠ୔ᆙ̝ UALB ̡ LFAB/Cr ̝CysC ඐѤ̝ DM-STD ऍќ Cont ऍѠཿѮഄ݈ьєс̝DM+VLPD ऍќค݁ьє̞Cont ऍѠཿ޶ьћ DM-STD ऍќѴѾҁҀఠಧ‫̡݂ڦ‬ໝ੎ࠊ੎ၙௐ‫ܑ̡ޕ‬ஶ̝ඊဧ̡݂ၷ݂ Mt ࣞͅ‫ڕ‬ໝ੎ࠊ੎ၙ͆пѽѨҕӐһ̷ҪҬѣഄ݈Ѥйяҁѷ
DM+VLPD ऍќ‫ރ‬ಸьє̞ъѾѠ DM-STD ऍѣໝ੎ࠊᆛ‫ڱ‬ќѤ p73пѽѨ p-S7RP IHC ಠ௲ࢬ๘ѣഄࢬ҇໢Ѷєс̝DM+VLPD ऍќ‫ރ‬ಸьє̞ѳє DM-STD ऍќѤ Cont ऍѝཿѮћ HbA2c̝
T-CHO̝TG ѣ௒஧сѴѾҁ̝HbA2c ѝ T-CHO Ѥ VLPD Ѡѽѿค݁҇૙ьє̞џпန࣎े‫پ‬Ѥ5ऍࠗќਮѤџрјє̞͕೴ߊ͖๻ໝྐྵѣࣞ‫ڕ‬ໝ੎ࠊ੎ၙќѤ̝mTORC2ߋౖ݂Ѡࡎ‫ہ‬юҀ AP ค݁ѝ๻ໝྐྵќௐ‫҇ޕ‬ଦцඊဧ݂ьє Mt ѣഄ݈сѴѾҁ̝ॆ‫̝ݑ‬ઓ݂ҬһӟҬܑ̡ஶ̡ҕӐһ̷ҪҬѣഄ݈̝ъѾѠఠࡀ໸ค݁Ѡ࠴ᄮюҀ̞VLPD Ѥ๻ໝྐྵѠпцҀ mTORC2ߋౖ݂҇ᅍ౒юҀшѝќໝ੎ࠊѠпцҀ AP ࡀ໸҇‫ݸ‬࿳ь̝ໝ੎ࠊࠗ૲ဲধ঳‫҇ݑ‬཈࠹юҀ݉໸ౖс৤нѾҁє̞㸫  㸫

ㅽঙᠬংම⏄᫛✤‫ׅ‬⍗ᲇકᮾ᳣⤴ㅾ
̜ॶ੔̝3ఘѠ2ఘс͑с҈͒Ѡџѿ̝4ఘѠ2ఘс͑с҈͒ќળၧюҀ૑ൊѠџјћйҀ̞с҈੎ၙѹђѣߵ੎ၙѣതᄼౖѣᅬ‫ݷ‬ѝ౒টѣєѶѠ్̝‫މ‬ඩќౣᆜษѠ̓ҝӒҶҢҬ̈́Һ̷Ҳ‫ݷ‬౸сџъҁ̝ҼӜҗӃ̷‫ڭ‬เથ̝კ‫۽‬ҴҚҶҢӐҗӦһ๸҇ྯษѝьє৊с҈੓‫ގ‬཈сకѶѾҁћйҀ̞ьрь̝‫ڵ‬࿫ѣຠ‫ڤ‬џс҈‫ޓړ‬ѣ̝‫ڵ‬ཥѣс҈ѠവьћѤ̝৊с҈੓ѣᄜ঳ᅵѤѐ
йёй21̼31% น๘ѠॻѾҁћпѿ̝ంєџೖᄅѣӉӟҗҢҬӞ̷с࠽ഹъҁћйҀ̞̜шҁѳќ̝‫ڭ‬เથࡀ໸य़ࢅခჿѝ݈ᆽ౒টय़ࢅခჿѤࢣຎќय़ࢅ҇కѶ̝ຠ‫ڤ‬џ඄༭૲ೱঘ੣ᅀͅPPI͆҇ᄜюҀึ಺ဦౖ඄༭૲ѣ཈ॶ҇౒টюҀѝ̝৊с҈੣ᅀсѴѾҁҀшѝ҇၈ਇьћтє̞шѣ඄༭૲ѣ৔౗юҀ࿸৾ളѤ੎ၙခᇃଯ࠽ѣඩќ̝‫ڤ‬џҀ૑ೱќిଠᆭѣ੣ᅀ҇ᄜьћйҀшѝсბѾрѠџјћйҀ̞љѳѿ̝ѧѝљѣຠ‫ ڤ‬PPI ᅍ౒ᄅс̝ిр୹ѣӐҗӦһќ੣ᅀюҀшѝс࠽ഹъҁ̝ంєџ৊с҈੓‫ގ‬཈ѣӉӟҗҢҬӞ̷ѠџҀѷѣѝ‫ޱ‬௹ьћйҀ̞ႏय़ࢅѣඑ।҇࠱Ѡ̝ӅҶһ݂৾࿿̝ӝ̷Ҽ݂৾࿿҇‫ގ‬཈юҀєѶ̝೴৾‫޻ڮ‬य़ࢅ୹ӊӠҫҚҢһय़ࢅҮӦҲ̷࠴࿤य़ࢅ࿫Ѡึ಺ဦౖ඄༭૲ೖᄅ‫޻ݏ‬य़ࢅ࿫҇‫ގ‬ಈьє̞̜ॶ੔̝ึ಺ဦౖ඄༭૲ѣ PPI ҇ᅍ౒юҀ݂৾࿿Ѥшҁѳќ‫ގ‬཈сਙ໎ѝъҁ̝Ⴕѕ‫ڮ‬ᄅ࿁݂ѠѤઽјћйџй̞೴৾‫޻ڮ‬य़ࢅ୹ӊӠҫҚҢһय़ࢅҮӦҲ̷Ѡಈ඙ъҁє࠴࿤य़ࢅ࿫ќѤ̝௒ࡌึ಺ဦౖ඄༭૲҇ྯษѝьєೖᄅҕӊӠ̷Ҵѝьћ̝helix-loop-helix peptide ಈलၔ̝пѽѨ඄༭૲ᅶള৔ഉ௝၈Ѡ࠱њфᄅ੓ಈलၔͅStructure Based Drug Design͆ѣᆋၔ҇࣫છьћӜҗӉӜӝ̷҇৔ඞь̝৊с҈੓ѣӅҶһ݂৾࿿̝ъѾѠӝ̷Ҽ݂৾࿿ѣ൸੬҇৫јћйҀ̞̜шѣѽлџ̝PPI ҇ྯษѝьєതӐҗӦһᅍ౒ᄅ‫ގ‬཈ѭѣ්ಘрѾౡѳҁҀ౗‫ݑ‬Ѥ̝ೖᄅ࡚ୠѣ޺ం҇ѷєѾюѝຎ૑Ѡ̝‫ڮ‬ᄅ࿁ѣय़ࢅ‫ގ‬཈‫ݦ‬นѠпцҀީଠ࡚ୠ࠱཰҇ႏ޻Ѡ৔ඞюҀшѝсќт̝ъѾѠ̝৊с҈੓ѣ‫ڮ‬ᄅ࿁݂Ѥ̝ഄ݈ѣ‫ڵ‬๒҇єўјћйҀс҈ળၧᅵѣᅍ౒Ѡभсѿ̝৹ᆽ݂ଃ‫ݶ‬ќѣ्৆ନაѣষ௒Ѡ৮फ़ќтҀѷѣѝ‫ޱ‬௹ьћйҀ̞ͅဍ౾̜ᄖౄ̜ෟࡶ͆㸫  㸫

ᄖౄ̜ෟࡶͅ௩൜ࢲ଩͆
य़ࢅ‫ݢ‬൏̢ೖᄅय़ࢅ‫ގ‬཈य़ࢅ‫ޘ‬ᅆ
̜ႏ໪๘Ѥ̝ൌ޻‫ۈ‬ౡќзҀ༊ஜ࿶ऊѣय़ࢅрѾ̝ҢқӦઓ്໐ำсᄜ঳џำ္ୋ੓ќзҀшѝсབბьєͅJ. Kanazawa Med. Univ. 52: 36, 3127̞͆
̜ຆ౸߶ଅѣීࠊрѾѣำࡺମѠ࠙ьћѤ̝ఠ࿋಻ѣєѶ९‫ہ‬Ѥ࿋ბќзҀс̝ำࡺମсௐ‫ޕ‬ъҁћйҀѝйл mucosal block ѣ‫ޘ‬໫с‫ڵ‬ཥѠఆຆьћпѿ̝फশำѤѰѝ҈ўછᅀъҁяѠ౮Ⴟ๩ᄮсଘᅻѠџјћйє̞ခથౡ࿿޻ษඑ।рѾѤ̝̝ීࠊ௒ྂ੎ၙќѤ̝apical site ѣ
DMT2ѝ HCP2рѾ̝ђҁѓҁрѾ჆ࡀำѝӋӓำ҇੎ၙ຿Ѡ uptake ьћпѿ̝basolaterl site ѣferroportin с੎ၙ຿ѣำ҇ेඩѠ࢞ࢊ transfer ьћйҀ̞шҁѾѣ౒টѤ̝ferroportin ҇े౟ҮӦҨ̷पѣ hepcidin ќ̝DMT2҇੎ၙ຿ҮӦҨ̷ѣ IRP ќ౒টъҁћйҀѝ৤нѾҁћйҀ̞̜шѣѽлѠ̝ำѣࡺମѹђѣঞѣำൊଆѤခથӟӌӞќѰѱᅬ‫ݷ‬ъҁћйҀс̝૳੒ѠफশษѠ๩ᄮъҁєำѣࡺମ҇ྵ݆юҀଛඍсџф̝ීࠊрѾўҁѰўѣ࠽ࠗќўҁѰўѣᆙсࡺମъҁћйҀѣрѤბѾрѠџјћйџй̞ႏय़ࢅќѤ̝फশษѠ๩ᄮъҁєำѣࡺମ௢഻̝҇े౟ำѝ UIBC ѣफ૑ษဦຍрѾྵ݆ь̝ेඩ hepcidin ໶๘с̝फশำѣࡺମѠൌтџۭࢾ҇ࡹѱьћйҀшѝсბѾрѠџјє̞̜ѳя̝ҢқӦઓ്໐ำ๩ᄮঞѣ̝ TSAT :6 % Ѡѳќ௒஧юҀൌтџे౟ำ /TSAT ѣဦຍрѾ̝ීࠊрѾѣำࡺମѣྵ݆ѠѤ̝फ૑ษџे౟ำ /TSAT ѣ഑ซсᄜ঳ќзҀшѝсခрјє̞ђѣࡺମӟӌӞѤ̝ำධ૾ঞѣे౟ำ /TSAT ѣဦຍѝཿ޶ьћѷ⋚௲џф̝ำ္ୋѠѤफশำ๩ᄮсᄜ঳џଛඍќзҀѝ৤нѾҁє̞ᆤடษѠѤ̝ำ੓࿵ᅀ3૑ࠗঞѣे౟ำ /TSAT ѣඐќࡺମӟӌӞ҇య഑юҀшѝсќтҀ̞ѳє̝े౟ำѣဦຍѤ̝े౟ำဦຍѣ7૑ࠗගҁќӇ̷Ң҇ѵрнҀ hepcidin ઍౡ҇જाьћйҀшѝсბѾрѠџѿ̝шѣ hepcidin ѣ௒஧૑ࠗസѠ਻๘๩ᄮъҁєҢқӦઓ്໐ำѣࡺମѤ̝41% น๘ᅍ౒ъҁћйє̞ᆤடษѠѤ̝ࡺମ঳ᅵ҇৤ᆅьћ࿵ᅀࠗ޹҇ซѶҀྣᅆౖсќћтє̞̜‫ڵ‬ၒ̝ૐഘษ hepcidin ௒஧҇ᄥຐюҀධ૾ำᄥຐำ‫ݦ‬ௗ௢഻ќѤ̝फশำࡺମѤරბѠᅍ౒ъҁћйє̞ຆ౸ᆤடѣ௙ќѤ̝ຆ౸߶ଅѤआѿါьำ੓сධ૾ъҁћйҀшѝсതф̝඼ഇำ҇৹ඐѠဲљऔষѠзѿ̝шѣѽлџ߶ଅќѤ̝फশำѣࡺମѤ࠽ഹќтџйшѝс૙ਫъҁєܑ̞ஶ૑Ѡѷ̝ૐഘษѠ hepcidin ѣ௒஧сѴѾҁҀѣќ̝ຎᄼѣ໢ૢсྣᅆќзҀ̞̜‫ړ‬௒ѣѽлѠ̝ීࠊрѾѣำࡺମсᅍ౒ъҁҀ௟ॊ҇ྋцҀшѝсќтҁѥ̝ຆ౸߶ଅѠпйћѷҢқӦઓ്໐ำѤᄜ঳џำ္ୋ੓ѠџѿлҀѷѣѝપ҄ҁҀ̞㸫  㸫

ӽ۴֐᧸㉹㊱㉽ㅖㅽӽ۴֐᧸㉹㊱㉽ㅖㅾ
2̠ຍ࿿ࠊᅬ૭
̜ຍ࿿ે‫ڲ‬યಈѤ̝ᆤடय़ࢅ๮8̝9‫࠱̝ޏ‬ೊय़ࢅ๮4̝6‫̝ޏ‬ඒ݁2‫࠱̝ޏ‬ೊय़ࢅ๮အ๮Ѡે‫ڲ‬૭ࡹѨ૳६૭҇ᄜьћйҀͅ೴டო౺2674.3‫̞͆ف‬໪ࠗᅧᅀଅిѤ̝28,927ఘќзјє̞န౗38໪๘ຍ࿿૳६ल‫ݭ‬ѣ஢໢ిѤ226ॊзѿ̝຿ᄆѝьћ̝߷ಠࡹѨ݂޻཈ࠣѠ࠙юҀ૳६̢6ॊ̝
DNA ೏ߺнຍ࿿Ѡ࠙юҀ૳६̢56ॊ̝޻ౡ૳଻̢6ॊ̝ђѣണ̢71ॊќзјє̞୹ക৭਷Ѥ࠱ೊप:̝ᆤடप26̝ࠈধ2̝‫ڵ‬ཥࢲ‫ࡀڲ‬৔2̝೴৾‫޻ڮ‬य़ࢅ୹6ќзјє̞̜န౗39໪4ॉ31໙૑฿ќѤ̝ӑҙҬ 3,561ྛ̝ӜҶһ 47:ྛ̝ҙҨҡ 81ྛ̝ӕӞӕҶһ 2ྛ̝
җҿ 25ྛсે‫ڲ‬ъҁћйє̞ѳє̝ຠซྐྵ९ളѠവюҀྒౡ࿿ग़ਯ҇4‫ͅݸ‬6̝21̝2ॉ͆૳યьє̞̜န౗38໪6ॉ36໙̝ຍ࿿૳६૳યଅ๸ѣࢲ‫ڲ‬ऌᇊ҇৫јєͅ‫ڲࢲ޻ڮ‬๮5‫ ޏ‬E52৭ࡠ૭̞͆અ
݈ଅѤ221჏ќ̝ใ੟ᆁઞ୩ࢲ଩с૳६ຍ࿿࿶શѝຍ࿿૳६ल‫̝஀ݭ‬યಈᅧᅀၔѠљйћಋბьє̞๵໙અ݈ќтџрјєఘ҇വொѠ̝DVD ௒‫҇ݶۮ‬5‫ͅݸ‬7/26~7/2:͆‫਺ގ‬ьє̞ђҁ‫ޓړ‬ѣႵଦ৭ଅѠѤ̝ӆҺҝ̡ҝӦ̡ҺӑӦҼ҇ᅀйћࢲ‫ڲ‬ऌᇊ҇৫јє̞໙௜ࠊᅬѤ̝ຍ࿿૳६
‫ͅݶۀښ‬24჏̝౹‫ޣ‬ᄈఘ‫ۀښ‬ේ͆ѣѷѝ̝ใ੟ᆁઞ୩ࢲ଩ͅ୒‫ڮ‬ન͆҇ඩ௿Ѡ̝৪‫৻گ‬઩ଘໟ࡚ୠ‫̝ۀ‬ၿჿ୤ପ̝ࡧႏ۰૔̝෌આୢ৫̝ಝඑᅱީ࡚໸‫ۀ‬с൷јћйҀ̞̜य़ଳѝьћ̝ใ੟୩ࢲ଩с̝န౗38໪๘঱ષᅶൌ޻૳६ຍ࿿યಈࢥࡣ‫ݶ‬ซ࠽೴‫ࡹݶ‬ѨҪӦӐҫҙӓͅန౗38໪7ॉ23໙്̝͆7‫૳ݸ‬६ຍ࿿ࠊᅬଅय़ଳ‫ͅݶ‬န౗39໪3ॉ39໙̼4ॉ2໙͆Ѡઅ݈ьє̞̜ਘঞѤຍ࿿૳६ѣ৹๘݂ѹതᄼ݂Ѡവ‫ܥ‬ь̝‫ޓ‬࿫рѾѣग़ேѠശнѾҁҀѽлѠ̝ࠊᅬള౒
ѣ।ෟь̝ࡀ࠰ౙྐѹఘ੕‫ڲ‬౗џўѷࠟѶћग़ກьћйфྣᅆсзҀ̞3̠ၑ૾ಧ‫ࠊ಻ڋ‬ᅬ૭̜ၑ૾ಧ‫ࠊ಻ڋ‬ᅬ૭ѤၔᆮѠ࠱њтၑ૾ಧѠ࠙ओюҀࠊᅬ҇൷๵ьћйҀ̞ђѣᄃ߇ѝьћѤ2͆ྌႺ࿬ಧॴͅ૳६ᅀ RI ๸͆ѣဲࠊ̡ࠊᅬ̝3͆Ⴚ࿬ಧॴѣဲࠊ̡ࠊᅬͅ৒౞ᅀ RI ๸̝͆4͆қҶҢҬಧ཈ౡ೼඙ѣ‫ڦ‬ૐ̡ࠊᅬ̝5͆ޮ໮ᆎ࿿૲ͅҙӜӦ݂৾࿿͆ѣဲࠊ̡ࠊᅬџўс࢒чѾҁҀ̞ྌႺ࿬ RI ҇ᅧᅀюҀєѶѣ RI ҮӦҲ̷Ѥᆤடय़ࢅ๮:̝21‫ޏ‬ѝ࠱ೊय़ࢅ๮5‫ޏ‬Ѡಈ඙ъҁ̝ၔᆮѠ࠱њйћय़ࢅѠߋᅀъҁћйҀ̞ީ૳६૭ѠѤ഑ซࡀ࠰҇ѤэѶѝьћީଠ‫ܚ‬௿ࡀ̝Ҩ̷ӑӞҨҗҢӜ̷̝੎ၙ༘ᅋಈྐ̝ᆱഇ̡ᆱ๟঄џўсಈ඙ъҁћйҀ̞છᅀ݉໸џޮଠѤ̝H-4̝C-25̝P-43̝P-44̝S-46̝Cr-62̝I-236џўќ̝‫޻ڮ‬य़ࢅѠྣᅆѝъҁҀѰѱ಻ћѣޮଠѠљйћ෭௜ѣय़ࢅߋຍѠୌခџᆙѣဲࠊѝછᅀс݉໸џള౒ѝџјћйҀ̞ႏ޻ѠпцҀࢲ‫ڲ‬य़ࢅѣєѶѣၑ૾ಧ‫ࠊ಻ڋ‬ᅬѤࣟ൙‫ݏڮ‬ൌ޻ၑ૾ಧௐ‫ޕ‬ᄬၼࡋนѠ࠱њйћ޻ේѣஎใஷজ಑ౡсၑ૾ಧ‫ۀښݶۀښ಻ڋ‬ේѝьћ๼ߊъҁћпѿ̝ၑ૾ಧયಈ౾ໟଅѠ౧ྑᣨᄖࢲ
଩̝‫ࠊ಻ڋ‬ᅬ౾ໟଅѠ஛ਖ਼्࿎ࢲ଩̝યಈࠊᅬ౾ໟଅѠ஫ใࡶ࿎࿫ේсໟაъҁћйҀ̞ၑ૾ಧଙ‫ڀ‬ଘໟଅѤ౹‫ޣ‬ᄈఘࢲ଩с൷๵ь̝ॶ௙ѣ૳ჄѤ൮শఊ৭નс RI ଙ‫ڀ‬౾ໟଅѝьћ൷๵㸫  㸫

ь̝ީଠఈ౪҇ࠟѶєૉჄଛഘтѤय़ࢅయక‫ݢ‬с൷๵ьћйҀ̞̜޻຿Ѡಈ඙ъҁєқҶҢҬಧ཈ౡ೼඙Ѡ࠙ьћѤ̝࠱ೊपѣ৭਷̝ྐྵ‫ۈ‬пѽѨຍ࿿ࠊᅬ૭ѝࢣຎќࠊᅬѠзєјћйҀ̞̜ޮ໮ᆎ࿿૲Ѥ̝RI ҮӦҲ̷຿Ѡಈ඙ьєય௨ъҁєဲࠊ঄Ѡဲഝь̝໪3‫ݸ‬ѣ⋶ᆙѠѽҀ੔঄‫ޱ‬໢̝છᅀ૑ѠпцҀిᆙ‫ޱ‬໢ѝ༌࠿࿿ѣဲࠊ҇৫јћйҀ̞̜ႏ໪๘ѣછᅀ௢ࢴѤ̝RI છᅀࡹѨયಈᅶ໛࢕݉ଅс49჏ќзѿ̝ᆤடय़ࢅ๮:̝21‫ ޏ‬RI ૳६યಈѠпйћѤᄄ31჏ / ॉͅᅶ໛೴ి362჏̝͆࠱ೊय़ࢅ๮5‫ ޏ‬RI ૳६યಈќѤᄄ:჏ / ॉͅᅶ໛೴ి21:჏͆ѣӍ̷Ҭќછᅀъҁћйє̞ᆤடय़ࢅ๮ RI યಈќѤྌႺ࿬ಧॴѣછᅀѤ჆йс̝યಈ҇੎ၙ༘ᅋџўྌ RI ૳६ѠᅧᅀюҀєѶѣᅶ໛сൌ࿴Ѡഄ݈ьє̞࠱ೊय़ࢅ๮ RI ૳६યಈќѤ̝છᅀᅶ໛ిѤ੧໪๘ѠཿѮзѳѿဦ݂сџрјєс̝ྌႺ࿬ಧॴѣ৯໛ిѤ2ॽѣѴќзѿ̝੧໪๘ѠཿѮъѾѠॳஜьћйє̞ѳє̝ᅶ໛ిс੧໪๘ѝзѳѿဦ҄Ѿџрјєѣ
Ѥ̝ᆤடय़ࢅ๮ѝຎᄼѠ෗‫ܚ‬௿ࡀџўѣಈ඙ࡀ࠰ᅧᅀѣᅶ໛сഄ݈ьє‫ڢ‬ќзҀ̞ьрь̝ᅶ໛ଅѣࠊᅬࣥ‫ڱ‬຿ќѣ੣ࣅѠവюҀࢲ‫ڲ‬ѹࡀ࠰ѣ‫ܟ‬ಠ௢ࢴѣ‫ޱ‬໢џўѣฯญсྣᅆќзҀ̞̜ਘ໪๘Ѥ̝22ॉ24໙Ѡ९થᆜࡋ౒‫ݶۀښ‬ၑ૾ಧࡋ౒૭ѠѽҀᅶ໛ग़ਯс૳યъҁ̝ၑ૾ಧग़
ਯ߲3჏ѠѽҀ஀ᆭग़ਯ̝યಈग़ਯ҇ଦцє̞஀ᆭпѽѨયಈѝѷѠධ‫ڞ‬юѮт฿Ѥзјєѷ
ѣѣ̝ѽѿ‫ރ‬ಸ҇ુѴҀѽлѠѝѣশຉફຐѣѴќହᆈьє̞ৃй̝ႏ޻યಈсหಃѠ‫ڦ‬ૐъҁћйҀшѝс໢ѶѾҁєс̝ࠊᅬѝѤඑૢѝफ६҇ࢣᄜьћჵ൏฿҇൸੬ь̝௜Ѡ৾ᅬษџ‫ރ‬ಸ҇ഘцћйф੣ࣅќзѿ̝ਘঞѝѷ RI ᅧᅀсबഘќтҀѽлѠၔᆮ҇୴ଚьє‫҇۫ۦ‬௿сцী࿎҇बഘьћйфྣᅆсзҀ̞̜ѳє̝੧໪๘ѽѿ౹‫ࢲޣ‬଩ѝ൮শ৭નѤန౗38໪๘ၑ૾ಧ‫಻ڋ‬ଙ‫ڀ‬࿫‫̡ݶ‬໪૒ൌ‫૳ݶ‬৫‫ۀښ‬Ѡ଱ໟьћпѿ̝22ॉ37໙̝38໙Ѡࣟ൙ધဍ݂ӎ̷Ӟќ‫਺ގ‬ъҁє໪૒ൌ‫്ͅݶ‬67‫ ݸ‬ၑ૾ಧࠊᅬय़ଳ‫͆ݶ‬ѣ‫۫ۦ‬ҬҲҶӈѝьћઅ݈ьє̞ႏ໪๘ѣ໪૒ൌ‫ݶ‬Ѥ498჏ѝᆰ໪҇௒‫ݸ‬Ҁઅ݈ଅсେѳѿ়̝ྵѣліѠမ႞ьє̞ຠѠ౹‫ࢲޣ‬଩ѤӐҬҲ̷௾ਯ‫ۀښ‬ේѝьћ਼ᄔଷோпѽѨᄔଷோѣಱซ̝ྴ஡ѝѝѷѠӐҬҲ̷཈ྴѣ৭ྵџўѣ୔౾҇಻льє̞஝̝ႏൌ‫ݶ‬ѣ၈ਇс Isotope News 3127໪5ॉ৽ͅNo.855͆ѠढੑъҁћйҀ̞4̠ࡀ࠰ࠊᅬ૭
̜ࡀ࠰ࠊᅬ૭Ѥࢣຎᅧᅀ҇ჭษѝьћಈ඙ъҁћйҀࡀ࠰ѹҰӈһҙқҕџўѣࠊᅬ̝‫ۦ‬ᅀ҇৫јћйҀ̞य़ࢅ୹сࠊᅬюҀൌचय़ࢅࡀ࠰҇ࡀ࠰ࠊᅬ‫ۀښͅݶۀښ۫ۦ‬ේ౹‫ޣ‬ᄈఘࢲ଩͆ѣફຐѣ̝݁य़ࢅ୹ҬҲҶӈсඩ௿ѝџѿࠊᅬ̡‫҇۫ۦ‬৫јћйҀ̞ࢣຎᅧᅀय़ࢅࡀ࠰ѹय़ࢅҷ̷ӞѤ೴ి291҇෗нћйҀс̝ђѣൌ࿫ခѤңӞ̷ӊҙқҕ຿Ѡढ૙ьћзѿ̝ࡀ࠰ӝҬһѠ໛ҁѥ̝ђҁѓҁѣࡀ࠰ѣ૽ఊ̝ࠊᅬଅ̝છᅀѠзєјћѣධ‫ڞ‬ૉ৷๸с‫܃‬ᅦќтҀ̞ᄬᄄсྣᅆџࡀ࠰ѠљйћѤ̝޻຿җӦһӜӀҶһ҇‫ݵ‬ьћңӞ̷ӊҙқҕ௒рѾᄬᄄѣಈซѹછᅀᅩᆿсગѐҀѽлѠџјћпѿ୍̝ᅗѣҞӟӦҳ̷Ѡ஀тਕѵၒૡѠཿ޶ьћᅧိౖѤྍᄇษѠষ௒ьћйҀ̞ᅧᅀଅѕцќџф̝ᄬᄄѹછᅀѣᅩᆿ๸ѷ‫ߊڵ‬ьћେलќтҀєѶѠ̝ࠊᅬଅѣ࿠൷ѷवॳќтҀѝ৤нѾҁҀ̞ࡀ໸҇ߋᅀьћ̝ѽѿ‫ڵ‬೟ѣ঳ᅵ݂҇఩јћйтє㸫  㸫

йѝ৤нћйҀ̞̜ච९ଘໟ࡚ୠ‫ۀ‬Ѥ̝ᆤடय़ࢅ๮ඒ݁2‫ޏ‬Ѡಈ඙ъҁћйҀҺҫҲӞຆ‫ݦ‬चไથ५ྒࢽ H-8761ͅ໙ᅶӂҗҹҢ͆҇ઢѶѝьћ̝೽ਯचไથ५ྒࢽ S-4511Nͅ໙ᅶӂҗҹҢ͆пѽѨଯဪࡀ࠰ѣࠊᅬѣѴџѾя̝ႏ޻य़ࢅଅѣไ५ુᆎ੣౦҇৫јћйҀ̞ъѾѠӔҶҨ̷C ѠѽҀҟӜҬ
ҽҗӈѣ੣౦̝LKB ͘3119҇છᅀьє෗༱ಃဧ੣౦ѣ࡚ୠફຐѹબ܎ѷ৫јћйҀ̞5̠ྐྵᅬ೏௰૭
̜ྐྵᅬ೏௰૭Ѥႏ޻ީ‫ݏ‬рѾѣ‫ږ‬ᅙѠѽҀय़ࢅᅀྐྵᅬ೏௰ྯႏ੣౦ѣબ܎҇৫јћйҀ̞໐ࡻ࡚໸‫ۀ‬Ѥႏ޻ѣതిѣ৭਷̡ခჿрѾѣ‫ږ‬ᅙ҇лц̝،ӄӜӈҖӦӉӠҶҢѣ੣౦̝‫؍‬ӄӜӈҖӦӉӠҶҢѠѽҀ HE ಠ௲ྯႏѣ੣౦̝࠶ၱюҁѥ PAS̝Azan̝EVG џўѣຠଝಠ௲ྯႏ
ѣണ̝Ⴕಠ௲ྯႏѣ੣౦̝؎ৱ೎კ‫۽‬ಠ௲ྯႏѣ੣౦̝؏๟ॆྯႏѣ੣౦̝ؐไ५ྯႏѣ੣౦๸҇৫јћйҀ̞ъѾѠൌ޻‫ۈ‬ౡџў୸௿ଅ҇വொѠьє̝ಠ௲ၔѣҕҼӃҗҬѷ৫јћпѿ̝ൌ޻‫ۈ‬ౡ҇വொѝьєय़ࢅબ܎ѷ৫јє̞̜̜̜̜̜
ͅဍ౾̜౹‫̜ޣ‬ᄈఘ͆㸫  㸫

ඩಗ̜ଷனͅ௩൜ࢲ଩͆
य़ࢅ‫ݢ‬൏̢୪ࠅ࠰૱߶ѣ‫޻۽‬य़ࢅय़ࢅ‫ޘ‬ᅆ
̜2:96໪ѽѿ࿐આॢѠзҀࠬࣅѣ୍ࣅ‫ۀ‬ᄄ8,111ఘ҇෪ಀюҀ௱‫ڱ‬Ҧӎ̷һय़ࢅ҇ᅶі௒чय़ࢅ҇ഘцћйҀ̞଱ᇖඩѣඎஆ̟ຠѠඒ‫ڱ‬ќѤҦӎ̷һಈซсਙ໎џຌтౢѿѣඩ৹໪ඎౖѠпцҀ୪ࠅ࠰૱߶ѣӝҬҢѣྵ݆ѹӝҬҢѝ଱ࣅ௢഻ѣ࠙ᇍ҇ბѾрѠюҀшѝ҇ჭษѝьћйҀ̞шѣࠬࣅѤ಻ਈќᄄ291,111ఘѣ୍ࣅ‫҇ۀ‬ᄜь̝ѳє‫ޓއ‬Ѡѷ2,111ఘࣞфѣ୍ࣅ‫҇ۀ‬༄२ьћйҀ̞ॶ੔࿐આॢѕцќџф̝಻ਈษѠҦӎ̷һ҇ޫൌь̝‫ڵ‬೟ൌࡋრџय़ࢅѠষцћ୯ྐ҇కѶћйҀ̞୪ࠅ࠰૱߶ѣ‫޻۽‬Ѡ࠙ᇍюҀᇫဍѤႏҦӎ̷һ҇ࠟѶєਈ຿‫ޓ‬ѣࢣຎय़ࢅѝьћ3ႏ҇၈ਇьєѰр:ႏѣᇫဍ҇ࢣຎ཈ྴьћйҀ̞ਘ‫ݸ‬Ѥ঵ౡᇖຌ‫ݏ‬य़қӆҺӦҬརͅརේ̢ܱഡट‫ܥ‬ൌ޻ࢲ଩͆Ѡઅ݈ь‫ݷ‬౸҇৫јєᇫဍ҇ி‫ݵ‬юҀ̞̜ࡩ‫ܓ‬ѝ୪ࠅ࠰૱߶ͅߨຍႿ૱߶̝໹ങඩ͆ળၧͅKidney Int. 99: 2255, 3126͆
̜қӆҺӦҬརѠҺ̷Ҳ҇ด࢞ьє̝EPOCH-JAPAN ѣ24Ҧӎ̷һѣлі̝ࡩ‫߸଻ܓ‬пѽѨ୪ࠅ࠰૱߶ળၧѠ࠙юҀ௝၈҇ᄜюҀ21Ҧӎ̷һͅൿჿ̡೛⌅̝ൌ੟ਈဲ̝ൌ༲̝஛ᄁ࿫̝
YKK̝ၑ૾ಧۭࢾय़ࢅ୹̝ࡶઆා̝JACC̝NIPPON DATA91̝NIPPON DATA:1͆҇๼৾ьєҺ̷ҲҮҶһͅn=:1,639͆҇ᅀйћ̝ࡩ‫ܓ‬ѝ୪ࠅ࠰૱߶ળၧѝѣ࠙ᇍ҇ग़ກьє̞Cox ཿᆰӂҩ̷ҼӕҺӞ҇ᅀйћ̝ྌࡩ‫࠱҇ܓ‬୯Ѡьєॶ੔ࡩ‫ܓ‬пѽѨ‫ܓࡩࢍݦ‬ѣ಻୪ࠅ࠰૱߶̝ߨຍႿ
૱߶̝໹ങඩͅ໹⊺ਾ̝໹຿ୟे͆ળၧѣӂҩ̷Ҽཿ҇ल઎ьє̞ӂҩ̷Ҽཿѣᄜ‫ڞ‬џ௒஧с।ѾҁєྐྵचѠљйћ̝ॶ੔ࡩ‫ܓ‬пѽѨ‫ܓࡩࢍݦ‬ѠѽҀީળၧѣఘশ࠴ᄮ࠮४߇৾҇ल઎ьє̞ђѣॆ‫̝ݑ‬ඎஆѝѷॶ੔ࡩ‫ܓ‬ଅќѤߨຍႿ૱߶ળၧѝ໹⊺ਾળၧѣӝҬҢсᄜ‫ڞ‬Ѡ৹рјє̞64.8% ѝйл৹йࡩ‫ܓ‬ᅵ҇ᄜюҀඎౖќѤ̝େඇ಻ളѣߨຍႿ૱߶ળၧѣ45.1%̝໹⊺ਾળၧѣ36.6% Ѥࡩ‫߸଻ܓ‬Ѡࡎ‫ہ‬юҀѝయ഑ъҁє̞৹े‫پ‬ѣॶ੔ࡩ‫ܓ‬ଅѣ࿈๘Ѥඎౖќ31.6%
ќзѿ̝шѣଅѣ౞௜े‫ܓࡩྌپ‬ଅ҇࠱୯ѠьєߨຍႿ૱߶ળၧпѽѨ໹⊺ਾળၧѣതဦᆙ෕ౙӂҩ̷ҼཿѤђҁѓҁ3.68ͅ2.62-5.49͆пѽѨ4.39ͅ2.9:-6.82͆ќзѿ̝ॶ੔ࡩ‫ܓ‬ႧѤ৹े‫پ‬ѣйяҁр‫ڵ‬љѕц҇ᄜюҀଅѽѿѷђҁѾѣӝҬҢс৹рјє̞ђьћ̝шҁѾ໐љѣ࠮४‫ہ‬થѣ৾တѠѽҀળၧѣఘশ࠴ᄮ࠮४߇৾Ѥ̝ߨຍႿ૱߶ળၧс35 . 7 % ̝໹⊺ਾળၧс
39.2% ќзјє̞৹ҦӟҬҹӠ̷Ӟेஶѣॶ੔ࡩ‫ܓ‬ଅѣ࿈๘Ѥඎౖќ5.3% ќзѿ̝шѣଅѣ౞௜ҦӟҬҹӠ̷Ӟྌࡩ‫ܓ‬ଅ҇࠱୯ѠьєߨຍႿ૱߶ળၧпѽѨ໹⊺ਾળၧѣതဦᆙ෕ౙӂҩ̷ҼཿѤђҁѓҁ5.2:ͅ3.44-8.64͆пѽѨ2.83ͅ1.95-4.63͆ќзѿ̝ఘশ࠴ᄮ࠮४߇৾Ѥђҁѓ
ҁ7.4% пѽѨ2.5% ќзјє̞юџ҄і̝ඎஆѝѷॶ੔ࡩ‫ܓ‬ଅќѤߨຍႿ૱߶ળၧпѽѨ໹⊺ਾળၧѣӝҬҢсᄜ‫ڞ‬Ѡ৹рјєс̝ࡩ‫ܓ‬ᅵѣ৹йඎౖќѤେඇ಻ളѣߨຍႿ૱߶ળၧѣᄄ
2/4̝໹⊺ਾળၧѣᄄ2/5Ѥࡩ‫߸଻ܓ‬Ѡࡎ‫ہ‬юҀѝయ഑ъҁє̞৹े‫پ‬ѹ৹ҦӟҬҹӠ̷Ӟेஶ҇ᄜюҀࡩ‫ܓ‬ଅѤъѾѠӝҬҢс৹йшѝсბѾрѠџјє̞㸫  㸫

ඩഡ̜৏ͅࢲ଩͆
य़ࢅ‫ݢ‬൏̢ҕӟӞҡ̷пѽѨ૜ঃკ‫۽‬૱߶ѣྐྵ഻‫ݷ‬ბय़ࢅ‫ޘ‬ᅆ
̜ҕӟӞҡ̷ౖ૱߶ѹ૜ঃკ‫۽‬૱߶ѣ཈ஶࡀ৔ѣ‫ݷ‬ბ҇Ѷыь̝ൌтф3љѣҹ̷ӑ҇৫јћйҀ̞2љѤҮӝӦӊӠҹҕ̷үҗӦӅӆҲ̷ѠѽҀҕӟӞҡ̷౒টࡀ৔ѣ‫ݷ‬ბќзҀ̞ҕӟӞҡ̷ѣқӈҚҢҲ̷੎ၙќзҀӑҬһ੎ၙ়̝‫়̝ࢄ࠱ܝ‬ઓࢄѤӅҬҲӒӦџўѣ݂޻เ൦࿿૲ѹҨҗһҞҗӦ҇ၑୟ̡ઍౡюҀс̝Ҡӑ̷үѹңӜӦҩҗӓџўѣҮӝӦӊӠҹҕ̷үѷൌᆙѠၑୟюҀ̞‫ݦ‬ௗџҮӝӦӊӠҹҕ̷үѤ೏௰༆‫ݺ‬ѠෟॆюҀс̝шҁѾѣৱ೎ߋౖ҇౒টюҀҮӝӦӊӠҹҕ̷үҗӦӅӆҲ̷ѣ੣ᅀѤ࿋ბџѳѳќзҀ̞‫̴ݫ‬ѤҮӝӦӊӠҹ
ҕ̷үѣлі SLPIͅsecretory leukoprotease inhibitor͆Ѡධჭь̝‫ݷ‬౸҇৫јћйҀ̞̜ਘ໪๘ѠпйћѤ̝SLPI с়‫়̡ࢄ࠱ܝ‬ઓࢄѣҪңҽӞเ൦҇౒টьћйҀшѝ҇ბѾрѠьє̞ѝфѠ়ઓࢄѠпйћ TLR 5݁ᅻѣҪңҽӞเ൦ခથ҇ᅍ౒юҀшѝќ̝ MMP
ͅmatrix metallopeptidase͆-:ѣ฽૽҇౒টьћйҀшѝ҇।ୟьє̞ѳє3љჭѣҹ̷ӑѤ̝૜ঃკ‫۽‬૱߶ѣ཈ஶѠఇф࠙ᄮюҀӊӜҭӑҨҗһҗҼପ௢੎ၙͅPlasmacyotoid dendritic cell,
pDC͆ѣ౒টࡀ৔ѣ‫ݷ‬ბќзҀ̞pDC Ѥ̝ౡളѠпйћѷјѝѷ I चҗӦҲ̷ӈҚӠӦ҇ઍౡюҀკ‫۽‬੎ၙќзҀ̞ਘ໪๘ѠпйћѤ̝ᄑ೾ҲӦӄҢ૲ Sortilin с IFN ѣѴџѾя̝ъѳыѳџҨҗһҞҗӦѠॆ৾ь̝TLR5જाѠ႐ᄆঞ౒ট҇ଦцћйҀшѝ҇ბѾрѠьє̞ъѾѠਘ໪๘ѠпйћѤ̝‫ݦ‬࿉ౖ༔ആܑӕҺӞѠпцҀ C चӟҢҴӦᄼଦᄵളӈҔӒӝ̷ќзҀ
Dectin-2ѣ੣ᅀѠљйћ၈ਇьєͅ,QÀDPP5HV 76: 346, 3127̞͆ѳє̝໹౽఼ܑ҇‫ۃ‬тࡎшюҲҗӜ̷ҙҗӞҬ߷ಠѠѽҀҨҗһҞҗӦઍౡ̝҇ᅍ౒चଦᄵള PIRͅPaired immunoglobulinlike receptor͆-B с౒টьћйҀшѝ҇।ୟьћпѿ̝ҙҗӞҬଦᄵളѣম္‫ڭ‬เથѣຎซѠ౗লьє̞ਘঞ̝ҙҗӞҬഄ௮ѠᄮнҀۭࢾ҇ग़ກюҀᄬซќзҀ̞㸫  㸫

㇐㇎㇏㇓౫ㄻᏡㄻὧ

᧯ܶᲇકᮾ᳣ⲏࣕ
⊣Ʒሤ
̜2̠ใඩᔣથ̢৊ҕҢҕӐӝӦ5৊ള̟ᆤடग़ਯҟҗҼ̜3126໪‫ރ‬ผའͅઃࢳඑბ̟811͘
812̟ဍরຏ̟๫̟࢝3126.
̜3̠ใඩᔣથ̢ၨଡ᢮ౖఋफஶমऍ໋̟આຏ‫޻ڮ‬ൌ૞ิ്̜31འ̟3397໋̟આຏ̟๫̟࢝
3126.
̜4̠ใඩᔣથ̢ၨଡ᢮ౖఋफஶমऍ̟ఋफ૱߶਼̜ంѣ૔ᆒ 3126-3128ͅ஛ᆠ஺ാ̝రែ۸
ᄽ̝આশଳန̟͆378͘379໋̟৕ຏ̟๫̟࢝3126.
̜5̠ͅJ.Bestard-Escalas͆, M.D.Ledesma, M.Taniguchi, T.Okazaki, M.L.Martin, G.Barceló-Coblijn :8QUDYHOLQJWKHVSHFL¿FUROHRIVSKLQJRP\HOLQVLQFHOOSK\VLRORJ\:KHUHDUHZH"6SKLQJROLSLGV
Biology, Synthesis and FunctionsͅAngel Catalá͆, :2-239, Nova Science Publishers, America,
3126.
̜6̠ใඩᔣથ̢৊ఋफ৊ളग़ਯ̟य़ଳӁ̷һҪӝ̷ҭ̜ఋफ຿‫ݏ‬य़ଳӁ̷һͅ۱‫گ‬ᆖઃ̝ᆸძഌি̝৪ძ௹࿎̝ఋใ̜ᆁ̝ࡧᆖ୰‫ܝ̝ڵ‬ಗၚன̝౧ჿ‫ڵ‬ઃ̝రែ۸ᄽ̟͆69-6:̟ఒඊѝ૔ᆒଃ̟๫̟࢝3126.
̜7̠ใඩᔣથ̢ၨଡ᢮ౖఋफஶমऍ̟य़ଳӁ̷һҪӝ̷ҭ̜ఋफ຿‫ݏ‬य़ଳӁ̷һͅ۱‫گ‬ᆖઃ̝ᆸძഌি̝৪ძ௹࿎̝ఋใ̜ᆁ̝ࡧᆖ୰‫ܝ̝ڵ‬ಗၚன̝౧ჿ‫ڵ‬ઃ̝రែ۸ᄽ̟441444̟ఒඊѝ૔ᆒଃ̟๫̟࢝3126.
̜8̠൮শ̜ఊ̟ܱ੟ୢᇚ്̢9ಊ̜ҬӈҖӦҧӒқӝӦ৾౗ৱ೎̡ҬӈҖӦҧӒқӝҽ̷ү̟૱߶ӕҺӞѣ੣౦ѝᅧᅀ઼̜૲ൊଆ‫ڤ‬௜ѝ࠙ᇍ૱߶̜݁߭ͅྑඖᄩ‫̟ڵ‬਩̴ძᄩྞ ̟͆
459-468̟қӞ̡ҕҗ̡Ҫ̷̟๫̟࢝3126.
̜9̠ච௒̜ီ̟ใ੟ᆁઞ̟ഡ௒̜޻̟౹‫ޣ‬ᄈఘ̟൮শ̜ఊ̟ჿ๦া໲̟๚ࡶਿ೶‫̢ڵ‬໙ႏ໹ܑҙҗӞҬѣ߷ಠѝ࿸౦̢ૐഘ߷ಠѠпцҀྌ৔ഉҲӦӄҢ NS5a ѝ4' ྌ႐ᄆᆛ‫ڱ‬ѣౡ࿿޻ษᄃ߇̟Japanese Encephalitis, 2-28, SMGroupͅUSA͆, USA, 3126.
̜:̠ͅH.Sawai͆, M.Taniguchi, T.Okazaki : Role of sphingolipids in hematological malignancies :Lymphoproliferative disorders, Bioactive Sphingolipids in Cancer Biology and TherapyͅYusuf A.
Hannun, Chiara Luberto, Cungui Mao, Lina Marie Obeid͆, 34-62, Springer, Bundesrepublik
Deutschland, 3126.

ક⒈☟ᄙƷ‫ڤ‬Ʒ⊣
̜2̠T.Ota, M.Maeda, M.Okamoto, M.Tatsuka : Positive regulation of Rho GTPase activity by
RhoGDIs as a result of their direct interaction with GAPs, BMC Systems Biology, ::4, 3126.
̜3̠J.Zhang, Y.Ishigaki, T.Takegami : Hepatitis C virus NS 4 protein modulates the biologicalbehaviors of malignant hepatocytes by altering the expression of host cell microRNA, Molecular
Medicine Reports, 23:5:621:-6226, 3126.
̜4̠Y.Ishigaki, Y.Nakamura, T.Tatsuno, S.Ma, N.Tomosugi : Phosphorylation status of human RNAbinding protein 9A in cells and its inhibitory regulation by Magoh, Experimental Biology andMedicine, 351:5:549-556, 3126.

㸫  㸫

̜5̠Y.Tachi, T.Okuda, N.Kawahara, N.Kato, Y.Ishigaki, T.Matsumoto : Expression of hyaluronidase-5
in a rat spinal cord hemisection model, Asian Spine Journal, ::2:8-24, 3126.
̜6̠M.Taniguchi, H.Ogiso, T.Takeuchi, K.Kitatani, H.Umehara, T.Okazaki : Lysososomal ceramide
generated by acid sphingomyelinase triggers cytosolic cathepsin B-mediated degradation of
X-linked inhibitor of apoptosis protein in natural killer/T lymphoma cell apoptosis, Cell Death andDisease, 7:e2828:2-23, 3126.
̜7̠A.Nakajima, Y.Masaki, T.Nakamura, T.Kanawami, Y.Ishigaki, T.Takegami, M.Kawano, K.Yamada,
N.Tsukamoto, S.Matsui, T.Saeki, K.Okazaki, T.Kamisawa, T.Miyashita, Y.Yakushijin, K.Fujikawa,
M.Yamamoto, H.Hamano, T.Origuchi, S.Hirata, H.Tsuboi, T.Sumida, H.Morimoto, T.Sato,
H.Iwao, M.Miki, T.Sakai, Y.Fujita, M.Tanaka, T.Fukushima, T.Okazaki, H.Umehara : Decreased
expression of innate immunity-related genes in peripheral blood mononuclear cells from patientswith IgG5-related disease, PLoS One, 21:6:e1237693, 3126.
̜8̠J.Moriya, Q.He, H.Uenishi, S.Akazawa, J.Yamakawa, J.Kobayashi, Y.Ishigaki : Induction murine
models of chronic fatigue syndrome by brucella abortus antigen injections : is anemia induced or
QRW"%LRPHG5HVHDUFK,QWHUQDWLRQDO3126:2:259:, 3126.
̜9̠F.Wang, Y.Zhang, L.Wang, P.Sun, X.Luo, Y.Ishigaki, T.Sugai, R.Yamamoto, N.Kato :Improvement of spatial learning by facilitating large-conductance calcium-activated potassiumchannel with transcranial magnetic stimulation in Alzheimer's disease model mice,
Neuropharmacology, :8:321-32:, 3126.
̜:̠H.Ogiso, M.Taniguchi, T.Okazaki : Analysis of lipid-composition changes in plasma membrane
microdomains, Journal of Lipid Research, 67:9:26:5-2716, 3126.
21̠Y.Li, K.Tanaka, L.Wang, Y.Ishigaki1.DWR,QGXFWLRQRIPHPRU\GH¿FLWLQPLFHZLWKFKURQLF
exposure to cerebrospinal fluid from patients with Anti-N-Methyl-D-Aspartate receptor
encephalitis, The Tohoku Journal of Experimental Medicine, 348:5:43:-449, 3126.
22̠ͅN.Tachibana͆, M.Kinoshita, F.Kametani, K.Tanaka, Y.Une, Y.Komatsu, Y.Kobayashi, S.Ikeda
̜̜S.Ikeda : Expression of N-methyl-D-aspartate receptor subunits in the bovine ovum : Ova as apotential source of autoantigens causing anti-NMDAR encephalitis, The Tohoku Journal of
Experimental Medicine, 346:4:334-342, 3126.
23̠ͅR.Matsuda͆, T.Kezuka, A.Umazume, Y.Okunuki, H.Goto, K.Tanaka : Clinical profile of antimyeli oligodendrocyte glycoprotein antibody seropositive cases of optic neuritis, Neuro-Ophtha
lmology, 4::6:324-32:, 3126
24̠ͅH.Nakajima͆, M.Motomura, K.Tanaka, A.Fujikawa, R.Nakata, Y.Maeda, T.Shima, A.Mukaino,
S.Yoshimura, T.Miyazaki, H.Shiraishi, A.Kawakami, A.Tsujino : Antibodies to myelin
oligodendrocyte glycoprotein in idiopathic optic neuritis, BMJ Open, 6:5:2-5, 3126.
25̠ͅRS.Tsuburaya͆, N.Miki, K.Tanaka, T.Kageyama, K.Irahara, S.Mukaida, K.Shiraishi, M.Tanaka :Anti-myelin oligodendrocyte glycoproteinͅMOG͆antibodies in a Japanese boy with recurrent
optic neuritis, Brain & Development, 48:2:256-259, 3126.
26̠ͅS.Nukuzuma͆, S.Sugiura, K.Nakamichi, M.Kameoka, C.Nukuzuma, T.Tasaki, T.Takegami :Replication of IMR-43-adapted JC virus clones in human embryonic kidney cells, Microbiology
and Immunology, 6::5, 349-353, 3126.

㸫  㸫

ƷἕƷ◻
̜2̠K.Tanaka : Recent update on autoimmune encephalitis/encephalopathy, Clinical and Experimental
Neuroimmunology, 7:81-93, 3126.
̜3̠ͅK.Kitatani͆, M.Taniguchi, T.Okazaki : Role of sphingolipids and metabolizing enzymes inhematological malignancies, Molecules and Cells, 49:7:593-5:6, 3126.
̜4̠ใඩᔣથ̢૜ঃკ‫ౖ۽‬໹ܑ - ৊९̡৊ളѤ݄҇ьћйҀ "̜ңӞҲӒӦઓଦᄵള̜৊ңӞҲӒӦઓଦᄵള৊ള̟Clinical Neuroscience, 44:2:39-42, 3126.
̜5̠ͅใ੟ᇭ৕̟͆ඩჿߵ࿎̟ච९வბ̟౹‫ޣ‬ᄈఘ̟ඩಗଷბ̢౹ᄎ౦࿁ѣನ‫҇ڦ‬ᅧᅀьєၑ૾໸஋ಠ૳६̟ඒࢄ‫ݏ‬ᐻ̟7::3:::-219, 3126.
̜6̠ච௒̜ီ̢ంࢺ̡਻ࢺ߷ಠஶ - ߷ಠᄬၼӢҢҴӦ̜໙ႏ໹ܑ̟BIO Clinica, 41:5:445-449,
3126.
̜7̠ේઆ౗ྗ̟ใඩᔣથ̢ਓޭࣗஶমऍ്ͅ3འ͆- ђѣണѣఋफࣗ૱߶҇ࠟѶћ -̜[ ௒ ] ܑஶౖࣗ૱߶̜ྌ߷ಠܑౖ̜ࣗത཈ܑ̡ࣗྂ࿝ܑ̡ࣗ࿬໛ളܑ̜ࣗ৊ҕӒӁҕҪӞ tRNA৾౗ৱ೎ͅARS͆৊ളஶমऍ̟໙ႏᆤட̟43:43:-443, 3126.
̜8̠ใඩᔣથ̢ћ҈р҈‫ڮ‬ᆒѣതᄼџื‫ ގ‬- ࠱ೊрѾᆤடѳќ -̜૜ঃკ‫ౖ۽‬ћ҈р҈਼̟ం‫̟޻ڮ‬81:7:2189-2194, 3126.
̜9̠ใඩᔣથ̢კ‫ౖ۽‬ఋफ૱߶ - ࠱ೊ̡ᆤடय़ࢅѣ਼ంඑ। -̜კ‫ౖ۽‬ඩీఋफ૱߶̜ાఋफ
౽఼ܑͅNMO̜͆ાఋफ౽఼ܑѝ৊ҕҢҕӐӝӦ5৊ള̟໙ႏᆤட̟84̢ഄߪ8 კ‫ౖ۽‬ఋफ૱߶̢376-381, 3126.
̜:̠ใඩᔣથ̢კ‫ౖ۽‬ఋफ૱߶ - ࠱ೊ̡ᆤடय़ࢅѣ਼ంඑ। -̜ђѣണѣკ‫ౖ۽‬ఋफ૱߶̜૜
ঃკ‫ౖ۽‬໹ܑ̡໹ஶ̜૜ঃკ‫ౖ۽‬໹ܑ̡໹ஶ̜‫ޘ‬ᇫ̟໙ႏᆤட̟84̢ഄߪ8 კ‫ౖ۽‬ఋफ
૱߶̢6:6-713, 3126.
21̠ใඩᔣથ̢კ‫ౖ۽‬ఋफ૱߶ - ࠱ೊ̡ᆤடय़ࢅѣ਼ంඑ। -̜ђѣണѣკ‫ౖ۽‬ఋफ૱߶̜ၨ
ଡ᢮ౖఋफஶমऍ̜ၨଡ᢮ౖ஛໹ဦౖஶ̟໙ႏᆤட̟84̢ഄߪ8 კ‫ౖ۽‬ఋफ૱߶̢864868, 3126.
22̠ͅใඩ౞ྗ̟͆ใඩᔣથ̢კ‫ౖ۽‬ఋफ૱߶ - ࠱ೊ̡ᆤடय़ࢅѣ਼ంඑ। - ̜৊ myelin
oligodendrocyte glycoproteinͅMOG͆৊ള̟໙ႏᆤட̟84̢ഄߪ8 კ‫ౖ۽‬ఋफ૱߶̢953957, 3126.
23̠ใඩᔣથ̢კ‫ౖ۽‬ఋफ૱߶ - ྐྵ഻‫ݷ‬ბѝ૔ᆒѣ਼ಷಧ̜ђѣണѣკ‫ౖ۽‬ఋफ૱߶̜ၨଡ
᢮ౖఋफஶমऍ̟‫޻ڮ‬ѣзѻѴ̟366:6:654-658, 3126.
24̠ใඩᔣથ̢ၨଡ᢮ౖဪ‫ܖ‬प໹ܑ̟အੲ໙ႏᆤட̜ంᆛ‫ڱ‬အஶমऍҪӝ̷ҭ̜No.45ͅ3126
໪22ॉ31໙̜͆კ‫۽‬ஶমऍ്ͅ3འ̟͆45:254-258, 3126.
25̠ඩഡᄜ৸̟൧ჿࡍഌ̟౹‫ޣ‬ᄈఘ̢җҝӦ‫ۼ‬ള҇ᅀйє೽ਯचไથ५ྒࢽࠒੴ̟ࣟ൙‫ݏڮ‬ൌ޻੻ૂ̟51:236-241, 3126.
Ʒᩲόअ‫ܝ‬̜2̠S.Nakada, H.Minato, T.Takegami, N.Kurose, H.Ikeda, M.Kobayashi, Y.Sasagawa, T.Akai, T.Kato,
N.Yamamoto, T.Nojima : NAB3-STAT7 fusion gene analysis in two cases of meningeal solitary¿EURXVWXPRUKHPDQJLRSHULF\WRPDZLWKODWHGLVWDQWPHWDVWDVHV%UDLQ7XPRU3DWKRORJ\43:5:379385, 3126.

㸫  㸫

̜3̠ͅR.Matsumoto͆, N.Mikuni, K.Tanaka, K.Usami, K.Fukao, T.Kunieda, Y.Takahashi, S.Miyamoto,
H.Fukuyama, R.Takahashi, A.Ikeda : Possible induction of multiple seizure foci due to parietal
tumour and anti-NMDAR antibody, Epileptic Disorders, 28:2:9:-:5, 3126.
̜4̠ͅ H.Yaguchi ͆, K.Tsuzaka, S.Shirai, M.Niino, T.Takahashi, K.Tanaka, I.Yabe, H.Sasaki :Importance of T2-MRI enhanced pyramidal tracts in differential diagnosis as to paraneoplastic
encephalomyelitis, Clinical Neurology and Neurosurgery, 243::-22, 3126.
Ʒ᮲Ʒअ
̜2̠M.Fujita-Nakata, R.Tomioka, K.Tanaka, M.Nakanishi, S.Nagayama, R.Takahashi, T.Machiya,
T.Hamada, M.Matsui : Intractable cough as Characteristic symptom of neuromyelitis optica andneuromyelitis optica spectrum disorder, Multiple Sclerosis Journal, 33:5:687-688, 3126.
̜3̠K.Tanaka : Debate on the pathogenesis of paraneoplastic cerebellar degeneration with anti-Yo
DQWLERG\7FHOOPHGLDWHGRUDQWLERG\PHGLDWHG"&OLQLFDODQG([SHULPHQWDO1HXURLPPXQRORJ\
7:4:333-335, 3126.
̜4̠ͅM.Tanaka͆, M.Kinoshita, K.Tanaka : Corticosteroid and tacrolimus treatment in neuromyelitis
optica related disorders, Multiple Sclerosis Journal, 32:6:77:, 3126.
̜5̠ͅ M.Tanaka ͆, M.Kinoshita, JF.Foley, K.Tanaka, J.Kira, WM.Carroll : Body weight-based
natalizumab treatment in adult patients with multiple sclerosis, Journal of neurology, 373:4:892893, 3126.
̜6̠ͅM.Tanaka͆, M.Kinoshita, K.Tanaka : Anti-John Cunningham virus index in Japanese patientswith multiple sclerosis and neuromyelitis optica-related disorder, Clinical and Experimental
Neuroimmunology, 7:4:41:-422, 3126.
̜7̠ͅH.Yoshida͆, Y.Ishigaki, A.Takizawa, K.Moro, Y.Kishi, T.Takahashi, H.Matsui : Comparative
genomics of the mucoid and nonmucoid strains of streptococcus pyogenes, isolated from the same
patient with streptococcal meningitis, Genome Annoucements, 4:3:e11332, 3126.
ƷǬǽ͙̜2̠ใඩᔣથ̢૜ঃ৊ള‫ݵ‬੔ౖკ‫ౖ۽‬ఋफ૱߶ѣ཈ஶྐྵ഻ѣ‫ݷ‬ბ̟ћ҈р҈૔ᆒय़ࢅఁࢺ੗
ඇ̜य़ࢅ໪၈̟37:94-:1, 3126.
̜3̠౹‫ޣ‬ᄈఘ̟ඩഡᄜ৸̢ҳҾѤఊࣲќѷౡഝќтє̟݂޻ѝౡ࿿̟64:5:369-371, 3126.
̜4̠ใඩᔣથ̢͕຿‫ݏ‬૱߶ѣఒඊ࠱୯̡ྐྵचခᆭ̡୔ஶ๘്͖ͅ8஼͆ఋफ̡̜ࣗఒඊӔӕ ၨଡ᢮ౖఋफஶমऍ̟຿‫̟ݏ‬226:7:2367, 3126.

કΉɿᮾ᳣Ή᫘⒙Ʒ࡛⭾કΉ⾷ȿɻɥɀȮɨ⾸̜2̠K.Tanaka, Yongzhi Li, N.Kato : Memory disturbance in mice treated with intraventricularadministration of CSF from NMDAR-encephalitis patients, The Lancet Neurology Autoimmune
Disorders Conference, Balcerona, 3126.14

㸫  㸫

Ʒ࡛⭾કΉ⾷ʶⅺ᜵Ⲥ⾸̜2̠K.Tsutsui, M.Fujita, T.Kanbayashi, M.Matsui, K.Tanaka : Clinical features of anti-NMDAR
antibody-positive patients predominantly presenting with chronic psychosis and acuteexacerbations, The Lancet Neurology Autoimmune Disorders Conference, Balcerona, 3126.14
̜3̠K.Tanaka, M.Fujita, K.Tsutsui, T.Kanbayashi, M.Matsui : Clinical features of anti-NMDAR
antibody-positive patients predominantly presenting chronic psychosis with acute exacerbations,
78th AAN Annual Meeting, Washington, 3126.15
̜4̠ஈ̜ࣄข̟ࡧ੟஝ᆖ̟౹‫ޣ‬ᄈఘ̟ࡶဲ৕ᅬ̟౟ಗ‫܀‬થ̢Regulation of the lens epithelial cellmorphology by Dock6̟ం޻ୠᆛ‫ڱ‬य़ࢅ͑௒ྂࠊ১೏௰ज౗്͒3‫ݸ‬ਈ੒ҪӦӐҫҙӓ̟੸
ႍ̟3126.19
ƷӴ࡛કΉɿᮾ᳣Ή⾷ȿɻɥɀȮɨ⾸̜2̠ใඩᔣથ̟๺‫̟ৃ̜گ‬஫‫̜گ‬ఊ̢৊ NMDAR ৊ളѣଦᄵളॆ৾ຠౖѝᆤடษຠ෈Ѡљйћѣग़ກ്̟67‫ݸ‬໙ႏఋफ޻‫޻ݶ‬ୠൌ‫̟ݶ‬ం߆̟3126.16
̜3̠ใඩᔣથ̢ࡽౖ໹ܑ̡ࡽౖ໹ஶѣᅬ‫҇ݷ‬ఇѶҀєѶѠ̷̢ࡽౖ໹ܑ̡໹ஶѣఒඊѠᄃᅶљ৊ളग़ਯ്̟68‫ݸ‬໙ႏ஛ૌఋफ޻‫޻ݶ‬ୠେ‫̟ݶ‬ൌਗ਼̟3126.16
̜4̠K.Tanaka : Diagnostic markers in the CSF of autoimmune encephalitis -Focused on anti-NMDA
receptor antibodies-, Neuroscience 3126, Kobe, 3126.18
̜5̠ใඩᔣથ̢৊ NMDAR ໹ܑѣఒඊѝ૔ᆒ്̟38‫ݸ‬໙ႏఋफკ‫࠵̟ݶ޻۽‬࿣̟3126.1:
̜6̠ใඩᔣથ̢৊ NMDA ଦᄵള໹ܑѣခથྐྵ഻̟ఒඊ̟૔ᆒ്̟31‫ݸ‬໙ႏఋफౣఋ‫̟ݶ޻ڮ‬ࣟ൙̟3126.23
ƷӴ࡛કΉɿᮾ᳣Ή⾷ʶⅺ᜵Ⲥ⾸̜2̠౟రࡠᇚ̟‫ܣ‬ใำఘ̟ಗ९ཨ࿎̟݈຀௸ᇥ̟౹‫ޣ‬ᄈఘ̟஫ႏඬྗ̢ӜҶһ౽఼ಃඊӕҺӞѠпцҀ hyaluronidase- 5ѣᅍ౒঳‫ݑ‬Ѡљйћ്̟55‫ݸ‬໙ႏ౽෨౽఼ྐྵ޻‫̟ݶ‬࿶ܱ̟
3126.15̜3̠ඩใ೶થ̟Ⴜ̜ি̟ච௒̜ီ̟਌౎̜ၱ̟ძ݁۸ᅬથ̟ઃᆥᄜ৸થ̟‫ܝ‬൮৏ৄ̟ඖใ༩
થ̟஛ᆠ‫ݲ‬થ̟ჿ๦া໲̢฽‫҇ڥ‬ᅗьє఼႟९཈ FHOOXODUVROLWDU\¿EURXVWXPRU 3ᆰѠпцҀ NAB3-STAT7ᄪ৾‫ڭ‬เથ‫ݷ‬౸്̟215‫ݸ‬໙ႏྐྵᅬ޻‫ݶ‬೴‫̟ݶ‬჏ॾ̟ܵ3126.16
̜4̠ใ੟ᆁઞ̟ၿಗᅊથ̟ൌᆭ̜༩̟ె९໐ઃඎ̟ච௒̜ီ̢D-ribose ᄥຐള EdAP ѠѽҀ໙ႏ໹ܑҙҗӞҬ࿸౦೒‫്̟ޕ‬61‫ݸ‬໙ႏ໹ܑҙҗӞҬౡ഻޻य़ࢅ‫̟࢝ݶ‬๓̟3126.16
̜5̠౹‫ޣ‬ᄈఘ̟ඩഡᄜ৸̟൧ჿࡍഌ̟๦੟ქ࿎̢Ӆһᄢᅗ੎ၙ‫ޓ‬஛ၙѣ‫ݷ‬౸്̟42‫޻ڮݸ‬ౡ࿿޻ไથ५ྒࢽ࡚ୠ޻‫̟ݶ‬჏ॾ̟ܵ3126.17
̜6̠౹‫ޣ‬ᄈఘ̟ඩഡᄜ৸̟൧ჿࡍഌ̟๦੟ქ࿎̢Ӆһे౟ᄢᅗ੎ၙ‫ޓ‬஛ၙѣ೽ਯचไથ५ྒ
ࢽࠒੴ്̟8‫ݸ‬໙ႏ RNAi य़ࢅ‫ ݶ‬/ ്3‫ݸ‬໙ႏ੎ၙ‫ޓ‬஛ၙ޻‫ৄ̟ݶ‬๦̟3126.19
̜7̠ᅪ̜ბ̟ใඩ౞ྗ̟ใඩᔣથ̢৊ NMDA ଦᄵള໹ܑѠпцҀ఼‫ۼ‬ҝӝҧҢӠ̷ҽӞӃӦҼѣ‫ݷ‬౸്̟38‫ݸ‬໙ႏఋफკ‫࠵̟ݶ޻۽‬࿣̟3126.19
̜8̠‫ࡧێ৾ݔ‬ᇥ̟࿐޼̜ᆉ̟຿ใ௹஡̟ൌჿྗପ̟ඩ౧ञྗ̟ఊใ̜ୋ̟ේઆ౗ྗ̟ใඩᔣ
થ̟஫‫̜گ‬ఊ఼̢‫ ۼ‬IL-7ѝ IL-9৹ඐ҇ཕй਻཈ౖѣܑஶౖඩీఋफྐྵဦ҇ฉьє‫ڵ‬ᆰ്̟38‫ݸ‬໙ႏఋफკ‫޻ݶ޻۽‬ୠେ‫࠵̟ݶ‬࿣̟3126.1:

㸫  㸫

̜9̠ේઆ౗ྗ̟ඩ౧ञྗ̟࿐޼̜ᆉ̟ใඩᔣથ̟஫‫̜گ‬ఊ̢ӟҫҝӀӜ༔ܑ࠙ᇍ໹ஶѣ2ᆰ̟
്31‫ݸ‬໙ႏఋफ߷ಠஶ޻‫ݶ‬೴‫̟ݶ‬ේჿ̟3126.21
̜:̠ใ੟ᆁઞ̟ၿಗᅊથ̟ൌᆭ̜ᄽ̟ె९໐ઃඎ̟๚ࡶਿ೶‫̟ڵ‬ච௒̜ီ̢ҺҝҠҪҿҢӟ
ҝҴҼᆭ૊ള EdAP ѠѽҀ৊໙ႏ໹ܑҙҗӞҬ੣ᅀ്̟74‫ݸ‬໙ႏҙҗӞҬ޻‫޻ݶ‬ୠେ‫̟ݶ‬࿶ܱ̟3126.22
21̠ഥใᆁ۸̟຀९̜ଚ̟൦‫ݲݍ‬ბ̢RhoGDI ԓѣ੎ၙ຿ࣆ੔Ѥ੎ၙଠѠѽѿ‫ڤ‬џҀ്̟85‫ݸ‬໙ႏࠣ޻‫̟ݶ‬჏ॾ̟ܵ3126.21
22̠ഥใᆁ۸̟຀९̜ଚ̟൦‫ݲݍ‬ბ̢ӑҢӠӈҔ̷ҫѣၑ૾ಧᄥ཈ҕӐһ̷ҪҬѠпцҀ
RhoGDI ԓѣᄃ߇്̟35‫ݸ‬໙ႏс҈฽‫̟ݶ޻ڥ‬ൌਗ਼̟3126.18
23̠ใ੟ᆁઞ̢UBR5-E8ೱঘ੣ᅀѤ UBR box ᆛ‫ݵ҇ڱ‬ьћйҀ്̟49‫ݸ‬໙ႏခથౡ࿿޻‫ݶ‬໪‫̟ݶ‬ఋআ̟3126.23
24̠ͅ຀९̜ଚ̟͆ഥใᆁ۸̟൦‫ݲݍ‬ბ̢4चҞҬӄ̷үಃඊचဦᄼ RhoGDI ԓѣ੎ၙࣈౖ࠙ᇍ
ज૲ѭѣۭࢾ്̟85‫ݸ‬໙ႏࠣ޻‫̟ݶ‬჏ॾ̟ܵ3126.21
25̠ͅ຀९̜ଚ̟͆ഥใᆁ۸̟൦‫ݲݍ‬ბ̢ӂҗӐҠҪҕࠅࢪ݁ѠпцҀၵహളҴҚҶҢӐӦһ
౒ট‫ڤ‬௜தᅗѣӔҞҾҭӓ്̟35‫ݸ‬໙ႏс҈฽‫̟ݶ޻ڥ‬ൌਗ਼̟3126.18
ƷࢄᅀકΉɿᮾ᳣Ή⾷ȿɻɥɀȮɨ⾸̜2̠൮শ̜ఊ̟஛ძ೅۸࿎̟ၿಗᅊથ̟র࿧̜క̟গୌᅡᄈ໲̟ܱ੟ୢᇚ̟ච௒̜ီ̢໙ႏ
໹ܑҙҗӞҬ߷ಠѠпцҀҬӈҖӦҧӒқӝӦѣᄃ߇്̟44‫ ݸ‬໙ႏౡ݂޻‫ݶ‬ၿᅳબ࿫‫̟ݶ‬࿐આ̟3126.16
ƷࢄᅀકΉɿᮾ᳣Ή⾷ʶⅺ᜵Ⲥ⾸̜2̠਩຀ఙ઩̟ం‫گ‬ใᅆ̟৹̜ࡖᄵ̟৹౎‫܀‬થ̟࡫৹ᄣથ̟ସใಒᅱ̟ใඩञથ̟ࠥభ఻
ျ̟‫ڔ‬຀୶ᄶ̟ඩഡ௜໲̟੉ಗ̜ഥ̢໚ઓҕҪҼ̷ҪҬѝ໹ങඩᄼஶ௢҇ཕлӒһҦӦ
Ҽӝҕ໹ࣗஶͅMELAS͆ѣ‫ݍڵ‬पѣ‫ڭ‬เҞҙӦҮӝӦң്̟46‫ݸ‬ၿᅳᆤட‫ڭ‬เय़ࢅ‫̟ݶ‬຿⋱̟3126.12
̜3̠ඩ‫̜گ‬උ̟‫گ‬௒ఀჺ̟ඩែᄓ‫̟ݵ‬ఄใืൊ̟ࡻែਅఘ̟౹‫ޣ‬ᄈఘ̢Febuxostat ѠѽҀఠໝ੎ࠊ௒ྂ੎ၙௐ‫ޕ‬ѝໝᇔॆ౹ज౗ѠവюҀᅍ౒঳‫്̟ݑ‬2:‫ݸ‬ၿᅳྀໝ࠰‫ ݏ‬Basic
Research Meeting̟ࣟ൙̟3126.14
̜4̠ඩ౧ञྗ̟‫ࡧێ৾ݔ‬ᇥ̟ძ݁ࡶພ̟຀ใୋ్̟࿐޼̜ᆉ̟ใඩᔣથ̟஫‫̜گ‬ఊ̟౞ძ৆
ઞ̟ඩใ೶થ̟Ⴜ̜ি̢ANCA ࠙ᇍेࠊܑѠཕл྇঵ౖড়႟ܑѣ2ᆰ്̟336‫ݸ‬໙ႏ຿‫ݏ‬޻‫ݶ‬ၿᅳඒၒ‫̟ࣟݶ‬൙̟3126.14
̜5̠຿ใ௹஡̟࿐޼̜ᆉ̟‫ࡧێ৾ݔ‬ᇥ̟ൌჿྗପ̟ඩ౧ञྗ̟ఊใ̜ୋ̟ේઆ౗ྗ̟ใඩᔣ
થ̟Ⴜ̜ি̟஫‫̜گ‬ఊ̢Mollaret ఼႟ܑѣ2ᆰ്̟253‫ݸ‬໙ႏఋफ޻‫ݶ‬๫‫އ‬ၿᅳඒၒ‫̟ݶ‬
჏ॾ̟ܵ3126.17
̜6̠ಬ—‫̟݉ٯ‬ఊใ̜ୋ̟຿ใ௹஡̟‫ࡧێ৾ݔ‬ᇥ̟ൌჿྗପ̟ඩ౧ञྗ̟ේઆ౗ྗ̟࿐޼̜
ᆉ̟ใඩᔣથ̟஫‫̜گ‬ఊ̢མവഋѣ‫ଁޓ‬ા҇ཕл MLF ஶমऍѝ ataxic hemiparesis Ѡћ཈ஶьєඩ໹⊺ਾѣ2ᆰ്̟338‫ݸ‬໙ႏ຿‫ݶ޻ݏ‬ၿᅳඒၒ‫̟ࣟݶ‬൙̟3126.1:
̜7̠຿ใ௹஡̟ේઆ౗ྗ̟‫ࡧێ৾ݔ‬ᇥ̟ൌჿྗପ̟ඩ౧ञྗ̟ఊใ̜ୋ̟࿐޼̜ᆉ̟ใඩᔣ
થ̟ො‫܂‬ञ‫ڵ‬ᇥ̟๙ใ۸ன̟஫‫̜گ‬ఊ̢ড়႟‫ޓ‬૜ঃेධ໛ঞѠຉ෬сഄ‫ٶ‬ьє໹౽఼‫ۼ‬ᇞୟஶѣ‫ڵ‬ᆰ്̟254‫ݸ‬໙ႏఋफ޻‫ݶ‬๫‫އ‬ၿᅳඒၒ‫̟ݶ‬࿐આ̟3126.21

㸫  㸫

ƷǬǽ͙⾷ᣀ֌♠᜵⾸̜2̠ใඩᔣથ̢૜ঃკ‫ౖ۽‬໹ܑѣంєџื‫͘ގ‬૜ঃ৊ള‫ݵ‬੔ౖკ‫ౖ۽‬ఋफ૱߶̟͘๫ၿკ‫۽‬ౖఋफ૱߶૔ᆒय़ࢅ‫̟ݶ‬ಐോ̟3126.1:
̜3̠ใඩᔣથ̢૜ঃკ‫ౖ۽‬໹ܑѣఒඊѝ૔ᆒѣॶ௢̜͘৊ NMDA ଦᄵള໹ܑ҇ඩ௿Ѡ̟͘ౣఋఋफᆛ‫޻̜ڱ‬ୠ৭‫̜ݶܐ‬in ၿൌਗ਼̟ൌਗ਼̟3126.21
̜4̠ใඩᔣથ̢૜ঃკ‫ౖ۽‬໹ܑѣఒඊѝ૔ᆒѣॶ௢͘৊ NMDAR ໹ܑ҇ඩ௿Ѡ്̟͘8‫ݸ‬ସใത཈ౖড়݂ஶय़ࢅ‫̟ݶ‬ସใ̟3126.22
ƷǬǽ͙⾷ȿɻɥɀȮɨ⾸̜2̠ͅ຀९̜ଚ̟͆ࢌ۹Ⴥ‫̟ێ‬ᄜᅾᇭࡐ̟ె̜ᄤ̟ඪྑ૒ ৗ‫់̟ڵ‬ใᇭྞ̟ഥใᆁ۸̟൦‫ݲݍ‬
ბ̢4चҞҬӄ̷үಃඊच N Ⴉू૫ RhoGDI ԓѣ੎ၙࣈౖ࠙ᇍज૲౒টࡀ৔य़ࢅ്̟23‫ݸ‬ӢҗӦ௘ҪӦӐҫҙӓ̟ఋআ̟3126.23
̜3̠ͅᄜᅾᇭࡐ̟͆ࢌ۹Ⴥ‫̟ێ‬຀९̜ଚ̟ె̜ᄤ̟ഥใᆁ۸̟൦‫ݲݍ‬ბ̢RhoGDI ѣခથక݂ᇫษ৤ੴͅ2͆: alpha ̝ beta ̝ gamma Ѡљйћ്̟23‫ݸ‬ӢҗӦ௘ҪӦӐҫҙӓ̟ఋআ̟
3126.23ƷǬǽ͙⾷ʶⅺ᜵Ⲥ⾸̜2̠ใඩᔣથ̟຀ใୋ్̟๺‫̟ৃ̜گ‬ఋᆠ̜ఽ̟஫‫̜گ‬ఊ̢৊ NMDAR ৊ളѣଦᄵളॆ৾ຠ
ౖѝᆤடษຠ෈Ѡљйћѣग़ກ̟঵ᇖஷკ‫ౖ۽‬ఋफ૱߶य़ࢅར̜ར‫̟ࡣݶ‬๫̟࢝3126.12
̜3̠ใඩᔣથ̢૜ঃ৊ള‫ݵ‬੔ౖკ‫ౖ۽‬ఋफ૱߶ѣ཈ஶྐྵ഻ѣ‫ݷ‬ბ̟ћ҈р҈૔ᆒఁࢺ੗ඇ၈
ਇ‫̟ݶ‬ൌਗ਼̟3126.14

㸫  㸫

Ӟᴻٛ᪭ᮾ᳣ⲏࣕ
⊣ሤ
̜2̠८ᄩᆖ૔̢ࠂၒᄅ̟૔ᆒᄅӂӦҼӉҶҢ ᄅ੓ಱൗѝ୷ၒѣӐҗӦһ3126ͅႌ̜౞໐̟ె
ჿ्ഥᇥ̟ჸᇱ া̝ߦ ०‫̟ڵ‬ᆠ நᄽ̟͆2533-2577̟эѰл̟๫̟࢝3126.
̜3̠८ᄩᆖ૔̢୸Ѷѣ‫့ڵ‬Ѥ‫ދ‬ќ޻ѫ̜ଡ᢮޻̢එјћптєйс҈ѣඑૢѝҤҕ̟୸Ѷѣ‫့ڵ‬Ѥ‫ދ‬ќ޻ѫ̜ଡ᢮޻̢එјћптєйс҈ѣඑૢѝҤҕ̟2 -277̟эѰл̟๫̟࢝3126.
̜4̠८ᄩᆖ૔̢‫آ‬஼ ࡽౖ࠽ྐྵ๮ѝႰౖ࠽ќѣࠂၒ૔ᆒ̢ 22с҈‫ڮ‬ᆒѝࠂၒ̟છјћѴѽлࠂၒᄅͅ஛ჿাྞ̟BEAM ဩେ‫̟͆ݶۀښ‬218-223̟ဍরຏ̟๫̟࢝3126.
̜5̠८ᄩᆖ૔̢Chapter ‫ࠂ͑آ‬ၒ͒ఒᆒѠ࠙юҀҢӝҾҞӞҢқҬҴӚӦ̢Q51 с҈‫ڮ‬ᆒќѣࠂၒѣછйၒѣҦҷѹຠ௲҇ࢲнћфѕъй .̟ࠂၒఒᆒҢӝҾҞӞҢқҬҴӚӦ61ͅঞઆ஝ࡶ̟͆228-22:̟ఒඊѝ૔ᆒଃ̟๫̟࢝3126.
̜6̠८ᄩᆖ૔̢Chapter ‫ࠂ͑ء‬ၒ͒୷ၒѠ࠙юҀҢӝҾҞӞҢқҬҴӚӦ̢Q23 ࠂၒᄅѤဲ४ఒᆒс݉໸ќьѼлр̤ѳєҞӞҹѠѤўѣѽлѠࡌੑюҁѥѽ҂ьйќьѼлр̤̟ࠂၒఒᆒҢӝҾҞӞҢқҬҴӚӦ61ͅঞઆ஝ࡶ̟͆47 - 48̟ࠂၒఒᆒҢӝҾҞӞҢқҬ
ҴӚӦ̟๫̟࢝3126.
̜7̠८ᄩᆖ૔̢Chapter ‫ࠂ͑ؠ‬ၒ͒಻ཥѠ࠙юҀҢӝҾҞӞҢқҬҴӚӦ̢Q3 ඩਈ‫޻ڮ‬ѝࠂၒѤ‫ڬ‬лѣќьѼлр̤ѳєਈ੒ษѠเ๼‫޻ڮ‬ѣҟҗҼӜҗӦџўѤзѿѳюр̤̟ࠂၒఒᆒҢӝҾҞӞҢқҬҴӚӦ61ͅঞઆ஝ࡶ̟͆5-7̟ఒඊѝ૔ᆒଃ̟๫̟࢝3126.
̜8̠൮শ̜ఊ̟ܱ੟ୢᇚ്̢9ಊ̜ҬӈҖӦҧӒқӝӦ৾౗ৱ೎̡ҬӈҖӦҧӒқӝҽ̷ү̟૱߶ӕҺӞѣ੣౦ѝᅧᅀ઼̜૲ൊଆ‫ڤ‬௜ѝ࠙ᇍ૱߶̜݁߭ͅྑඖᄩ‫̟ڵ‬਩̴ძᄩྞ ̟͆
459-468̟қӞ̡ҕҗ̡Ҫ̷̟๫̟࢝3126.
̜9̠ͅJ.Bestard-Escalas͆, M.D.Ledesma, M.Taniguchi, T.Okazaki, M.L.Martin, G.Barceló-Coblijn :8QUDYHOLQJWKHVSHFL¿FUROHRIVSKLQJRP\HOLQVLQFHOOSK\VLRORJ\:KHUHDUHZH"6SKLQJROLSLGV
Biology, Synthesis and FunctionsͅAngel Catalá͆, :2-239, Nova Science Publishers, America,
3126.
̜:̠ͅH.Sawai͆, M.Taniguchi, T.Okazaki : Role of sphingolipids in hematological malignancies :Lymphoproliferative disorders, Bioactive Sphingolipids in Cancer Biology and TherapyͅYusuf A.
Hannun, Chiara Luberto, Cungui Mao, Lina Marie Obeid͆, 34-62, Springer, Bundesrepublik
Deutschland, 3126.

ક⒈☟ᄙƷ‫⊣ڤ‬̜2̠Y.Ishigaki, Y.Nakamura, T.Tatsuno, S.Ma, N.Tomosugi : Phosphorylation status of human RNAbinding protein 9A in cells and its inhibitory regulation by Magoh, Experimental Biology andMedicine, 351:5:549-556, 3126.
̜3̠M.Takeuchi, J.Takino, H.Shirai, M.Kawakami, S.Furuno, Y.Kobayashi : Assessment of total sugar
and glucose concentrations in commonly consumed beverages in Japan, Nutrition and Food
Technology : Open Access, 2:3:2-:, 3126.
̜4̠M.Takeuchi, J.Takino, S.Furuno, H.Shirai, M.Kawakami, M.Muramatsu, Y.Kobayashi,㸫  㸫

S.Yamagishi : Assessment of the concentrations of various advanced glycation end-products inbeverages and foods that are commonly consumed in Japan, PLoS One, 21:4:e1229763, 3126.
̜5̠T.Sakai, Y.Masaki, N.Otsuki, I.Sakamaki, S.Kishi, T.Miyazono, Y.Urasaki, J.Murakami, T.Satoh,T.Nakamura, H.Iwao, A.Nakajima, T.Kawanami, M.Miki, Y.Fujita, M.Tanaka, T.Fukushima,
T.Okazaki, T.Ueda : Prospective clinical study of R-CMD therapy for indolent B cell lymphoma
and mantle cell lymphoma from the Hokuriku Hematology Oncology Study Group, Medical
Oncology, 43:343-349, 3126.
̜6̠M.Taniguchi, H.Ogiso, T.Takeuchi, K.Kitatani, H.Umehara, T.Okazaki : Lysososomal ceramide
generated by acid sphingomyelinase triggers cytosolic cathepsin B-mediated degradation of
X-linked inhibitor of apoptosis protein in natural killer/T lymphoma cell apoptosis, Cell Death andDisease, 7:e2828:2-23, 3126.
̜7̠H.Ogiso, M.Taniguchi, T.Okazaki : Analysis of lipid-composition changes in plasma membrane
microdomains, Journal of Lipid Research, 67:9:26:5-2716, 3126.
̜8̠ͅT.Suzuki͆, A.Yamamoto, M.Ohsawa, Y.Motoo, H.Mizukami, T.Makino : Ninjin'yoeito andginseng extract prevent oxaliplatin-induced neurodegeneration in PC23 cells, Journal of Natural
Medicines, 7::5:642-648, 3126.
̜9̠ͅS.Y.Kong͆, M.Takeuchi, H.Hyogo, G.McKeown-Eyssen, S.Yamagishi, K.Chayama, P.J.O'Brien,
P.Ferrari, K.Overvad, A.Olsen, A.Tjonneland, M.Boutron-Ruault, N.Bastide, F.Carbonnel, T.
Kuehn, R.Kaaks, H.Boeing, K.Aleksandrova, A.Trichopoulou, P.Lagiou, E.Vasilopoulou, G.
Masala, V.Pala, M.D.Magistris, R.Tumino, A.Naccarati, H.B.Bueno-De-Mesquita, P.H.Peeters,
E.Weiderpass, J.R.Quiros, P.Jakszyn, M.Sanchez, M.Dorronsoro, D.Gavrila, E.Ardanaz, M.
Rutegard, H.Nystroem, N.Wareham, K.Khaw, K.Bradbury, I.Romieu, H.Freisling, F.Stavropoulou,
M.J.Gunter, A.J.Cross, E.Riboli, M.Jenab, W.R.Bruce : The association between glyceraldehydederived advanced glycation end-products and colorectal cancer risk, Cancer Epidemiology
Biomarkers & Prevention, 35:23:2966-2974, 3126.
̜:̠ͅM.Kajikawa͆, A.Nakashima, N.Fujimura, T.Maruhashi, Y.Iwamoto, A.Iwamoto, T.Matsumoto,
N.Oda, T.Hidaka, Y.Kihara, K.Chayama, C.Goto, Y.Aibara, K.Noma, M.Takeuchi, T.Matsui, S.
Yamagishi, Y.Higashi : Ratio of serum levels of AGEs to soluble form of RAGE is a predictor ofendothelial function, Diabetes Care, 49:2:22:-236, 3126.
21̠ͅ K.Fukami ͆, S.Yamagishi, K.Sakai, Y.Kaida, M.Yokoro, S.Ueda, Y.Wada, M.Takeuchi,
M.Shimizu, H.Yamazaki, S.Okuda : Oral L-carnitine supplementation increases trimethylamineN-oxide but reduces markers of vascular injury in hemodialysis patients, Journal of Cardiovascular
Pharmacology, 76:4:39:-3:6, 3126.
22̠ͅJ.Takino͆, K.Nagamine, M.Takeuchi7+RUL,QYLWURLGHQWL¿FDWLRQRIQRQDOFRKROLFIDWW\OLYHU
disease-related protein hnRNPM, World Journal of Gastroenterology, 32:7:2895-28:4, 3126.
23̠ͅY.Koriyama͆, A.Furukawa, M.Muramatsu, J.Takino, M.Takeuchi : Glyceraldehyde caused
Alzheimer's disease-like alterations in diagnostic marker levels in SH-SY6Y human neuroblastoma
FHOOV6FLHQWL¿F5HSRUWV6:2-8, 3126.
24̠ͅH.Kan͆, S.Yamagishi, A.Ojima, K.Fukami, S.Ueda, M.Takeuchi, H.Hyogo, H.Akita, K.Chayama: Elevation of serum levels of advanced glycation end products in patients with non-B or non-C
hepatocellular carcinoma, Journal of Clinical Laboratory Analysis, 3::7:591-595, 3126.
25̠ͅN.Tahara͆, S.Yamagishi, N.Kodama, A.Tahara, A.Honda, Y.Nitta, S.Igata, T.Matsui, M.Takeuchi,
H.Kaida, S.Kurata, T.Abe, Y.Fukumoto : Clinical and biochemical factors associated with area and㸫  㸫

metabolic activity in the visceral and subcutaneous adipose tissues by FDG-PET/CT, Journal of
Clinical Endocrinology & Metabolism, 211:6:E84:-E858, 3126.
26̠ͅ M.Takeda ͆, T.Ohnuma, M.Takeuchi, N.Katsuta, H.Maeshima, Y.Takebayashi, M.Higa,
T.Nakamura, S.Nishimon, T.Sannohe, Y.Hotta, R.Hanzawa, R.Higashiyama, N.Shibata, T.Gohda,
Y.Suzuki, S.Yamagishi, Y.Tomino, H.Arai : Altered serum glyceraldehyde-derived advanced
glycation end product ͅAGE͆and soluble AGE receptor levels indicate carbonyl stress inpatients with schizophrenia, Neuroscience Letters, 6:4:62-66, 3126.
27̠ͅH.Sawai͆, H.Ogiso, T.Okazaki : Differential changes in sphingolipids between TNF-induced
necroptosis and apoptosis in U:48 cells and necroptosis-resistant sublines, Leukemia Research,
4:::75-:81, 3126.
28̠ͅM.Kuroda͆
, M.Shimizu, N.Inoue, I.Ikeno, H.Nakagawa, A.Yokoi, Y.Niida, M.Konishi, H.Kaneda,
N.Igarashi, J.Yamahana, H.Taneichi, H.Kanegane, M.Ito, S.Saito, K.Furuichi, T.Wada, M.
Nakagawa, H.Yokoyama, A.Yachie : Serum tau protein as a marker of disease activity inenterohemorrhagic Escherichia coli O222-induced hemolytic uremic syndrome, Neurochemistry
International, 96-97:35-41, 3126.
29̠ͅ H.Yazama ͆, K.Kitatani, K.Fujiwara, M.Kato, M.Hashimoto-Nishimura, K.Kawamoto,
K.Hasegawa, H.Kitano, A.Beilawska, J.Bielawski, T.Okazaki : Dietary glucosylceramides
suppress tumor growth in a mouse xenograft model of head and neck squamous cell carcinoma by
the inhibition of angiogenesis through an increase in ceramide, International Journal ClinicalOncology, 31:4:549-557, 3126.
2:̠ͅA.Okumura͆, M.Ozaki, Y.Niida : Development of a practical NF2 genetic testing method through
WKHSLORWDQDO\VLVRI¿YH-DSDQHVHIDPLOLHVZLWKQHXUR¿EURPDWRVLVW\SH 2., Brain & Development,
48:8:788-79:, 3126.
31̠ඩែᄓ‫̟ݵ‬ई಑ఃန̟‫گ‬௒ఀჺ̟ඩ‫̜گ‬උ̟ఄใืൊ̟࡫̜িิ̟ࣞ൙‫ڸ‬န̟ใඩ൦
ᇚ̟८ᄩᆖ૔̟ࡻែਅఘ̢ࢍ౓ฒ৊ౖಷᅶಪࠣѠവюҀқӦҩӞҲӒҼѣ୸࠽છᅀफ
६̟ࣟ൙‫ݏڮ‬ൌ޻੻ૂ̟51:2:7-311, 3126.
Ʒἕ◻
̜2̠ච຿౞ࡠ̟൒ჿ୲‫ͅگࡴ̟ڵ‬ਖ਼‫͆گ‬٪ࡉથ̟৹ใട௹̟௒ใඬઝ̢ౡߋ଻߸ྐྵѣ཈ஶ̡కืѠпцҀ Toxic AGEsͅTAGE͆ѣ࠙ᄮ̜- ంєџᄬၼಘᅹ -̜̼௴ૉౖ AGEs пѽѨ๻຤ౖѣఊ૳̼̟ࣟ൙‫ݏڮ‬ൌ޻੻ૂ̟51::6-214, 3126.
̜3̠ం‫گ‬ใᅆ̢‫ڭ‬เથဦ‫ڤ‬ҬҢӝ̷ҾӦңၔ CHIPS ѣ‫ގ‬཈ѝᆤட‫ܥ‬ᅀ̟ࣟ൙‫ݏڮ‬ൌ޻੻ૂ̟
51:95-:2, 3126.
̜4̠८ᄩᆖ૔̢ࠂၒ҇лѳфછл - ਘюхછнҀ୷ၒҟҗҼ̜‫ౖٶ‬૱߶ѠവюҀࠂၒ̟౗ఘ
ྐྵѝౡߋ଻߸ྐྵ̟56:3:352-357, 3126.
̜5̠८ᄩᆖ૔̢৊с҈੓ѣ࿲੣ᅀѝબૐᆒၔ - ѽѿหಃџ৊с҈੓ѣ‫಻ڋ‬છᅀ҇Ѷыьћ ৊с҈੓ѣ࿲੣ᅀѠവюҀྵ݆ѝ୷඙̜৊с҈੓ѣ࿲੣ᅀѠ࠙юҀ߶ଅࢲ‫̟ڲ‬໙ႏᆤ
ட̟84̢ഄߪ3 ৊с҈੓ѣ࿲੣ᅀѝબૐᆒၔ̢:9-212, 3126.
̜6̠८ᄩᆖ૔ౖ̢ਮ‫ڮ‬ᆒѣ਼ಷಧ - ౡߋ଻߸ྐྵ҇ඩ௿Ѡ -ౖ̜ਮ҇৤ᆅюѮт૱߶̜‫ౖٶ‬ଡ᢮߶ଅѣఒᆒѝౖਮ̟໙ႏᆤட̟84:5:777-781, 3126.
̜7̠ᒽ౞ଳ‫̟ڵ‬ච຿౞ࡠ઼̢૲‫ڤ‬௜ஶ߶ଅѠവюҀ઼૲ค݁ᆒၔс Glycer-AGEs ѠѷєѾю
ۭࢾ̟ఒᆒѝంᄅ̟63:6:624-62:, 3126.

㸫  㸫

̜8̠ͅం‫ڵگ‬ᇥ̟͆८ᄩᆖ૔္̢߱ൊഽ‫ڮ‬ᆒѝқӆҺӦҬ̢ ္߱ൊഽ‫ڮ‬ᆒѣఒᆒҟҗҼӜҗ
Ӧ̟‫޻ڮ‬ѣзѻѴ̟364:22:2232-2236, 3126.
̜9̠८ᄩᆖ૔̟๱ಗटથ̢ൊഽ‫ڮ‬ᆒ Complementary and Alternative MedicineͅCAM͆ѝඒ‫ڮڱ‬ᆒ̜໙ႏѠпцҀൊഽ‫ڮ‬ᆒѣᅧᅀ૳഻̜‫ܩ‬ଲѝѣཿ޶ѷࠟѶћ̟ඒ‫̟޻ڮڱ‬3: : 7 : 521 524, 3126.
̜:̠ͅK.Kitatani͆, M.Taniguchi, T.Okazaki : Role of sphingolipids and metabolizing enzymes inhematological malignancies, Molecules and Cells, 49:7:593-5:6, 3126.
21̠M.Takeuchi, A.Sakasai-Sakai, J.Takino, T.Takata, T.Ueda, M.Tsutsumi : Toxic AGEsͅTAGE͆
theory in the pathogenesis of NAFLD and ALD, International Journal of Diabetes and ClinicalResearsh, 3:5:2-6, 3126.
22̠ͅ J.Takino ͆, K.Nagamine, T.Hori, A.Sakasai-Sakai, M.Takeuchi : Contribution of the toxic
advanced glycation end-products-receptor axis in nonalcoholic steatohepatitis-related
hepatocellular carcinoma, World Journal of Hepatology, 8:34:356:-357:, 3126.
23̠ం‫گ‬ใᅆ̢‫ڭ‬เ‫ڮ‬ᆒѣ‫ڵ‬ཥఒᆒ݂Ѡষцћ̟౹ಗ‫ڮ‬၈̟26:6:41-44, 3126.

Ʒᩲόअ‫ܝ‬̜2̠ͅ N.Hatta ͆, A.Takata, S.Ishizawa, Y.Niida : Family with MSH 3 mutation presenting withkeratoacanthoma and precancerous skin lesions, Journal of Dermatology, 53:22:2198-21:1, 3126.
̜3̠Y.Niida, M.Ozaki, E.Takase, T.Yokoyama, S.Yamada : A girl with greig cephalopolysyndactyly
contiguous gene deletion syndrome : The importance and usefulness of DNA microarray analysis,
Hereditary Genetics, S8:2-4, 3126.
̜4̠Y.Niida : Radiological diagnosis of a neonate with mucolipidosis IIͅI-cell disease͆, Clinical
Medical Image Library, 2:3:28-29, 3126.
̜5̠ଚܵ୲໐̟આಗ୮‫̟ڵ‬஛ᆠ୮໐̟ච຿्໐̟८ᄩᆖ૔̢ӑҗҦӊӜҭӑ߷ಠஶঞѠ཈ஶьєಧ‫ࣗڦ‬෬ஶѠവюҀࠂၒᄅѣછᅀफ६̟෬Ѵѝࠂၒ̟36:23:-244, 3126.
Ʒ᮲अ̜2̠M.Takeuchi, A.Sakasai-Sakai, T.Takata, T.Ueda, J.Takino, M.Tsutsumi, H.Hyogo, S.Yamagishi :Serum levels of toxic AGEsͅTAGE͆may be a promising novel biomarker in development andprogression of NASH, Medical Hypotheses, 95:5:1-5:4, 3126.
̜3̠Y.Niida, O.Ozaki, M.Inoue, E.Takase, M.Kuroda, Y.Mitani, A.Okumura, A.Yokoi, S.Fujita,
K.Yamada : CHIPS for genetic testing to improve a regional clinical genetic service, Clinical
Genetics, 99:3:266-271, 3126.
̜4̠Y.Niida+RZGR\RXDQDO\]HDPXWDWLRQRIWKHJHQHFRQVLVWLQJRIRQHKXQGUHGH[RQV"$GYDQFHG
Techniques in Biology & Medicine, 4:4:249, 3126.
̜5̠Y.Niida : CHIPS to disseminate the genetic testing of rare diseases, Gene Technology, 5:4:238,3126.
̜6̠Y.Niida : Finding gene mutations by the enzyme : Chips for a simple and highly sensitive enzyme
mismatch cleavage method, Enzyme Engineering, 5:3:242, 3126.
̜7̠Y.Niida : CHIPS for a mutation screening of a large sized gene : An example of NF2 analysis,㸫  㸫

Pharmaceutia Analytica Acta, 7:22:551, 3126.
ƷǬǽ͙̜2̠ࡴ‫ͅگ‬ਖ਼‫͆گ‬٪ࡉથ̟ఋჿ౞ᄩ̟ච຿౞ࡠ̢࿋໠૔ᆒӃҗҝӑ̷Ҟ̷ѝьћѣ Toxic
AGEsͅTAGE͆ѣᄜᅀౖ̟໙ႏႵྐྵҪҬҹӓ޻‫̟ૂ੻ݶ‬32:2::4, 3126.
̜3̠Y.Motoo : Description of Kampo medicines in the clinical practice guidelines for irritable bowel
syndrome, Journal of Gastroenterology, 61:8:927, 3126.
̜4̠ච຿౞ࡠ̟ॾჿᅬྗ̟༭‫گ‬ѧрѿ̟‫ݔ‬௒ྗျથ̟ഡ஫̜ୋ̟஛ᆠᄢ̟݇൒ჿ୲‫ॶ̢ڵ‬ൊѣ௴ౡߋѠಡѵᅝѝьॅ̜‫௴ۄ‬࿿ඩ AGEs ࡹѨ๻຤ౖѣఊ૳̟໙ႏႵྐྵҪҬҹӓ޻‫੻ݶ‬
ૂ̟33:241, 3126.

કΉɿᮾ᳣Ή᫘⒙Ʒ࡛⭾કΉ⾷ȿɻɥɀȮɨ⾸̜2̠Y.Motoo : Evidence Reports on Kampo TreatmentͅEKAT͆and Kampo medicines in clinicalpractice guidelinesͅKCPG͆, The 21th International Congress of Complementary Medicine
Research - ICCMR 3126, Jeju, Republic of Korea, 3126.16
̜3̠Y.Motoo, I.Arai, K.Tsutani : Systematic review on the use of Kampo diagnosis in randomized
controlled trials of Kampo medicines, 4rd International Symposium for Japanese Kampo Medicine
ͅISJKM͆, Vienna, Austria, 3126.17
ƷӴ࡛કΉɿᮾ᳣Ή⾷ᣀ֌♠᜵⾸̜2̠८ᄩᆖ૔̢ࠂၒ૔ᆒқӆҺӦҬӟӐ̷һͅEKAT͆ѝఒᆒҟҗҼӜҗӦѣ਼ࣞѣᇮ൏̟
്4‫ࣟݸ‬൙ࠂၒ‫޻ڮ‬ҪӦӐҫҙӓ̟ࣟ൙̟3126.13
ƷӴ࡛કΉɿᮾ᳣Ή⾷ȿɻɥɀȮɨ⾸̜2̠८ᄩᆖ૔̢݂޻ᆒၔѠѽҀႩ஬ఋफௐ‫ޕ‬ѠവюҀᄬၼѝ૔ᆒ്̟214‫ݸ‬໙ႏྀໝ࠰‫ݶ޻ݏ‬೴‫̟ࣟݶ‬൙̟3126.15
̜3̠८ᄩᆖ૔̢ఒᆒҟҗҼӜҗӦѝࠂၒ̢ ໙ႏѣఒᆒҟҗҼӜҗӦѠпцҀࠂၒѣࡌੑ̢
KCPG ѣ༓थ҇ඩ௿Ѡ്̟77‫ݸ‬໙ႏ๫ᄽ‫޻ݶ޻ڮ‬ୠ೴‫̟ݶ‬࿐આ̟3126.17
̜4̠๦੟ქ࿎̟८ᄩᆖ૔̟ॴ̜ᅧ౗̟ᄖౄෟࡶ̢৊ࠣ੓Ѡѽѿ᪴ࠣ੎ၙѠᄥຐъҁҀ EMT ഊక‫ہ‬થѣຎซѝࡀ໸‫ݷ‬౸̢ GSK 4ԓ೒‫ޕ‬Ѡѽѿ౒ট്̟57‫ݸ‬໙ႏ᪴ആ޻‫ݶ‬ൌ‫̟ݶ‬჏ॾ
̟ܵ3126.17
ƷӴ࡛કΉɿᮾ᳣Ή⾷ʶⅺ᜵Ⲥ⾸̜2̠A.Nakajima, H.Shimizu, T.Nakamura, T.Nakamura, H.Kawanami, M.Miki, T.Sakai, Y.Fujita,
M.Tanaka, T.Fukushima, T.Okazaki, Y.Hirose, Y.Masaki : Spontaneous remission of
FKHPRWKHUDS\UHVLVWDQW DFXWH P\HORLG OHXNHPLD DIWHU VHYHUH SQHXPRQLD"7KH 88th Annual
Meeting of the Japanese Society of Hamatology, Kanazawa, 3126.12
̜3̠H.Shimizu, Y.Masaki, T.Sato, T.Nakamura, T.Nakamura, H.Iwao, A.Nakajima, M.Miki, T.Sakai,
Y.Fujita, M.Tanaka, T.Okazaki, T.Fukushima : 25 cases of testicular lymphoma, The 88th Annual㸫  㸫

Meeting of the Japanese Society of Hematology, Kanazawa, 3126.21
̜4̠ͅ൒ჿ୲‫̟͆ڵ‬۱‫گ‬ఊჺ̟આਡ̜ິ̟ॾჿᅬྗ̟༭‫گ‬ѧрѿ̟‫ݔ‬௒ྗျથ̟ഡ஫̜ୋ̟஛
ᆠᄢ̟݇ච຿౞ࡠ̢‫௴ۄ‬࿿ඩ AGEs ࡹѨ๻຤ౖѣఊ૳̟໙ႏᄅ޻‫്ݶ‬246໪‫̟ݶ‬ఋআ̟
3126.14̜5̠ͅ౧ಗ্ౕ̟͆ర൮തञથ̟ܱჿᄢᅧ̟ච຿౞ࡠ̟౞ძ̜ఙ̢ఊྂಧ‫ݯڦ‬੎ၙѣࡀ໸Ѡࡹ
ѱю Toxic AGEs ѣ੣ᅀ̟໙ႏᄅ޻‫്ݶ‬246໪‫̟ݶ‬ఋআ̟3126.14
̜6̠ͅઆਡ̜ິ̟͆۱‫گ‬ఊჺ̟൒ჿ୲‫̟ڵ‬ේ။ॖഥᇥ̟ච຿౞ࡠ̟ႌ̜ᆁর̢๻݂ѣҲ̷ҥҶһ඄༭૲ќзҀ hnRNPM ѣ‫ݷ‬౸̟໙ႏᄅ޻‫്ݶ‬246໪‫̟ݶ‬ఋআ̟3126.14
̜7̠ච຿౞ࡠ̟ࡴ‫ͅگ‬ਖ਼‫͆گ‬٪ࡉથ̟ఋჿ౞ᄩ̢࿋໠૔ᆒӃҗҝӑ̷Ҟ̷ѝьћѣ Toxic
AGEsͅTAGE͆ѣᄜᅀౖ̟໙ႏᄅ޻‫്ݶ‬246໪‫̟ݶ‬ఋআ̟3126.14
̜8̠݁ୟᄣഉ̟ช຿ୢ࠯̟⋥̜ᄤ໲̟८ᄩᆖ૔̟༱ใஎඎ̟਩ಗ८ဲ̟ܱႏ‫ڵ‬ჺ̢RAI ฒ৊ౖ৹ခ݂च৚௢ಪࠣѠവюҀခથྯษᄅѣછᅀफ६്̟38‫ݸ‬໙ႏ຿ခྀ‫̟ݶ޻ݏޓ‬࿶
๦̟3126.16
̜9̠࿶ഡ̜ີ̟ච຿౞ࡠ̟ช̜ߵি̢ҕӞҦ̷Ӟౖࠏௐ‫ޕ‬ѝ NAFLD ѣྐྵ഻Ѡ࠙ᄮюҀହႩ๻݂ઍ࿿̢ AA-AGEs ѝ GA-AGEs Ѡ࠙юҀग़ກ്̟62‫ݸ‬໙ႏࠏആ޻‫ݶ‬೴‫ं̟ݶ‬ႏ̟
3126.16̜:̠ච຿౞ࡠ̟൒ჿ୲‫ॾ̟ڵ‬ჿᅬྗ̟༭‫گ‬ѧрѿ̟‫ݔ‬௒ྗျથ̟ഡ஫̜ୋ̟஛ᆠᄢ̟݇આࠠ
ந‫௴ۄ̢ڵ‬࿿ඩ AGEs ࡹѨ๻຤ౖѣఊ૳̼ంєџ௴ૉફຐѣ‫ޘ‬໫്̼̟69‫ݸ‬໙ႏ๻ໝྐྵ
޻‫ݶ‬໪૒޻ୠେ‫̟̟࠙݁ݶ‬3126.16
21̠ච຿౞ࡠ̟ॾჿᅬྗ̟༭‫گ‬ѧрѿ̟‫ݔ‬௒ྗျથ̟ഡ஫̜ୋ̟஛ᆠᄢ̟݇આࠠந‫̟ڵ‬൒ჿ୲‫௴ۄ̢ڵ‬࿿ඩ AGEs ࡹѨ๻຤ౖѣఊ૳̼ॶൊѣ௴ౡߋѠಡѵᅝѝьॅ്̼̟26‫ݸ‬໙ႏ৊݈ᆽ‫ݶ޻ڮ‬೴‫̟ݶ‬࿶ܱ̟3126.16
22̠ం‫گ‬ใᅆ̟ઃ൮ᄤ‫̟ݵ‬਌ใဍఘ̟‫ੁگܨ‬໰̢KAT7B ‫ڭ‬เથ21‫୔࠱ܝ‬࿸ဦ‫ڤ‬ѠѽҀ୔ஶचYoung-Simpson ஶমऍѣ‫ڵ‬ᆰ്̟68‫ݸ‬໙ႏ஛ૌఋफ޻‫޻ݶ‬ୠେ‫̟ݶ‬ൌਗ਼̟3126.16
23̠ࡶഡᇭျ̟ൌఄபથ̟๎ᵂຽ̴થ̟෌ႏᅙથ̟൒ႏ୮થ̟ྑ޴ᄤྗ̟આ݁ྗ෦৕̟۱ใ
ଔ੏̟८ᄩᆖ૔̢с҈ೱඏબ܎ҮӦҲ̷ѠпцҀ଱ᇖೱඏҾ̷ҭѣॶ௢̢с҈߶ଅ଱ᇖೱඏૉࣅѣᅧᅀ௢ࢴѠ࠙юҀ૳഻෕ਯ്̟31‫ݸ‬໙ႏࠌᇭ‫ڮ‬ᆒ޻‫޻ݶ‬ୠൌ‫ܨ̟ݶ‬࿄̟
3126.1724̠ͅඩែᆈ‫̟͆ڵ‬౟రᄽ‫̟ڵ‬ൌಗ̜ඕ̟᤺຀ᄓઝ̟༫९۸ྞ̟஛ჿ̜ᆁ̟஫ࣟᆁ࿎̟୑൮ാ
ઞ̟๫̜ඪಔ̟ච຿౞ࡠ̢ҝӦӜҗӦे‫ۼ‬ຆ౸។‫ݦ‬ѣे౟ңӝҮӞҕӞҺӅҼᄢᅗAGEsͅTAGE͆ѭѣ঳‫്̟ݑ‬71‫ݸ‬໙ႏຆ౸‫޻ݶ޻ڮ‬ୠେ‫̡ݶ‬೴‫ܨ̟ݶ‬࿄̟3126.17
25̠ͅᆸძୢ஼̟͆આႏੁ໰̟ൌែࢦে̟८ᄩᆖ૔̟ర௒८̟ႅჿᅧბ̢Oxaliplatin ѠѽҀႩ஬ఋफௐ‫⌣ౖޕ‬෬ѠവюҀఘઅᅋ۰๱ѣ੣ᅀѣग़ກ̟໙ႏౡᄅ޻‫്ݶ‬73‫ݸ‬໪‫࠵̟ݶ‬࿣̟
3126.1:26̠ែใႵ‫̟ܢ‬ଚܵ୲໐̟આಗ୮‫̟ڵ‬௒౧༩஼̟౿ែ୲ൊ̟஛ᆠ୮໐̟८ᄩᆖ૔̢໚ࠣୠঞ
ၑ૾ಧவ૾с९‫ہ‬ѝ৤нѾҁє९཈ౖ৚௢ಪࡀ໸ค݁ஶѣ2ᆰ̟໙ႏ຿‫ݶ޻ݏ‬ၿᅳબ࿫ଘ
਺്338‫ݸ‬ၿᅳඒၒ‫̟ࣟݶ‬൙̟3126.1:
27̠ච຿౞ࡠ̟ॾჿᅬྗ̟༭‫گ‬ѧрѿ̟‫ݔ‬௒ྗျથ̟ഡ஫̜ୋ̟஛ᆠᄢ̟݇આࠠந‫̟ڵ‬൒ჿ୲‫௴ۄ̢ڵ‬࿿ඩ AGEs ࡹѨ๻຤ౖѣఊ૳̼ॶൊѣ௴ౡߋѠಡѵᅝѝьॅ്̼̟33‫ݸ‬໙ႏႵྐྵҪҬҹӓ޻‫ݶ‬೴‫޻ݶ‬ୠ೴‫੸̟ݶ‬ႍ̟3126.21
28̠ͅఋჿ౞ᄩ̟͆๎ᵁ‫ٯ‬થ̟ངઆ஝ࡶ̟৾ใᄖ਽̟໙ۡᅬ‫̟ދ‬ච݁஺થ̟௒ഡඑৄ̟આใຘ㸫  㸫

ౡ̟ච຿౞ࡠ̢৊๻݂ࡀ໸ౖ௴࿁ ӅҪқҠҬѠѽҀ ART ໠௼ᅵѣරьй‫ރ‬ಸ̢ART མ࿳࿋౗লѣ৹ᆽ࿋໠ѠവюҀହႩ๻݂ઍ࿿ค݁ѣ୔ᅆ്ౖ̟44‫ݸ‬໙ႏଦౣඨட޻‫ݶ‬೴‫޻̡ݶ‬ୠ৭‫̟ݶܐ‬๫̟࢝3126.22
29̠ͅძ൮਩‫ܢ‬ᅬ̟͆Ꭵઆാઞ̟๦̜াᄓ̟ච݁ᄜྗ઱̟ট⌗༩ဍ̟ం‫گ‬ใᅆ̟ᦜ̜ୢ౗̢ӆҲӒӦ D ฒ৊ౖфҀྐྵஶᆰќ।ୟьєంࡋ PHEX ‫ڭ‬เથဦ‫്̟ڤ‬36‫ݸ‬ᆤ᠗຿ခྀൊଆ
Update̟๫̟࢝3126.22
2:̠ͅ ේ ᆳ ॖ ഥ ᇥ ̟͆ ൒ ჿ ୲ ‫ ̟ ڵ‬ච ຿ ౞ ࡠ ̟ ႌ ̜ ᆁ র ̢ ྌ ҕ Ӟ Ҧ ̷ Ӟ ౖ ઼ ၶ ౖ ࠏ ૱ ߶ͅNAFLD͆ѣఒඊӑ̷Ҟ̷ѣ൸੬്̟49‫ݸ‬໙ႏခથౡ࿿޻‫ݶ‬໪‫ ݶ‬/ ്99‫ݸ‬໙ႏౡ݂޻‫ݶ‬ൌ‫̜৾ݶ‬ຎൌ‫̟ݶ‬ఋআ̟3126.23
31̠આႏ೶થ̟๦੟ქ࿎̟ᄜ൙࿐৆̟ॴ̜ᅧ౗̟ᄖౄෟࡶ̢қҢҰҰ̷ӓ҇‫ݵ‬юҀࠣ੎ၙࠗೱঘ੣ᅀ̢ంьй੎ၙ༘ᅋӊӟ̷һѠѽҀ‫ݷ‬౸്̟85‫ݸ‬໙ႏࠣ޻‫޻ݶ‬ୠ೴‫̟ݶ‬჏ॾ̟ܵ
3126.2132̠౹‫ޣ‬ᄈఘ̟ඩഡᄜ৸̟൧ჿࡍഌ̟๦੟ქ࿎̢Ӆһे౟ᄢᅗ੎ၙ‫ޓ‬஛ၙѣ೽ਯचไથ५ྒ
ࢽࠒੴ്̟8‫ݸ‬໙ႏ RNAi य़ࢅ‫ ݶ‬/ ്3‫ݸ‬໙ႏ੎ၙ‫ޓ‬஛ၙ޻‫ৄ̟ݶ‬๦̟3126.19
33̠౹‫ޣ‬ᄈఘ̟ඩഡᄜ৸̟൧ჿࡍഌ̟๦੟ქ࿎̢Ӆһᄢᅗ੎ၙ‫ޓ‬஛ၙѣ‫ݷ‬౸്̟42‫޻ڮݸ‬ౡ࿿޻ไથ५ྒࢽ࡚ୠ޻‫̟ݶ‬჏ॾ̟ܵ3126.17
34̠๦੟ქ࿎̟આႏ೶થ̟ॴ̜ᅧ౗̢৊с҈੓Ѡѽѿ᪴с҈੎ၙѠᄥຐъҁҀခથѝқҢҰҰ̷ӓ҇‫ݵ‬ьє੎ၙࠗೱঘ੣ᅀѣ‫ݷ‬౸്̟37‫ݸ‬໙ႏர݂࠰ࠣ཈ౡ޻‫ݶ‬೴‫̟ݶ‬ရથ̟
3126.2235̠๦੟ქ࿎̟આႏ೶થ̟ຏႏࡍ̟߳ᄜ൙࿐৆̟ᄖౄෟࡶ̟ॴ̜ᅧ౗̢ҥӓҪҲӆӦѠѽѿ
᪴ࠣ੎ၙѠᄥຐъҁҀ EMT ഊక‫ہ‬થѣຎซѝࡀ໸‫ݷ‬౸̢GSK4ԓ೒‫ޕ‬ѠѽҀ౒ট്̟85‫ݸ‬໙ႏࠣ޻‫޻ݶ‬ୠ೴‫̟ݶ‬჏ॾ̟ܵ3126.21
36̠ྑ੟̜ଚ̟ం‫گ‬ใᅆ̟৹౎‫܀‬થ̟‫ڔ‬຀୶ᄶ̟਩຀ఙ઩̢21໪ࠗѣ၁ളे౟ӑ̷Ҟ̷ҹҬһ̝NT ѣᅬᄢќ૳યъҁєᅂరग़ਯѣయ‫്̟ڥ‬4:‫ݸ‬໙ႏ‫ڭ‬เҞҙӦҮӝӦң޻‫޻ݶ‬ୠେ‫̟ݶ‬ಒᅄ̟3126.17
37̠৹౎‫܀‬થ̟ం‫گ‬ใᅆ̟౹ใྗৃ̟๫̜‫ݲ‬ൊ̟ᇭใ̜๓̟਩຀ఙ઩̟‫ڔ‬຀୶ᄶ̟ྑ੟̜ଚ̟
৹ྑநბ̢ࣟ൙‫ݏڮ‬ൌ޻ྐྵ‫ۈ‬ѠпцҀҳҙӦஶૌѣ౿іѸ҈ള೧ࢲ૭̜-21໪ѣफ‫ ݦ‬-̟
്4:‫ݸ‬໙ႏ‫ڭ‬เҞҙӦҮӝӦң޻‫̟ݶ‬ಒᅄ̟3126.17
38̠৹౎‫܀‬થ̟ใဪরથ̟౹ใྗৃ̟ᇭใ̜๓̟ච݁ৃથ̟ం‫گ‬ใᅆ̢ୟઍෟঞрѾѣ‫ڲ‬ૌબ܎ҪҬҹӓѠљйћ̝౿іѸ҈ള೧ࢲ૭ѣி‫ݵ‬फᇔрѾ৤нҀ്̟2:‫ݸ‬ҳҙӦᆒ‫ڲ‬य़ࢅ‫ं̟ݶ‬ႏ̟3126.19
ƷࢄᅀકΉɿᮾ᳣Ή⾷ȿɻɥɀȮɨ⾸̜2̠൮শ̜ఊ̟஛ძ೅۸࿎̟ၿಗᅊથ̟র࿧̜క̟গୌᅡᄈ໲̟ܱ੟ୢᇚ̟ච௒̜ီ̢໙ႏ
໹ܑҙҗӞҬ߷ಠѠпцҀҬӈҖӦҧӒқӝӦѣᄃ߇്̟44‫ ݸ‬໙ႏౡ݂޻‫ݶ‬ၿᅳબ࿫‫̟ݶ‬࿐આ̟3126.16
ƷࢄᅀકΉɿᮾ᳣Ή⾷ʶⅺ᜵Ⲥ⾸̜2̠H.Yoshizaki, H.Ogiso, T.Okazaki, E.Kiyokawa : Comparative lipid analysis in the normal andcancerous organoids of MDCK cells., 21th SphingoTherapy ConferenceͅSTC̟݈͆‫̟ݱ‬3126.17
̜3̠਩຀ఙ઩̟ం‫گ‬ใᅆ̟৹̜ࡖᄵ̟৹౎‫܀‬થ̟࡫৹ᄣથ̟ସใಒᅱ̟ใඩञથ̟ࠥభ఻㸫  㸫

ျ̟‫ڔ‬຀୶ᄶ̟ඩഡ௜໲̟੉ಗ̜ഥ̢໚ઓҕҪҼ̷ҪҬѝ໹ങඩᄼஶ௢҇ཕлӒһҦӦ
Ҽӝҕ໹ࣗஶͅMELAS͆ѣ‫ݍڵ‬पѣ‫ڭ‬เҞҙӦҮӝӦң്̟46‫ݸ‬ၿᅳᆤட‫ڭ‬เय़ࢅ‫̟ݶ‬຿⋱̟3126.12
̜4̠‫ڋ‬࿫ᄣથ̟஛ಗ৏‫̟ڵ‬৹๦୲န̟౿ែॆࡍ̟௒ჿ౟௸̟൮ྑࡧᇥ̟ಬ‫܂‬৆௹̟ൌఄ॥
‫ܵॾ̟ڵ‬ୋથ̟ం‫گ‬ใᅆ̢ࡃࢸќ཈ஶьє Birt-Hogg-Dubé ஶমऍͅBHD͆ѝ༔ӝӦӄႿࠊࣗଡஶͅLAM്̟͆318‫ݸ‬໙ႏ຿‫ࡅࣞݶ޻ݏ‬ඒၒ‫̟ݶ‬ൌਗ਼̟3126.14
̜5̠ࣞ൙‫ڸ‬န̟ई಑ఃန̟‫گ‬௒ఀჺ̟ඩែᄓ‫̟ݵ‬ඩ‫̜گ‬උ̟࡫̜িิ̟ఄใืൊ̟ใඩ൦
ᇚ̟ࡻែਅఘ̟८ᄩᆖ૔̟ె̜ৃൌ̟࠯ࡶઆბ̟౹‫्گ‬࿎̢ࢍ౓ฒ৊ౖಷᅶಪࠣѠവюҀҼҮҲҠҮӞᆒၔѣᆤடษग़ກ്̟31‫ݸ‬ၿᅳಷᅶಪࠣय़ࢅ‫̟ࣟݶ‬൙̟3126.17
̜6̠౹ಗ۸ᄽ̟൳‫̜ې‬ຣ̟ఊᆸಗ೶̟ం‫گ‬ใᅆ̟෌໙̜ᅬ̟࿑ႏଷᇭ̢ા޳ௐ‫ޕ‬ѣѴ҇ฉь̝54੅ќఒඊъҁєॆಊౖড়݂ஶѣ‫ڵ‬ᆰ്̟254‫ݸ‬໙ႏఋफ޻‫ݶ‬๫‫އ‬ၿᅳඒၒ‫̟ݶ‬࿐આ̟3126.21
̜7̠ෆ̜ଷ‫̟ڵ‬ਖ਼‫گ‬එ໲̟౟రगඕ̟਩຀ඕྗ̟ඩഡ൘ᇔ̟ඩ๦஼࿎̟ࠥඎ̜ᄙ̟ઃძྗᄢ
ࡍ̟຀ใࡠ౞̟ใඩఊౡ̟࿶๦ୢᄽ̟ܱ੟ୢᇚ̟౞ძ৆ઞ̢஛ӝӦӄࢄౖӝӦӄଡѝьћ཈ஶь̝ႰౖӝӦӄౖ༭ेྐྵѠྐྵच‫ڥ‬৫ьє‫ڵ‬ᆰ്̟44‫ݸ‬໙ႏे‫ݶ޻ۼ‬ၿᅳඒၒ‫̟ݶ‬
ࣟ൙̟3126.18
ƷǬǽ͙⾷ʶⅺ᜵Ⲥ⾸̜2̠਩຀ఙ઩̟࡫৹ᄣથ̟৹̜ࡖᄵ̟ඖჿࠒନ̟ସใಒᅱ̟‫ڔ‬຀୶ᄶ̟஛ᆠзяъ̟ඩഡ௜໲̟੉ಗ̜ഥ̟౹‫ີگ‬ડ̟ᒽ౎௸‫̟ڵ‬આ੟਩ᇭથ̟ం‫گ‬ใᅆ̟‫ޤ‬யিბ̢ࡽౖ໹ஶᄼ཈
੣҇आѿါю̝஛໹૫෕҇৾တьєဧ႖ᢪౖဧຉ෬ѣ‫ڵ‬ஆૌᆰ്̟24‫ݸ‬໙ႏ஛ૌ‫ݶ޻ݏ‬౹ಗඒၒ‫̟ݶ‬຿⋱̟3126.1:

㸫  㸫

ɟɵɀȯȷɐᮾ᳣Ƀɻɇʀ
⾷༦ᨪ᫢ᮾ᳣⤴⾸ક⒈☟ᄙƷ‫⊣ڤ‬̜2̠PT.Tai, M.Nishijo, NTN.Anh, TN.Nghi, HV.Luong, TH.Anh, VT.Nguyen, H.Nishijo : Perinatal
dioxin exposure and the neurodevelopment of Vietnamese toddlers at 2 year of age, Science of the
Total Environment, 647:686-692, 3126.
̜3̠E.Simamura, T.Arikawa, T.Ikeda, H.Shimada, H.Shoji, H.Masuta, Y.Nakajima, H.Otani,
H.Yonekura, T.Hatta : Melanocortins contribute to sequential differentiation and enucleation ofhuman erythroblasts via melanocortin receptors 2, 3 and 6, PLoS One, 21:5:e1234343, 3126.
̜4̠M.Nishijo, PT.Tai, NTN.Anh, TN.Nghi, H.Nakagawa, HV.Luong, TH.Anh, Y.Morikawa, T.Waseda,
T.Kido, H.Nishijo : Urinary amino acid alterations in 4-year-old children with neurodevelopmental
effects due to perinatal dioxin exposure in Vietnam : a nested case-control study forneurobiomarker discovery, PLoS One, 21:e1227889, 3126.
̜5̠TN.Nghi, M.Nishijo, HD.Manh, PT.Tai, HV.Luong, TH.Anh, PN.Thao, NV.Trung, T.Waseda,
H.Nakagawa, T.Kido, H.Nishijo : Dioxins and nonortho PCBs in breast milk of vietnamese
mothers living in the largest hot spot of dioxin contamination, Environmental Science &Technology, 5::::6843-6853, 3126.
̜6̠M.Ishizaki, Y.Suwazono, T.Kido, M.Nishijo, R.Honda, E.Kobayashi, K.Nogawa, H.Nakagawa :Estimation of biological half-life of urinary cadmium in inhabitants after cessation ofenvironmental cadmium pollution using a mixed linear model, Food Additives and Contaminants
Part A-Chemistry Analysis Control Exposure & Risk Assessment, 43:9:2384-2387, 3126.
̜7̠S.Ueda, T.Ichiseki, Y.Yoshitomi, H.Yonekura, Y.Ueda, A.Kaneuji, T.Matsumoto : Osteocytic cell
necrosis is caused by a combination of glucocorticoid-induced Dickkopf-2 and hypoxia, Medical
Molecular Morphology, 59:3:7:-86, 3126.
̜8̠ͅK.Nogawa͆, T.Kido, M.Nishijo, H.Nakagawa, Y.Suwazono : Benchmark dose of cadmium
concentration in rice for renal effects in a cadmium-polluted area in Japan, Journal of Applied
Toxicology, 46:2:35-39, 3126.
̜9̠ͅHD.Manh͆, T.Kido, PT.Tai, R.Okamoto, S.Honma, SX.Liang, LT.Anh, S.Maruzeni, TN.Nghi,
M.Nishijo, H.Nakagawa, DD.Nhu, DV.Tung, NN.Hung, LK.Son : Levels of polychlorinateddibenzodioxins and polychlorinated dibenzofurans in breast milk samples from three dioxincontaminated hotspots of Vietnam, Science of The Total Environment, 622:527-533, 3126.
̜:̠ͅ Y.Suwazono ͆, K.Nogawa, Y.Morikawa, M.Nishijo, E.Kobayashi, T.Kido, H.Nakagawa,
K.Nogawa : Renal tubular dysfunction increases mortality in the Japanese general population
living in cadmium non-polluted areas, Journal of Exposure Science & Environmental
Epidemiology, 36:5:4::-515, 3126.
21̠ͅ Y.Suwazono ͆, K.Nogawa, Y.Morikawa, M.Nishijo, E.Kobayashi, T.Kido, H.Nakagawa,
K.Nogawa : All-cause mortality increased by environmental cadmium exposure in the Japanesegeneral population in cadmium non-polluted areas, Journal of Applied Toxicology, 46:8:928-934,
3126.
22̠஫ใৃࡶ̟๎ဪ्‫ڵ‬ᇥ̟ძ९েப̟ಗ—৆ে̢лљྐྵ̡᳞лљྐྵѠпцҀ NIRS Һ̷Ҳ㸫  㸫

ѣ૑ࣲࠗຠౖ҇ߋᅀьєࡀ‫ކ‬ษࠖအ္஄ၔѣ੣౗̟௹޻࡚၈̟51:36:-373, 3126.
23̠ఄ‫ݔ‬ᄤથ̟౧௟રથ̟ඩഡৃ઩̟᛾‫̜گ‬எ̟ේែః਽̟ඩ౧ᄢྗથ̟஛௘ᄢྗથ̟ඩಗ
ଷன̢౹ಗॢѠпцҀඒ‫ڱ‬ӌ̷ҬѣӕҾҲӝӦңѠѷѝњф‫࠲ྴޓ‬जѣ཈ౡຍষ̝2:923121̟ၿᅳ঱ି۹ౡ޻‫̟ૂݶ‬52:2:5-21, 3126.
24̠ͅ஛આ൦ჺ̟͆ᄢใਅડ̟৪‫گ‬ᄤ‫̟ݵ‬ඩഡৃ઩̟᛾‫̜گ‬எ̟౧௟રથ̟ේែః਽̟ఄ‫ݔ‬ᄤથ̟ใགྷ౞ઝ̟ඩಗଷன̢૜ᅶ৹ᆽଅѠпцҀ۰ᅋ೎๸ಆଙ௢ࢴрѾѴєห౞є҈Ѧф૲ಆଙᆙѣग़ກ̟ၿᅳ঱ି۹ౡ޻‫̟ૂݶ‬52:3:26-32, 3126.
ƷἕƷ◻
̜2̠ͅC.Chen͆, P.Xun, M.Nishijo, A.Sekikawa, K.He : Cadmium exposure and risk of pancreaticcancer : a meta-analysis of prospective cohort studies and case-control studies among individuals
without occupational exposure history, Environmental Science and Pollution Research,
33:33:28576-28585, 3126.

કΉɿᮾ᳣Ή᫘⒙Ʒ࡛⭾કΉ⾷ʶⅺ᜵Ⲥ⾸̜2̠H.Osada, Y.Yoshitomi, T.Ikeda, Y.Yoshitake, H.Yonekura, E.Kubo, H.Sasaki : Identification of
UVB responsive genes in invivo mouse lens by cDNA microarray, The 4 rd International
Conference on the Lens 3126, Kona, 3126.23
ƷӴ࡛કΉɿᮾ᳣Ή⾷ʶⅺ᜵Ⲥ⾸̜2̠ࡧච݇ѣ̟ඖใఽ໲̟ࡧ࿑৆‫̟ܢ‬ရ೙ଷఘ̢ფ੎ेࠊ຿ྂ੎ၙѣӑһӝҥӞ௒ќѣࠊ১ज౗ѠпцҀ Epac3ѣ੣ᅀ്̟99‫ݸ‬໙ႏౡ݂޻ൌ‫̟ݶ‬ఋআ̟3126.23
̜3̠ࡧ࿑৆‫̟ܢ‬ඖใఽ໲̟ࡧච݇໰̟ရ೙ଷఘ̢ఋफ͘ेࠊೱঘ੣ᅀѠѽѿेࠊ຿ྂ੎ၙќߋౖ݂ъҁҀ JunB ѣᄃ߇്̟99‫ݸ‬໙ႏౡ݂޻ൌ‫̟ݶ‬ఋআ̟3126.23

⾷ᦹऴ‫ڤ‬ම╋╏ᩰຎᮾ᳣⤴⾸ક⒈☟ᄙƷ‫ڤ‬Ʒ⊣
̜2̠M.Fukuda, H.Sasaki : The transcorneal penetration of commercial ophthalmic formulations
containing timolol maleate in rabbit eyes, Journal of Ocular Pharmacology and Therapeutics,
42:2:68-71, 3126.
̜3̠ͅH.Maeda͆, T.Takata, N.Fujii, H.Sakaue, S.Nirasawa, S.Takahashi, H.Sasaki, N.Fujii : Rapid
survey of four asp isomers in disease-related proteins by LC-MS combined with commercial
enzymes, Analytical Chemistry, 98:672-679, 3126.
̜4̠M.Kojima, Y.Suzuki, CY.Tsai, K.Sasaki, K.Wake, S.Watanabe, M.Taki, Y.Kamimura, A.Hirata,
K.Sasaki, H.Sasaki : Characteristics of ocular temperature elevations after exposure to quasi- andmillimeter wavesͅ29-51 GHz͆, Journal of Infrared Millimeter and Terahertz Waves, 47:5:4:1-

㸫  㸫

4::, 3126.
̜5̠ͅ‫ܚ‬ใીჿ̟͆୸ਖ਼ຽ෦થ̟ਖ਼ႏဲ࿎̟ઃใฮൌ̟৹ࢳ̜࿨̟ේใѧ҂Ѵ̟ࡶဲ৕ᅬ̟
਩̴ძᄽ̢༭຿ௐѣਣ൞ྐྵचрѾѣࢷ౞ાᆜпѽѨҦӦһӜҬһાᆜᄬ഑̟໙ႏ༭຿ௐ
޻‫̟ૂݶ‬38:79-84, 3126.
̜6̠ͅ K.Sasaki ͆, Y.Isimura, K.Fujii, K.Wake, S.Watanabe, M.Kojima, R.Suga, O.Hashimoto :Dielectric property measurement of ocular tissues up to 221 GHz using 2 mm coaxial sensor,
Physics in Medicine and Biology, 71:7384-7399, 3126.
̜7̠M.Fukuda, H.Sasaki : Effects of fluoroquinolone-based antibacterial ophthalmic solutions on
corneal wound healing, Journal of Ocular Pharmacology and Therapeutics, 42:::647-651, 3126.
̜8̠Y.Takahashi, T.Kawamorita, N.Mita, N.Hatsusaka, S.Shibata, N.Shbata, E.Kubo, H.Sasaki :Optical simulation for subsurface nanoglistening, Journal of Cataract and Refractive Surgery,
52:2:4-2:9, 3126.
ƷἕƷ◻
̜2̠ͅK.Minami͆, K.Miyata, N.Nagai, H.Sasaki : Use of a warmed ophthalmic viscoelastic device toaccelerate the unfolding of 2-piece intraocular lenses in the capsular bag, Correspondence,
52:3443-3444, 3126.
̜3̠਩̴ძᄽ̢ၑ૾ಧௐ‫ޕ‬ѣྐྵᅬ̜ၑ૾ಧѠѽҀ੎ၙળ̜༭຿ௐ̟ྐྵᅬѝᆤட̟44:2:55-5:,
3126.
̜4̠਩̴ძᄽ̢തழ฿ࠤ຿ӟӦҭҕҶӊҺ̷һ̟໙ႏࠤ‫̟ૂ੻ݶ޻ݏ‬22::2:4-6, 3126.

કΉɿᮾ᳣Ή᫘⒙Ʒ࡛⭾કΉ⾷ʶⅺ᜵Ⲥ⾸̜2̠H.Sasaki : Standardized classifications and severity scales of cataract, Asia Arvo, Yokohama,
3126.13
̜3̠ͅY.Suzuki͆, M.Sasaki, S.Onishi, R.Imai, M.Takamura, M.Taki, J.Chakarothai, K.Sasaki, K.Wake,
S.Watanabe, M.Kojima, C-Y.Tsai, H.Sasaki : Acceleration of large-scale multi-physics simulation
for biomedical EMC with many-core architecture based computing, URSI AT-RASC, Canary
Istands, 3126.16
̜4̠H.Sasaki, E.Shibuya, M.Takahashi, A.Okamoto, N.Mita, N.Hatsusaka, S.Shibata, T.Shibata,
K.Sasaki, E.Kubo : Effect of forward light scattering on visual function ineyes with cortical
cataract, Association for Research inVision and Ophthalology, Denver, 3126.16
̜5̠T.Shibata, S.Shibata, N.Shibata, E.Kiyokawa, H.Sasaki, DP.Singh, E.Kubo : FGF-3 regression of
the tropomyosin expression through MAPK/ERK kinase pathway in lens epithelial cells,
Association for Research inVision and Ophthalology, Denver, 3126.16
̜6̠E.Kubo, S.Shibata, N.Shibata, T.Shibata, E.Kiyokawa, H.Sasaki, DP.Singh : Gene expression
SUR¿OLQJRIOHQVHSLWKHOLDOFHOOVLQDUDWSRVWHULRUFDSVXODURSDFLW\PRGHOLQYLYR$VVRFLDWLRQIRU
Research inVision and Ophthalology, Denver, 3126.16
̜7̠Y.Seki, T.Shibata, Y.Yabata, M.Sasaki, H.Osada, T.Saruta, H.Asano, E.Kubo, A.Sanyiwa, H.Sasaki :Prevalence of pinguecula in children living in rural Tanazania, Association for Research inVision㸫  㸫

and Ophthalology, Denver, 3126.16
̜8̠H.Sasaki, E.Shibuya, M.Takahashi, N.Shibata, Y.Takahashi, S.Shibata, T.Shibata, N.Mita, E.Kubo :Effect of forward light scattering on visual function in eyes with retrodots, XXXIII Congress of
the RSCRS, Barcelona, 3126.1:
̜9̠ͅY.Suzuki͆, M.Kojima, A.KIK, M.Taki : Non-destructive 4D temperature measurement for
dosimetries of the thermal dose due to high frequency electromagnetic field exposure withmicroencapsulated thermo-chromic liquid crystal, First PEM International Workshop in Kyoto,
Kyoto, 3126.22
̜:̠E.Kubo, S.Shibata, N.Shibata, T.Shibata, E.Kiyokawa, H.Sasaki, DP.Singh : Gene expressin
profiling of lens epithelial cells in posterior capsular opacity and the role of decorin, The 4rd
International Conference on the Lens 3126, Kona, 3126.23
21̠N.Mita, M.Sasaki, Y.Takahashi, Y.Seki, A.Okamoto, T.Shibata, S.Shibata, R.Kubo, H.Sasaki :Higher-order aberrations in Japanese eyes with cataract and eyes with aspherical intraocularlenses, The 4rd International Conference on the Lens 3126, Kona, 3126.23
22̠S.Shibata, N.Shibata, T.Shibata, N.Tanimura, H.Sasaki, E.Kubo : Human age related cataract anddecorin: correlations among opacity severity, age and decorin expression, The 4rd International
Conference on the Lens 3126, Kona, 3126.23
23̠H.Osada, Y.Yoshitomi, T.Ikeda, Y.Yoshitake, H.Yonekura, E.Kubo, H.Sasaki : Identification of
UVB responsive genes in invivo mouse lens by cDNA microarray, The 4 rd International
Conference on the Lens 3126, Kona, 3126.23
24̠E.Shibuya, N.Mita, N.Hatsusaka, S.Shibata, N.Shibata, T.Shibata, E.Kubo, H.Sasaki : Infuence on
visual function by high-order aberration, forward and backward light scattering in eyes with
nuclear opacity, The 4rd International Conference on the Lens 3126, Kona, 3126.2
25̠N.Hatsusaka, H.Osada, E.Shibuya, A.Okamoto, M.Sasaki, M.Takahashi, A.Nakano, Y.Seki,
E.Kubo, H.Sasaki/HQWLFXODU¿QGLQJVLQHPHUJHQF\ZRUNHUVDW7RN\R(OHFWULF3RZHU)XNXVKLPD
Nuclear Power Plant ats post-exposure 5 year post-exposure, The 4rd International Conference on
the Lens 3126, Kona, 3126.23
26̠H.Sasaki, H.Asano, T.Hiraoka, H.Osada, T.Shibata, M.Sasaki, Y.Seki, T.Saruta, F.Fujikake,
Y.Tabata, T.Oshika, A.A.Sanyiwa : Mopia and related factors in Tanzanian adults, The 4rd
International Conference on the Lens 3126, Kona, 3126.23
27̠T.Shibata, S.Shibata, H.Sasaki, DP.Singh, E.Kiyokawa, M.Ikawa, E.Kubo : Suppression of injuryinduced epithelial-mesenchymal transition in tropomyosin 3 mutant mouse lenses created by
CRISPR-CAS:, The 4rd International Conference on the Lens 3126, Kona, 3126.23
ƷӴ࡛કΉɿᮾ᳣Ή⾷ȿɻɥɀȮɨ⾸̜2̠਩̴ძᄽ̢༭຿ௐࠤѝࠤ຿ӟӦҭ೥໛ࠤѣાࡀ໸്̟62‫ݸ‬໙ႏࠤর޻޻‫ݶ‬೴‫ܱ̟ݶ‬આ̟
3126.1:ƷӴ࡛કΉɿᮾ᳣Ή⾷ʶⅺ᜵Ⲥ⾸̜2̠਩̴ძᄽ̢ୠಷ੎⊴๳୹।ѣఒၒѝ༭຿ௐခᆭ്̟49‫ݸ‬໙ႏࠤ‫ݏ‬ଛୠ޻‫޻ݶ‬ୠ೴‫̟࢝ݶ‬
๓̟3126.12

㸫  㸫

̜3̠൮ഡෟࡉ̟༦९्ഥ̟૷ใ௸ᆉ̟ࡻ݁ࡶཨ̟౞ძ৆ઞ̟਌౎̜ၱ̟਩̴ძᄽ̟ၿಗᇭ
થ̢ҼӜҗҕҗѣഄ‫҇ٶ‬཈཈ஶ௢Ѡ໢Ѷє IgG5࠙ᇍ૱߶ѣ2ᆰ്̟9‫ ݸ‬IgG5य़ࢅ‫̟ݶ‬࿶ܱ̟3126.14
̜4̠୑൮ञᅬ̟৹ࢳ̜࿨̟਩̴ძ႖‫૷̟ڪ‬ใຽ‫ܢ‬થ̟৹ࢳ‫ږ‬થ̟૷ใ௸ᆉ̟ઃใฮൌ̟ࡶဲ
৕ᅬ̟਩̴ძᄽ̢ Retrodots ൴ລਣ൞ࠤѣಷၒઉᅟѝાࡀ໸്̟22:‫ݸ‬໙ႏࠤ‫ݶ޻ݏ‬೴‫੸̟ݶ‬ႍ̟3126.15
̜5̠૷ใฮန̟ใགྷ‫ݱ‬஼̟਩̴ძ႖‫̜̟࠙ڪ‬ᄤ‫̟ݵ‬ේใѧ҂Ѵ̟૷ใຽ‫ܢ‬થ̟‫ܕ‬ใࡍࡉ̟຀
߀࿶ྗ̟ಞჿিࡋ̟ࡶဲ৕ᅬ̟਩̴ძᄽ̢ҲӦҩҾҕѣ໻ഡ࿫੔୊ѣଔ໪ଅѠпцҀᤀᇃཛྷᄜྐྵᅵ്̟22:‫ݸ‬໙ႏࠤ‫ݶ޻ݏ‬೴‫੸̟ݶ‬ႍ̟3126.15
̜6̠૷ใ௸ᆉ̟૷ใຽ‫ܢ‬થ̟૷ใฮန̟౟ಗ‫܀‬થ̟਩̴ძᄽ̟ࡶဲ৕ᅬ̢ӜҶһঞ໴ਣ൞ѠпцҀ‫ڭ‬เથ཈ॶѣყᅔษ‫ݷ‬౸ѝ decorinno ѣరபളѠпцҀᄃ߇്̟22:‫ݸ‬໙ႏࠤ‫޻ݏ‬‫ݶ‬೴‫੸̟ݶ‬ႍ̟3126.15
̜7̠࿶ใ౞ຘ̟ᄜႏ̜୮̟༦९्ഥ̟̜࠙ᄤ‫૷̟ݵ‬ใຽ‫ܢ‬થ̟૷ใ௸ᆉ̟ࡶဲ৕ᅬ̟਩̴ძ
ᄽ̢ӟӃӒӇҼ฿ࠤ‫ۼ‬ѠѽҀ޴႟௒ྂೖ஌૔ᄏ঳‫്̟ݑ‬22:‫ݸ‬໙ႏࠤ‫ݶ޻ݏ‬೴‫੸̟ݶ‬ႍ̟
3126.15̜8̠ઃใฮൌ̟਩̴ძ႖‫̟ڪ‬৹ࢳ̜࿨̟ܱႏ‫چ‬થ̟̜࠙ᄤ‫̟ݵ‬৹ࢳ‫ږ‬થ̟ࡶဲ৕ᅬ̟਩̴ძ
ᄽ̢র޻ҪӒӘӟ̷ҪӚӦѠѽҀࠤ຿ӟӦҭ೥໛ࠤѠпцҀᅟાѝດঽझсાᆜѠࡹѱюۭࢾ്̟22:‫ݸ‬໙ႏࠤ‫ݶ޻ݏ‬೴‫੸̟ݶ‬ႍ̟3126.15
̜9̠୸ਖ਼ຽ෦થ̟ේใѧ҂Ѵ̟୑൮ञᅬ̟ܱႏ‫چ‬થ̟਩̴ძ႖‫̟ڪ‬৹ࢳ̜࿨̟ඩჿ̜ੁ̟࠙
ᄤ‫ဲࡶ̟ݵ‬৕ᅬ̟਩̴ძᄽ̢๫࢝ไᆜ࿶๦്‫ڵ‬९થᆜ཈ไ୹ѠпцҀࣘࡽ੣ࣅ୍ૉଅѣྈѥфঞᄄ4໪ќѣరபള୹।്̟22:‫ݸ‬໙ႏࠤ‫ݶ޻ݏ‬೴‫੸̟ݶ‬ႍ̟3126.15
̜:̠৹ࢳ̜࿨̟୑൮ञᅬ̟୸ਖ਼ຽ෦થ̟ઃใฮൌ̟ේใѧ҂Ѵ̟૷ใฮန̟৹ࢳ‫ږ‬થ̟૷ใຽ‫ܢ‬થ̟૷ใ௸ᆉ̟ࡶဲ৕ᅬ̟਩̴ძᄽ̢༭຿ௐࠤѣાࡀ໸ѝ໪ᆽ്̟22:‫ݸ‬໙ႏࠤ‫޻ݏ‬‫ݶ‬೴‫੸̟ݶ‬ႍ̟3126.15
21̠૷ใຽ‫ܢ‬થ̟૷ใ௸ᆉ̟৹ࢳ‫ږ‬થ̟૷ใฮန̟਩̴ძᄽ̟ࡶဲ৕ᅬ̢ᅒ௢ဧ೏௰ѠпцҀ‫ڭ‬เથ཈ॶဦ݂ѣ‫ݷ‬౸ѝᅒ௢ဧ཈ஶࡀ৔ѣ‫ݷ‬ბ്̟22:‫ݸ‬໙ႏࠤ‫ݶ޻ݏ‬೴‫੸̟ݶ‬ႍ̟
3126.1522̠ܱႏ‫چ‬થ̟৹ࢳ̜࿨̟୑൮ञᅬ̟ඩჿ̜ੁ̟৹ࢳ‫ږ‬થ̟૷ใ௸ᆉ̟૷ใຽ‫ܢ‬થ̟ࡶဲ৕
ᅬ̟਩̴ძᄽ̢തழ฿ࠤ຿ӟӦҭѝതழ฿һ̷ӝҶҢࠤ຿ӟӦҭѣાࡀ໸ཿ޶്̟41‫ݸ‬
JSCRS ޻ୠ೴‫̟ݶ‬๫̟࢝3126.17
23̠ઃใฮൌ̟਩̴ძ႖‫̟ڪ‬৹ࢳ‫ږ‬થ̟̜࠙ᄤ‫ܱ̟ݵ‬ႏ‫چ‬થ̟૷ใฮန̟૷ใ௸ᆉ̟ࡶဲ৕
ᅬ̟਩̴ძᄽ̢ᅟાѝດঽझс൴ழ฿ࠤ຿ӟӦҭ೥໛ࠤѣᅖࠤბા‫ڱ‬ѠᄮнҀۭࢾ്̟41‫ ݸ‬JSCRS ޻ୠ೴‫̟ݶ‬๫̟࢝3126.17
24̠ឲ൮৕ᅬ̟‫ܚ‬ใીჿ̟৹ࢳ̜࿨̟ܱႏ‫چ‬થ̟ඩჿ̜ੁ̟਩̴ძ႖‫̟ڪ‬৹ࢳ‫ږ‬થ̟ࡶဲ৕
ᅬ̟਩̴ძᄽ̢ᆋࠤҕӐҳҗҭ‫ݸ‬౸चതழ฿ӟӦҭ೥໛ࠤќ।Ѿҁє࿋Ⴑᆰѣग़ກ്̟41‫ ݸ‬JSCRS ޻ୠ೴‫̟ݶ‬๫̟࢝3126.17
25̠૷ใฮန̟৹ࢳ‫ږ‬થ̟ܱႏ‫چ‬થ̟਩̴ძᄽ̟ၿಗᇭથ̢ၯరѽѿҙҗӞҬ RNA ҇ग़ୟќтєऻஶचӓӦӊҬ޴႟ܑ౗ఘᆰ്̟63‫ݸ‬໙ႏ߷ಠஶ޻‫̟ݶ‬ൌਗ਼̟3126.18
26̠਩̴ძᄽ̢3ଠᆭѣࠤ຿ӟӦҭѣ࢖ᅲအાᆜҪӒӘӟ̷ҪӚӦ്̟65‫ݸ‬໙ႏ༭຿ௐ޻‫ݶ‬೴‫്̡ݶ‬52‫ݸ‬రபളय़ࢅ‫̟ݶ‬๫̟࢝3126.1:
27̠ၿ̜࿨̟ܱႏ‫چ‬થ̟ඩჿ̜ੁ̟਩̴ძ႖‫૷̟ڪ‬ใຽ‫ܢ‬થ̟৹ࢳ‫ږ‬થ̟૷ใฮန̟૷ใ௸
ᆉ̟ࡶဲ৕ᅬ̟਩̴ძᄽ̢4ଠѣྌࢄოࠤ຿ӟӦҭѣાࡀ໸്̟65‫ݸ‬໙ႏ༭຿ௐ޻‫ݶ‬೴㸫  㸫

‫്̡ݶ‬52‫ݸ‬రபളय़ࢅ‫̟ݶ‬๫̟࢝3126.1:
28̠૷ใฮန̟૷ใ௸ᆉ̟૷ใຽ‫ܢ‬થ ̟ ౟ ಗ ‫ ܀‬થ ̟ ‫ ڔ‬ಗ ౞ ఘ ̟ ਩ ̴ ძ ᄽ ̟ ࡶ ဲ ৕ ᅬ ̢
CRISPR-Cas:ҪҬҹӓ҇ᅀйє Tpm3ӁҶҢҕҙһӑҙҬѠѽҀঞ཈༭຿ௐय़ࢅ്̟65‫ݸ‬໙ႏ༭຿ௐ޻‫ݶ‬೴‫്̡ݶ‬52‫ݸ‬రபളय़ࢅ‫̟ݶ‬๫̟࢝3126.1:
29̠࿶ใ౞ຘ̟̜࠙ᄤ‫̟ݵ‬༦९्ഥ̟൮ഡෟࡉ̟ࡻ݁ࡶཨ̟૷ใฮန̟૷ใຽ‫ܢ‬થ̟૷ใ௸
ᆉ̟ࡶဲ৕ᅬ̟਩̴ძᄽ̢N ͘ҕҮҴӞҪҬҹҗӦѠѽҀҙҨҡࠤ޴႟௒ྂௐ‫୹ޕ‬।ѣग़ກ്̟46‫ݸ‬໙ႏࠤ뢰޻‫̟ݶ‬๫̟࢝3126.1:
2:̠਩̴ძᄽ̢Retrodots ѝ Water clefts ѣાࡀ໸ѝଛୠห‫്̟ܥ‬65‫ݸ‬໙ႏ༭຿ௐ޻‫ݶ‬೴‫്̡ݶ‬52‫ݸ‬రபളय़ࢅ‫̟ݶ‬๫̟࢝3126.1:
31̠ͅේ‫ࡉگ‬஼̟͆ఊჿ̜ᄤ̟஛൮ৃൊ̟‫ڔ‬຀ࡧᑑ̟૷ใฮန̟ࡶဲ৕ᅬ̟਩̴ძᄽ̢Ӆһ༭຿ௐ߶ଅѠпцҀరபളਣ൞ӄҲ̷ӦѝҕӒӠҗҼԓජ౺ѣ࠙ओ്̟65‫ݸ‬໙ႏ༭຿ௐ޻
‫ݶ‬೴‫്̡ݶ‬52‫ݸ‬రபളय़ࢅ‫̟ݶ‬๫̟࢝3126.1:
32̠૷ใ௸ᆉ̟૷ใຽ‫ܢ‬થ̟૷ใฮန̟൮ഡෟࡉ̟਩̴ძᄽ̟ࡶဲ৕ᅬ̢ӊӠҹҝңӝҞӦ
decorin ѣӅһరபള௒ྂ੎ၙѠпцҀ཈ॶ്̟65‫ݸ‬໙ႏ༭຿ௐ޻‫ݶ‬೴‫്̡ݶ‬52‫ݸ‬రபളय़ࢅ‫̟ݶ‬๫̟࢝3126.1:
33̠୑൮ञᅬ̟ઃใฮൌ̟ၿ̜࿨̟̜࠙ᄤ‫୸̟ݵ‬ਖ਼ຽ෦થ̟૷ใ௸ᆉ̟૷ใຽ‫ܢ‬થ̟૷ใฮ
န̟ࡶဲ৕ᅬ̟਩̴ძᄽ̢৹૒ମਮ̡ಷၒઉᅟ̡ঞၒઉᅟѠѽҀޮ൴ລਣ൞ࠤѣાࡀ໸ѭѣۭࢾ്̟65‫ݸ‬໙ႏ༭຿ௐ޻‫ݶ‬೴‫്̡ݶ‬52‫ݸ‬రபളय़ࢅ‫̟ݶ‬๫̟࢝3126.1:
34̠୸ਖ਼ຽ෦થ̟ේใѧ҂Ѵ̟୑൮ञᅬ̟ܱႏ‫چ‬થ̟਩̴ძ႖‫̟ڪ‬৹ࢳ̜࿨̟ඩჿ̜ੁ̟࠙
ᄤ‫ဲࡶ̟ݵ‬৕ᅬ̟਩̴ძᄽ̢๫࢝ไᆜ࿶๦്‫ڵ‬९થᆜ཈ไ୹ѠпцҀࣘࡽ੣ࣅ୍ૉଅѣྈѥфঞᄄ5໪ќѣరபള୹।്̟65‫ݸ‬໙ႏ༭຿ௐ޻‫ݶ‬೴‫്̡ݶ‬52‫ݸ‬రபളय़ࢅ‫̟ݶ‬๫̟࢝3126.1:
35̠ઃใฮൌ̟਩̴ძ႖‫̟ڪ‬৹ࢳ‫ږ‬થ̟̜࠙ᄤ‫ܱ̟ݵ‬ႏ‫چ‬થ̟૷ใฮန̟૷ใ௸ᆉ̟ࡶဲ৕
ᅬ̟਩̴ძᄽ̢໙ႏఘඩ৹ᆽଅѣࠤࢄज௢്̟62‫ݸ‬໙ႏࠤর޻޻‫ݶ‬೴‫ܱ̟ݶ‬આ̟3126.1:
36̠ઃใฮൌ̟਩̴ძ႖‫̟ڪ‬৹ࢳ‫ږ‬થ̟ၿ̜࿨̟̜࠙ᄣ‫ܱ̟ݵ‬ႏ‫چ‬થ̟૷ใฮန̟૷ใ௸
ᆉ̟ࡶဲ৕ᅬ̟਩̴ძᄽ̢໙ႏఘඩ৹ᆽଅѣಷࠤ࿫ज௢ѣຠ෈്̟65‫ݸ‬໙ႏ༭຿ௐ޻‫ݶ‬೴‫്̡ݶ‬52‫ݸ‬రபളय़ࢅ‫̟ݶ‬๫̟࢝3126.1:
37̠ඩჿ̜ੁ̟ၿ̜࿨̟ઃใฮൌ̟ܱႏ‫چ‬થ̟਩̴ძ႖‫૷̟ڪ‬ใ௸ᆉ̟৹ࢳ‫ږ‬થ̟૷ใฮ
န̟ࡶဲ৕ᅬ̟਩̴ძᄽ̢༭຿ௐୠಷঞѣ૳ດঽझ്̟65‫ݸ‬໙ႏ༭຿ௐ޻‫ݶ‬೴‫്̡ݶ‬52‫ݸ‬రபളय़ࢅ‫̟ݶ‬๫̟࢝3126.1:
38̠࿶ใ౞ຘ̟ᄜႏ̜୮̟༦९्ഥ̟̜࠙ᄤ‫૷̟ݵ‬ใຽ‫ܢ‬થ̟૷ใ௸ᆉ̟ࡶဲ৕ᅬ̟਩̴ძ
ᄽ̢ҙҨҡࠤ޴႟௒ྂௐ‫ޕ‬ӕҺӞѠവюҀӟӃӒӇҼ฿ࠤ‫ۼ‬ѣ૔ᄏഊక঳‫്̟ݑ‬7:‫ݸ‬໙ႏᆤடࠤ‫̟ݶ޻ݏ‬჏ॾ̟ܵ3126.21
39̠ܱႏ‫چ‬થ̟ၿ̜࿨̟਩̴ძ႖‫̜̟࠙ڪ‬ᄤ‫̟ݵ‬ඩჿ̜ੁ̟৹ࢳ‫ږ‬થ̟૷ใຽ‫ܢ‬થ̟ࡶဲ৕
ᅬ̟਩̴ძᄽ̢һ̷ӞҶҢࠤ຿ӟӦҭࠤѣୠಷঞಷၯఇ๘ѝᅟાࢷ౞঳‫്̟ݑ‬7:‫ݸ‬໙ႏᆤடࠤ‫̟ݶ޻ݏ‬჏ॾ̟ܵ3126.21
3:̠ઃใฮൌ̟਩̴ძ႖‫̟ڪ‬৹ࢳ‫ږ‬થ̟̜࠙ᄤ‫ܱ̟ݵ‬ႏ‫چ‬થ̟૷ใฮန̟૷ใ௸ᆉ̟ࡶဲ৕
ᅬ̟਩̴ძᄽ्̢௜໙ႏఘඩ৹ᆽଅѣ৹૒ମਮ്̟7:‫ݸ‬໙ႏᆤடࠤ‫̟ݶ޻ݏ‬჏ॾ̟ܵ
3126.2141̠୸ਖ਼ຽ෦થ̟຀ใ௹໲̟૷ใฮန̟ේใѧ҂Ѵ̟̜࠙ᄤ‫̟ݵ‬਩̴ძ‫ڵ‬໲̟ࡶဲ৕ᅬ̟
਩̴ძᄽ̢౗ఘѝ஛ૌӑӀҠӦच UV ल഑ҪҬҹӓѠпцҀࠤ࿫઺‫ޓ‬ಧྈѥфѣཿ޶̟
്7:‫ݸ‬໙ႏᆤடࠤ‫̟ݶ޻ݏ‬჏ॾ̟ܵ3126.21

㸫  㸫

42̠૷ใ௸ᆉ̟૷ใฮန̟‫ܕ‬ใࡍࡉ̟਩̴ძ႖‫̟ڪ‬ේใѧ҂Ѵ̟̜࠙ᄤ‫̟ݵ‬຀߀࿶ྗ̟ใགྷ
‫ݱ‬஼̟ಞჿিࡋ̟਩̴ძᄽ̢໙ႏఘ̝ോᇼఘ̝ҲӦҩҾҕఘඩ৹৒ౡѣાᆜѝࠤ૥ේ̟
്7:‫ݸ‬໙ႏᆤடࠤ‫̟ݶ޻ݏ‬჏ॾ̟ܵ3126.21
43̠୑൮ञᅬ̟ၿ̜࿨̟਩̴ძ႖‫ܱ̟ڪ‬ႏ‫چ‬થ̟ඩჿ̜ੁ̟̜࠙ᄤ‫̟ݵ‬ઃใฮൌ̟৹ࢳ‫ږ‬થ̟ࡶဲ৕ᅬ̟਩̴ძᄽ̢༭຿ௐ൴ລਣ൞ࠤѠпцҀಷၒઉᅟѣཿ޶്̟7:‫ݸ‬໙ႏᆤடࠤ‫̟ݶ޻ݏ‬჏ॾ̟ܵ3126.21
ƷࢄᅀકΉɿᮾ᳣Ή⾷ʶⅺ᜵Ⲥ⾸̜2̠ͅᆸძतࡶ̟͆ത᜵நౡ̟஛๦౞ྗ̢߷ܾ‫ۼ‬பӑҗҢӠҞӊҮӞ҇ᅀйє৹ଯ༃ไ૘‫މ‬ѥфᇕྵ݆̟র‫ܥ‬ᅀไ૘‫މ‬ल഑ͅ PEM ͆૑ॻय़ࢅಕჸ‫്̜ݶۀښ‬4‫ݸ‬य़ࢅ‫̟ݶ‬ພ๦̟
3126.13̜3̠࿶ใ౞ຘ̟ᄜႏ̜୮̟༦९्ഥ̟̜࠙ᄤ‫૷̟ݵ‬ใຽ‫ܢ‬થ̟૷ใ௸ᆉ̟ࡶဲ৕ᅬ̟਩̴ძ
ᄽ̢ӟӃӒӇҼ฿ࠤ‫ۼ‬ѣ޴႟௒ྂೖ஌૔ᄏ঳‫്̟ݑ‬446‫ࣟݸ‬൙ࠤ‫ݏ‬େඏ‫̟ࣟݶ‬൙̟
3126.15̜4̠୑൮ञᅬ̟ၿ̜࿨̟ܱႏ‫چ‬થ̟ඩჿ̜ੁ̟਩̴ძ႖‫̟ڪ‬৹ࢳ‫ږ‬થ̟૷ใຽ‫ܢ‬થ̟຀ใ௹
໲̟ࡶဲ৕ᅬ̟਩̴ძᄽ̢һ̷ӝҶҢ൴ழ฿ࠤ຿ӟӦҭ҇೥໛ьୠঞ೨࠽Ѡ૥‫ݸ‬ય҇ࡎшьє3ᆰ്̟72‫ݸ‬࿶‫ݏࠤॢگ‬େඏ‫̟ݶ‬࿶‫̟گ‬3126.1:
̜5̠̜࠙ᄣ‫̟ݵ‬ઃใฮൌ̟ၿ̜࿨̟ܱႏ‫چ‬થ̟਩̴ძ႖‫ࡶ݁ࡻ̟ڪ‬ཨ̟ࡶဲ৕ᅬ̟਩̴ძ
ᄽ̢3ଠᆭѣࠤ຿ӟӦҭѣ࢖ᅲအાᆜҪӒӘӟ̷ҪӚӦ്̟84‫ݸ‬࿐આେඏ‫̟ݶ‬࿐આ̟
3126.1:̜6̠୸ਖ਼ຽ෦થ̟ේใѧ҂Ѵ̟਩̴ძ႖‫̟ڪ‬ઃใฮൌ̟୑൮ञᅬ̟̜࠙ᄤ‫̟ݵ‬ၿ̜࿨̟ඩჿ
ੁ̟਩̴ძ‫ڵ‬໲̟਩̴ძᄽ̢ంьйࠋᘛचฯவҞӔӜѠѽҀਣ൞రபളѣྵ്݆̟447‫ݸ‬ࣟ൙ࠤ‫ݏ‬େඏ‫̟ࣟݶ‬൙̟3126.23
ƷǬǽ͙⾷ʶⅺ᜵Ⲥ⾸̜2̠൮ഡෟࡉ̟༦९्ഥ̟૷ใ௸ᆉ̟ࡻ݁ࡶཨ̟౞ძ৆ઞ̟਌౎̜ၱ̟਩̴ძᄽ̟ၿಗᇭ
થ̢ҼӜҗҕҗഄ‫҇ٶ‬छࡀѠఒඊъҁє IgG5࠙ᇍ૱߶ѣ‫ڵ‬ᆰ്̟46‫ࣟݸ‬൙‫ݏڮ‬ൌ޻ࠤ‫ݏ‬य़ࢅ‫̟ࣟݶ‬൙̟3126.22
̜3̠୸ਖ਼ຽ෦થ̟຀ใ௹໲̟૷ใฮန̟ේใѧ҂Ѵ̟̜࠙ᄤ‫̟ݵ‬਩̴ძ‫ڵ‬໲̟ࡶဲ৕ᅬ̟
਩̴ძᄽ̢ӑӀҠӦच UV ल഑೼඙҇ᅀйєࠤ࿫ UV ྈѥфᆙѣ౗ఘѝ஛ૌѣཿ޶̸མ૾
ࠅࢪѣ‫ڬ‬йѠѽҀ UV വ੫ҕҗҹӓѣ঳‫̸്̟ݑ‬46‫ࣟݸ‬൙‫ݏڮ‬ൌ޻ࠤ‫ݏ‬य़ࢅ‫̟ࣟݶ‬൙̟
3126.22̜4̠୑൮ञᅬ̟਩̴ძ႖‫̟ڪ‬ઃใฮൌ̟ܱႏ‫چ‬થ̟ඩჿ̜ੁ̟ၿ̜࿨̟૷ใຽ‫ܢ‬થ̟৹ࢳ‫ږ‬થ̟ࡶဲ৕ᅬ̟਩̴ძᄽ̢ӢӦӇ̷Ҭࠤ຿ӟӦҭѣબૐ࿫ѝঞ໴ѣь҄ѣ࠙ओ്̟46‫ݸ‬ࣟ൙‫ݏڮ‬ൌ޻ࠤ‫ݏ‬य़ࢅ‫̟ࣟݶ‬൙̟3126.22
̜5̠ࡻ݁ࡶཨ̟૷ใຽ‫ܢ‬થ̟୑൮ञᅬ̟ܱႏ‫چ‬થ̟৹ࢳ‫ږ‬થ̟૷ใฮန̟૷ใ௸ᆉ̟ࡶဲ৕
ᅬ̟਩̴ძᄽ̢ࠤ຿ӟӦҭ‫ގ‬ၑ૑ࠗѠവюҀଛୠࠅࢪܾ๘ѣۭࢾ്̟46‫ࣟݸ‬൙‫ݏڮ‬ൌ޻ࠤ‫ݏ‬य़ࢅ‫̟ࣟݶ‬൙̟3126.22
̜6̠ඩჿ̜ੁ̟ၿ̜࿨̟ઃใฮൌ̟ܱႏ‫چ‬થ̟਩̴ძ႖‫૷̟ڪ‬ใ௸ᆉ̟৹ࢳ‫ږ‬થ̟૷ใฮ
န̟ࡶဲ৕ᅬ̟਩̴ძᄽ̢༭຿ௐୠಷୠঞѣດঽझ്̟46‫ࣟݸ‬൙‫ݏڮ‬ൌ޻ࠤ‫ݏ‬य़ࢅ‫̟ݶ‬
ࣟ൙̟3126.22

㸫  㸫

⾷Ӟ֝ո੿Ⳓᄦᲇકᮾ᳣⤴⾸⊣Ʒሤ̜2̠‫ܨ‬આ̜ఙ̟ॾ‫ݍ‬ൌᄣ̟ണ57჏̢ఠௐ‫ޕ‬కืᄬၼѝఠൊഽᆒၔѭѣ‫ڥ‬৫ CKD Ҭҹ̷ҫ G4b
̼6ఒᆒҟҗҼӜҗӦ̜3126̟2-258̟๫࢝‫޻ڮ‬ଃ̟๫̟࢝3126.
̜3̠ၿใରে̟ॾ‫ݍ‬ൌᄣ̢‫̠ء‬Clinical nephrology̜B̠ໝ੎ࠊ̡ࠗ૲ௐ‫̜ޕ‬3̠ఠ૱߶ѝ Sirt2̸ໝ੎ࠊ૲ྐྵဦѠпцҀᄃ߇̸̟Annual Review ఠആ 3126ͅ࿑ჿ৆໙ঃ̟༫९ෟପ̟౗
ใ‫ڵ‬۹ဩେ̟͆248-253̟ඩ‫޻ڮޓ‬ଃ̟๫̟࢝3126.
̜4̠ࣟ—गഉ̢:̠ఠ૱߶̜๻ໝྐྵౖఠஶ̟ਘ໙ѣ૔ᆒફఖ 3126໪འͅVolume 68͆ͅ࿶‫گ‬૒ᄁ̟৹ძ̜౨̟஛૭‫ڵ‬౗೴ဩେ̟͆6:5-6::̟‫̟ۈ஀޻ڮ‬๫̟࢝3126.
̜5̠ၿใରে̟ॾ‫ݍ‬ൌᄣ̢6஼ ৾တஶѣ౗‫ྐྵ̡ہ‬഻̡૔ᆒ̜9. ๻ໝྐྵఠஶѣ૔ᆒ̟๻ໝྐྵ޻
ͅჸᇱ̜া̟৪ძ۰‫ޣڹ̟ڵ‬෋ჺ̟௭ძৗ໐ᇥ̟‫ې‬ใஎल̟მใᄤাဩେ̟͆582-589̟౧
ഡ஀ุ̟๫̟࢝3126.
̜6̠ॾ‫ݍ‬ൌᄣ̢ҮӒҽ̷‫ ؠ‬๻ໝྐྵѣఒඊѝྐྵ௢໿‫ٷ‬ѣక့̜཈ॹ4 ๻ໝྐྵౖఠஶѣఒඊѝྐྵ௢໿‫̟ٷ‬๻ໝྐྵ UP ¦ DATE ०๦ҮӒҽ̷42 ఒඊрѾ૔ᆒѭѣҪ̷ӓӟҬџӈҜӠ̷̡ҕҶӊ̸ఒඊѝྐྵ௢໿‫ٷ‬ѣӑ̷Ҟ̷ѝђѣߋᅀ̸ͅႌใ̜Ṩ̟౟ჿ̜ᄤ̟ჸᇱ̜া̟‫ې‬ใஎल̟ඩഡ໐ᇥ̟͆49-54̟ӔҺҖҞӞ̡ҫӖ̷ҽӞଃ̟๫̟࢝3126.
̜7̠ၿใରে̟ॾ‫ݍ‬ൌᄣ്̢3஼ ๻ໝྐྵఠஶѣ౗‫ྐྵ̡ہ‬഻̝ྐྵ࠽Ѡ‫ܥ‬эє૔ᆒ̟ҽ̷ҬѣєѶѣ๻ໝྐྵຆ౸ᄬၼબ܎ҟҗҼͅ‫ڵ‬ཥଃඇၔఘ໙ႏ๻ໝྐྵࢲ‫ࠈ̡ڲ‬ধ޻‫ݶ‬ဩ̟͆9-44̟໙ႏࠈধࢥ‫ݶ‬ୟའ‫̟ݶ‬๫̟࢝3126.
̜8̠ॾ‫ݍ‬ൌᄣ̢‫ࡀ̠ء‬໸ౖ࠙ᄮ౗ခҺ̷Ҳେ̜ൊଆ̡຿ခྀᆛ‫̜ڱ‬Ҧ̷Ӆ̷ᄢᅗҢӠӠҥӦ
ઓ̟ࡀ໸ౖྴ૙௴࿁ DATA BOOKͅ໙ႏ৊݈ᆽࢥ‫ࠇݶ‬ଳ̟͆73-77̟ӔҺҖҞӞӟӆӘ̷ଃ̟๫̟࢝3126.

ક⒈☟ᄙƷ‫ڤ‬Ʒ⊣
̜2̠S.Shi, S.P.Srivastava, M.Kanasaki, J.He, M.Kitada, T.Nagai, K.Nitta, S.Takagi, K.Kanasaki,
D.Koya : Interactions of DPP-5 and integrin ԓ2LQÀXHQFHVHQGRWKHOLDOWRPHVHQFK\PDOWUDQVLWLRQ
Kidney International., 99:4:58:-59:, 3126.
̜3̠ͅM.Yasuda-Yamahara͆, S.Kume, K.Yamahara, J.Nakazawa, M.Chin-Kanasaki, H.Araki, S.Araki,
D.Koya, M.Haneda, S.Ugi, H.Maegawa, T.Uzu : Lamp-3GH¿FLHQF\SUHYHQWVKLJKIDWGLHWLQGXFHG
obese diabetes via enhancing energy expenditure, Biochemical and Biophysical ResearchCommunications, 576:3:35:-366, 3126.
̜4̠ͅS.Araki͆, M.Haneda, D.Koya, K.Kondo, S.Tanaka, H.Arima, S.Kume, J.Nakazawa, M.ChinKanasaki, S.Ugi, H.Kawai, H.Arai, T.Uzu, H.Maegawa : Urinary potassium excretion and renal
and cardiovascular complications in patients with type 3 diabetes and normal renal function,
Clinical journal of the American Society of Nephrology : CJASN., 21:23:3263-3269, 3126.
̜5̠ͅS.Kato͆, S.Maruyama, H.Makino, J.Wada, D.Ogawa, T.Uzu, H.Araki, D.Koya, K.Kanasaki,
Y.Oiso, M.Goto, A.Nishiyama, H.Kobori, E.Imai, M.Ando, S.Matsuo : Anti-albuminuric effects of
spironolactone in patients with type 3 diabetic nephropathy : a multicenter, randomized clinical
trial, Clinical and Experimental Nephrology, 2::7:21:9-2217, 3126.

㸫  㸫

̜6̠ͅY.Tanaka͆, S.Kume, H.Araki, J.Nakazawa, M.Chin-Kanasaki, S.Araki, F.Nakagawa, D.Koya,
M.Haneda, H.Maegawa, T.Uzu : 2-Methylnicotinamide ameliorates lipotoxicity-induced oxidative
stress and cell death in kidney proximal tubular cell, Free Radical Biology & Medicine., 9::942952, 3126.
ƷἕƷ◻
̜2̠T.Nagai, K.Nitta, M.Kanasaki, D.Koya, K.Kanasaki7KHELRORJLFDOVLJQL¿FDQFHRIDQJLRWHQVLQFRQYHUWLQJHQ]\PHLQKLELWLRQWRFRPEDWNLGQH\¿EURVLV&OLQLFDODQG([SHULPHQWDO1HSKURORJ\
2::2:76-85, 3126.
̜3̠ͅM.Haneda͆, K.Utsunomiya, D.Koya, T.Babazono, T.Moriya, H.Makino, K.Kimura, Y.Suzuki,
T.Wada, S.Ogawa, M.Inaba, Y.Kanno, T.Shigematsu, I.Masakane, K.Tsuchiya, K.Honda, K.
Ichikawa, K.Shide : A new classification of diabetic nephropathy 3125 : a report from jointcommittee on diabetic nephropathy, Clinical and Experimental Nephrology, 2::2:2-6, 3126.
̜4̠ͅM.Haneda͆, K.Utsunomiya, D.Koya, T.Babazono, T.Moriya, H.Makino, K.Kimura, Y.Suzuki,
T.Wada, S.Ogawa, M.Inaba, Y.Kanno, T.Shigematsu, I.Masakane, K.Tsuchiya, K.Honda, K.
Ichikawa, K.Shide : A new classification of diabetic nephropathy 3125 : a report from jointcommittee on diabetic nephropathy, Journal of Diabetes Investigation, 7:3:353-357, 3126.
̜5̠N.Ueki, S.Takeda, D.Koya, K.Kanasaki : The relevance of the renin-angiotensin system in thedevelopment of drugs to combat preeclampsia, International Journal of Endocrinology [Electronic
Resource], 3126:683824:2-23, 3126.
̜6̠ͅS.Kume͆, D.Koya : Autophagy : A novel therapeutic target for diabetic nephropathy, Diabetes &Metabolism Journal, 4::4:562-571, 3126.
̜7̠ၿใରে̟ॾ‫ݍ‬ൌᄣ̢ຠେ21 Topics in diabetic complications and diabetes-related diseases̸๻ໝྐྵ৾တஶѝ࠙ᇍ૱߶ѣంєџҀืၱ̜๻ໝྐྵఠஶ̜ఒඊѝ૔ᆒѠпцҀక့̟ਘঞ
ѣืၱ̟๻ໝྐྵఒᆒӑҬҲ̷̟24:2:27-33, 3126.
̜8̠ၿใରে̟ॾ‫ݍ‬ൌᄣ̢ຠେ 3च๻ໝྐྵఒᆒѣంื‫ގ‬3126̜๻ໝྐྵ߶ଅѣࠊᅬ̸ఠஶ̟ᆤ
᠗ѝय़ࢅ̟:3:2:67-73, 3126.
̜9̠ॾ‫ݍ‬ൌᄣ̢޻ୠຠେ ๻ໝྐྵ৾တஶѣ೨࠽಑౒૔ᆒ̜ఠ࿋಻ѣ೨࠽಑౒૔ᆒ̟໙ႏ‫ڮ‬ૉం
၈̟5848:37-43, 3126.
̜:̠ℛძ̜ః̟ࣟ—गഉ̟ॾ‫ݍ‬ൌᄣ̢ຠେ̢।нћтє SGLT3೒‫ޕ‬ᄅѣ૳ᆜѝంєџ๻ໝྐྵ૔ᆒᄅѣ݉໸ౖ̜ᆤட঳‫ݑ‬рѾ।Ҁ SGLT3೒‫ޕ‬ᄅѣরѝ̢ۭ҄сਈѠпцҀ૳ඒછᅀ҇ଦцћ̜ఠࡀ໸ѠѽҀᄜ঳ౖѣ‫ڬ‬йѝఠဲধ঳‫ݑ‬ѣ݉໸ౖ̟Mebio̟43:4:43-46, 3126.
21̠ၿใରে̟ॾ‫ݍ‬ൌᄣ̢ຠେ ૑ൊѝѝѷѠৄсҀ͑๻ໝྐྵ৾တஶ͒ѣॗ໫̜ީᇫ‫̠ؠ‬੎஛ेࠊௐ‫ޕ‬ѣఒඊѝ૔ᆒ̜๻ໝྐྵఠஶѣ૔ᆒͅఠஶಷ࠽̼५ౖఠஶ࠽̟͆ఒඊѝ૔ᆒ̟
214:4:432-438, 3126.
22̠ၿใରে̟ॾ‫ݍ‬ൌᄣ̢Special issue ๻ໝྐྵఠஶ̜ਘঞѣืၱѝ‫ݢ‬൏̜ຠେ2 ๻ໝྐྵఠஶѣ‫޻۽‬ษ৤ੴ̟Diabetes Contemporary̟3:2:7-22, 3126.
23̠ࣟ—गഉ̢ຠେ ૑ൊѝѝѷѠৄсҀ͑๻ໝྐྵ৾တஶ͒ѣॗ໫̜ީᇫ‫̠ؠ‬੎஛ेࠊௐ‫ޕ‬ѣఒඊѝ૔ᆒ̜ຆ౸ຐ໛ಷঞѣ๻ໝྐྵࠊᅬ̟ఒඊѝ૔ᆒ̟214:4:43:-444, 3126.
24̠ၿใରে̟ॾ‫ݍ‬ൌᄣ̢ຠେ ๻ໝྐྵ৾တஶѣ೨࠽ఒඊѝకืᄬၼ̜2. ఠஶѣ೨࠽ఒඊѝకืᄬၼ̟๻ໝྐྵ̟69:5:345-348, 3126.

㸫  㸫

25̠ॾ‫ݍ‬ൌᄣ̢๻ໝྐྵ৾တஶ̸ᄬၼѝ૔ᆒѣక့̜๻ໝྐྵఠஶѣ૔ᆒѠ࠶ၱѣরс̟๻ໝྐྵ৾တஶ̟3::2:45-48, 3126.
26̠ၿใରে̟ॾ‫ݍ‬ൌᄣ̢ຠେ ৹ᆽଅѣఠྀໝ࠰૱߶̜৹ᆽଅѣ຿‫ݏ‬૱߶̜๻ໝྐྵౖఠஶ̟
ఠѝຆ౸̟89:7:973-978, 3126.
27̠ၿใରে̟ॾ‫ݍ‬ൌᄣ̢ຠେ ๻ໝྐྵѝҝ̷һӈҔҫ̷̜๻ໝྐྵఠஶѝҝ̷һӈҔҫ̷̟຿ခྀ̡๻ໝྐྵ̡ൊଆ຿‫̟ݏ‬51:7:56:-575, 3126.
28̠ၿใରে̟ॾ‫ݍ‬ൌᄣ̢ຠେ ྀໝ࠰ѣҕӦҴқҗҫӦң̜6. ఠആѣҕӦҴқҗҫӦң̟
Progress in Medicine̟46:7::78-:83, 3126.
29̠ࣟ—गഉ̟ॾ‫ݍ‬ൌᄣ̢‫ء‬๻ໝྐྵౖఠஶ೴ᇫ̜8. ఠஶྐྵ࠽ခᆭ̟ఠѝຆ౸̟89̢ഄߪ̢9499, 3126.
2:̠ၿใରে̟ॾ‫ݍ‬ൌᄣ̢‫ݷ‬ಋ ӟҬӌӜһӠ̷Ӟѣఠဲধ঳‫̟ݑ‬ఠആ຿‫ྀ̡ݏ‬ໝ࠰‫̟ݏ‬
3:2:226-233, 3126.
31̠ၿใରে̟ॾ‫ݍ‬ൌᄣ̢๻ໝྐྵႰౖ৾တஶѣ཈ஶӔҞҾҭӓ̜ӊӠҹҗӦҠҽ̷ү C
ͅPKC͆ѣߋ਼ౖ݂̟ం‫̟޻ڮ‬81̢8ॉഄߪ̢2475-2485, 3126.
32̠ࣟ—गഉ̟ॾ‫ݍ‬ൌᄣ̢ຠେ ఠആѝқӀӞҡ̷ൊଆ̜๻ໝྐྵఠஶ̟ఠആ຿‫ྀ̡ݏ‬ໝ࠰‫̟ݏ‬
3:3:242-248, 3126.
33̠ࣟ—गഉ̟ॾ‫ݍ‬ൌᄣ̢ຠେ ๻ໝྐྵ̡CKD ৾တ৹े‫پ‬ѣ৶‫پ‬ჭྯѝ്‫ڵ‬ಱൗᄅ̼ॾфћంьйჵ൏҇ўл৤нҀр̼̜5. ๻ໝྐྵ৾တஶ CKD ѣ৹े‫̜پ‬5-3 ്‫ڵ‬ಱൗᄅ̟ॉߪ๻ໝ
ྐྵ̟8:9:77-83, 3126.
34̠ၿใରে̟ॾ‫ݍ‬ൌᄣ̢ຠେ ๻ໝྐྵѣ௴ૉᆒၔ up to date̜8. ๻ໝྐྵఠஶѣ௴ૉᆒၔͅຆ౸
ᄬၼ̡ຆ౸࠽̟͆ॉߪ๻ໝྐྵ̟8:::58-63, 3126.
35̠ࣟ—गഉ̢ຠେ̢ఠಧ‫̜݂ڦ‬ఠಧ‫݂ڦ‬ѝ຿ྂ੎ၙௐ‫̟ޕ‬໙ႏఠആ޻‫̟ૂݶ‬68 : 8 : 2311 2316, 3126.
36̠ࣟ—गഉ̟ॾ‫ݍ‬ൌᄣ̢ຠେ ๻ໝྐྵѤ‫ݸ‬࿳юҀѕ҂лр Part3̸ఠௐ‫ޕ‬Ѥ߳‫ݷ‬юҀр̜ఠௐ‫ޕ‬сલѶсєйҲҗӊѝѤ̤̟๻ໝྐྵఒᆒӑҬҲ̷̟24:22:996-9:1, 3126.
37̠ၿใରে̟ॾ‫ݍ‬ൌᄣ̢ຠେ ႰౖఠആྐྵӟҪӇ̸௴ѣᆜѭѣ࠽ഹ̜͕૱ྐྵӝҬҢคॳ঳‫͖ݑ‬๻ໝྐྵ̟ఠѝຆ౸̟8::6:793-797, 3126.
38̠ంใࢰથ̟ࣟ੟ѶхѴ̟ࣟ—गഉ̟ॾ‫ݍ‬ൌᄣ̢ఠಧ‫݂ڦ‬૔ᆒಘᅹѠпцҀҕӦҫҝҹӦ
ҪӦဦߺৱ೎೒‫ޕ‬ѣౡ࿿޻ษ୔ᅆౖ̟ࣟ൙‫ݏڮ‬ൌ޻੻ૂ̟51:242-249, 3126.
39̠ၿใରে̟ॾ‫ݍ‬ൌᄣ̢ຠେ ๻ໝྐྵ૔ᆒం૑ൊ̸๻ໝྐྵ૔ᆒѣ update̸̜‫̠آ‬QOL ѣষ௒҇ჭફьє๻ໝྐྵ৾တஶѣఒඊѝ૔ᆒ̜3 . ๻ໝྐྵౖఠஶѣఒඊѝ૔ᆒ̟໙ႏᆤ᠗̟
84:23:3148-3154, 3126.
3:̠ℛ‫ޣ‬ᄩഥ̟ࣟ—गഉ̟ॾ‫ݍ‬ൌᄣ̢ຠେ ๻ໝྐྵѣఒඊѝ૔ᆒ Up To Date̜‫̠أ‬๻ໝྐྵఠஶ
ਅ࿵Ѡગъҁє‫ݢ‬൏ѭ්ಘ̜җӦҢӟҴӦ࠙ᇍᄅѭѣ࠽ഹ̟ॉߪ๻ໝྐྵ̟8 : 23 : 71 - 79 ,3126.
41̠ၿใରে̟ॾ‫ݍ‬ൌᄣ̢ຠେ CKD ߶ଅѣࠊᅬ̜:. े๻ࠊᅬ̟ຍႿড়݂ᄬၼ̟25:5:74-7:,3126.
42̠ၿใରে̢ຠେ ๻ໝྐྵఠஶѣఒඊѝ૔ᆒ Up To Date̜‫̠آ‬૔ᆒѣ૳ರ̜ౡߋ଻߸ѣଳ౞̟ॉߪ๻ໝྐྵ̟8:23:33-38, 3126.

㸫  㸫

Ʒᩲόअ‫ܝ‬
̜2̠Y.Sasagawa, O.Tachibana, A.Nakagawa, D.Koya, H.Iizuka : Pituitary apoplexy following
gonadotropin-releasing hormone agonist administration with gonadotropin-secreting pituitaryadenoma, Journal of Clinical Neuroscience, 33:4:712-714, 3126.
Ʒ᮲Ʒअ
̜2̠D.Koya : Epidermal growth factor receptor signaling and the progression of diabetic nephropathy,
Journal of Diabetes Investigation, 7:6:62:-632, 3126.
ƷǬǽ͙̜2̠ၿใରে̟ॾ‫ݍ‬ൌᄣ̢ўлఒҀ̟ўлҤҕюҀ ๻ໝྐྵѣ৾တஶ̜Ⴐౖ৾တஶ̜7. ๻ໝྐྵ҇၏нҀఠௐ‫߶ޕ‬ଅѣҤҕ̟Modern Physician̟46:2:52-56, 3126.
̜3̠ॾ‫ݍ‬ൌᄣ्̢৆৭਷͑ӔҲӏ̜͒͑๻ໝྐྵᄬྐऎ̜͒зҀйѤ͑๻ໝྐྵ͒ѝॹ҄ҁєѾ̟
Our Health HOKURIKU, 395:9-:, 3126.
̜4̠ॾ‫ݍ‬ൌᄣ̢ဩେঞࡌ̟ఠആ̟48:223:227-227, 3126.
̜5̠‫ܨ‬આ̜ఙ̟ॾ‫ݍ‬ൌᄣ̢๻ໝྐྵౖఠஶџѾѨѠఠড়݂ஶѣఒᆒర୯ষ௒ѝ୔ஶ݂ၼલѠѵцє෕ਯ̡य़ࢅ͕य़ࢅ‫ݢ‬൏჏͖ఒᆒర୯ষ௒Ѡѵцє୔ஶ๘ྵ݆ၔѣ‫ގ‬཈̟๻ໝྐྵౖఠ
ஶџѾѨѠఠড়݂ஶѣఒᆒర୯ষ௒ѝ୔ஶ݂ၼલѠѵцє෕ਯ̡य़ࢅͅ H 35 - ໎૔๸ͅఠ͆- ‫ڵ‬ཥ -112̜͆န౗35-37໪๘̜೴৾य़ࢅ၈ਇ஀̟32-36, 3126.
̜6̠‫ܨ‬આ̜ఙ̟ॾ‫ݍ‬ൌᄣ̢๻ໝྐྵౖఠஶџѾѨѠఠড়݂ஶѣఒᆒర୯ষ௒ѝ୔ஶ݂ၼલѠѵцє෕ਯ̡य़ࢅ͕य़ࢅ‫ݢ‬൏჏͖ఒᆒర୯ষ௒Ѡѵцє୔ஶ๘ྵ݆ၔѣ‫ގ‬཈̟๻ໝྐྵౖఠ
ஶџѾѨѠఠড়݂ஶѣఒᆒర୯ষ௒ѝ୔ஶ݂ၼલѠѵцє෕ਯ̡य़ࢅͅ H 35 - ໎૔๸ͅఠ͆- ‫ڵ‬ཥ -112̜͆န౗37໪๘̜೴ߊ̡ခ൷य़ࢅ၈ਇ஀̟32-36, 3126.
̜7̠‫ܨ‬આ̜ఙ̟ॾ‫ݍ‬ൌᄣ̢๻ໝྐྵౖఠஶџѾѨѠఠড়݂ஶѣఒᆒర୯ষ௒ѝ୔ஶ݂ၼલѠѵцє෕ਯ̡य़ࢅ̟๻ໝྐྵౖఠஶџѾѨѠఠড়݂ஶѣఒᆒర୯ষ௒ѝ୔ஶ݂ၼલѠѵцє෕ਯ̡य़ࢅͅH35- ໎૔๸ͅఠ͆- ‫ڵ‬ཥ -112͆
̜န౗35-37໪๘̜೴৾य़ࢅ၈ਇ஀̟2-25, 3126.
̜8̠‫ܨ‬આ̜ఙ̟ॾ‫ݍ‬ൌᄣ̢๻ໝྐྵౖఠஶџѾѨѠఠড়݂ஶѣఒᆒర୯ষ௒ѝ୔ஶ݂ၼલѠѵцє෕ਯ̡य़ࢅ̟๻ໝྐྵౖఠஶџѾѨѠఠড়݂ஶѣఒᆒర୯ষ௒ѝ୔ஶ݂ၼલѠѵцє෕ਯ̡य़ࢅͅH35- ໎૔๸ͅఠ͆- ‫ڵ‬ཥ -112̜͆န౗37໪๘̜೴ߊ̡ခ൷य़ࢅ၈ਇ஀̟2-24,3126.
̜9̠‫ܨ‬આ̜ఙ̟ॾ‫ݍ‬ൌᄣ̢ໝग़ളମେ҇ཕјє๻ໝྐྵౖఠஶӟҫҬһӝ̷ѣ‫ۦ‬ᅀ̟๻ໝྐྵౖ
ఠஶџѾѨѠఠড়݂ஶѣఒᆒర୯ষ௒ѝ୔ஶ݂ၼલѠѵцє෕ਯ̡य़ࢅͅH 35 - ໎૔๸ͅఠ͆- ‫ڵ‬ཥ -112̜͆န౗35-37໪๘̜೴৾य़ࢅ၈ਇ஀̟26-2:, 3126.
̜:̠‫ܨ‬આ̜ఙ̟ॾ‫ݍ‬ൌᄣ̢ໝग़ളମେ҇ཕјє๻ໝྐྵౖఠஶӟҫҬһӝ̷ѣ‫ۦ‬ᅀ̟๻ໝྐྵౖ
ఠஶџѾѨѠఠড়݂ஶѣఒᆒర୯ষ௒ѝ୔ஶ݂ၼલѠѵцє෕ਯ̡य़ࢅͅH 35 - ໎૔๸ͅఠ͆- ‫ڵ‬ཥ -112̜͆န౗37໪๘̜೴ߊ̡ခ൷य़ࢅ၈ਇ஀̟26-2:, 3126.
21̠ၿใରে̟ॾ‫ݍ‬ൌᄣ̢ຠେ ӃӜӦҬҕҶӊѣඑૢ҇ҡӘҶ̥௴ૉᆒၔѣєѶѣҠӎӦѣ
ౡ݂޻Ͱ۰ᅋ޻̜3 пйьфඑ҂л̥ҠӎӦѣ۰ᅋ೎̜4 . є҈Ѧф૲̟๻ໝྐྵҤҕ̟
23:8:37-42, 3126.
22̠ࣟ—गഉ̟ॾ‫ݍ‬ൌᄣ̢௴ૉᆒၔ࠱୯3125҇Ѷхјћ̜Q-29 є҈Ѧф૲Ѥ̝CKD Ҭҹ̷ҫ4a ќѤ1.9̼2.1g/kg ള୔ / ໙̝Ҭҹ̷ҫ4b̝5̝6ќѤ1.7̼1.9g/kg ള୔ / ໙ѝџјћйѳ㸫  㸫юс̝шѣཨ‫ژ‬ѽѿതфћѷஜџфћѷйцџйѣќьѼлр̤ђѣ॰Ⴚౖѹ࢕ᄵཨ‫ژ‬҇ࢲнћфѕъй̞ᆤட۰ᅋအੲ ۰ᅋફຐ̡ࠊᅬѣєѶѣҬҠӞҕҶӊҪӝ̷ҭ vol.4
CKDͅႰౖఠആྐྵ͆ѣ਼ం௴ૉᆒၔѣџёѠ๹нҀ ࠱ೊဩ̟4:85-88, 3126.
23̠ॾ‫ݍ‬ൌᄣ̢͑ຠେѠзєјћ͒๻ໝྐྵఠஶѣఒඊѝ૔ᆒ Up To Date̟ॉߪ๻ໝྐྵ̟8:23:66, 3126.

કΉɿᮾ᳣Ή᫘⒙Ʒ࡛⭾કΉ⾷ȿɻɥɀȮɨ⾸̜2̠D.Koya : S32 Diabetic complications The role of autophagy in diabetic nephropathy, The Korean
Society for Biochemistry and Molecular Biology International Conference 3126, Seoul, 3126.22
̜3̠D.Koya : Symposium23 Diverse cell signaling in metabolic syndrome High fat diet-induced
hepatosteatosis was ameliorated by the treatment with ketogeic amino acid, 3126 International
Congress on Obesity and Metabolic Syndrome in conjunction with the 54rd Annual Scientific
Meeting of KSSO, Seoul, 3126.22
Ʒ࡛⭾કΉ⾷ʶⅺ᜵Ⲥ⾸̜2̠K.Kanasaki, S.Shi, M.Kanasaki, D.Koya : The interaction between DPP- 5 and intergrin ԓ2
regulates the signaling responsible for induction of the endothelial to mesenchymal transition indiabetic kidney, American Diabetes Association 85WK6FLHQWL¿F6HVVLRQV%RVWRQ3126.17
ƷӴ࡛કΉɿᮾ᳣Ή⾷ȿɻɥɀȮɨ⾸̜2̠ॾ‫ݍ‬ൌᄣ̢ҪӦӐҫҙӓ2̢͑ॳ‫̡ܝ‬ค඄༭̡ค๻૲̡ค઼ၶ̸݄͒с୔ᅆ̤݄с࠮џй̸̤̜๻ໝྐྵఠஶѠпцҀє҈Ѧф૲౒ॻ്̟5:‫ݸ‬๻ໝྐྵ޻ѣక့̟ܱઆ̟3126.13
̜3̠ॾ‫ݍ‬ൌᄣ̟ࣟ—गഉ̟ၿใରে̢๻ໝྐྵఠஶ૔ᆒѣఇ݂ѝืၱ̜ఠ ¿EURVLV ҇Ҳ̷ҥҶһѝьє๻ໝྐྵఠஶѣ૔ᆒಘᅹ്̟69‫ݸ‬໙ႏ๻ໝྐྵ޻‫ݶ‬໪૒޻ୠେ‫̟̟࠙݁ݶ‬3126.16
̜4̠ࣟ—गഉ̢ҕӦҴ̡қҗҫӦңษџ๻ໝྐྵһ̷ҲӞҤҕ̜๻ໝྐྵఠѣಧ‫ྯ݂҇ڦ‬ษѝьє૔ᆒಘᅹ̢຿ྂ੎ၙৈ௜ౖѠධჭьћ്̟26‫ݸ‬໙ႏ৊݈ᆽ‫ݶ޻ڮ‬೴‫̟ݶ‬࿶ܱ̟3126.16
̜5̠ඩಗბྞ ,̜આႏ৸ൊ ,̜ඩჿ̜ს ,̜ॾ‫ݍ‬ൌᄣ ,̜ഡใ̜৏्̢௜ଅс‫ۦ‬ຍ଻߸҇बഘьє௙৾ѣेឦӆҲӒӦඐ̝ӎӕҪҬҹҗӦඐѠࡹѱюۭࢾ̜ӆҲӒӦ۰ᅋ္஄௴࿁ѣᄜᅀౖ̟໙ႏӆҲӒӦ޻‫്ݶ‬78‫ݸ‬ൌ‫̟ݶ‬ຽᆖ̟3126.17
̜6̠ࣟ—गഉ̢ COMT ࿋಻ѝ๻ൊଆ‫ڤ‬௜്̟47‫ݸ‬໙ႏ໠௼৹े‫޻ݶ޻پ‬ୠେ‫੸̟ݶ‬ႍ̟
3126.1:̜7̠஛౧‫̟ิڵ‬ඩჿ̜ს̟ॾ‫ݍ‬ൌᄣ̢Ӣ̷ҢҪӚҶӊ2‫ ̡޻۽‬EBM̜๻ໝྐྵ߶ଅѠпцҀૈଯྐྵѣᆤடษ‫̢ࡠڞ‬ඒ‫ڱ‬ᇍणѠѽҀതયಈࢣຎय़ࢅ്̟41‫ݸ‬໙ႏ๻ໝྐྵ৾တஶ޻‫്̡ݶ‬32‫ݸ‬໙ႏ๻ໝྐྵࠤ޻‫ݶ‬೴‫̟ݶ‬჏ॾ̟ܵ3126.22
̜8̠ॾ‫ݍ‬ൌᄣ̟ၿใରে̟ࣟ—गഉ̢๻ໝྐྵ৾တஶѣ‫޻۽‬ѝ਼ంѣఒඊၔѠљйћ̜๻ໝྐྵఠஶѣ‫޻۽‬ѝఒඊ਼̼ࣞѣᇮ൏്̼̟41‫ݸ‬໙ႏ๻ໝྐྵ৾တஶ޻‫്̡ݶ‬32‫ݸ‬໙ႏ๻ໝྐྵࠤ
޻‫ݶ‬೴‫̟ݶ‬჏ॾ̟ܵ3126.22
̜9̠ၿใରে̟ॾ‫ݍ‬ൌᄣ̢๻ໝྐྵ৾တஶѣ૔ᆒ̼࠱ೊрѾᆤடѭѣҕӊӠ̷Ҵ̼̜๻ໝྐྵఠ
ஶѣ૔ᆒͅ௴ૉᆒၔ҇ඩ௿Ѡ്̟͆41‫ݸ‬໙ႏ๻ໝྐྵ৾တஶ޻‫്̡ݶ‬32‫ݸ‬໙ႏ๻ໝྐྵࠤ޻‫ݶ‬㸫  㸫೴‫̟ݶ‬჏ॾ̟ܵ3126.22
̜:̠ॾ‫ݍ‬ൌᄣ̢DG ҪңҽӝӦңѝ๻ໝྐྵ࠙ᇍ૱߶̜DG-PKC फᇔѣߋౖ݂౒টѤ๻ໝྐྵఠஶ
ѣ཈ஶ̡కื҇೒લќтҀ്̟49‫ݸ‬໙ႏခથౡ࿿޻໪‫്̡ݶ‬99‫ݸ‬໙ႏౡ݂޻‫ݶ‬ൌ‫৾ݶ‬ຎൌ‫̟ݶ‬ఋআ̟3126.23
21̠ॾ‫ݍ‬ൌᄣ̢ҮҶҪӚӦ3͑๻ໝྐྵѣҕӦҴқҗҫӦң̜͒๻ໝྐྵрѾఠആ҇ধҀ̼є҈Ѧф૲ಆଙс⊷്̟8‫ྀݸ‬ໝ࠰৊݈ᆽ‫޻ڮ‬य़ࢅ‫̟ݶ‬ൌਗ਼̟3126.23
22̠۱‫ࡍگ‬થ̟S.P.Srivastava̟ࣟ—गഉ̟ॾ‫ݍ‬ൌᄣ̢Ӣ̷ҢҪӚҶӊ5๻ໝྐྵఠஶ2̜๻ໝྐྵఠಧ‫݂ڦ‬ѠпцҀ຿‫ౖہ‬৊ಧ‫݂ڦ‬ӍӊҴҼ AcSDKP ѣ‫ࡠڞ‬ѝђѣ੣ᅀࡀஇѠпцҀ৊ಧ‫ ݂ڦ‬microRNA ҢӠҬһ̷Ң്̟41‫ݸ‬໙ႏ๻ໝྐྵ৾တஶ޻‫്̡ݶ‬32‫ݸ‬໙ႏ๻ໝྐྵࠤ޻‫ݶ‬೴‫̟ݶ‬჏ॾ̟ܵ3126.22
ƷӴ࡛કΉɿᮾ᳣Ή⾷ʶⅺ᜵Ⲥ⾸
̜2̠ࣟ—गഉ̟஛౧‫̟ิڵ‬ၿใରে̟໸ഡৃઝ̟๙આࣔྗ̟ଚ̜৆થ̟ႌಗધᇥ̟इჿඕ
થ̟ࠞઆᇭྗ̟ఋဲ݈ઃ૒̟ࡧჿಒञથ̟ಒᅄ৆‫̟ݲ‬ୟশ̜৆̟౹ಗࡠ႔̟ែใ૓ପ̟
ഥใাఙ̟ॾ‫ݍ‬ൌᄣ̢๻ൊଆ‫ڤ‬௜ѣ݉໸ౖ҇ᄜюҀफࠊ۰ᅋஶᆰѠവюҀ L- җҰӠҗҪ
Ӧ༖৾ᅻຍ௴ѠѽҀ‫ݵ‬໛঳‫ͅݑ‬തયಈࢣຎय़ࢅ്̟͆29‫ݸ‬໙ႏྐྵ഻۰ᅋ޻‫ݶ‬໪૒޻ୠେ
‫̟࢝ݶ‬๓̟3126.12
̜3̠ඩಗ࿧ઞ̟ࡻ๫ᅧञ̟஛ඖใᆵથ̟আ෮েৃ̟૷ใॆ࠶໰̟ത‫ڽݱ‬ୢ̟ၿใରে̟ॾ‫ݍ‬ൌᄣ̟౧ྑৗ૒̢TPN ๩ᄮҞӠӝ̷҇ѷѝѠьє۰ᅋҬҢӝ̷ҾӦңѣᄜᅀౖѠ࠙юҀग़ກ്̟41‫ݸ‬໙ႏ౮Ⴟफී۰ᅋ޻‫޻ݶ‬ୠେ‫̟ݶ‬ఋআ̟3126.13
̜4̠ంใࢰથ̟ඩಗ̜୮̟ᅶ‫̜ݛ‬ଳ̟ੰಗാౡ̟෦ใఊ‫ཬ̟ڵ‬෮ଷბ̟ॾ‫ݍ‬ൌᄣ̢݁భളങ
ඩঞѠेඩ cortisol ‫ڤ‬௜৹ඐ҇૙ьє silent corticotroph adenoma ѝ৤нѾҁҀ3ᆰ്̟36‫ݸ‬໙ႏࠗ໹݁భളଡ᢮޻‫̟࢝ݶ‬๓̟3126.13
̜5̠ᅶ‫̜ݛ‬ଳ̟ੰಗാౡ̟ඩಗ̜୮̟ॾ‫ݍ‬ൌᄣ̟౞๦েᆁ̟ො‫܂‬ञ‫ڵ‬ᇚ̟༭ఋୢᄣ̟ܱႏ‫ڵ‬ჺ̟౿‫گ‬൓ჺ̟ཬ෮ଷბ̢ஶমౖӜһҤ໴ၙпѽѨ݁భളѠпцҀҕҢҕӐӝӦ཈ॶѝ໴ၙഄൌࡀஇѣग़ກ്̟36‫ݸ‬໙ႏࠗ໹݁భളଡ᢮޻‫̟࢝ݶ‬๓̟3126.13
̜6̠ੰಗാౡ̟ᅶ‫̜ݛ‬ଳ̟ຘ৾Ⴏᅱથ̟ඩಗ̜୮̟ॾ‫ ݍ‬ൌᄣ̟ᅧ༃ࡶᄩ̟ཬ෮ଷბ̢಑ൿ࢏
ൌஶѠпцҀଛਡࠊஶমऍѣྐྵ഻‫ݷ‬౸̢ఋफเຐഓ๘ѝ MRI ѠѽҀ౞ඩఋफѣྵ്݆̟36‫ݸ‬໙ႏࠗ໹݁భളଡ᢮޻‫̟࢝ݶ‬๓̟3126.13
̜7̠ᅶ‫̜ݛ‬ଳ̟ੰಗാౡ̟ඩಗ̜୮̟ॾ‫ݍ‬ൌᄣ̟ཬ෮ଷბ̢ஶমౖӜһҤ໴ၙ௒ྂѠпцҀҕҢҕӐӝӦ཈ॶѝ໴ၙഄൌࡀஇѣग़ກ്̟99‫ݸ‬໙ႏ຿ခྀ޻‫޻ݶ‬ୠ೴‫̟ݶ‬๫̟࢝
3126.15̜8̠ͅ৪ძ௹‫ې̟͆ڵ‬ใஎल̟ॾ‫ݍ‬ൌᄣ̟ࡶရఊઝ̟৪ძࡶొ̟‫ێ‬෦̜ࡍ̟ಷಗ̜೶̢3च๻ໝྐྵ߶ଅѣఠ̡௿ेࠊҗӌӦһѣ཈ஶѝໝඩҞӝҙӓ̡ҽһӝҙӓ༎ᝄᆙѝѣ࠙ᇍ്̟69‫ݸ‬໙ႏ๻ໝྐྵ޻‫ݶ‬໪૒޻ୠେ‫̟̟࠙݁ݶ‬3126.16
̜9̠ͅใඩᄤࡉ̟͆ࡶရఊઝ̟ඩែ̜୲̟ࣟ੟‫̟ྗݲ‬৪ძࡶొ̟৪ძ௹‫ݍॾ̟ڵ‬ൌᄣ̟‫ې‬ใஎल̟‫ێ‬෦̜ࡍ̟ಷಗ̜೶̢AD ൊଆ࠙ᇍৱ೎ Nicotinamide n-methyltransferaseͅNNMT͆Ѥ๻ໝྐྵౖఠஶѣ઼ၶઓॆ৾ҕӞӉӒӦѠѽҀࣞ‫ڕ‬ໝ੎ࠊௐ‫҇ޕ‬ᅍ౒юҀ്̟69‫ݸ‬໙ႏ๻ໝྐྵ޻‫ݶ‬໪૒޻ୠେ‫̟̟࠙݁ݶ‬3126.16
̜:̠ࣟ—गഉ̟ય̜ఄ̟ࣟ—ѶхѴ̟ॾ‫ݍ‬ൌᄣ̢DPP-5ѝ integrin ԓ2ѣೱঘ੣ᅀѤ๻ໝྐྵఠѣಧ‫݂ڦ‬ѝ຿ྂ੎ၙ̸ࠗᅄपခ݂҇ଗࡎюҀ്̟69‫ݸ‬໙ႏ๻ໝྐྵ޻‫ݶ‬໪૒޻ୠେ‫̟݁ݶ‬
̟࠙3126.16

㸫  㸫21̠ၿใରে̟๎ᵂ̜‫̟ٯ‬஛೙टᄩ̟ᆸძჀથ̟ࣟ—गഉ̟౧ែ̜౨̟ඩಗ̜୮̟ॾ‫ݍ‬ൌᄣ̢є҈Ѧф૲౒ॻѣ3च๻ໝྐྵӜҶһఠஶѠവюҀఠဲধ঳‫്̟ݑ‬69‫ݸ‬໙ႏ๻ໝྐྵ޻‫ݶ‬໪૒޻ୠେ‫̟̟࠙݁ݶ‬3126.16
22̠આႏఊᅬ٪̟ၿୟᄔ‫ݟ‬થ̟આ݁ѧѝѴ̟஛౧‫ݍॾ̟ิڵ‬ൌᄣ̢ਣ৾ྐྵ๮ќѣӈҶһҤҕ
ѭѣ࠙௿сത௱ଠѠޫчѾҁє‫ݦ‬นѝਘঞѣืၱ്̟69‫ݸ‬໙ႏ๻ໝྐྵ޻‫ݶ‬໪૒޻ୠେ
‫̟̟࠙݁ݶ‬3126.16
23̠ᅶ‫̜ݛ‬ଳ̟ੰಗാౡ̟ඩಗ̜୮̟ॾ‫ݍ‬ൌᄣ̟਌౎̜ၱ̟ඩใ೶થ̟ჿ๦া໲̟ཬ෮ଷ
ბ̢ஶমౖӜһҤ໴ၙѠпцҀ໐૒ౖ݁భളಷᅄܑѣᆤடྐྵᅬ޻ษग़ກѝ཈ౡࡀஇѣ‫ݷ‬ბ്̟44‫ ݸ‬໙ႏ໹ଡ᢮ྐྵᅬ޻‫̟ݶ‬৹஫̟3126.16
24̠આႏ৸ൊ̟ඩಗბྞ̟ඩჿ̜ს̟ඩಗ̜୮̟ॾ‫ݍ‬ൌᄣ̢๻ໝྐྵ૔ᆒѠпцҀ໛‫ۈ‬ಷঞѣ۰ᅋࠊᅬ̡ेඩӆҲӒӦѣྵ്݆̟69‫ݸ‬໙ႏ๻ໝྐྵ޻‫ݶ‬໪૒޻ୠେ‫̟̟࠙݁ݶ‬3126.16
25̠ၿୟᄔ‫ݟ‬થ̟આ݁ѧѝѴ̟஛౧‫̟ิڵ‬ඩಗ̜୮̟ॾ‫ݍ‬ൌᄣ̢๻ໝྐྵ୔ஶ݂ᄬၼѠষцєྐྵఒᇍणѣєѶѣҦӔҺҖҞӞ҇വொѝьєള६च৭଻‫ݶ‬ѣુѴѝ૳੒്̟69‫ݸ‬໙ႏ๻ໝྐྵ޻‫ݶ‬໪૒޻ୠେ‫̟̟࠙݁ݶ‬3126.16
26̠۱‫ࡍگ‬થ̟S.P.Srivastava̟ࣟ—गഉ̟ॾ‫ݍ‬ൌᄣ̢๻ໝྐྵఠಧ‫݂ڦ‬ѠпцҀ຿‫ౖہ‬৊ಧ‫ڦ‬݂ӍӊҴҼ AcSDKP ѣ‫ࡠڞ‬ѝђѣ੣ᅀࡀஇѠпцҀ৊ಧ‫ ݂ڦ‬microRNA ҢӠҬһ̷Ң̟
്69‫ݸ‬໙ႏ๻ໝྐྵ޻‫ݶ‬໪૒޻ୠେ‫̟̟࠙݁ݶ‬3126.16
27̠ͅइज஝জ̟͆ࡶရఊઝ̟ඩែ̜୲̟ࣟ੟‫̟ྗݲ‬৪ძࡶొ̟৪ძ௹‫ݍॾ̟ڵ‬ൌᄣ̟‫ې‬ใஎल̟‫ێ‬෦̜ࡍ̟ಷಗ̜೶̢๻ໝྐྵౖఠஶѠпцҀࣞ‫ڕ‬ໝ੎ࠊௐ‫ ҇ޕ‬mTORC2‫ږ‬ഝౖѠ౒টюҀంࡋ microRNAs ѣຎซ്̟69‫ݸ‬໙ႏ๻ໝྐྵ޻‫ݶ‬໪૒޻ୠେ‫̟̟࠙݁ݶ‬3126.16
28̠ంใࢰથ̟۱‫ࡍگ‬થ̟ࣟ—ѶхѴ̟‫ې‬ใஎल̟ࣟ—गഉ̟ॾ‫ݍ‬ൌᄣ̢຿‫ౖہ‬৊ಧ‫݂ڦ‬ӍӊҴҼ AcSDKP Ѥ๻ໝྐྵఠѣಧ‫݂ڦ‬ѠവюҀफশ૔ᆒᄅѠџѿлҀ്̟69‫ݸ‬໙ႏ๻ໝྐྵ
޻‫ݶ‬໪૒޻ୠେ‫̟̟࠙݁ݶ‬3126.16
29̠ၿใରে̟๎ᵂ̜‫̟ٯ‬஛೙टᄩ̟ࣟ—गഉ̟ॾ‫ݍ‬ൌᄣ̢є҈Ѧф૲౒ॻѠѽҀ3च๻ໝྐྵఠໝ੎ࠊѠпцҀӒһҦӦҼӝҕѣඊဧ݂ѝᄪ৾ӃӜӦҬѣ౐౞ѝఠဲধ঳‫്̟ݑ‬69‫ݸ‬ͅန౗38໪๘͆໙ႏఠആ޻‫޻ݶ‬ୠ೴‫̟ݶ‬჏ॾ̟ܵ3126.17
2:̠ͅใಗ‫ڋ‬๓થ̟͆‫ڋ‬ใఊથ̟ࡶရఊઝ̟ඩែ̜୲̟ࣟ੟‫̟ྗݲ‬৪ძࡶొ̟৪ძ௹‫ݍॾ̟ڵ‬ൌᄣ̟‫ې‬ใஎल̟‫ێ‬෦̜ࡍ̟ಷಗ̜೶̢સࢄള௒ྂ੎ၙѠпцҀҝ̷һӈҔҫ̷࿋಻Ѥ๻ໝྐྵౖఠஶѠпцҀ඄༭ໝ҇അ‫ٶ‬ъѐҀ്̟69‫ͅݸ‬န౗38໪๘͆໙ႏఠആ޻‫޻ݶ‬ୠ೴‫̟ݶ‬჏ॾ̟ܵ3126.17
31̠ͅ஛ჿఊჺ̟͆‫ڋ‬ใఊથ̟ࡶရఊઝ̟࠙ਡ̜ᅬ̟ඩែ̜୲̟ࣟ੟‫̟ྗݲ‬৪ძࡶొ̟৪ძ௹
‫ݍॾ̟ڵ‬ൌᄣ̟‫ې‬ใஎल̟‫ێ‬෦̜ࡍ̟ಷಗ̜೶̢સࢄള௒ྂ੎ၙѣࡀ໸‫ڦ‬ૐѠпцҀ඄༭ O-GlcNAc ଳ௫ѣᄃ߇്̟69‫ͅݸ‬န౗38໪๘͆໙ႏఠആ޻‫޻ݶ‬ୠ೴‫̟ݶ‬჏ॾ̟ܵ
3126.1732̠આႏ৸ൊ̟આႏಒ౓̟ඩಗბྞ̟ॾ‫ݍ‬ൌᄣ̟஛ᆠ୮໐̢ౡߋ଻߸ྐྵѠпцҀॳᆙңӞ̷ӊအѣ௴৫ຍѠ࠙ьћѣခ౸്̟44‫ݸ‬໙ႏ྇Ⴑஶ૔ᆒ޻‫޻ݶ‬ୠେ‫̟ݶ‬ಒᅄ̟3126.17
33̠ͅइज஝জ̟͆ࡶရఊઝ̟ඩែ̜୲̟ࣟ੟‫̟ྗݲ‬৪ძࡶొ̟৪ძ௹‫ݍॾ̟ڵ‬ൌᄣ̟‫ې‬ใஎल̟‫ێ‬෦̜ࡍ̟ಷಗ̜೶̢๻ໝྐྵѠпцҀࣞ‫ڕ‬ໝ੎ࠊௐ‫౒҇ޕ‬টюҀంࡋ microRNAs ѣຎซ്̟69‫ͅݸ‬န౗38໪๘͆໙ႏఠആ޻‫޻ݶ‬ୠ೴‫̟ݶ‬჏ॾ̟ܵ3126.17
34̠௭ძิᇭ̟චใ̜ஷ̟ࣟ—ѶхѴ̟ॾ‫ݍ‬ൌᄣ̟ࣟ—गഉ̢COMT ࿋಻сӑҙҬѠпйћ
angiotensin ‫ء‬ѠവюҀ஧‫߷پ‬ଦౖሿక҇ଗࡎюҀ്̟47‫ݸ‬໙ႏ໠௼৹े‫੸̟ݶ޻پ‬ႍ̟
3126.1:㸫  㸫35̠આႏ৸ൊ̟ஜ࡫ੁથ̟ੰಗྗඕൊ̟આႏಒ౓̟ඩಗბྞ̟‫ݫ‬ਿাഌ̟ॾ‫ݍ‬ൌᄣ̟஛ᆠ୮
໐̢ҺӘҕӞҗӦӇ̷ҳӦҬၔѠѽҀ຿ആ઼ၶ઼̝ྂ݁ၶო౺ѝ ALT̝े౟ TG̝HbAlc
ѣೱ്ౖ̟࠙47‫ݸ‬໙ႏ྇Ⴑ޻‫̟ݶ‬჏ॾ̟ܵ3126.21
36̠ᅶ‫̜ݛ‬ଳ̟ੰಗാౡ̟ඩಗ̜୮̟ॾ‫ݍ‬ൌᄣ̟౞๦েᆁ̟ො‫܂‬ञ‫ڵ‬ᇚ̟༭ఋୢᄣ̟ܱႏ‫ڵ‬ჺ̟౿‫گ‬൓ჺ̟ཬ෮ଷბ̢ஶমౖӜһҤ໴ၙѠпцҀ໐૒ౖ݁భളܑѣग़ກ݁͘భളпѽѨӜһҤ໴ၙѠпцҀܑஶౖҨҗһҞҗӦпѽѨଦᄵളѣ཈ॶ്̟͘85‫ݸ‬໙ႏ໹ఋफ
‫޻ݶ޻ݏޓ‬ୠ೴‫੸̟ݶ‬ႍ̟3126.21
37̠ಗ๧̜஽̟৹ძ̜ః̟ඩಗ̜୮̟۱‫ࡍگ‬થ̟ᅶ‫̜ݛ‬ଳ̟ੰಗാౡ̟ఄใืൊ̟‫گ‬௒ఀჺ̟਌౎̜ၱ̟ඩใ೶થ̟஛೙टᄩ̟஛౧‫̟ิڵ‬ၿใରে̟ॾ‫ݍ‬ൌᄣ̢క৫ಷᅶಪࠣ҇཈ஶьєཟ݁భളࡀ໸ค݁ஶѣ2ᆰ്̟36‫ݸ‬ᆤட຿ခྀൊଆ Update̟๫̟࢝3126.22
38̠ᅶ‫̜ݛ‬ଳ̟ੰಗാౡ̟ඩಗ̜୮̟຀‫఻گ‬઱̟ො‫܂‬ञ‫ڵ‬ᇥ̟༭ఋୢᄣ̟౿‫گ‬൓ჺ̟ॾ‫ݍ‬ൌᄣ̟ཬ෮ଷბ̢ఒඊѠࣩᆅь̝ӎӞӕӦ္ୋᆒၔঞѠࡽഄьє‫ڑ‬௒࿫࠲जଡѣ2ᆰ്̟36‫ݸ‬ᆤட຿ခྀൊଆ Update̟๫̟࢝3126.22
ƷࢄᅀકΉɿᮾ᳣Ή⾷ᣀ֌♠᜵⾸̜2̠ॾ‫ݍ‬ൌᄣ̢ࢲ‫ڲ‬৭‫̜ܐ‬๻ໝྐྵఠஶѣఒඊѝ૔ᆒ്̟56‫ͅݸ‬န౗38໪๘͆໙ႏఠആ޻‫ݶ‬౧࿫޻ୠൌ‫̟ࣟݶ‬൙̟3126.21
ƷࢄᅀકΉɿᮾ᳣Ή⾷ʶⅺ᜵Ⲥ⾸̜2̠ၿใରে̟ᝩ੟‫ڵێ‬ᇥ̟ॾ‫ݍ‬ൌᄣ̟ࡻఄে໪̢Ⴐౖ C चࠏܑѠവюҀҗӦҲ̷ӈҚӠӦ૔ᆒঞѠ཈ஶьєࠌஈక৫च2च๻ໝྐྵѣ2ᆰ̟໙ႏ຿‫ݶ޻ݏ‬ၿᅳબ࿫ଘ਺്336‫ݸ‬ၿᅳඒၒ‫̟ࣟݶ‬൙̟3126.14
̜3̠ඩಗ̜୮̟ᅶ‫̜ݛ‬ଳ̟ੰಗാౡ̟ཬ෮ଷბ̟ॾ‫ݍ‬ൌᄣ̢ᆤடษ̓ྌࡀ໸ౖ̈́݁భളಪଡ
ѣӎӞӕӦခྀ໸̸ลୟ೏௰༘ᅋѠѽҀग़ກ̸്̟32‫ݸ‬ၿᅳࠗ໹݁భളଡ᢮य़ࢅ‫̟ݶ‬࿶‫̟گ‬3126.19
̜4̠ಗ๧̜஽̟৹ძ̜ః̟ඩಗ̜୮̟۱‫ࡍگ‬થ̟ᅶ‫̜ݛ‬ଳ̟ఄใืൊ̟஛೙टᄩ̟๦ใघ
ઝ̟৹‫ޣ‬ᄩഥ̟ॾ‫ݍ‬ൌᄣ̢ཟ݁భളࡀ໸ค݁ஶѠ཈ஶьє క৫ಷᅶಪࠣѣ2ᆰ̟໙ႏ຿
‫ݶ޻ݏ‬ၿᅳબ࿫ଘ਺്338‫ݸ‬ၿᅳඒၒ‫̟ࣟݶ‬൙̟3126.1:
̜5̠຀‫ဲࡶ̟ٯ̜گ‬ใ݇થ̟஛೙टᄩ̟๦ใघઝ̟஛౧‫̟ิڵ‬ၿใରে̟ࣟ—गഉ̟౧ែ̜
౨̟ඩಗ̜୮̟ॾ‫ݍ‬ൌᄣ̢ӝҽңӝӊҴӦѠѽѿࡽഓѠे๻ඐс‫ރ‬ಸьєႰౖ C चࠏܑ
৾တ3च๻ໝྐྵѣ2ᆰ്̟9:‫ݸ‬໙ႏ๻ໝྐྵ޻‫ݶ‬ඩ࿫ඒၒ‫̟ݶ‬౮ܱ̟3126.21
̜6̠ࣟ—गഉ̟๎ᵂ̜‫̟ٯ‬ඩಗ̜୮̟ၿใରে̟۱‫ࡍگ‬થ̟‫ڔ‬຀েପ̟෦ใఊ‫̟ڵ‬஛౧‫ڵ‬ิ̟౧ែ̜౨̟ॾ‫ݍ‬ൌᄣ̢‫ݺ‬ળౖࣗ႟ܑ҇ཕјє๻ໝྐྵౖఠஶѣ2ஶᆰ്̟56‫ͅݸ‬န౗38໪๘͆໙ႏఠആ޻‫ݶ‬౧࿫޻ୠൌ‫̟ࣟݶ‬൙̟3126.21
̜7̠ಬ෦૔ྞ̟৹‫ޣ‬ᄩഥ̟ඩಗ̜୮̟݁ୟᄣഉ̟આใ्ഥᇥ̟๎ᵂ̜‫̟ٯ‬຀‫఻گ‬઱̟஛౧‫ڵ‬ิ̟ॾ‫ݍ‬ൌᄣ̢ Cinacalcet ๩ᄮඩѠ૔ᆒฒ৊ౖ҇ฉьє९཈ౖ࿲৚௢ಪࡀ໸ሿకஶѣ2
ᆰ്̟26‫ݸ‬໙ႏ຿ခྀ޻‫ݶ‬ၿᅳબ࿫޻ୠେ‫̟ݶ‬࿐આ̟3126.22
̜8̠ࡶဲใ݇થ̟஛೙टᄩ̟஛౧‫̟ิڵ‬຀‫̟ٯ̜گ‬ၿใରে̟๦ใघઝ̟৹‫ޣ‬ᄩഥ̟৹ძ̜
ః̟ంใࢰથ̟෦ใఊ‫—̟ࣟڵ‬गഉ̟౧ែ̜౨̟ඩಗ̜୮̟ॾ‫ݍ‬ൌᄣ̢Ⴐౖ C चࠏܑ৾တ3च๻ໝྐྵѠӝҽңӝӊҴӦс೜লьє2ᆰ്̟:2‫ݸ‬ၿᅳ๻ໝྐྵେඏ‫̟ࣟݶ‬൙̟3126.22

㸫  㸫ƷǬǽ͙⾷ʶⅺ᜵Ⲥ⾸̜2̠ඩಗ̜୮̟۱‫ࡍگ‬થ̟ॾ൮घ‫ݍॾ̟ݵ‬ൌᄣ̢࿋ซ଴೑ग़੬Ѡћ।йୟъҁє व๘ѣ݁భളࡀ໸ค݁ஶс࡞҄ҁҀ3ஆౖᆰ̟຿ခྀҞӦӈҔӜӦҬ in TOYAMA 3126̟࿐આ̟
3126.17

⾷ঙᠬংම⏄᫛✤‫ׅ‬⍗ᲇકᮾ᳣⤴⾸⊣Ʒሤ̜2̠ච௒̜ီ̟ใ੟ᆁઞ̟ഡ௒̜޻̟౹‫ޣ‬ᄈఘ̟൮শ̜ఊ̟ჿ๦া໲̟๚ࡶਿ೶‫̢ڵ‬໙ႏ໹ܑҙҗӞҬѣ߷ಠѝ࿸౦̢ૐഘ߷ಠѠпцҀྌ৔ഉҲӦӄҢ NS5a ѝ4' ྌ႐ᄆᆛ‫ڱ‬ѣౡ࿿޻ษᄃ߇̟Japanese Encephalitis, 2-28, SMGroupͅUSA͆, USA, 3126.

ક⒈☟ᄙƷ‫ڤ‬Ʒ⊣
̜2̠Y.Ishigaki, Y.Nakamura, T.Tatsuno, S.Ma, N.Tomosugi : Phosphorylation status of human RNAbinding protein 9A in cells and its inhibitory regulation by Magoh, Experimental Biology andMedicine, 351:5:549-556, 3126.
̜3̠J.Zhang, Y.Ishigaki, T.Takegami : Hepatitis C virus NS 4 protein modulates the biologicalbehaviors of malignant hepatocytes by altering the expression of host cell microRNA, Molecular
Medicine Reports, 23:5:621:-6226, 3126.
̜4̠Y.Tachi, T.Okuda, N.Kawahara, N.Kato, Y.Ishigaki, T.Matsumoto : Expression of hyaluronidase-5
in a rat spinal cord hemisection model, Asian Spine Journal, ::2:8-24, 3126.
̜5̠J.Moriya, Q.He, H.Uenishi, S.Akazawa, J.Yamakawa, J.Kobayashi, Y.Ishigaki : Induction murine
models of chronic fatigue syndrome by brucella abortus antigen injections : is anemia induced or
QRW"%LRPHG5HVHDUFK,QWHUQDWLRQDO3126:2:259:, 3126.
̜6̠A.Nakajima, Y.Masaki, T.Nakamura, T.Kanawami, Y.Ishigaki, T.Takegami, M.Kawano, K.Yamada,
N.Tsukamoto, S.Matsui, T.Saeki, K.Okazaki, T.Kamisawa, T.Miyashita, Y.Yakushijin, K.Fujikawa,
M.Yamamoto, H.Hamano, T.Origuchi, S.Hirata, H.Tsuboi, T.Sumida, H.Morimoto, T.Sato,
H.Iwao, M.Miki, T.Sakai, Y.Fujita, M.Tanaka, T.Fukushima, T.Okazaki, H.Umehara : Decreased
expression of innate immunity-related genes in peripheral blood mononuclear cells from patientswith IgG5-related disease, PLoS One, 21:6:e1237693, 3126.
̜7̠F.Wang, Y.Zhang, L.Wang, P.Sun, X.Luo, Y.Ishigaki, T.Sugai, R.Yamamoto, N.Kato :Improvement of spatial learning by facilitating large-conductance calcium-activated potassiumchannel with transcranial magnetic stimulation in Alzheimer's disease model mice,
Neuropharmacology, :8:321-32:, 3126.
̜8̠Y.Li, K.Tanaka, L.Wang, Y.Ishigaki1.DWR,QGXFWLRQRIPHPRU\GH¿FLWLQPLFHZLWKFKURQLF
exposure to cerebrospinal fluid from patients with Anti-N-Methyl-D-Aspartate receptor
encephalitis, The Tohoku Journal of Experimental Medicine, 348:5:43:-449, 3126.

㸫  㸫ƷἕƷ◻
̜2̠ඩഡᄜ৸̟൧ჿࡍഌ̟౹‫ޣ‬ᄈఘ̢җҝӦ‫ۼ‬ള҇ᅀйє೽ਯचไથ५ྒࢽࠒੴ̟ࣟ൙‫ݏڮ‬ൌ޻੻ૂ̟51:236-241, 3126.
̜3̠ͅใ੟ᇭ৕̟͆ඩჿߵ࿎̟ච९வბ̟౹‫ޣ‬ᄈఘ̟ඩಗଷბ̢౹ᄎ౦࿁ѣನ‫҇ڦ‬ᅧᅀьєၑ૾໸஋ಠ૳६̟ඒࢄ‫ݏ‬ᐻ̟7::3:::-219, 3126.
Ʒ᮲Ʒअ̜2̠ͅH.Yoshida͆, Y.Ishigaki, A.Takizawa, K.Moro, Y.Kishi, T.Takahashi, H.Matsui : Comparative
genomics of the mucoid and nonmucoid strains of streptococcus pyogenes, isolated from the same
patient with streptococcal meningitis, Genome Annoucements, 4:3:e11332-26, 3126.
ƷǬǽ͙̜2̠౹‫ޣ‬ᄈఘ̟ඩഡᄜ৸̢ҳҾѤఊࣲќѷౡഝќтє̟݂޻ѝౡ࿿̟64:5:369-371, 3126.

કΉɿᮾ᳣Ή᫘⒙Ʒ࡛⭾કΉ⾷ʶⅺ᜵Ⲥ⾸̜2̠ஈ̜ࣄข̟ࡧ੟஝ᆖ̟౹‫ޣ‬ᄈఘ̟ࡶဲ৕ᅬ̟౟ಗ‫܀‬થ̢Regulation of the lens epithelial cellmorphology by Dock6̟ం޻ୠᆛ‫ڱ‬य़ࢅ͑௒ྂࠊ১೏௰ज౗്͒3‫ݸ‬ਈ੒ҪӦӐҫҙӓ̟੸
ႍ̟3126.19
ƷӴ࡛કΉɿᮾ᳣Ή⾷ȿɻɥɀȮɨ⾸̜2̠๦੟ქ࿎̟८ᄩᆖ૔̟ॴ̜ᅧ౗̟ᄖౄෟࡶ̢৊ࠣ੓Ѡѽѿ᪴ࠣ੎ၙѠᄥຐъҁҀ EMT ഊక‫ہ‬થѣຎซѝࡀ໸‫ݷ‬౸̢ GSK 4ԓ೒‫ޕ‬ѠѽҀ౒ট്̟57‫ݸ‬໙ႏ᪴ആ޻‫ݶ‬ൌ‫̟ݶ‬჏ॾ
̟ܵ3126.17
ƷӴ࡛કΉɿᮾ᳣Ή⾷ʶⅺ᜵Ⲥ⾸̜2̠౟రࡠᇚ̟‫ܣ‬ใำఘ̟ಗ९ཨ࿎̟݈຀௸ᇥ̟౹‫ޣ‬ᄈఘ̟஫ႏඬྗ̢ӜҶһ౽఼ಃඊӕҺӞѠпцҀ hyaluronidase- 5ѣᅍ౒঳‫ݑ‬Ѡљйћ്̟55‫ݸ‬໙ႏ౽෨౽఼ྐྵ޻‫̟ݶ‬࿶ܱ̟
3126.15̜3̠౹‫ޣ‬ᄈఘ̟ඩഡᄜ৸̟൧ჿࡍഌ̟๦੟ქ࿎̢Ӆһᄢᅗ੎ၙ‫ޓ‬஛ၙѣ‫ݷ‬౸്̟42‫޻ڮݸ‬ౡ࿿޻ไથ५ྒࢽ࡚ୠ޻‫̟ݶ‬჏ॾ̟ܵ3126.17
̜4̠౹‫ޣ‬ᄈఘ̟ඩഡᄜ৸̟൧ჿࡍഌ̟๦੟ქ࿎̢Ӆһे౟ᄢᅗ੎ၙ‫ޓ‬஛ၙѣ೽ਯचไથ५ྒ
ࢽࠒੴ്̟8‫ݸ‬໙ႏ RNAi य़ࢅ‫ ݶ‬/ ്3‫ݸ‬໙ႏ੎ၙ‫ޓ‬஛ၙ޻‫ৄ̟ݶ‬๦̟3126.19
̜5̠આႏ೶થ̟๦੟ქ࿎̟ᄜ൙࿐৆̟ॴ̜ᅧ౗̟ᄖౄෟࡶ̢қҢҰҰ̷ӓ҇‫ݵ‬юҀࠣ੎ၙࠗೱঘ੣ᅀ̢ంьй੎ၙ༘ᅋӊӟ̷һѠѽҀ‫ݷ‬౸്̟85‫ݸ‬໙ႏࠣ޻‫޻ݶ‬ୠ೴‫̟ݶ‬჏ॾ̟ܵ
3126.21̜6̠๦੟ქ࿎̟આႏ೶થ̟ॴ̜ᅧ౗̢৊с҈੓Ѡѽѿ᪴с҈੎ၙѠᄥຐъҁҀခથѝқҢҰҰ̷ӓ҇‫ݵ‬ьє੎ၙࠗೱঘ੣ᅀѣ‫ݷ‬౸്̟37‫ݸ‬໙ႏர݂࠰ࠣ཈ౡ޻‫ݶ‬೴‫̟ݶ‬ရથ̟
3126.22㸫  㸫̜7̠๦੟ქ࿎̟આႏ೶થ̟ຏႏࡍ̟߳ᄜ൙࿐৆̟ᄖౄෟࡶ̟ॴ̜ᅧ౗̢ҥӓҪҲӆӦѠѽѿ
᪴ࠣ੎ၙѠᄥຐъҁҀ EMT ഊక‫ہ‬થѣຎซѝࡀ໸‫ݷ‬౸̢GSK4ԓ೒‫ޕ‬ѠѽҀ౒ট്̟85‫ݸ‬໙ႏࠣ޻‫޻ݶ‬ୠ೴‫̟ݶ‬჏ॾ̟ܵ3126.21
ƷࢄᅀકΉɿᮾ᳣Ή⾷ʶⅺ᜵Ⲥ⾸̜2̠ඩ‫̜گ‬උ̟‫گ‬௒ఀჺ̟ඩែᄓ‫̟ݵ‬ఄใืൊ̟ࡻែਅఘ̟౹‫ޣ‬ᄈఘ̢Febuxostat ѠѽҀఠໝ੎ࠊ௒ྂ੎ၙௐ‫ޕ‬ѝໝᇔॆ౹ज౗ѠവюҀᅍ౒঳‫്̟ݑ‬2:‫ݸ‬ၿᅳྀໝ࠰‫ ݏ‬Basic
Research Meeting̟ࣟ൙̟3126.14

㸫  㸫ӽ۴֐᧸Ƀɻɇʀ
⊣Ʒሤ
̜2̠ච௒̜ီ̟ใ੟ᆁઞ̟ഡ௒̜޻̟౹‫ޣ‬ᄈఘ̟൮শ̜ఊ̟ჿ๦া໲̟๚ࡶਿ೶‫̢ڵ‬໙ႏ໹ܑҙҗӞҬѣ߷ಠѝ࿸౦̢ૐഘ߷ಠѠпцҀྌ৔ഉҲӦӄҢ NS5a ѝ4' ྌ႐ᄆᆛ‫ڱ‬ѣౡ࿿޻ษᄃ߇̟Japanese Encephalitis, 2-28, SMGroupͅUSA͆, USA, 3126.

ક⒈☟ᄙƷ‫ڤ‬Ʒ⊣
̜2̠Y.Ishigaki, Y.Nakamura, T.Tatsuno, S.Ma, N.Tomosugi : Phosphorylation status of human RNAbinding protein 9A in cells and its inhibitory regulation by Magoh, Experimental Biology andMedicine, 351:5:549-556, 3126.
̜3̠J.Zhang, Y.Ishigaki, T.Takegami : Hepatitis C virus NS 4 protein modulates the biologicalbehaviors of malignant hepatocytes by altering the expression of host cell microRNA, Molecular
Medicine Reports, 23:5:621:-6226, 3126.
̜4̠M.Nishijo, PT.Tai, NTN.Anh, TN.Nghi, H.Nakagawa, HV.Luong, TH.Anh, Y.Morikawa, T.Waseda,
T.Kido, H.Nishijo : Urinary amino acid alterations in 4-year-old children with neurodevelopmental
effects due to perinatal dioxin exposure in Vietnam : a nested case-control study forneurobiomarker discovery, PLoS One, 21:e1227889, 3126.
̜5̠Y.Tachi, T.Okuda, N.Kawahara, N.Kato, Y.Ishigaki, T.Matsumoto : Expression of hyaluronidase-5
in a rat spinal cord hemisection model, Asian Spine Journal, ::2:8-24, 3126.
̜6̠TN.Nghi, M.Nishijo, HD.Manh, PT.Tai, HV.Luong, TH.Anh, PN.Thao, NV.Trung, T.Waseda,
H.Nakagawa, T.Kido, H.Nishijo : Dioxins and nonortho PCBs in breast milk of vietnamese
mothers living in the largest hot spot of dioxin contamination, Environmental Science &Technology, 5::::6843-6853, 3126.
̜7̠J.Moriya, Q.He, H.Uenishi, S.Akazawa, J.Yamakawa, J.Kobayashi, Y.Ishigaki : Induction murine
models of chronic fatigue syndrome by brucella abortus antigen injections : is anemia induced or
QRW"%LRPHG5HVHDUFK,QWHUQDWLRQDO3126:2:259:, 3126.
̜8̠A.Nakajima, Y.Masaki, T.Nakamura, T.Kanawami, Y.Ishigaki, T.Takegami, M.Kawano, K.Yamada,
N.Tsukamoto, S.Matsui, T.Saeki, K.Okazaki, T.Kamisawa, T.Miyashita, Y.Yakushijin, K.Fujikawa,
M.Yamamoto, H.Hamano, T.Origuchi, S.Hirata, H.Tsuboi, T.Sumida, H.Morimoto, T.Sato,
H.Iwao, M.Miki, T.Sakai, Y.Fujita, M.Tanaka, T.Fukushima, T.Okazaki, H.Umehara : Decreased
expression of innate immunity-related genes in peripheral blood mononuclear cells from patientswith IgG5-related disease, PLoS One, 21:6:e1237693, 3126.
̜9̠M.Ishizaki, Y.Suwazono, T.Kido, M.Nishijo, R.Honda, E.Kobayashi, K.Nogawa, H.Nakagawa :Estimation of biological half-life of urinary cadmium in inhabitants after cessation ofenvironmental cadmium pollution using a mixed linear model, Food Additives and Contaminants
Part A-Chemistry Analysis Control Exposure & Risk Assessment, 43:9:2384-2387, 3126.
̜:̠F.Wang, Y.Zhang, L.Wang, P.Sun, X.Luo, Y.Ishigaki, T.Sugai, R.Yamamoto, N.Kato :Improvement of spatial learning by facilitating large-conductance calcium-activated potassiumchannel with transcranial magnetic stimulation in Alzheimer's disease model mice,
Neuropharmacology, :8:321-32:, 3126.

㸫  㸫

21̠Y.Li, K.Tanaka, L.Wang, Y.Ishigaki1.DWR,QGXFWLRQRIPHPRU\GH¿FLWLQPLFHZLWKFKURQLF
exposure to cerebrospinal fluid from patients with Anti-N-Methyl-D-Aspartate receptor
encephalitis, The Tohoku Journal of Experimental Medicine, 348:5:43:-449, 3126.
22̠ͅD.Sugiyama͆, T.Okamura, M.Watanabe, A.Higashiyama, N.Okuda, Y.Nakamura, A.Hozawa,
Y.Kita, A.Kadota, Y.Murakami, N.Miyamatsu, T.Ohkubo, T.Hayakawa, Y.Miyamoto, K.Miura,
A.Okayama, H.Ueshima ; NIPPON DATA 91/:1 Research Group : Risk of hypercholesterolemia
for cardiovascular disease and the population attributable fraction in a 35-year Japanese cohort
study, Journal of Atherosclerosis and Thrombosis, 33:2::6-218, 3126.
23̠ͅK.Nogawa͆, T.Kido, M.Nishijo, H.Nakagawa, Y.Suwazono : Benchmark dose of cadmium
concentration in rice for renal effects in a cadmium-polluted area in Japan, Journal of Applied
Toxicology, 46:2:35-39, 3126.
24̠ͅM.Satoh͆, T.Ohkubo, K.Asayama, Y.Murakami, M.Sakurai, H.Nakagawa, H.Iso, A.Okayama,
K.Miura, Y.Imai, H.Ueshima, T.Okamura ; Evidence for Cardiovascular Prevention From
Observational Cohorts in Japanͅ(32&+"-$3$1͆Research Group : Combined effect of bloodpressure and total cholesterol levels on long-term risks of subtypes of cardiovascular death :Evidence for cardiovascular prevention from observational cohorts in Japan, Hypertension,
76:4:628-635, 3126.
25̠ͅ T.Hisamatsu ͆, K.Miura, A.Fujiyoshi, T.Okamura, T.Ohkubo, SY.Nagasawa, M.Horie,
A.Okayama, H.Ueshima ; NIPPON DATA91 Research Group : Long-term outcomes associatedwith prolonged PR interval in the general Japanese population, International Journal of
Cardiology, 295:3:2-3:4, 3126.
26̠ͅHD.Manh͆, T.Kido, PT.Tai, R.Okamoto, S.Honma, SX.Liang, LT.Anh, S.Maruzeni, TN.Nghi,
M.Nishijo, H.Nakagawa, DD.Nhu, DV.Tung, NN.Hung, LK.Son : Levels of polychlorinateddibenzodioxins and polychlorinated dibenzofurans in breast milk samples from three dioxincontaminated hotspots of Vietnam, Science of The Total Environment, 622:527-533, 3126.
27̠ͅ N.Okuda ͆, K.Miura, A.Okayama, T.Okamura, RD.Abbott, N.Nishi, A.Fujiyoshi, Y.Kita,
Y.Nakamura, N.Miyagawa, T.Hayakawa, T.Ohkubo, Y.Kiyohara, H.Ueshima ; NIPPON DATA91
Research Group : Fruit and vegetable intake and mortality from cardiovascular disease in Japan : a
35-year follow-up of the NIPPON DATA 91 Study, European Journal of Clinical Nutrition,
7::5:593-599, 3126.
28̠ͅ Y.Suwazono ͆, K.Nogawa, Y.Morikawa, M.Nishijo, E.Kobayashi, T.Kido, H.Nakagawa,
K.Nogawa : Renal tubular dysfunction increases mortality in the Japanese general population
living in cadmium non-polluted areas, Journal of Exposure Science & Environmental
Epidemiology, 36:5:4::-515, 3126.
29̠ͅIR.White͆, E.Rapsomaniki ; Emerging Risk Factors Collaboration : Covariate-adjusted measuresof discrimination for survival data, Biometrical Journal, 68:5:6:3-724, 3126.
2:̠ͅ Y.Suwazono ͆, K.Nogawa, Y.Morikawa, M.Nishijo, E.Kobayashi, T.Kido, H.Nakagawa,
K.Nogawa : All-cause mortality increased by environmental cadmium exposure in the Japanesegeneral population in cadmium non-polluted areas, Journal of Applied Toxicology, 46:8:928-934,
3126.
31̠ͅK.Nakamura͆, H.Nakagawa, Y.Murakami, A.Kitamura, M.Kiyama, K.Sakata, I.Tsuji, K.Miura,
H.Ueshima, T.Okamura ; EPOCH-JAPAN research group. : Smoking increases the risk of allcause and cardiovascular mortality in patients with chronic kidney disease, Kidney International.,
99:6:2255-2263, 3126.

㸫  㸫32̠ͅM.Nagai͆, T.Ohkubo, Y.Murakami, N.Takashima, A.Kadota, N.Miyagawa, Y.Saito, N.Nishi,
N.Okuda, Y.Kiyohara, H.Nakagawa, Y.Nakamura, A.Fujiyoshi, RD.Abbott, T.Okamura,
A.Okayama, H.Ueshima, K.Miura : Secular trends of the impact of overweight and obesity on
hypertension in Japan, 2:91-3121, Hypertension Research, 49:22:8:1-8:6, 3126.
33̠ͅၿܱᇭൊ͆
̟ഄใఊჺ̟ఄ‫ݔ‬ᄤથ̟ඩಗଷன̢໙ႏའ Areas of Worklife SurveyͅAWS̸͆ॽఘѝ௱௙ࠅࢪ7љѣӒҬӑҶҴఒඊ̸̟फ۫৫ຍ‫̟޻ݏ‬39:2:64-74, 3126.
34̠ఄ‫ݔ‬ᄤથ̟౧௟રથ̟ඩഡৃ઩̟᛾‫̜گ‬எ̟ේែః਽̟ඩ౧ᄢྗથ̟஛௘ᄢྗથ̟ඩಗ
ଷன̢౹ಗॢѠпцҀඒ‫ڱ‬ӌ̷ҬѣӕҾҲӝӦңѠѷѝњф‫࠲ྴޓ‬जѣ཈ౡຍষ̟2:923121̟ၿᅳ঱ି۹ౡ޻‫̟ૂݶ‬52:2:5-21, 3126.
35̠࿄੟ᄔથ̟ఄ‫ݔ‬ᄤથ̟ఄႏსఘ̟ඩ๦೎થ̟ේ‫گ‬႖࠶৕̟ඩಗଷன̢࢔ଖ৹ᆽଅѠവюҀ͑౥рцၟჵ͒ѣєѶѣ‫ݵ‬ধᄬၼҨӐ̷Ҳ̷ᅋ౗ӊӠңӜӓѣ૳યѝྵ݆̟ၿᅳ঱ି
۹ౡ޻‫̟ૂݶ‬52:3:33-42, 3126.
36̠ͅ஛આ൦ჺ̟͆ᄢใਅડ̟৪‫گ‬ᄤ‫̟ݵ‬ඩഡৃ઩̟᛾‫̜گ‬எ̟౧௟રથ̟ේែః਽̟ఄ‫ݔ‬ᄤથ̟ใགྷ౞ઝ̟ඩಗଷன̢૜ᅶ৹ᆽଅѠпцҀ۰ᅋ೎๸ಆଙ௢ࢴрѾѴєห౞є҈Ѧф૲ಆଙᆙѣग़ກ̟ၿᅳ঱ି۹ౡ޻‫̟ૂݶ‬52:3:26-32, 3126.
37̠ͅઃែଜ૳̟͆ᄢใਅડ̟࿶ഡඕञ̟ใඩഥ‫ڵ‬ᇥ̟ࣉ඙୮થ̟࿧ᆠ̜࢛̟໙݁ৃഌ̟ඩಗ
ଷன̟ൌᇭ̜ৗ̟ܱઆ̜ბ̟ઃۡਅ໲̟ܱഡඕࢲ̟௒๦েટ̟ HIPOP-OHP ResearchGroup୍̢ࣅ‫௴ۀ‬ຏѠпцҀේ࠽ࠗѣ௴ࠅࢪ‫ݵ‬໛сჿ੏ᆭѣಆଙᆙѠࡹѱю঳‫̟ݑ‬ઍࣅ۹ౡ޻੻ૂ̟68:4::8-218, 3126.
ƷἕƷ◻
̜2̠ඩഡ̜৏̢ॿࡺ࠰पѣ୘ଘკ‫ܥ۽‬๹̟ॿࡺ̟45:4:352-357, 3126.
̜3̠ඩഡᄜ৸̟൧ჿࡍഌ̟౹‫ޣ‬ᄈఘ̢җҝӦ‫ۼ‬ള҇ᅀйє೽ਯचไથ५ྒࢽࠒੴ̟ࣟ൙‫ݏڮ‬ൌ޻੻ૂ̟51:236-241, 3126.
̜4̠ͅใ੟ᇭ৕̟͆ඩჿߵ࿎̟ච९வბ̟౹‫ޣ‬ᄈఘ̟ඩಗଷბ̢౹ᄎ౦࿁ѣನ‫҇ڦ‬ᅧᅀьєၑ૾໸஋ಠ૳६̟ඒࢄ‫ݏ‬ᐻ̟7::3:::-219, 3126.
̜5̠ͅၿܱᇭൊ̟͆ഄใఊჺ̟ఄ‫ݔ‬ᄤથ̟ඩಗଷன̢ຌфఘ̴ѣӃ̷Ӧҕҙһѝ௱௙ࠅࢪѠ࠙юҀ਼ࣞѣय़ࢅ౗‫̟ݑ‬ઍࣅҬһӟҬय़ࢅ̟33:3:224-229, 3126.
Ʒ᮲Ʒअ̜2̠ͅH.Yoshida͆, Y.Ishigaki, A.Takizawa, K.Moro, Y.Kishi, T.Takahashi, H.Matsui : Comparative
genomics of the mucoid and nonmucoid strains of streptococcus pyogenes, isolated from the same
patient with streptococcal meningitis, Genome Annoucements, 4:3:e11332-26, 3126.
ƷǬǽ͙̜2̠᛾‫̜گ‬எ̟ඩಗଷன̟ේែః਽̢ຠ཈ౖ௿ࣗஶѣᄬঞᄬ഑Ѡ࠙юҀय़ࢅ̠঵ౡᇖຌ‫޻ݏ‬य़ࢅྊ္஄̜ࣟ໎૔ౖ૱߶๸ౘ੫य़ࢅૉࣅ̜໎૔ౖ૱߶ѣबഘษџ‫޻۽‬Һ̷Ҳѣମେ̡‫ݷ‬౸Ѡ࠙юҀय़ࢅ̟န౗37໪๘೴ߊ̡ခ൷य़ࢅ၈ਇ஀ͅय़ࢅൊྴଅ̜ඩഡ়‫̟͆ڵ‬2:8589, 3126.
̜3̠౹‫ޣ‬ᄈఘ̟ඩഡᄜ৸̢ҳҾѤఊࣲќѷౡഝќтє̟݂޻ѝౡ࿿̟64:5:369-371, 3126.

㸫  㸫કΉɿᮾ᳣Ή᫘⒙Ʒ࡛⭾કΉ⾷ȿɻɥɀȮɨ⾸̜2̠M.Nishijo, H.Nakagawa : A Study on life prognosis of Itai-Itai disease patients and residents
living in the cadmium-polluted Jinzu river basin in Toyama, 24th International Conference on the
Biogeochemistry of Trace ElementsͅICOBTE 3126͆
, Fukuoka, 3126.18
Ʒ࡛⭾કΉ⾷ʶⅺ᜵Ⲥ⾸̜2̠ͅTT.Pham͆, M.Nishijo, MT.Do, NT.Pham, VL.Hoang, HA.Tran, VL.Nguyen, NN.Tran, VK.Tran,
TT.Dang, TL.Nguyen, H.Nishijo, H.Nakagawa : Dioxin concentrations in blood and foodconsumption habits of a population living near Bian Hoa airbase a "hot spot" of dioxin
contamination in Vietnam, The 46th international Symposium on Halogenated Persistent Organic
pollutants-Dioxin 3126, San Paulo, Brazil, 3126.21
̜3̠Y.Morikawa, M.Sakurai, S.Nagasawa, K.Nakamura, M.Nakashima, M.Ishizaki, H.Nakagawa,T.Kido, Y.Naruse : Interaction of shift work and aging on sleep : a longitudinal study among
factory workers, 33nd International Symposium on Shiftwork and Working Time, Denmark,3126.17̜4̠ஈ̜ࣄข̟ࡧ੟஝ᆖ̟౹‫ޣ‬ᄈఘ̟ࡶဲ৕ᅬ̟౟ಗ‫܀‬થ̢Regulation of the lens epithelial cellmorphology by Dock6̟ం޻ୠᆛ‫ڱ‬य़ࢅ͑௒ྂࠊ১೏௰ज౗്͒3‫ݸ‬ਈ੒ҪӦӐҫҙӓ̟੸
ႍ̟3126.19
ƷӴ࡛કΉɿᮾ᳣Ή⾷ʶⅺ᜵Ⲥ⾸̜2̠౟రࡠᇚ̟‫ܣ‬ใำఘ̟ಗ९ཨ࿎̟݈຀௸ᇥ̟౹‫ޣ‬ᄈఘ̟஫ႏඬྗ̢ӜҶһ౽఼ಃඊӕҺӞѠпцҀ hyaluronidase- 5ѣᅍ౒঳‫ݑ‬Ѡљйћ്̟55‫ݸ‬໙ႏ౽෨౽఼ྐྵ޻‫̟ݶ‬࿶ܱ̟
3126.15̜3̠౹‫ޣ‬ᄈఘ̟ඩഡᄜ৸̟൧ჿࡍഌ̟๦੟ქ࿎̢Ӆһᄢᅗ੎ၙ‫ޓ‬஛ၙѣ‫ݷ‬౸്̟42‫޻ڮݸ‬ౡ࿿޻ไથ५ྒࢽ࡚ୠ޻‫̟ݶ‬჏ॾ̟ܵ3126.17
̜4̠౹‫ޣ‬ᄈఘ̟ඩഡᄜ৸̟൧ჿࡍഌ̟๦੟ქ࿎̢Ӆһे౟ᄢᅗ੎ၙ‫ޓ‬஛ၙѣ೽ਯचไથ५ྒ
ࢽࠒੴ്̟8‫ݸ‬໙ႏ RNAi य़ࢅ‫ ݶ‬/ ്3‫ݸ‬໙ႏ੎ၙ‫ޓ‬஛ၙ޻‫ৄ̟ݶ‬๦̟3126.19
̜5̠ࡹಗᅊઃᇥ̟ഡ௒̜޻̢౹ಗॢ໸๏ඒၒѠпцҀҠҴӑҳҾѝӈҲһҥҴӑҳҾѣர
ේ്̟81‫ݸ‬໙ႏ۹ౡຍ࿿޻‫ݶ‬౧໙ႏબ࿫‫̟ݶ‬ൌ෦̟3126.21
̜6̠ͅH.D.Phuc̟͆௘আவྞ̟దၟ‫܇‬ᄈ̟໸ಗᇭৗ̟ඩಗଷன̢ҞҼӒҙӓ‫ܟ‬ಠඒ‫ڱ‬ѠпцҀໝඩҞҼӒҙӓѝԓ3- ӒҢӠңӠӉӝӦᆙѣဦ݂ The changes of urinary cadmium and ԓ3microglobulin in cadmium polluted areas̟໙ႏ঱ି۹ౡ޻‫ݶ‬೴‫̟ݶ‬ේ੟̟3126.22
̜7̠ͅ໸ಗᇭৗ̟͆దၟ‫܇‬ᄈ̟ఄ‫ݔ‬ᄤથ̟౧௟રથ̟௘আவྞ̟ඩಗଷன̢ҞҼӒҙӓྌ‫ܟ‬ಠඒ୊ჂѠпцҀఠໝ੎ࠊફྯѝળၧӝҬҢѣ࠙ᇍ̟໙ႏ۹ౡ޻‫޻ݶ‬ୠ೴‫̟ݶ‬ᇭ‫ݓ‬આ̟
3126.14̜8̠ͅᄢใਅડ̟͆ࣞ຀ਘથ̟৪‫گ‬ᄤ‫ྑ̟ݵ‬๦ୢ໲̟຀ࡧ̜ᇚ̟ඩಗଷன̟ჸใ̜ဍ̟‫ܣ‬ใຽ‫ݱ‬થ̟ൌࡶဲাࡠ̟ܱഡඕࢲ̟௒๦েટ̟ܱઆ̜ბ̟ઃۡਅ໲̢‫ڮ‬ᆒࡀ࠙ѹ्ఒѠпцҀ৹े‫پ‬ѣફลѣᄜ჆ѹ૔ᆒѣबഘѝॳ‫ܝ‬৫ຍѣ࠙ओ̜NIPPON DATA 3121̟໙ႏ৹े
‫ݶ޻پ‬೴‫̟ݶ‬஫આ̟3126.21
̜9̠ͅᄢใਅડ̟͆ࣞ຀ਘથ̟৪‫گ‬ᄤ‫ྑ̟ݵ‬๦ୢ໲̟຀ࡧ̜ᇚ̟ඩಗଷன̟ჸใ̜ဍ̟‫ܣ‬ใຽ㸫  㸫‫ݱ‬થ̟ൌࡶဲাࡠ̟ܱഡඕࢲ̟௒๦েટ̟ܱઆ̜ბ̟ઃۡਅ໲̢ჿ੏ѣ౺ࣈษಆଙѭѣᅾ‫ڞ‬ѝ৹े‫پ‬ફลѣᄜ჆ѣ࠙ᇍ̜ NIPPON DATA 3121̟໙ႏ঱ି۹ౡ޻‫̟ݶ‬ේ੟̟
3126.22
̜:̠NN.Tran, K.Ozawa, TT.Pham, AT.Nguyen, M.Nishijo, Y.Morikawa, H.Nakagawa, H.Nishijo :Effects of perinatal exposure to dioxins on neurodevelopment in Vietnamese children at 6 years ofage്̟96‫ݸ‬໙ႏ۹ౡ޻‫ݶ‬೴‫̟ݶ‬ᇭ‫ݓ‬આ̟3126.14
21̠S.Matsuba, K.Takeda, T.Yabe-Wada, T.Takai, A.Nakamura : SLPI regulates eosinophil-mediated
DOOHUJLFLQÀDPPDWLRQ്̟52‫ݸ‬໙ႏკ‫޻ݶ޻۽‬ୠେ‫੸̟ݶ‬ႍ̟3126.22
22̠T.N.Nghi̟஛൙࢝થ̟P.T.Tai̟N.Anh̟౧௟રથ̟ఄ‫ݔ‬ᄤથ̟ඩಗଷன̟౧௟ନ࿎̢ӌһҽӓѠпцҀଯઍ࠽ҳҗҝҠҪӦၰᇕѣ6੅ૌ໹ఋफ཈൦ѠᄮнҀۭࢾ̟໙ႏ۹ౡ޻‫޻ݶ‬ୠ೴‫̟ݶ‬ᇭ‫ݓ‬આ̟3126.14
23̠T.Yabe-Wada, S.Matsuba, K.Takeda, C.C.Philpott, A.Nakamura : Functional analysis of Sortilin inplasmacytoid dendritic cells്̟55‫ݸ‬໙ႏკ‫޻ݶ޻۽‬ୠେ‫੸̟ݶ‬ႍ̟3126.22
24̠T.Yabe-Wada, S.Matsuba, K.Takeda, T.Sato, M.Suyama, Y.Ohkawa, C.C.Philpott, A.Nakamura :Functional analysis of Sortilin in plasmacytoid dendritic cells, BMB3126̟ఋআ̟3126.23
25̠ඩ๦೎થ̟ఄ‫ݔ‬ᄤથ̟᛾‫̜گ‬எ̟ේែఃჺ̟౹੟ந࿎̟௘আவྞ̟౗౎ᄔඑ̟దၟ‫̜܇‬ᄈ̟໸ಗᇭৗ̟ඩಗଷன̢ᇖຌେඇѠпцҀలჃ௢ࢴѝे‫پ‬ဦ݂Ѡ࠙юҀ୓ඊษग़ກ̟
്85‫ݸ‬໙ႏ঱ି۹ౡ޻‫̟ݶ‬ේ੟̟3126.22
26̠๫ჿ᫸ᬖ̟ࡹಗ̜൓̟ඩಗ̜य़̟రჿઞᇚ̟ේ຿ᇭে̟౧௘̜໡̟௭ഡৗ‫̟ࠥڵ‬೙ᄽ‫ڵ‬ᇥ̟ඩഡ̜৏̟෯̜༩ࡶ̢Trichosporon asahii ѠѽҀ‫ݦ‬࿉ౖ༔ܑӕҺӞѠпцҀ Dectin-2ѣࡀ໸‫ݷ‬౸്̟66‫ݸ‬໙ႏॿࡺ࠰޻‫޻ݶ‬ୠ৭‫̟ݶܐ‬๫̟࢝3126.15
27̠᛾‫̜گ‬எ̟஛ᆠ୮໐̟චใ৆ඎ̟ේែః਽̟આಗ୮‫̟ڵ‬ଚܵ୲໐̟ఄ‫ݔ‬ᄤથ̟ඩಗଷ
ன̟༊ᝩ̜ি̢ӔҲӏӝҶҢҪӦҼӠ̷ӓѝႰౖఠആྐྵѝѣ࠙ᇍѠпцҀౖਮѣग़ກ̟
്62‫ݸ‬໙ႏ୪ࠅ࠰ྐྵᄬၼ޻‫޻ݶ‬ୠେ‫̟ݶ‬ൌਗ਼̟3126.17
ƷࢄᅀકΉɿᮾ᳣Ή⾷ʶⅺ᜵Ⲥ⾸̜2̠ඩ‫̜گ‬උ̟‫گ‬௒ఀჺ̟ඩែᄓ‫̟ݵ‬ఄใืൊ̟ࡻែਅఘ̟౹‫ޣ‬ᄈఘ̢Febuxostat ѠѽҀఠໝ੎ࠊ௒ྂ੎ၙௐ‫ޕ‬ѝໝᇔॆ౹ज౗ѠവюҀᅍ౒঳‫്̟ݑ‬2:‫ݸ‬ၿᅳྀໝ࠰‫ ݏ‬Basic
Research Meeting̟ࣟ൙̟3126.14

㸫  㸫ᮾ᳣౺अᘍؔゝㅀゝ㈨㈹͙

ㅽギㄿ ㉹㊝㊈ㅖㅾἕ۰ٛકᮾ᳣ཀలᕡӸ⫳Ƀɧɒʀ໙̜૑̢န౗38໪21ॉ28໙ͅ๙͆24:41̼27:26
௙̜୹̢ၿᎣంဎ31‫ޏ‬ӎ̷ӞҦ̷ҺҖӀ̷Ҳ̷̜ใඩ̜ᔣથ̜ࢲ଩
ͅ೴৾‫޻ڮ‬य़ࢅ୹̜ౡა‫޻ݏ‬य़ࢅᆛ‫͆ڱ‬ԙ᧯ٛ᪭ǛȑǮȘǨቈቻ
Ǉ♠Ʒ᜵ ギǈ਻ౡ‫ڮ‬ᆒјћ̝џ̼Ѡ̤ࣟ൙‫ݏڮ‬ൌ޻ྐྵ‫਻̜ۈ‬ౡ‫ڮ‬ᆒҮӦҲ̷ේͅࠏඃ᪴຿‫ࢲ̜͆ݏ‬଩̜ช̜ߵি
਷ේ̜౹‫̜ޣ‬ᄈఘ̜೴৾‫޻ڮ‬य़ࢅ୹̜ౡა‫޻ݏ‬य़ࢅᆛ‫ࢲ̜ڱ‬଩

Ǉ♠Ʒ᜵ クǈшшѳќక҈ѕࠤѣ਻ౡ‫ڮ‬ᆒࣟ൙‫ݏڮ‬ൌ޻̜‫޻ڮ‬࿫̜ࠤ‫ࢲ̜޻ݏ‬଩̜ࡶဲ̜৕ᅬ
਷ේ̜๦੟̜ქ࿎̜೴৾‫޻ڮ‬य़ࢅ୹̜಑ൿ‫ڮ‬ᆒय़ࢅᆛ‫̜ڱ‬୩ࢲ଩

Ǉᣀ֌♠᜵ǈ௿ആྐྵѭѣႵᅗ‫ڮ‬ᆒ̜͘Ⴏ໸੎ၙ҇ᅀйє਻ౡୠ͘ොଙൌ޻ൌ޻‫޻ڮۈ‬पय़ࢅ‫ࡀ̜ݏ‬໸਻ౡ‫޻ݏڮ‬ಕ্̜਻ౡ‫ڮ‬ᆒ޻ခჿ̜୩ࢲ଩̜༭ࡧ̜‫ڋ‬ன਷ේ̜ใඩ̜ᔣથ̜೴৾‫޻ڮ‬य़ࢅ୹̜ౡა‫޻ݏ‬य़ࢅᆛ‫ࢲ̜ڱ‬଩㸫  㸫ἕ۰ٛકᮾ᳣ཀలᕡӸ⫳㉹㊝㊈ㅖ⫳ҁ㈶㈍㈪㈮㈱̜န౗38໪๘ધჂ঱‫ގ‬ҮӒҽ̷ͅଘ਺̢ࣟ൙‫ݏڮ‬ൌ޻೴৾‫޻ڮ‬य़ࢅ୹̡ၿᎣంဎଃ̝ঞ܎̢౹
ಗॢ‫ڮ‬ન‫̡ݶ‬ҹӟӆࣟ൙̡қӈқӓ౹ಗ͆с̝န౗38໪21ॉ28໙ͅ๙͆ѠၿᎣంဎ31‫ޏ‬ӎ̷Ӟќ‫਺ގ‬ъҁє̞̜ਘ‫ݸ‬ѣҹ̷ӑѝьћ͑਻ౡ‫ڮ‬ᆒсѷєѾюႵᅗ͒҇ढч̝4჏ѣ಑ౡѠщ৭‫҇ܐ‬йєѕйє̞̜ѤэѶѠ̝͑਻ౡ‫ڮ‬ᆒјћ̝џ̼Ѡ̤͒ѝ൏ьћ̝ชߵি಑ౡрѾ̝ࠏആ̡ఠആџўള຿ѣആ࠰сࡀ໸ௐ‫ޕ‬Ѡࠚјє੒Ѡ̝ђҁѓҁѣ೏௰ѣඩѠഝ੔юҀ͑೏௰ߵ੎ၙ͒҇ഄѹьћђѣ
ࡀ໸҇ॣൊ҄ѿъѐҀଛၔсࡽഓѠక့ьћйҀшѝ҇҄рѿѹюйথѿশќ‫ݷ‬ಋьћйєѕ
йє̞̜ഘйћ̝͑шшѳќక҈ѕࠤѣ਻ౡ‫ڮ‬ᆒ͒ѣ‫ܐ‬൏ќ̝ࡶဲ৕ᅬ಑ౡрѾ̝ાᆜค݁҇ౡэҀᄼ̴џྐྵ഻Ѡ഍ьћાࡀ໸‫ݸ‬࿳ѣ૔ᆒсక့ьћйҀॶ௢҇щி‫ݵ‬йєѕт̝࣮ളษѠ༭຿ௐଛୠџўѣ੒ѠછᅀъҁҀࠤ຿ӟӦҭѣక့рѾܰཛྷဦౖஶѠവюҀ iPS ੎ၙᆒၔѣ૳੒ษଛ࡚ѳќ࿴ৄф‫ݷ‬ಋ҇ьћйєѕйє̞̜ຠအ৭‫ܐ‬Ѥ̝͑௿ആྐྵѭѣႵᅗ‫ڮ‬ᆒ̜͘Ⴏ໸੎ၙ҇ᅀйє਻ౡୠ͒͘ѣҹ̷ӑќ̝༭ࡧ‫ڋ‬ன಑ౡѠ୔ஶ௿࿋಻ѭѣ਻ౡ‫ڮ‬ᆒ̝ஈႿౖ࿋ౙႿѭѣ਻ౡ‫ڮ‬ᆒ̝߶ଅᄢᅗ iPS ੎ၙ҇ᅀйє௿ࣗҪ̷һ҇ᅀйє૔ᆒѣ4љѣදѠљйћ҄рѿѹюфщಋბйєѕйє̞шѣ4઴ѣщ৭‫҇ܐ‬෭ьћ̝਻ౡ‫ڮ‬ᆒѣॶ௢̝ࣞႵᅗѭѣ࠽ഹ̝਻ౡ‫ڮ‬ᆒѣॻ‫މ‬Ѡљйћѷᅬ‫҇ݷ‬ююѶҀшѝсќ
тєᄜ‫ࡠڞ‬џҮӒҽ̷ќзјє̞џп̝๵໙Ѥ‫ڵ‬ཥધჂ̝޻ౡ̝‫ڮ‬ᆒ࠙ओଅ৾҄ѐћ211჏‫ړ‬௒ѣઅ݈сзѿౢࢴќзјє̞̜̜̜̜̜̜̜̜
̜̜ͅခથଡ᢮य़ࢅခჿ̜ใඩ̜ᔣથ͆㸫  㸫♠᜵ ギƷǃԙ᧯ٛ᪭ǲǵƸǹ」Ǻ⿎Ǆ̜̜̜̜̜̜̜ࣟ൙‫ݏڮ‬ൌ޻ྐྵ‫਻̜ۈ‬ౡ‫ڮ‬ᆒҮӦҲ̷̡ࠏඃ᪴຿‫ࢲ̜ݏ‬଩̜ช̜ߵি
̜ࣞ໪ѣߵ੎ၙౡ࿿޻ѣక့Ѥჭ޳ѳьф̝2:92໪ѠѤଦౣᅠрѾ ES ੎ၙͅembryonic stem
cell: ᪒ౖߵ੎ၙ͆с̝3117໪ѠѤള੎ၙрѾ iPS ੎ၙͅinduced pluripotent stem cell: ఘীത໸ౖ
ߵ੎ၙ͆с੣౗ъҁ̝ᄼ̴џആ࠰ѹ೏௰рѾѷంьйߵ੎ၙс૒̴ѝ੣౗ъҁћтћйҀ̞ђьћ̝шҁѾѣߵ੎ၙ҇ᅀйє਻ౡ‫ڮ‬ᆒѣय़ࢅс̝࠱ೊрѾᆤட‫ܥ‬ᅀѠઽҀѳќ్̝‫މ‬ඩќౢ҈Ѡ৫҄ҁҀѽлѠџјћтћпѿ̝ి໪ঞѠѤ਻ౡ‫ڮ‬ᆒсॶ૳ѣѷѣѠџҀѕцќџф̝‫ڮ‬ᆒѣඩ௿ѠџҀ݉໸ౖсзҀ̞шѣѽлџ༓थѣѷѝ̝ࣟ൙‫ݏڮ‬ൌ޻ќѷ਻ౡ‫ڮ‬ᆒҮӦҲ̷҇ᅶі௒чҀшѝѠџјєс̝ႏҮӒҽ̷ќѤ̝਻ౡ‫ڮ‬ᆒѣॶ௢҇ி‫ݵ‬юҀѝѝѷѠ̝ࣟ൙‫ݏڮ‬ൌ޻сჭફю਻ౡ‫ڮ‬ᆒѠљйћѷୡѮҀшѝѝюҀ୍̞̜ᅗ̝‫޻ڮ‬ѣय़ࢅѤ̝૱߶ѣ཈ౡࡀஇѣ‫ݷ‬ბѠଘࠤспрҁ̝ђѣ౗‫࠱҇ݑ‬Ѡ૱߶ѣᄬၼѝ૔ᆒс৫҄ҁћтє̞ђьћ̝ђѣక့Ѥჭ޳ѳьйѷѣќзѿ̝с҈҇౒টюҀшѝѷѰѱ
݉໸ѠџѿљљзҀ̞ьрь̝йјє҈૫҄ҁєആ࠰ѹ೏௰ѣଳ࿳Ѡ࠙ьћѤ୍̝ᅗѣ‫ڮ‬ᆒќѤт҄Ѷћਙ໎ќзҀ̞‫ڵ‬ၒ̝਻ౡ‫ڮ‬ᆒѝѤ̝੎ၙѹ೏௰္҇ୋюҀшѝѠѽѿ̝૱߶Ѡѽјћࡀ໸࿋಻ѝџјєആ࠰ѣࡀ໸‫ݸ‬࿳҇఩Ҁ૔ᆒၔѝซࡠъҁ୍̝ᅗѣ‫ڮ‬ᆒќѤവ‫ܥ‬ьтҁџрјє૱߶Ѡ࠙ьћѷᄜ঳џ૔ᆒၔѝџҀ݉໸ౖс྄ѶѾҁћйҀ̞̜ߵ੎ၙѤ̝ത໸ౖߵ੎ၙѝ೏௰ߵ੎ၙѠൌအъҁҀс̝ES ੎ၙѹ iPS ੎ၙсൊྴษџത໸ౖߵ੎ၙќзѿ̝ఓളѣўѣ੎ၙѠѷခ݂юҀшѝсќтҀ̞‫ڵ‬ၒ̝೏௰ߵ੎ၙѤ̝ީആ࠰̡೏
௰Ѡഝ੔юҀ૜ঃ࿸౦໸ѝ୹ക೏௰ѣ৔౗੎ၙଠѭѣခ݂໸҇ᄜюҀߵ੎ၙќ̝ީ೏௰ѣ৔౗੎ၙ҇࢞ࢊюҀшѝѠѽѿ̝೏௰ѣ‫ڦ‬ૐ̝ଳ࿳̝਻ౡџўѠ࠴ᄮьћйҀ̞ॶ੔৫҄ҁћйҀ
਻ౡ‫ڮ‬ᆒѤ̝ଘѠ೏௰ߵ੎ၙ҇ᅀйєѷѣќзҀ̞̜ࣟ൙‫ݏڮ‬ൌ޻਻ౡ‫ڮ‬ᆒҮӦҲ̷Ѥ̝3127໪5ॉѠ‫ݙ‬ຌюҀᄬซќзҀ̞๵୸Ѥ೏௰ߵ੎ၙ҇ᅀйєࠏആ҇ඩ௿Ѡ਻ౡ‫ڮ‬ᆒ҇৫лшѝѠьћйҀс̝சᅗѤ̝಻ఒᆒ‫̝ݏ‬юџ҄і಻ആ࠰ѣ਻ౡ‫ڮ‬ᆒ҇৫нҀѽлѠьћйтєйѝ৤нћйҀ̞㸫  㸫♠᜵ クƷǢǢȍǶ⢳Ȣǯ᭩ǽԙ᧯ٛ᪭ࣟ൙‫ݏڮ‬ൌ޻̜ࠤ‫ࢲ̜޻ݏ‬଩̜ࡶဲ̜৕ᅬ
̜਻ౡ‫ڮ‬ᆒѝѤ̝Ҥҟѹྐྵࡃќࡀ໸сഠџ҄ҁє೏௰ѹആ࠰҇૜ခ૜ఓѣߵ੎ၙ҇ᅀйћ८෭ѿѣजѹຌт҇਻ౡюҀ਼಑ൿѣ‫ڮ‬ᆒ࡚ୠќзҀ̞ъѾѠ̝ী޻ษ࡚ୠ҇࣫છьћౡളѣ್௰҇છᅀьћ਻ౡюҀ೏௰ী޻ѷ̝ѷл‫ڵ‬љѣ୔ᅆџ਻ౡ࡚ୠќзҀ̞਻ౡ‫ڮ‬ᆒќѤ‫ٶ‬фџјєആ࠰Ѥଙѿࢍѿ̝ൊഽѣആ࠰ѠဦߺюҀ̞шѣൊഽнѣആ࠰ѝьћ̝ఘীษџѷѣ̝૜‫ݍ‬೏௰҇છлѷѣ̝ђьћ iPS ੎ၙѹߵ੎ၙ҇છлၒၔсзҀ̞̜ࠤ‫ݏ‬ᆛ‫ڱ‬ѣ਻ౡ‫ڮ‬ᆒѤ̝༭຿ௐѠവюҀ૔ᆒѠછᅀюҀࠤ຿ӟӦҭрѾઢѳјєѝॹнҀ̞༭຿ௐଛୠќѤ̝൞јєరபള҇஋ࢍь̝ఘীѣࠤ຿ӟӦҭѠফߺюҀ਼̞ࣞѤࠤ຿ӟӦҭѷక݂҇శч̝‫ࣞܚ‬ᆋᅀѣࠤ຿ӟӦҭѹ̝ᅟાᅀࠤ຿ӟӦҭс‫ގ‬཈ъҁ̝ѽѿ૳੒ѣࠤѠࣞй।нၒѠࣞњйћтћйҀ̞̜޴႟ᆛ‫ڱ‬ќѷ̝޴႟௒ྂѣߵ੎ၙ҇‫ڥ‬௭юҀшѝѠѽҀ޴႟ѣ਻ౡ‫ڮ‬ᆒсઢѳјћйҀ̞шҁѠѽѿ̝୔ஶџ޴႟ྴო૱߶ѣ૔ᆒсక့ьћтє̞޴႟Ѥ̝޴႟௒̝ྂ૳૲̝຿ྂѣ4೟৔ഉ҇ૐљ̞޴႟௒ྂߵ੎ၙѝйлѣѤ̝ဧࠤс्௜џ௙৾ѠѤ૜ঃѣ޴႟ဪ‫ܖ‬࿫ͅᆥ࿫͆рѾѣ੃ଙс݉໸ќзѿ̝ђҁс࿋݉໸џ௙৾Ѥ఑ഗѹҕҗӃӦҢ҇෭ь޴႟ด࢞ଅрѾѣ੎ၙ҇ᅀйҀ̞ࣞ໪ќѤ̝૜ঃѣশ১໯႟҇ᅂ႟௒Ѡ༘ᅋьћ޴႟௒ྂѣൊ҄ѿѠ‫ڥ‬௭ѠᅀйҀশ১໯႟༘ᅋ‫ڥ‬௭ѷᆤட‫ܥ‬ᅀъҁћйҀ̞ѳє̝iPS ੎ၙѠѽҀ޴႟௒ྂ਻ౡѷय़ࢅсక҈ќйҀ̞ॶ੔Ѥ̝޴႟௒ྂѣѴџѾя̝૳૲̝຿ྂ੎ၙѣ਻ౡय़ࢅѷ౺ࣈษѠ৫҄ҁћпѿ̝சᅗѤ޴႟಻ളѣ਻ౡѷ݉໸ѝџҀѕ҂л̞ђҁѠѽјћ̝޴႟಻೟҇‫ڥ‬௭юҀѣќѤџф̝ྣᅆџ࿫ခѕц҇‫ڥ‬௭юҀ޴႟࿫ခ‫ڥ‬௭с݉໸ѠџҀрѷьҁџй̞̜ iPS ੎ၙѠѽҀ݈ᆽܰཛྷဦౖ૔ᆒѤ̝ంဎѹީଠ၈ຘѠѽѿ̝ৄфඑѾҁћйҀᇮ൏ќзҀ̞ႏ৭‫ܐ‬ќѤ̝݈ᆽܰཛྷဦౖஶѣ਼ం૔ᆒѹ iPS ੎ၙѠѽҀ૔ᆒၔѣ‫ޘ‬ᅹпѽѨசᅗѣืၱѠљйћѷпᇮььєй̞㸫  㸫ᣀ֌♠᜵Ʒൺℼᩰȇǽቈቻٛ᪭ොଙൌ޻ൌ޻‫޻ڮۈ‬पय़ࢅ‫ࡀ̜ݏ‬໸਻ౡ‫޻ݏڮ‬ಕ্਻ౡ‫ڮ‬ᆒ޻ခჿ̜୩ࢲ଩̜༭ࡧ̜‫ڋ‬ன̜௿ആѤ̝‫ݺ‬ҁҀѝ૜಺Ѡ૔Ҁшѝѣџйആ࠰ќзҀ̞шѣєѶ̝૔ᆒၔѝьћѤ̝ไથࡀ࠰
ќѣ඙тߺн̝ѳєѤആ࠰‫ڥ‬௭с৫҄ҁћйҀ̞ьрь̝ࡀ࠰Ѥ̝йѳѕѠ‫̴ݫ‬ѣആ࠰ѠཿѮћ໸ᆜѠॻ‫މ‬сзѿ̝ആ࠰‫ڥ‬௭ѠѤᆖфඑѾҁєҼҽ̷࿋ഒѣჵ൏сзҀ̞шѣєѶ̝௿ആᆛ‫ڱ‬ќѣႵᅗ‫ڮ‬ᆒѝьћ̝ఘীษѠആ࠰҇੣Ҁ̝зҀйѤഠ஌࿫‫҇ڕ‬੎ၙќ඙тߺнҀшѝс৤нѾҁћйҀ̞шҁс̝਻ౡ‫ڮ‬ᆒѝॿѥҁҀ਼಑ൿѣુѴќзҀ̞̜ગ໫џшѝѠ̝32్ࡉ҇हнєс̝‫̴ݫ‬Ѥ̝੎ၙђѣѷѣ҇ᄜࡀ࿿рѾ੣౦юҀшѝѠѤ౗লьћйџй̞љѳѿఘীษѠആ࠰҇੣౦юҀєѶѠѤ̝੎ၙрѾ੎ၙ҇੣ҀྣᅆсзҀ̞ਘ‫ݸ‬Ѥ̝Ⴏ໸੎ၙѝॿѥҁҀ iPS/ES ੎ၙрѾ̝ўѣѽлѠьћ௿ആ҇੣౦юҀѣр̝‫ݺ‬ҁє௿ആ҇ўѣѽлѠьћ૔ᆒюҀѣр̝шѣ૔ᆒၔс̝йѳѕ၏нћйҀჵ൏฿̝ਈ຿‫ޓ‬ѣॶ௢ͅॻ‫͆މ‬Ѡљйћி‫ݵ‬ьєй̞㸫  㸫౪༔౫ಏƷ⦘ᖴٛᲇগકἕ۰ٛકᮾ᳣ཀƷᮾ᳣Ƀɧɒʀ
໙૑̢န౗39໪3ॉ23໙̜ࣟ͆ͅ24:11̼29:11
௙୹̢ࣟ൙‫ݏڮ‬ൌ޻̜࠱ೊय़ࢅ๮3‫ࡣݶ̜ޏ‬૭

Ǉ⢋⁬‫▉‮‬ඔ♠᜵ǈ͑ӌҶҼҨҗҼѝӌӦҴ҇љџйѕ41໪͒ౡა‫޻ݏ‬य़ࢅᆛ‫ࢲ̜ڱ‬଩̜ใඩ̜ᔣથ
਷ේ̜౧ྑ̜ᣨᄖ̜̜೴৾‫޻ڮ‬य़ࢅ୹̜୹ේ

Ǉཀ‫ڽݲ‬Ȃᮾ᳣⤴ᵱƷᮾ᳣༔እ᫘⒙ǈ⿋᧯ܶᲇકᮾ᳣ⲏࣕ⿍
2̠RS-rich ᆛ‫ڱ‬ӝӦઓ݂Ҡҽ̷үѠѽҀ Y25ӝӦઓ݂ࡀ৔ѣ‫ݷ‬ბ̜̜̜̜౹‫̜ޣ‬ᄈఘခથଡ᢮य़ࢅခჿ

3̠ҥӁӓဩେѠѽҀ TAR ஶমऍӕҺӞ੎ၙѣ੣౦̜̜̜̜ඩഡ̜ᄜ৸

‫ڭ‬เથࡀ໸य़ࢅခჿ

4̠CRISPR/Cas:҇ᅀйє EJC ‫ہ‬થѣඩ௿ളࣆ੔ࡀ৔ѣ‫ݷ‬౸̜̜̜̜൧ჿ̜ࡍഌ

ခથଡ᢮य़ࢅခჿ

5̠ҬӈҖӦҧӒқӝӦ৾౗ৱ೎ӁҶҢҕҙһӑҙҬѣྴॶच‫ݷ‬౸̜̜̜̜൮শ̜̜ఊ

੎ၙ‫޻ڮ‬य़ࢅခჿ̜

6̠ϫ༗ള XP-C ੎ၙсѷљ઺‫ޓ‬ಧഠ஌ѠпцҀଳ࿳໸̜̜̜̜ࡻ‫̜̜܂‬Ⴞ੎ၙ‫޻ڮ‬य़ࢅခჿ7̠ҹһӜӅӔҽѠпйћ basal body ѣ౗୞Ѡ࠙҄Ҁ k-antigens Ѥ RhoGDI р̤̜̜̜̜ഥใ̜ᆁ۸

ଡ᢮ౡ࿿य़ࢅခჿ

8̠UBR5-E8ೱঘ੣ᅀѤ UBR box ᆛ‫ݵ҇ڱ‬ьћйҀ̜̜̜̜ใ੟̜ᆁઞ

‫ڭ‬เથ‫ރ‬ဦຍ࿿ͅ඄༭૲౒ট͆य़ࢅခჿ

⿋Ӟᴻٛ᪭ᮾ᳣ⲏࣕ⿍9̠с҈૔ᆒ‫ܥ‬ᅀ҇ჭફьєқҢҰҰ̷ӓ౒টࡀ৔ѣ‫ݷ‬ბ̜̜̜̜આႏ̜೶થ

݈ᆽ౒টय़ࢅခჿ

:̠৊ࠣ੓Ѡѽѿ᪴ࠣ੎ၙѠᄥຐъҁҀ EMT ഊక‫ہ‬થѣຎซѝࡀ໸‫ݷ‬౸̜̜̜̜๦੟̜ქ࿎

݈ᆽ౒টय़ࢅခჿ

21̠Toxic AGEsͅTAGE͆य़ࢅ 3126
̜̜̜̜ච຿̜౞ࡠ

๻݂౒টय़ࢅခჿ㸫  㸫

22̠ӜҶһ୸ൊ༘ᅋ௿ࣗ੎ၙѠпцҀ੎ၙ຿ TAGE ජ౺ѝ੎ၙௐ‫ޕ‬̜̜̜̜௒ใ̜ඬઝ

๻݂౒টय़ࢅခჿ

23̠Ӆһ᪴ࠊ༘ࠣᅋ੎ၙѠпцҀ੎ၙ຿ TAGE ජ౺ѝ੎ၙௐ‫࠙ޕ‬ᇍ඄༭૲ѣ൸੬̜̜̜̜৹ใ̜ട௹

๻݂౒টय़ࢅခჿ

24̠ໟ‫ڞ‬ѣҥӁӓᆛ‫ڱ‬ѣҦӇ̷ి഑ซၔ̣ MugCap ͅ Multiple gene competitive ̜
DPSOL¿FDWLRQ͆ѣ‫ގ‬཈̜̜̜̜ం‫گ‬ใ̜ᅆ‫ڭ‬เથ૱߶य़ࢅခჿ

25̠੎ၙ‫ڭ‬เ޻ษग़ਯѠпцҀ࠱ೊษ࡚ୠѣ‫ۮ‬ഃ݂̜̜̜̜ྑ੟̜̜ଚ

‫ڭ‬เથ૱߶य़ࢅခჿ

⿋ɟɵɀȯȷɐᮾ᳣Ƀɻɇʀ⿍
26̠Ӓӝ༃༳ᇕѠѽҀࠤ‫ޓ‬࿫ѣ໩ຍ഻ѣҪӒӘӟ̷ҪӚӦѣુѴ̜̜̜̜஛๦̜౞ྗ

ࠅࢪ९ౖા޳ྐྵ഻य़ࢅ࿫

27̠TGF-beta ᄥຐ຿ྂ੎ၙ DPP-5཈ॶѠവюҀᅍ౒঳‫ݑ‬Ѥ DPP-5೒‫ޕ‬ᄅࠗќ‫ڤ‬џҀ̜̜̜̜ࣟ—̜गഉ಑౒ခથ௴ᆎ‫޻ݏ‬य़ࢅ࿫

28̠The absorption of iron in intestine is mainly regulated by serum hepcidin.
̜̜̜̜ᄖౄ̜ෟࡶ

ึ಺ဦౖ඄༭૲ೖᄅ‫޻ݏ‬य़ࢅ࿫

29̠ӌһҽӓѠпцҀంౡૌ໹༃෕ਯѣુѴ̜̜̜̜౧௟̜રથ

ಘᅹษय़ࢅ࿫㸫  㸫ἕ۰ٛકᮾ᳣ཀㄻ౪༔クゴ౫ಏᮾ᳣㉹㊝㊈ㅖ⫳ҁ㈶㈍㈪㈮㈱̜န౗38໪๘೴৾‫޻ڮ‬य़ࢅ୹ҮӒҽ̷с̝န౗39໪3ॉ23໙ࣟ͆ͅচঞ2૑рѾ̝࠱ೊय़ࢅ๮3‫ࡣݶޏ‬૭Ѡпйћ‫਺ގ‬ъҁє̞޻຿‫ޓ‬ѽѿ94჏ѝതфѣઅ݈ଅќзјє̞̜౧ྑᣨᄖ೴৾‫޻ڮ‬य़ࢅ୹ේѣٰੵѠഘт̝य़ࢅ୹‫ۀ‬ѠѽҀ2໪ࠗѣय़ࢅ౗‫ݑ‬཈ྴсခჿ൴‫ڕ‬ќ৫҄ҁє̞ౡა‫޻ݏ‬ᆛ‫ڱ‬ѽѿ8൏̝಑ൿ‫ڮ‬ᆒय़ࢅᆛ‫ڱ‬ѽѿ8൏̝ӊӠҫҚҢһय़ࢅҮӦҲ̷ѽ
ѿ5൏̝ल29൏ѣ཈ྴс୶૒৫҄ҁє̞य़ࢅҹ̷ӑѤ࠱ೊय़ࢅрѾᆤட‫ܥ‬ᅀѳќ࿴ৄф̝ॽ̴ѣ‫ܐ‬൏Ѡ࠙ьߋ཈џࡣᇫсื‫ގ‬ъҁ̝અ݈ଅѠѝјћᄜ‫ࡠڞ‬џҮӒҽ̷ѝџјє̞ᨀ˛฻੿ჹ࿽⢋⁬‫▉‮‬ඔ♠᜵̜य़ࢅ౗‫ݑ‬཈ྴѠ‫ۃ‬тഘт̝൅௱ଅࡌ໫৭‫ܐ‬с‫਺ގ‬ъҁє̞౧ྑ୹ේс਷ේ҇ჄѶ̝͑ӌҶҼҨҗҼѝӌӦҴ҇љџйѕ41໪͒ѣ‫ܐ‬൏ќ̝ใඩᔣથࢲ଩ѠѽҀ৭‫ܐ‬с৫҄ҁє̞̜৭‫ܐ‬ќѤ̝ใඩࢲ଩ѣшҁѳќѣय़ࢅᆿѹᆤடѝѣ࠙҄ѿ̝ᆤடрѾय़ࢅѭઽҀి̴ѣ౗‫ݑ‬с૙ъҁє̞ຠѠ̝ఋफ̡ࣗౡग़೏௰ќѣज഻޻ษྵ݆̝े‫̡ۼ఼̡ۼ‬ໝग़ള҇ᅀйћѣఒඊӑ̷Ҟ̷ѣ‫ޱ‬ᅶѝྐྵ഻ѭѣ࠙҄ѿѠ࠙юҀय़ࢅ̝૔ᆒၔಱൗѠষцћѣ௝၈ด࢞џў̝ത࠵Ѡ҄єҀय़ࢅќ̝ӌҶҼҨҗҼѠࠕ८юҀшѝ҇ჭษѠ̝ఋफ຿‫ݏ‬ᆛ‫ڱ‬ѣѴџѾя̝஛ૌ‫̝ݏ‬ౣఋ‫ݏ‬ᆛ‫ڱ‬ќѣఒඊ̝૔ᆒѠൌтф࠴ᄮъҁє૳౼Ѥ̝юѥѾьйѷѣќзѿ̝ᆤட‫ڮ‬џѾќѤѣय़ࢅ౗‫ݑ‬ќзјєѝйнѽл̞ຠѠ̝ҴӠҪӦరઓ݂ৱ೎ѣ္ৱ೎ќзҀҹһӜӅҼӠӆҝ
ӊҹӝӦѣൊଆ‫ڤ‬௜ѠѽҀႏၡ୸Ѷћѣ౗ఘᆰ҇।йѕь̝ӇӞӏҗӞҹһӜӅҼӠӆҝӊҹ
ӝӦूഠஶќзҀшѝ҇ბѾрѠьєшѝѹ̝ఋफஶমѝ༓थ‫ౖٶ‬ଡ᢮ѣ೏Ѵ৾҄ѐѠႺಅѠ࠙ᇍюҀ૜ঃ৊ളѣఒඊ࡚ୠѣ‫ޱ‬ᅶ̝৊ aquaporin5৊ളѣग़ୟपѣ੣౗ѠѽҀાఋफ౽఼ܑѣఒඊѝ૔ᆒၔಱൗѭѣ࠴ᄮ̝৊ NMDA ଦᄵള৊ളѣ cell-based assay ၔѣ‫ގ‬཈џўѤຠྥюѮтѷѣќзѿ̝തфѣय़ࢅ౗‫ݑ‬ѝйнѽл̞шҁрѾѷय़ࢅѠण҄јћйфшѝ҇ୡѮѾҁ̝৭‫ܐ‬Ѥହᆈь̝અ݈ଅ‫ڵ‬ຎѽѿ౴ьѴџй༪ଛс೾Ѿҁє̞ѳє̝ใඩࢲ଩ѭѣ߷ଆѣࡃૐі҇ਕѶћ̝޻຿ѣѴџѾя̝ం߆ѽѿઅ݈ъҁєၒрѾѷ‫ݛ‬ഐсഈฉъҁє̞̜य़ࢅҮӒҽ̷Ѥ̝ච຿౞ࡠ೴৾‫޻ڮ‬य़ࢅ୹࿲୹ේѣٰੵ҇ѷјћౢ‫ݶ‬ѣліѠ႞҇မэє̞ͅ಑ൿ‫ڮ‬ᆒय़ࢅᆛ‫̜ڱ‬๦੟̜ქ࿎͆㸫  㸫⢋⁬‫▉‮‬ඔ♠᜵⿉ǃɡɋɑȽȬɑǷɡɻɉȡǳǹǓǯ౫Ǆౡა‫޻ݏ‬य़ࢅᆛ‫ࢲ̜ڱ‬଩̜ใඩ̜ᔣથ
̜шшѠઽјћѷѳѕซ໪ѝйлॶ૳҇૳߷ќтћйџйс̝ᆤட‫ڮ‬ѝьћઘૉ҇ьћтєષ਼̝҇ঞѣ3໪ࠗ೴৾‫޻ڮ‬य़ࢅ୹ќ૜ᄢѠઘૉ҇юҀࡀ‫҇ݶ‬ᄮнћйєѕйє೴‫ڮ‬य़࠙ओଅѣ‫ފ‬ᄼѠ௿ѽѿ߷ଆь̝টᆶఈь௒чѳю̞̜шҁѳќѣේ໪Ѡ҄єјћଙѿ೏҈ќтєઘૉѤ̝‫ࠔڵ‬ьћ͑ӌҶҼҨҗҼѝӌӦҴ҇љџ
х͒ѷѣќзјєѽлѠપйѳю̞൷๵ьєஶᆰ̝зҀйѤঞ༕рѾ஄ॹ҇ࢀѶѾҁєஶᆰѠљйћ̝ђѣఒඊпѽѨ༓थѣྐྵ഻҇ბѾрѠюҀѮф̝ఋफ̡ࣗౡग़೏௰ќѣज഻޻ษྵ
݆̝े‫̡ۼ఼̡ۼ‬ໝग़ള҇ᅀйћѣఒඊӑ̷Ҟ̷ѣ‫ޱ‬ᅶѝྐྵ഻ѭѣ࠙҄ѿѠ࠙юҀय़ࢅ̝૔ᆒ
ၔಱൗѠষцћѣ௝၈ด࢞џў̝ത࠵Ѡ҄єҀय़ࢅѠ౺ࣈษѠ࠙҄јћтѳьє̞ଘџവொѤ̝ӒҝӄҴ̷ѠпцҀࣗ৔ഉ඄༭ѣ‫ݷ‬౸̝ӒһҦӦҼӝҕ໹ࣗஶѣྐྵचѝဦ‫ڭڤ‬เથѣവ‫ܥ‬пѽѨആ࠰အഝ੔ཿѝᕦ߶ആ࠰ѝѣ࠙ᇍ̝ҴӠҪӦరઓ݂ৱ೎ѣ္ৱ೎ќзҀҹһӜӅҼӠӆ
ҝӊҹӝӦѣൊଆ‫ڤ‬௜ѠѽҀႏၡ୸Ѷћѣ౗ఘᆰ҇।йѕь̝ӇӞӏҗӞҹһӜӅҼӠӆҝӊ
ҹӝӦूഠஶќзҀшѝ҇ბѾрѠьєшѝ̝ၨଡ᢮ౖఋफஶমऍѣྐྵ‫ہ‬сკ‫޻۽‬ษ‫ڤ‬௜ќзѿ̝ఋफ೏௰ѠവюҀ૜ঃ৊ളсྯษѝюҀ඄༭৊९҇।йѕьєшѝ̝ђѣঞბѾрѠџј
єఋफஶমѝ༓थ‫ౖٶ‬ଡ᢮ѣ೏Ѵ৾҄ѐѠႺಅѠ࠙ᇍюҀ૜ঃ৊ളѣఒඊ࡚ୠ҇‫ގ‬཈ь̝തфѣஶᆰќ̝‫ౖٶ‬ଡ᢮ѣ೨࠽཈।ѣтјрц҇੣јєшѝ̝ђҁѳќේй̟ࠗђѣ‫ڤ‬ຎѠљйћࡣᇫсഘйєાఋफ౽఼चത཈ౖড়݂ஶѝાఋफ౽఼ܑͅ Devic ྐྵ͆ѣఒඊ҇ခцҀшѝѠ
џјє৊ aquaporin5৊ളѣग़ୟप҇йі೨ф੣౗ь̝ાఋफ౽఼ܑѣఒඊѝ૔ᆒၔಱൗѠ࠴ᄮьєшѝ̝ౣఋஶ௢ќ཈ஶюҀ૜ঃკ‫ౖ۽‬໹ܑѣлі̝৊ NMDA ଦᄵള৊ളѣ cell-based assayၔ҇‫ގ‬཈ь̝ఋफ຿‫ݏ‬ѣѴџѾя̝஛ૌ‫̝ݏ‬ౣఋ‫ݏ‬ᆛ‫ڱ‬ќѣఒඊ̝૔ᆒѠ࠴ᄮьєшѝџў
ќ̝ӌҶҼҨҗҼѠࠕ८ь̝߶ଅъ҈ѣᄬঞ‫ރ‬ಸѠ৮फ़ќтєѝપјћйѳю̞̜൅ໟ৭‫ܐ‬ќѤ̝шҁѳќѣఒᆒ̡य़ࢅߋຍ҇ఁѿါѿ̝‫ھ‬ொѠગјћйҀߋຍ҇ѳѝѶћѴ
єйѝપйѳю̞㸫  㸫⿋⿁⾽౺अᘍؔ⿍Ṥ‫֝ك‬൧ᮾ᳣ո⦕
౫ɿሰɿᅠ

अ⣔ᑿ⬄

ɇȬɐɳ

3126/:/2:ຽᆖంဎଃધჂ৭‫͑ݶܐ‬ӆӘ̷ҹҖӈӞӜҗӈ്23஼͒๻݂҇ၼйќҕӦҴқҗҫӦң

3126/:/31ຽᆖంဎଃ৹ AGE ‫௴ۄ‬࿿ྋцћ͘߃९ќ͑ӆӘ̷ҹҖӈӞӜ
җӈ്23஼͒

ᦹऴ‫ڤ‬ම╋╏ᩰຎᮾ᳣⤴
౫ɿሰɿᅠ

अ⣔ᑿ⬄

ɇȬɐɳ

3126/5/3

ຽᆖంဎଃ஛ૌ࠽рѾѣ઺‫ޓ‬ಧവ੫̜சᅗѣ͑ࠤ૱߶͒ᄬၼѠ

3126/5/4

݁ჿంဎଃசᅗѣࠤ૱߶҇ᄬၼ̜஛ૌрѾჭѣ઺‫ޓ‬ಧവ੫̜ၬ
થѹѶсѢတᅀ҇

3126/5/4

ंႏ໙໙ంဎଃ

஛ૌ࠽рѾ઺‫ޓ‬ಧവ੫̜҇༭຿ௐ̝ᇢࠤ̿சᅗѣ཈ஶ҇ᄬၼ̜ܵ‫ޓ‬ѣේ૑ࠗߋຍ̜ၬથ̝ѶсѢတᅀьћ3126/5/4

້ܲҲҗӓҬଃ஛ૌѣჭѠ઺‫ޓ‬ಧ̜‫̜ࢾۭٶ‬சᅗѣࠤ૱߶Ѡѷ

3126/5/4

ҹӟӆ๫࢝૔Ҁ਼̥ಷಧ്̜56‫̜ݸ‬క݂юҀ༭຿ௐ૔ᆒ

3126/5/7

ఋআంဎଃჭѣᇢ݂కѶҀ઺‫ޓ‬ಧ̜஛ૌ࠽рѾၬથѝࠤࢽќവ੫҇ҲӦҩҾҕќ‫෕޻۽‬ਯ૳ય̜

3126/5/7

๫‫ܣ‬໙၈ଃ

‫ڮ‬ᆒం్ࡉ̜૱߶ᄬၼ ஛ૌ࠽рѾ̜ൌᆙѣ઺‫ޓ‬ಧќჭсᇢ݂̜ܵ‫ޓ‬ќѤၬથ̝ѶсѢ҇

3126/5/8

ઍफంဎଃᇢ݂೨ѶҀ઺‫ޓ‬ಧ̜ഥᅊрѾથ࢞ѣჭ҇ଚҁ3126/5/8

ࡻ੟໙໙ంဎଃ

઺‫ޓ‬ಧവ੫̜஛ૌ࠽рѾ̜ჭѣᇢ݂தф९‫ہ‬Ѡ̜ၬથѝѶсѢတᅀᄜ঳

3126/5/8

਩‫ݱ‬ంဎଃ

्৆‫ڮ‬ᆒ̜ჭѣ઺‫ޓ‬ಧവ੫̜થўѷѣਗрѾ̜சᅗѣࠤ૱߶҇ᄬၼ̜ၬથѹѶсѢတᅀьћ

3126/5/8

Medias)੻ૂ*͑૭຿ѠйҀрѾ̝͒͑іѼјѝ့фѕцѕрѾ̝͒͑ਘ໙ѤфѷѿѕрѾ͒̿шѣᄎඊс̝ྗགќйѾҁҀрўлрѣခрҁຘ̥̜઺‫ޓ‬ಧവ੫ႏ࿫̜ႏ໙
཈ഒ !!

3126/5/8௒ფంဎଃჭѣ઺‫ޓ‬ಧവ੫̜஛ૌ࠽рѾୌခѠ̜ၬથѝࠤࢽ҇တᅀ̜சᅗѣࠤ૱߶ᄬၼ

3126/5/9

੠ࣉంဎଃசᅗѣࠤ૱߶҇ᄬၼ̜஛ૌ࠽рѾ઺‫ޓ‬ಧവ੫҇

3126/5/:࿶๦Ⴢ၈ଃ஛ૌ࠽рѾჭѣ઺‫ޓ‬ಧവ੫̜சᅗѣࠤ૱߶҇ᄬၼ̜ၬથѹࠤࢽတᅀ҇

3126/5/21

ઍफంဎଃၬથ̝ѶсѢတᅀ̜҇஛ૌ࠽рѾჭѣ઺‫ޓ‬ಧവ੫㸫  㸫౫ɿሰɿᅠ

अ⣔ᑿ⬄ɇȬɐɳ

3126/5/22

ࠤࢽর޻ୟའ

઺‫ޓ‬ಧќ೨࠽ᇢાѷ̜ҫӚӦҰӦͰҫӚӦҰӦ ӔҺҖҕҮӒҽ̷̜਩̴ძࢲ଩сҲӦҩҾҕ෕ਯќ཈ྴ

3126/5/23આᅊంဎଃჭѣ઺‫ޓ‬ಧവ੫஛ૌ࠽рѾ̜ၬથ̝ѶсѢတᅀ̜૱߶ᄬၼѠ঳‫ݑ‬

3126/5/26

෌໙޻ౡంဎଃ

઺‫ޓ‬ಧѤჭѠѷ‫ٶ‬йѽ̜થўѷѣш҂рѾവ੫҇

3126/5/26

૭ᅥჂ၈઺‫ޓ‬ಧ̜ჭѷධ‫̜ڞ‬஛ૌ࠽рѾവ੫҇

3126/5/26

ࠤࢽর޻ୟའ

J&J ӔҺҖҕҮӒҽ̷̜͑઺‫ޓ‬ಧќ೨࠽ᇢાѠ͒

3126/5/27⊕௘ంဎଃ઺‫ޓ‬ಧ̝ჭѣۭࢾධ‫ڞ‬

3126/5/27

ସใ‫ބ‬ం၈ଃ

ჭѣ઺‫ޓ‬ಧവ੫̜஛ૌ࠽рѾྣᅆ

3126/5/28

௹໶ႛ໙ంဎଃ

થўѷѣჭ̜઺‫ޓ‬ಧവ੫҇

3126/5/28

ઠਈంဎଃ‫ڮ‬ᆒం్ࡉ̜஛ૌ࠽рѾჭѣ઺‫ޓ‬ಧവ੫̜சᅗѣࠤ૱߶҇ᄬၼ̜ၬથѹѶсѢတᅀ҇

3126/5/29

ҹӟӆࣟ൙ࡶဲ৕ᅬࢲ଩̢ᆝ຿ௐ਼̜ం૔ᆒ̜ၑ඙Ѥ૫ბѣࢯҁ ¦¦¦3126/5/2:

ພ๦ంဎଃჭ̜઺‫ޓ‬ಧവ੫஛ૌ࠽рѾ̜༭຿ௐѹᇢࠤ̜೨࠽཈
ஶѣࢯҁ̜ၬથѹѶсѢတᅀ҇

3126/5/31

ం߆໙၈ଃ‫ڮ‬ᆒం్ࡉ̜஛ૌ࠽рѾѣവ੫୔ᅆ̜ჭ҇ᇢ݂ъѐҀ઺‫ޓ‬ಧ̜ଔ໪ќ༭຿ௐѣࢯҁ̜ܵ‫ޓ‬Ѥၬથ̡ࠤࢽ
ѣတᅀ҇3126/5/31

ࢣຎ෭௹ଃфѾь3126̜஛ૌ࠽рѾჭѣ઺‫ޓ‬ಧവ੫

3126/5/34

ේ੟ంဎଃ஛ૌ࠽рѾჭѣ઺‫ޓ‬ಧവ੫̜சᅗѣࠤ૱߶ᄬၼ̜ၬ
થ̝ѶсѢတᅀьћ

3126/5/39TBS઺‫ޓ‬ಧ९‫ہ‬ѣࠤѣ૱߶̜஛ૌ࠽рѾവ੫҇

3126/5/39๫࢝ంဎଃ઺‫ޓ‬ಧ९‫ہ‬ѣࠤ૱߶̜஛ૌ࠽рѾവ੫̜҇ಧᆙതйਈથўѷѣ཈ஶᅵѷ৹й̜ၬથ̝ѶсѢတᅀ̜৹йᄬၼ঳‫ݑ‬

3126/5/39࢝๓ంဎଃசᅗѣࠤ૱߶҇ᄬၼ̜஛ૌ࠽рѾჭѣ઺‫ޓ‬ಧവ੫̜ၬથѹѶсѢတᅀ҇

3126/5/3:

આᅫ໙໙ంဎଃ

஛ૌ࠽рѾჭѣ઺‫ޓ‬ಧവ੫̜சᅗѣ༭຿ௐ̝ᇢࠤ҇ᄬၼљѥৄйၬથѹѶсѢတᅀ

3126/5/41

ၿ‫އ‬ຘంဎଃ

ჭѠൌᆙѣ઺‫ޓ‬ಧ̜༭຿ௐѹᇢࠤѣ݉໸ౖ̜ࠤ૱߶
ᄬၼ஛ૌ࠽рѾҕӈӝҞఘѣથўѷ̜Ѱѱᤀᇃཛྷ཈ஶ̜љѥѣৄйၬથ̝ѶсѢќവ੫҇

3126/6/2

৹එంဎଃჭѣ઺‫ޓ‬ಧവ੫̜஛ૌрѾ̜ҨӦңӜҬќࠤ૱߶ᄬၼ

3126/6/5࠵࿣ంဎଃჭѣ઺‫ޓ‬ಧവ੫̝஛ૌ࠽рѾ̜சᅗѣࠤ૱߶̝ᇢ݂҇ᄬၼ㸫  㸫౫ɿሰɿᅠ

अ⣔ᑿ⬄ɇȬɐɳ

3126/6/23

આजంဎଃசᅗѣࠤ૱߶҇ၼщл̜஛ૌ࠽рѾ઺‫ޓ‬ಧവ੫

3126/6/24

TBS਼ం઺‫ޓ‬ಧവ੫̜થўѷѣჭѷධ‫̥ڞ‬

3126/6/24

໋໙ႏంဎଃ

ჭѣ઺‫ޓ‬ಧവ੫஛ૌрѾ̜ၬથѹѶсѢඨᅀॿѨ߀ц3126/6/32

ಒᅄ໙၈சᅗѣࠤ૱߶҇ᄬၼ̜஛ૌ࠽рѾ઺‫ޓ‬ಧവ੫̜ၬથ
ѹѶсѢတᅀ҇

3126/6/3:

ҴӘ̷ӝҶӊTV઺‫ޓ‬ಧѠщධ‫̥ڞ‬ђѣۭࢾѝവ੫

3126/7/5

ႛ໙ంဎଃࠤྐྵ̢઺‫ޓ‬ಧс९‫̝ہ‬໙ႏѣ5༗̜ҲӦҩҾҕѣ஛ඩ৹ౡ෕ਯ

3126/7/6

આ‫ۉ‬ඩ‫ܢ‬ం၈ଃჭѣ઺‫ޓ‬ಧവ੫̜஛ૌ࠽рѾୌခѠ

3126/8/2⊤౹࿳ࢺంဎଃ

ѣѓѴྐྵ‫߶̜ۈ‬ଅ̝ॊిѝѷѠഄ݈̜༭຿ௐଛୠ‫ގ‬ઢрѾ4໪

3126/8/3:

෌໙ంဎଃ݃ಈ୊ൕѣ৹ᆽଅষц̜༭຿ௐѣ჆ᆎग़ఒ̜ࣟ൙‫ڮ‬‫ݏ‬ൌ̝⊤౹

3126/8/3:ࠥଛ໙၈ଃಸ‫ڞ‬ѣ჆ᆎࠤ‫ݏ‬ग़ఒ̜⊤౹ќ̜ࣟ൙‫ݏڮ‬ൌ̜݃ಈѣ৹ᆽଅവொ

3126/8/41໙ႏҹӟӆ઺‫ޓ‬ಧѣ࠮४̜џё̤̜ჭѹགѠ‫ڤ‬௜3126/9/6

NHK༭຿ௐ̥61ൊрѾѣࠤѣҕӦҴқҗҫӦң

3126/9/31

ၿᎣంဎଃ്͕53‫͖ݸ‬ᇢࠤѤ༭຿ௐѣ୸࠽ஶ௢̼ҳӉјћ।нҀѣѤᅆධ‫̜ڞ‬ൾ૑ࠗѣଛୠќ41੅ଔါѿ̜

3126/:/2

MRO༭຿ௐଛୠѠљйћ

3126/:/27йіѥ҈ଃ22ॉ৽‫݋‬сହ҄јћѷჭѣ໙ளцѠऴ‫ࠤ̥ށ‬ѣྐྵࡃ҇தф઺‫ޓ‬ಧѤ෌сථѽѿ໐༗ࢬйѝབბ

3126/21/4

ҹӟӆࣟ൙༭຿ௐ਼ం૔ᆒ

3126/21/31ၿᎣంဎଃಕჸ‫ڮ‬Ѡဎф༭຿ௐ̡ᆝ຿ௐѣ਼ಷಧ

3126/21/33

ߗૡ‫ݶ‬ଃӔҺҖҞӞһӝӆӘ̷Ӧ

്65‫ݸ‬໙ႏ༭຿ௐ޻‫ ݶ‬/ ്52‫ݸ‬రபളय़ࢅ‫̜ݶ‬ၑ૾ಧ༭຿ௐѣ୸࠽ྐྵဦ̤ྈ༳5໪ჭќᄜ୹।ᅵഄ݈р̼࿶๦്‫ڵ‬९཈ࣘࡽ੣ࣅ୍ૉଅѣరபള੶ۭ

3126/22/38

҄ръୟའࡽਇ̥ჭѠҪӒѣзҀఘѤ༭຿ௐѣ཈ஶᅵс৹ѳҀѝ҄рѿ̝઺‫ޓ‬ಧവ੫с෭໪ࡽჄ

3126/23/21

෌໙ంဎଃၑ૾ಧྈ༵̜ഒѿџй௝၈̜༭຿ௐ̜य़ࢅഒຄѴ௢഻3126/23/27

NHK༭຿ௐ૔̥61ൊрѾѣࠤѣҕӦҴқҗҫӦң

3127/2/27⊤౹ంဎଃ

4ఘѠ2ఘѤ༭຿ௐଛୠсྣᅆ̜݃ಈ୊ൕ৹ᆽଅ૳഻
෕ਯќབბ

3127/4/6

ӊӟҫҺӦһଃ‫̥ृݷ‬఑થҢӝҾҶҢ̜஛ૌ‫ޓ઺̜͑ݏ‬ಧќ૫ბѷ " થ࢞Ѡѷ୤рѾҨӦңӜҬ҇͒㸫  㸫౫ɿሰɿᅠ

अ⣔ᑿ⬄ɇȬɐɳ

3127/4/39

ၿᎣంဎଃྈੇଅѠরຬцҀ̜਩̴ძ‫ڮ‬ન̝⊤౹ќଛୠ

3127/4/42ၿᎣంဎଃҺҬҢ໙ૂ̜ଛୠ૭ѣ BGM
ണ̜Web ¼³Å3ॊӽ۴֐᧸Ƀɻɇʀ
౫ɿሰɿᅠ
3126/21/3:

अ⣔ᑿ⬄
ၿᎣంဎଃ

ɇȬɐɳ
ࣟ൙‫ݏڮ‬ൌќ૳६ຍ࿿‫ڟ‬ᆻ㸫  㸫⿋⿂⾽ᮾ᳣‫ۅݲ‬Ǡӱțɿ࡛⭾̰ᘓ⿍
࡛⭾̰ᘓ
ଓ⛅‫‮‬

լ⟘࡛

‫ۅ‬ӱቃ⫻‫ۅ‬ӱ⤴⫨ᮾ᳣☁Ⲥ༊̜ஜ࿶ͅൌ޻‫ۈ‬ౡ͆ඩਈ

3122.3.2̼
3127.4.42಑ൿ‫ڮ‬ᆒय़ࢅ
ᆛ‫ڱ‬݈ͅᆽ౒টय़ࢅ
ခჿ͆

Rapid Increase in Serum Iron Level
After Oral Iron Intake as an
Indicator of Duodenal Iron
Absorption and Inverse Regulationof Iron Absorption by Hepcidin
Expressionᅪ̜ბͅൾ࠽य़ࢅ‫͆ۀ‬ඩਈ

3126.4.:̼
3127.3.38

ౡა‫޻ݏ‬य़ࢅᆛ‫ڱ‬Study on the pathogenesis of
autoimmune neurological disorders
using disease model systems༊̜౟။̜̜
ͅൌ޻‫ۈ‬ౡ͆ඩਈ

3126.5.2̼
312:.4.42

ౡა‫޻ݏ‬य़ࢅᆛ‫ڱ‬ͅခથଡ᢮य़ࢅ
ခჿ͆

Analysis of phosphorylation of
RNA binding proteins in humancells.

ય̜ఄͅຠซ஄ଛ͆

ඩਈ

3126.5.2̼
3127.2.31

಑౒ခથ௴ᆎ
‫޻ݏ‬य़ࢅ࿫

Linagliptin but not sitagliptin
inhibited transforming growth
factor- ԓ3 -induced endothelial
DPP-5 activity and the endothelialmesenchymal transition

Seon Myeong
Leeͅຠซ஄ଛ͆

ࠛਈ

3126.2.34̼
3127.9.37

಑౒ခથ௴ᆎ
‫޻ݏ‬य़ࢅ࿫

ਓޭ̝ࣗ຿ྂ੎ၙѠпцҀҝ̷һӈҔҫ̷࿋಻㸫  㸫⿋⿃⾽ঋ⤴ᮾ᳣ⓝ‫⦘׬‬ᵱ⿍⿀⾸ᄙ⤴ᲇકᭉɿᅠቊક⒈࿑⅟Ήᲇકᮾ᳣⛻ⓝ‫⦘׬‬
Ჷᬶ۵

⁬۵

ᕟ۵

ᮾ᳣☁Ⲥᵱ

⦘ⲥ ٣Ԓ

࠱཰य़ࢅ
ͅB͆ ಑ൿ‫ڮ‬ᆒय़ࢅ
ᆛ‫ڱ‬

ࢲ଩

ච຿̜౞ࡠ

ॶൊѣ௴଻߸ѣຠ෈ѝྌҕӞҦ̷Ӟ઼ౖၶౖࠏௐ
‫ޕ‬ѣ཈ஶ̡కืѝѣ࠙ᇍౖѠ࠙юҀय़ࢅ

!4-711!

ӊӠҫҚҢһ
य़ࢅҮӦҲ̷

ࢲ଩ॾ‫̜ݍ‬ൌᄣ

۰ᅋ‫ܥ‬๹ҪңҽӞѣ༆ඁѠѽҀൊଆ૱߶ѣ཈ஶࡀ৔ѣᅬ‫ݷ‬ѝ౒টଛඍѣ‫ޱ‬ᅶ!4-111!

࠱཰य़ࢅͅB͆ ӊӠҫҚҢһ
‫ޓއ‬य़ࢅҮӦҲ̷

୩ࢲ଩౧௟̜રથӌһҽӓѠпцҀҳҗҝ
ҠҪӦѣീૌ໹ࡀ໸ѝ໚ᄳૌ໹ఋफ཈൦Ѡࡹѱюۭࢾ

!3-:11!

࠱཰य़ࢅͅC͆ ౡა‫޻ݏ‬य़ࢅ
ᆛ‫ڱ‬

ࢲ଩

౹‫̜ޣ‬ᄈఘ

ఋफߵ੎ၙѠпцҀంࡋඩ௿ള౒টࡀ৔ѣ‫ݷ‬౸

!2-311!

ౡა‫޻ݏ‬य़ࢅ
ᆛ‫ڱ‬

୩ࢲ଩

ใ੟̜ᆁઞ

UBR5/p711-HPV27 E8ೱঘ੣ᅀѠѽҀ཈с҈ӔҞ
Ҿҭӓ

!911!

಑ൿ‫ڮ‬ᆒय़ࢅ
ᆛ‫ڱ‬

୩ࢲ଩

๦੟̜ქ࿎

৊с҈੓ѠѽҀ᪴с҈੎ၙѣఆ୰ज૲ްຝѣခથࡀ৔ѣ‫ݷ‬ბѝс҈૔ᆒѭѣ‫ܥ‬ᅀ

!2-611!

ӊӠҫҚҢһ
य़ࢅҮӦҲ̷

୩ࢲ଩

ࣟ—̜गഉ

COMT ࿋಻сѷєѾю्৆ྈ‫ޕ‬ѣခથࡀ৔‫ݷ‬ბ

!2-311!

ࢣຎᅧᅀҮӦ
Ҳ̷

৭ન

ഡ௒̜̜޻

ౡߋ॒຿ќѣ߷ಠஶ༙‫ݵ‬ਠනͅ‫͆ݨ‬ѝӅһѣಅ௳࿈๘ѝ߶ଅిѣ࠙ओ

!711!

ࢣຎᅧᅀҮӦ
Ҳ̷

ࢲ଩

ඩഡ̜̜৏

ҮӝӦӊӠҹҕ̷үҗӦӅӆҲ̷ѠѽҀҕӟӞ
ҡ̷མ‫ܥ‬ѣ౒টࡀ৔ѣ‫ݷ‬ბ

!2-411!

ӊӠҫҚҢһ
य़ࢅҮӦҲ̷

୩ࢲ଩౧௟̜રથҳҗҝҠҪӦѠѽҀ૜မஶҬӍҢһӜӓௐ‫ޕ‬ѝӒӜ̷ҾӘ̷ӠӦपߋຍѝѣ࠙ᇍ!3-411!

ӊӠҫҚҢһ
य़ࢅҮӦҲ̷

ࢲ଩ॾ‫̜ݍ‬ൌᄣ

ҝ̷һӈҔҫ̷౒টѠѽҀ๻ໝྐྵఠஶѠവюҀంєџ૔ᆒᄅѣ‫ގ‬཈

!711!

ଔଛय़ࢅ
ͅB͆ ౡა‫޻ݏ‬य़ࢅ
ᆛ‫ڱ‬

৭ન

൮শ̜̜ఊ

໙ႏ໹ܑҙҗӞҬ߷ಠѠпцҀҬӈҖӦҧӒқӝ
Ӧ / ઼૲Ӝӈһѣᄃ߇!611!

්ಘษၛ‫ݯ‬य़ࢅཀୡ۵㸫  㸫

Ჷᬶ۵

ཀୡ۵

⁬۵

ᕟ۵

ᮾ᳣☁Ⲥᵱ

⦘ⲥ ٣Ԓ

಑ൿ‫ڮ‬ᆒय़ࢅ
ᆛ‫ڱ‬

஄ࢲ

৹ใ̜ട௹

ହႩ๻݂ઍ࿿Ѡඨჭьє๻ໝྐྵတ཈᪴ࠣഊక඄༭
૲ѣຎซࡹѨ߼࡫ᆭࠟᄜ
݂৾࿿ѣ੣ᅀ

!2-311!

಑ൿ‫ڮ‬ᆒय़ࢅ
ᆛ‫ڱ‬

ຠซ
஄ࢲ

ࡴ‫گ‬٪ࡉથ

ౡߋ଻߸ྐྵ҇ᄬ।юҀంьй๻݂඄༭૲ѣຎซ̝пѽѨ૱߶ᄬၼ௴࿁౗ခ
ѣ൸੬

!2-311!

⿁⾸‫׷᧯ڣ‬Ҙᭉᵱⓝ‫ڽ⦘׬‬ȂǬǽ͙Ӹ᫢ᑿ⬄ᵱ
Ჷᬶ۵

ᕟ۵

ཀୡ۵

⁬۵

ᮾ᳣☁Ⲥᵱ

⦘ⲥ⾷٣Ԓ⾸໎૔ౖ૱߶๸
ౘ੫य़ࢅૉࣅ
ͅ໎૔ౖ૱߶
ౘ੫य़ࢅૉࣅ͆

౹‫̜ޣ‬ᄈఘ

ౡა‫޻ݏ‬य़ࢅᆛ‫ڱ‬ࢲ଩ంࡋ૱߶̣ TAFRO ஶমऍѣ‫ޱ‬ᅶѣєѶѣय़ࢅൊྴଅ!
‫ࠊߊڵ‬ᅬ

໎૔ౖ૱߶๸
ౘ੫य़ࢅૉࣅ
ͅ໎૔ౖ૱߶
ౘ੫य़ࢅૉࣅ͆

ใඩ̜ᔣથౡა‫޻ݏ‬य़ࢅᆛ‫ڱ‬ࢲ଩ఋफკ‫޻۽‬ษા฿ѠѽҀ໎૔ౖાఋफܑѣఒ
ඊ࠱୯੣౗

3-5:7

ဍ࿫‫޻ݏ‬ஷඒ‫ڱ‬җӁӌ̷ҪӚӦಘᅹબ
܎ӊӠңӜӓ

ච຿̜౞ࡠ಑ൿ‫ڮ‬ᆒय़ࢅ
ᆛ‫ڱ‬ࢲ଩ౡߋ଻߸ྐྵѣ཈ஶ̡కืѠпцҀంࡋҲ̷ҥҶһѝьћѣ Toxic
AGEsͅTAGE͆ѣ࠙ᄮ
ѝђѣ೒લ

6-997

ͅ঱੗͆ၿᎣс҈य़ࢅఁࢺ੗
ඇ̜ၿᎣс҈࠱ࣟච຿̜౞ࡠ಑ൿ‫ڮ‬ᆒय़ࢅᆛ‫ڱ‬ࢲ଩‫ౖٶ‬ଡ᢮ѣ཈ஶ̡కื
ѠпцҀ຤ౖହႩ๻݂
ઍ࿿ѣ࠙ᄮ

2-111

य़ࢅ౗‫ގืݑ‬ૉࣅ̜य़ࢅ౗
‫਼ݑ‬หื‫ގ‬બ܎ӊӠңӜӓ
ͅA-STEP͆
FS Ҭҹ̷ҫҪ̷ҭ५੔݂Ҳҗӊܱ੟̜ୢᇚ಑ൿ‫ڮ‬ᆒय़ࢅ
ᆛ‫ڱ‬

ຠໟ
ࢲ଩

ҬӈҖӦҧӒқӝӦ৾౗ৱ೎ͅ SMS ͆2҇ྯษѝьє໎૔ౖс҈ѠവюҀ૒్ൊ৊с҈੓
ѣ‫ގ‬཈

6-621

ࢳ๎ьय़ࢅ݈
ഓӀҶһӢ̷
ҢӊӠңӜӓ
Ҫ̷ҭ A

๦੟̜ქ࿎

಑ൿ‫ڮ‬ᆒय़ࢅᆛ‫ڱ‬୩ࢲ଩క৫᪴ࠣѝђѣқҠҰ
Ұ̷ӓ҇ҳӉӞҲ̷ҥҶһѝьє૔ᆒᄅѣ
‫ގ‬཈

3-611

ࣟ൙ൌ޻с҈
కื౒টय़ࢅ
୹̜န౗38໪
๘ࢣຎय़ࢅ

๦੟̜ქ࿎

಑ൿ‫ڮ‬ᆒय़ࢅᆛ‫ڱ‬୩ࢲ଩᪴с҈қҠҰҰ̷ӓѝ
GSK 4ԓѣফᅜษྐྵᅬ
੣ᅀѣ‫ݷ‬ბѝс҈૔ᆒᄅҬҢӝ̷ҾӦңѭѣ
‫ܥ‬ᅀ

511

㸫  㸫

Ჷᬶ۵

ᕟ۵

ཀୡ۵

⁬۵

ᮾ᳣☁Ⲥᵱ

⦘ⲥ⾷٣Ԓ⾸໐ਈࠗফᅻૉ
ࣅॾ‫̜ݍ‬ൌᄣ

ӊӠҫҚҢһ
य़ࢅҮӦҲ̷

ࢲ଩

്25‫ݸ‬໙ႏࠛਈ๻ໝྐྵ
ఠஶҮӒҽ̷

2-191

ࢳ๎ьय़ࢅ݈
ഓӀҶһӢ̷
ҢӊӠңӜӓ
Ҫ̷ҭ A

ࣟ—̜गഉ

ӊӠҫҚҢһ
य़ࢅҮӦҲ̷

৭ન৊ಧ‫݂ڦ‬ӍӊҴҼᄅѣ
‫ގ‬཈

3-611

ͅ঱੗͆຿຀ࡌ
໫‫޻ݏ‬ఁࢺ੗
ඇ̜຿຀ࡌ໫
‫޻ݏ‬஖ᆲ̡ࣟ
य़ࢅ஄౗

ࣟ—̜गഉ

ӊӠҫҚҢһ
य़ࢅҮӦҲ̷

୩ࢲ଩๻ໝྐྵఠѣಧ‫݂ڦ‬ခથࡀ৔‫ݷ‬ბѝంࡋ૔ᆒಘ
ᅹѣ‫ގ‬཈

4-111‫ڵ‬ཥ੗ඇၔఘ
ౄۡඒ‫ڮڱ‬ᆒఁࢺ੗ඇ്̜
5‫ݸ‬ౄۡඒ‫ڱ‬‫ڮ‬ᆒఁࢺ஄౗

஫ใ̜ৃࡶӊӠҫҚҢһ
य़ࢅҮӦҲ̷

ӐҬһҼҢҲ̷໢එஶҬҢӝ̷ҾӦң෕ਯѝඒ‫ڮ̡ڱ‬ᆒ̡৫ౘѣ၆ߊษҢӝҹҖҞ
ӞӄҬѣ৔ඞ

2-931

ᇖੇ૱ྐྵᆤட
य़ࢅૉࣅྊ

਩̴ძ̜ᄽ

ӊӠҫҚҢһ
य़ࢅҮӦҲ̷

ࢲ଩๫ไ࿶๦്‫ڵ‬९཈ࣘࡽ੣ࣅ୍ૉଅѠവюҀ‫۽‬
޻ษय़ࢅ

6-111

ᇖຌ‫಻ڋ‬۹ౡ೴৾य़ࢅૉࣅ

਩̴ძ̜ᄽӊӠҫҚҢһ
य़ࢅҮӦҲ̷

ࢲ଩๫࢝ไᆜ࿶๦്‫ڵ‬९થᆜ཈ไ୹ѠпцҀࣘࡽ੣ࣅ୍ૉଅѣၑ૾ಧྈѥфᆙѝరபളਣ൞཈
ஶѠ࠙юҀ෕ਯ

2-:11ᇖຌ‫಻ڋ‬۹ౡ೴৾य़ࢅૉࣅ

୸ਖ਼ຽ෦થӊӠҫҚҢһ
य़ࢅҮӦҲ̷

஄ࢲ๫࢝ไᆜ࿶๦്‫ڵ‬९થᆜ཈ไ୹ѠпцҀࣘࡽ੣ࣅ୍ૉଅѣၑ૾ಧྈѥфᆙѝరபളਣ൞཈
ஶѠ࠙юҀ෕ਯ

ൊྴଅ!
‫ࠊߊڵ‬ᅬ

ࠅࢪஷ‫ښ‬൜ૉࣅඩಗ ଷனࢣຎᅧᅀҮӦҲ̷௩൜ࢲ଩ҞҼӒҙӓ‫ܟ‬ಠඒ‫ڱ‬ͅఋ෭ಗᅻ‫̝ڱ‬ตಗᅻ‫͆ڱ‬୊Ⴢѣ෪ಀय़ࢅ͘
ҞҼӒҙӓၰᇕѠཕлౡაᄬঞѝ्৆ۭࢾ͘

5-459

୪ࠅ࠰૱߶̡
๻ໝྐྵ๸ౡߋ
଻߸ྐྵവ੫೴
৾य़ࢅૉࣅ

ඩಗ̜ଷன

ࢣຎᅧᅀҮӦ
Ҳ̷ࢲ଩୪ࠅ࠰૱߶ѠпцҀେඇࠗѣ्৆ޭਮѣ૳഻໿‫ٷ‬ѝђѣവ੫҇ჭษѝьєൌࡋრҦӎ̷һ
ࢣຎय़ࢅ

2-661

୪ࠅ࠰૱߶̡
๻ໝྐྵ๸ౡߋ
଻߸ྐྵവ੫೴
৾य़ࢅૉࣅ

ඩಗ̜ଷன

ࢣຎᅧᅀҮӦҲ̷ࢲ଩ଃ‫ݶ‬ษᅆ‫ࠟ҇ہ‬ѵౡߋ଻߸ྐྵӝҬҢᅆ‫ہ‬ѣ‫ݷ‬ბ҇ჭફьєਈჂൊྴେඇѣൌࡋრҦӎ̷һ
य़ࢅ̢ NIPPON DATA
91/:1/3121

461

㸫  㸫

Ჷᬶ۵

ᕟ۵

ཀୡ۵

⁬۵

ᮾ᳣☁Ⲥᵱ

⦘ⲥ⾷٣Ԓ⾸๫ၿൌ޻݈ᆽ
‫޻ڮ‬य़ࢅ୹̜
ࢣຎय़ࢅ঱ြ

ඩഡ̜̜৏ࢣຎᅧᅀҮӦҲ̷ࢲ଩

TLR જाঞѣҨҗһҞ
җӦᄑ೾౒টࡀ৔ѣ‫ݷ‬ბ

561

ѧѾѶтʹѝ
тѶтҨҗқ
ӦҬ‫ښ‬൜ૉࣅ

ഡ௒̜̜޻ࢣຎᅧᅀҮӦҲ̷৭નఘѠྐྵࡃ҇лљюනͅ‫͆ݨ‬сў҈џ๚рࠒੴьћѴѽл

471

⿂⾸༦ᨪɟɵɀȯȷɐᮾ᳣౪༔౫ಏƷᲃᴗগક༦ᨪ᫢ᮾ᳣࣠ᬬബ༔ნ၇̗Ꮱ⾷౪༔౫ಏဖཾ⿉ᄙ⤴ᲇકᭉ⾸
ಘᅹ26઼̜૲Ӣ̷ӞҼѣᆤட‫ܥ‬ᅀ҇ჭફюय़ࢅ࢑฿ज౗ͅ3123.27͆
ཀୡ

⁬۵

ᕟ۵

ᮾ᳣☁Ⲥ

಑ൿ‫ڮ‬ᆒय़ࢅᆛ‫ڱ‬

ࢲ଩

ܱ੟̜ୢᇚ
ͅय़ࢅൊྴଅ͆

૱߶ຠ‫ڤ‬ษ੎ၙऍѣခᅲౣ౦઼̝૲ခથଠခ
౸̝ҬӈҖӦҧ઼૲ѠѽҀ༭ेྐྵߵ੎ၙѣഄ௮౒টࢣຎᅧᅀҮӦҲ̷ࢲ଩ඩഡ̜৏ҬӈҖӦҧ઼૲ѠѽҀҕӟӞҡ̷૱߶ѣᅍ౒चଦᄵളѠѽҀ౒টౡა‫޻ݏ‬य़ࢅᆛ‫ڱ‬

৭ન

൮শ̜ఊ

ҬӈҖӦҧ઼૲ѠѽҀे‫ۼ‬ଡ᢮੎ၙѣഄ௮ᅍ౒ࡀ৔ѣ‫ݷ‬ბ

ಘᅹ27̜৹ᆽ݂ѣకѵ‫ݦ‬೉ඒ‫ڱ‬ѠпцҀӜҗӈ̡җӁӌ̷ҪӚӦೖୟͅ3123.27͆
ཀୡ

⁬۵

ᕟ۵

ᮾ᳣☁Ⲥ

ӊӠҫҚҢһय़ࢅ
ҮӦҲ̷

ࢲ଩

ရ೙̜ଷఘ

ౣఋ૱߶ӕҺӞຍ࿿ѠпцҀेࠊ࠙ᇍ‫ہ‬થпѽѨ RAG ѣ࠙ᄮѣ‫ݷ‬ბౡა‫޻ݏ‬य़ࢅᆛ‫ڱ‬ࢲ଩౹‫̜ޣ‬ᄈఘ

ყᅔษ‫ڭ‬เથ‫ݷ‬౸ଛၔѠѽҀ૱߶ӑ̷Ҟ̷൸੬㸫  㸫ἮƷ⮥ƷൖƷ▉̜န౗38໪๘ѣࣟ൙‫ݏڮ‬ൌ޻೴৾‫޻ڮ‬य़ࢅ୹ѣय़ࢅߋຍѝࣅ౼̝͑ࣟ൙‫ݏڮ‬ൌ޻೴৾‫޻ڮ‬य़ࢅ
୹໪၈്38߭3127͒сѳѝѳѿѳьєѣќп೾ѿьѳю̞̜๵य़ࢅ୹Ѥ̝୹‫ۀ‬27჏ѣ஛ъџय़ࢅ୹ќюс̝န౗38໪๘ѽѿంєџय़ࢅ୹ේпѽѨ࿲୹ේс଱ໟь̝๵य़ࢅ୹ລ૜ѣ Only One ѣय़ࢅҹ̷ӑ҇ื‫ގ‬ьћпѿѳю̞ਘঞѣъѾџҀ཈ืѠщ࠽ഹෛцҁѥৃйќю̞̜ႏ໪၈҇തфѣၒ̴Ѡ຦҈ќෛт̝࠸ᕘѣџйщ‫ڞ‬।҇ૅѿєфഝэѳю̞̜ହ҄ѿѠ̝ႏ໪၈ѣ੣౗Ѡటᆜъҁєဩେ‫ۀښ‬ѣၒ̴Ѡ߷ଆьѳю̞໪၈ဩେ‫ۀښݶۀښ‬ේ̜ච຿̜౞ࡠ

ࣟ൙‫ݏڮ‬ൌ޻೴৾‫޻ڮ‬य़ࢅ୹໪၈്̜38̝߭3127
န౗39໪23ॉ཈৫ဩ̜େ̜̜ࣟ൙‫ݏڮ‬ൌ޻೴৾‫޻ڮ‬य़ࢅ୹໪၈ဩେ‫ݶۀښ‬̜̜̜̜̜̜ච຿̜౞ࡠ̜̜౹‫̜ޣ‬ᄈఘ̜̜ࠥᇱ̜ᆁ࿎
̜̜̜̜̜̜ഥใ̜ᆁ۸̜̜ใ੟̜ᆁઞ̜̜ం‫گ‬ใ̜ᅆ̜̜̜̜̜̜๦੟̜ქ࿎
཈̜৫̜̜ࣟ൙‫ݏڮ‬ൌ޻ୟའࣆ
̜̜̜̜̜̜̜΂:31͘13:4
̜̜̜̜̜̜̜̜౹ಗॢ‫ݔ‬ၿए຿⋱ාൌ޻2͘2̜̜̜̜̜̜̜̜ไ̜ᇮͅ187͆397͘3322ͅൊྴ͆‫̜ھ‬ੳ̜̜ӂӗҪ‫ھ‬ੳહীߗૡ‫ݶ‬ଃ